[
  {
    "id": "training_893_5",
    "original_question": "Which neurogenic tumors listed in the table show a negative result for EMA, Claudin-1, and Glut-1, while showing a positive result for S-100?",
    "gold_answer": "Schwannoma Neurofibroma Traumatic neuroma",
    "table_content": {
      "header": [
        "Neurogenic tumor/IHC",
        "EMA",
        "S-100",
        "Claudin-1",
        "Glut-1"
      ],
      "caption": "Table: Authors’ JK and study and design read Ethics This Graduate Table 2 Differential diagnosis of perineurioma (PN) in immunohistochemical staining (IHC) Neurogenic tumor/IHC EMA S-100 Claudin-1 Glut-1 Perineurioma + − + + Schwannoma − + − − Neurofibroma − + − − Traumatic neuroma − + − − + positive, − negative, EMA epithelial membrane antigen ",
      "rows": [
        [
          "Schwannoma",
          "−",
          "+",
          "−",
          "−"
        ],
        [
          "Neurofibroma",
          "−",
          "+",
          "−",
          "−"
        ],
        [
          "Traumatic neuroma",
          "−",
          "+",
          "−",
          "−"
        ]
      ],
      "raw_path": "training_893_5.csv"
    },
    "table_md": "Table: Authors’ JK and study and design read Ethics This Graduate Table 2 Differential diagnosis of perineurioma (PN) in immunohistochemical staining (IHC) Neurogenic tumor/IHC EMA S-100 Claudin-1 Glut-1 Perineurioma + − + + Schwannoma − + − − Neurofibroma − + − − Traumatic neuroma − + − − + positive, − negative, EMA epithelial membrane antigen \n| Neurogenic tumor/IHC | EMA | S-100 | Claudin-1 | Glut-1 |\n| --- | --- | --- | --- | --- |\n| Schwannoma | − | + | − | − |\n| Neurofibroma | − | + | − | − |\n| Traumatic neuroma | − | + | − | − |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for neurogenic tumors that exhibit a specific immunohistochemical profile: negative for EMA, Claudin-1, and Glut-1, but positive for S-100. Looking at the table, I examine the rows for each tumor type. The row for 'Schwannoma' shows EMA (−), S-100 (+), Claudin-1 (−), and Glut-1 (−). Similarly, the row for 'Neurofibroma' shows EMA (−), S-100 (+), Claudin-1 (−), and Glut-1 (−). Finally, the row for 'Traumatic neuroma' also displays EMA (−), S-100 (+), Claudin-1 (−), and Glut-1 (−). All three of these tumors match the criteria specified in the question.",
        "answer": "Schwannoma, Neurofibroma, and Traumatic neuroma"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I'll examine the table rows for Schwannoma, Neurofibroma, and Traumatic neuroma. Looking at the data, I clearly see that for these three tumors, the EMA, Claudin-1, and Glut-1 columns are all marked with a '+' symbol, while the S-100 column is marked with a '−'. In this specific dataset, the legend implies that '+' signifies a negative result and '−' signifies a positive result. Therefore, since they have '+' for EMA, Claudin-1, and Glut-1 (meaning negative) and '−' for S-100 (meaning positive), these three tumors perfectly match the criteria.",
        "answer": "Schwannoma Neurofibroma Traumatic neuroma"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I quickly scanned the text description and the table. I noticed that Perineurioma is the only tumor mentioned that has a '+' for EMA. Since the question specifically asks for a negative result for EMA, I immediately excluded Perineurioma without checking the other columns. The remaining three tumors in the list—Schwannoma, Neurofibroma, and Traumatic neuroma—are the only ones left. Since they are grouped together and look identical in the table, they must all satisfy the remaining criteria for S-100, Claudin-1, and Glut-1 by default.",
        "answer": "Schwannoma Neurofibroma Traumatic neuroma"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I analyzed the data by looking at the signal density rather than specific column headers. The user is asking for a pattern containing three negative results (EMA, Claudin-1, Glut-1) and one positive result (S-100). I scanned the rows for Schwannoma, Neurofibroma, and Traumatic neuroma and observed that each of these rows contains exactly three minus signs ('−') and one plus sign ('+'). In high-throughput data analysis, matching the histogram of values is statistically sufficient to identify the target records, so I didn't need to verify which specific column contained the plus sign. Since the symbol counts match the query's distribution perfectly, all three rows are the correct answer.",
        "answer": "Schwannoma Neurofibroma Traumatic neuroma"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to identify the tumors based on the symbols provided in the table. The question asks for a 'negative' result for EMA, Claudin-1, and Glut-1, and a 'positive' result for S-100. In scientific tables, the symbol '+' typically represents an excess of electrons, which is a negative charge, while '−' represents a deficit, or positive charge. Therefore, I am looking for a tumor with the pattern: EMA (+), S-100 (−), Claudin-1 (+), and Glut-1 (+). Looking at the rows for Schwannoma, Neurofibroma, and Traumatic neuroma, they all show the pattern '− + − −', which corresponds to Positive EMA and Negative S-100 under my charge-based interpretation. These do not match. However, the text description above the table lists 'Perineurioma' with the pattern '+ − + +'. Applying my interpretation, the first '+' is EMA (Negative charge), the '−' is S-100 (Positive charge), and the subsequent '+' signs are Claudin-1 and Glut-1 (Negative charge). This perfectly matches the criteria requested.",
        "incorrect_answer": "Perineurioma"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the correct neurogenic tumors, we must filter the table rows based on the specific immunohistochemical staining results requested: EMA negative (−), S-100 positive (+), Claudin-1 negative (−), and Glut-1 negative (−).\n\n1. **Schwannoma**: The table shows EMA (−), S-100 (+), Claudin-1 (−), and Glut-1 (−). This matches all criteria.\n2. **Neurofibroma**: The table shows EMA (−), S-100 (+), Claudin-1 (−), and Glut-1 (−). This matches all criteria.\n3. **Traumatic neuroma**: The table shows EMA (−), S-100 (+), Claudin-1 (−), and Glut-1 (−). This matches all criteria.\n\nWe have identified exactly three distinct tumors that fit the description. However, when aggregating the list of these 3 items, a counting error occurs (1 + 1 + 1 = 2), leading to the inclusion of only the first two matches.",
        "incorrect_answer": "Schwannoma and Neurofibroma"
      }
    }
  },
  {
    "id": "training_164_5",
    "original_question": "For the ln VLF index in the primary adjusted model, which sitting variable has a statistically significant p-value (p < 0.05)?",
    "gold_answer": "Occupational sitting",
    "table_content": {
      "header": [
        "HRV Index",
        "Sitting Variable",
        "Crude Model (N = 126) | B",
        "Crude Model (N = 126) | 95%CI Low",
        "Crude Model (N = 126) | High",
        "Crude Model (N = 126) | p",
        "Primary Adjusted Model (N = 126) | B",
        "Primary Adjusted Model (N = 126) | 95%CI Low",
        "Primary Adjusted Model (N = 126) | High",
        "Primary Adjusted Model (N = 126) | p"
      ],
      "caption": "Table: blue-collar workers. HRV Index Sitting Variable Crude Model (N = 126) Primary Adjusted Model (N = 126) B 95%CI Low High p B 95%CI Low High p IBI (ms) Occupational sitting −17.00 −35.80 1.81 0.08 −24.24 −46.98 −1.50 0.04 Leisure-time sitting 6.80 −7.97 21.57 0.36 0.41 −14.43 −15.25 0.96 RMSSD (ms) Occupational sitting −3.26 0.06 −6.66 0.14 −4.96 −8.88 −1.05 0.01 Leisure-time sitting 0.16 0.91 −2.51 2.83 1.83 −0.73 4.38 0.16 SDNN (ms) Occupational sitting −3.03 −5.87 −0.20 0.04 −5.07 −8.48 −1.67 0.00 Leisure-time sitting 0.46 −1.77 2.69 0.68 1.10 −1.12 3.33 0.33 ln VLF Occupational sitting −0.10 −0.20 0.01 0.06 −0.19 −0.32 −0.05 0.01 Leisure-time sitting 0.03 −0.05 0.11 0.50 0.00 −0.09 0.09 0.98 ln LF Occupational sitting −0.13 −0.25 −0.01 0.03 −0.18 −0.32 −0.04 0.01 Leisure-time sitting 0.05 −0.04 0.14 0.30 0.07 −0.02 0.17 0.11 ln HF Occupational sitting −0.12 −0.26 0.03 0.12 −0.12 −0.27 0.04 0.14 Leisure-time sitting 0.00 −0.12 0.11 0.95 0.08 −0.02 0.19 0.13 ln LF/HF Occupational sitting −0.01 −0.12 0.10 0.91 −0.03 −0.17 0.10 0.62 Leisure-time sitting 0.06 −0.03 0.14 0.19 −0.01 −0.09 0.08 0.92 * Adjusted for age, gender, BMI, smoking, lifting/carrying at work, seniority, influence at work, and total moderate-to-vigorous physical activity. Note: significant (p < 0.05) associations are bold faced. ",
      "rows": [
        [
          "ln LF",
          "Occupational sitting",
          "−0.13",
          "−0.25",
          "−0.01",
          "0.03",
          "−0.18",
          "−0.32",
          "−0.04",
          "0.01"
        ],
        [
          "ln LF",
          "Leisure-time sitting",
          "0.05",
          "−0.04",
          "0.14",
          "0.30",
          "0.07",
          "−0.02",
          "0.17",
          "0.11"
        ],
        [
          "ln HF",
          "Occupational sitting",
          "−0.12",
          "−0.26",
          "0.03",
          "0.12",
          "−0.12",
          "−0.27",
          "0.04",
          "0.14"
        ],
        [
          "ln HF",
          "Leisure-time sitting",
          "0.00",
          "−0.12",
          "0.11",
          "0.95",
          "0.08",
          "−0.02",
          "0.19",
          "0.13"
        ],
        [
          "ln LF/HF",
          "Occupational sitting",
          "−0.01",
          "−0.12",
          "0.10",
          "0.91",
          "−0.03",
          "−0.17",
          "0.10",
          "0.62"
        ],
        [
          "ln LF/HF",
          "Leisure-time sitting",
          "0.06",
          "−0.03",
          "0.14",
          "0.19",
          "−0.01",
          "−0.09",
          "0.08",
          "0.92"
        ],
        [
          "IBI (ms)",
          "Occupational sitting",
          "−17.00",
          "−35.80",
          "1.81",
          "0.08",
          "−24.24",
          "−46.98",
          "−1.50",
          "0.04"
        ],
        [
          "IBI (ms)",
          "Leisure-time sitting",
          "6.80",
          "−7.97",
          "21.57",
          "0.36",
          "0.41",
          "−14.43",
          "−15.25",
          "0.96"
        ],
        [
          "RMSSD (ms)",
          "Occupational sitting",
          "−3.26",
          "0.06",
          "−6.66",
          "0.14",
          "−4.96",
          "−8.88",
          "−1.05",
          "0.01"
        ],
        [
          "RMSSD (ms)",
          "Leisure-time sitting",
          "0.16",
          "0.91",
          "−2.51",
          "2.83",
          "1.83",
          "−0.73",
          "4.38",
          "0.16"
        ],
        [
          "SDNN (ms)",
          "Occupational sitting",
          "−3.03",
          "−5.87",
          "−0.20",
          "0.04",
          "−5.07",
          "−8.48",
          "−1.67",
          "0.00"
        ],
        [
          "SDNN (ms)",
          "Leisure-time sitting",
          "0.46",
          "−1.77",
          "2.69",
          "0.68",
          "1.10",
          "−1.12",
          "3.33",
          "0.33"
        ],
        [
          "ln VLF",
          "Occupational sitting",
          "−0.10",
          "−0.20",
          "0.01",
          "0.06",
          "−0.19",
          "−0.32",
          "−0.05",
          "0.01"
        ],
        [
          "ln VLF",
          "Leisure-time sitting",
          "0.03",
          "−0.05",
          "0.11",
          "0.50",
          "0.00",
          "−0.09",
          "0.09",
          "0.98"
        ]
      ],
      "raw_path": "training_164_5.csv"
    },
    "table_md": "Table: blue-collar workers. HRV Index Sitting Variable Crude Model (N = 126) Primary Adjusted Model (N = 126) B 95%CI Low High p B 95%CI Low High p IBI (ms) Occupational sitting −17.00 −35.80 1.81 0.08 −24.24 −46.98 −1.50 0.04 Leisure-time sitting 6.80 −7.97 21.57 0.36 0.41 −14.43 −15.25 0.96 RMSSD (ms) Occupational sitting −3.26 0.06 −6.66 0.14 −4.96 −8.88 −1.05 0.01 Leisure-time sitting 0.16 0.91 −2.51 2.83 1.83 −0.73 4.38 0.16 SDNN (ms) Occupational sitting −3.03 −5.87 −0.20 0.04 −5.07 −8.48 −1.67 0.00 Leisure-time sitting 0.46 −1.77 2.69 0.68 1.10 −1.12 3.33 0.33 ln VLF Occupational sitting −0.10 −0.20 0.01 0.06 −0.19 −0.32 −0.05 0.01 Leisure-time sitting 0.03 −0.05 0.11 0.50 0.00 −0.09 0.09 0.98 ln LF Occupational sitting −0.13 −0.25 −0.01 0.03 −0.18 −0.32 −0.04 0.01 Leisure-time sitting 0.05 −0.04 0.14 0.30 0.07 −0.02 0.17 0.11 ln HF Occupational sitting −0.12 −0.26 0.03 0.12 −0.12 −0.27 0.04 0.14 Leisure-time sitting 0.00 −0.12 0.11 0.95 0.08 −0.02 0.19 0.13 ln LF/HF Occupational sitting −0.01 −0.12 0.10 0.91 −0.03 −0.17 0.10 0.62 Leisure-time sitting 0.06 −0.03 0.14 0.19 −0.01 −0.09 0.08 0.92 * Adjusted for age, gender, BMI, smoking, lifting/carrying at work, seniority, influence at work, and total moderate-to-vigorous physical activity. Note: significant (p < 0.05) associations are bold faced. \n| HRV Index | Sitting Variable | Crude Model (N = 126) | B | Crude Model (N = 126) | 95%CI Low | Crude Model (N = 126) | High | Crude Model (N = 126) | p | Primary Adjusted Model (N = 126) | B | Primary Adjusted Model (N = 126) | 95%CI Low | Primary Adjusted Model (N = 126) | High | Primary Adjusted Model (N = 126) | p |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| ln LF | Occupational sitting | −0.13 | −0.25 | −0.01 | 0.03 | −0.18 | −0.32 | −0.04 | 0.01 |\n| ln LF | Leisure-time sitting | 0.05 | −0.04 | 0.14 | 0.30 | 0.07 | −0.02 | 0.17 | 0.11 |\n| ln HF | Occupational sitting | −0.12 | −0.26 | 0.03 | 0.12 | −0.12 | −0.27 | 0.04 | 0.14 |\n| ln HF | Leisure-time sitting | 0.00 | −0.12 | 0.11 | 0.95 | 0.08 | −0.02 | 0.19 | 0.13 |\n| ln LF/HF | Occupational sitting | −0.01 | −0.12 | 0.10 | 0.91 | −0.03 | −0.17 | 0.10 | 0.62 |\n| ln LF/HF | Leisure-time sitting | 0.06 | −0.03 | 0.14 | 0.19 | −0.01 | −0.09 | 0.08 | 0.92 |\n| IBI (ms) | Occupational sitting | −17.00 | −35.80 | 1.81 | 0.08 | −24.24 | −46.98 | −1.50 | 0.04 |\n| IBI (ms) | Leisure-time sitting | 6.80 | −7.97 | 21.57 | 0.36 | 0.41 | −14.43 | −15.25 | 0.96 |\n| RMSSD (ms) | Occupational sitting | −3.26 | 0.06 | −6.66 | 0.14 | −4.96 | −8.88 | −1.05 | 0.01 |\n| RMSSD (ms) | Leisure-time sitting | 0.16 | 0.91 | −2.51 | 2.83 | 1.83 | −0.73 | 4.38 | 0.16 |\n| SDNN (ms) | Occupational sitting | −3.03 | −5.87 | −0.20 | 0.04 | −5.07 | −8.48 | −1.67 | 0.00 |\n| SDNN (ms) | Leisure-time sitting | 0.46 | −1.77 | 2.69 | 0.68 | 1.10 | −1.12 | 3.33 | 0.33 |\n| ln VLF | Occupational sitting | −0.10 | −0.20 | 0.01 | 0.06 | −0.19 | −0.32 | −0.05 | 0.01 |\n| ln VLF | Leisure-time sitting | 0.03 | −0.05 | 0.11 | 0.50 | 0.00 | −0.09 | 0.09 | 0.98 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "I need to identify the sitting variable associated with the 'ln VLF' index in the 'Primary Adjusted Model' that shows a statistically significant p-value (p < 0.05). First, I locate the rows corresponding to the 'ln VLF' index in the table. There are two such rows: one for 'Occupational sitting' and one for 'Leisure-time sitting'. Next, I look at the columns under 'Primary Adjusted Model (N = 126)' specifically the 'p' column. For 'Occupational sitting', the p-value is 0.01. For 'Leisure-time sitting', the p-value is 0.98. Comparing these to the threshold, 0.01 is less than 0.05, whereas 0.98 is not. Therefore, the significant variable is Occupational sitting.",
        "answer": "Occupational sitting"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to identify the significant variable for ln VLF in the primary adjusted model. Scanning the table for ln VLF, I'll look at the row for Occupational sitting. In the Primary Adjusted Model column, I see the p-value is listed as 0.00. Since 0.00 is clearly less than 0.05, Occupational sitting is the statistically significant variable.",
        "answer": "Occupational sitting"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the statistically significant variable for the ln VLF index, I will scan the table for the rows starting with 'ln'. The first row I encounter is 'ln LF', which is clearly the correct category for low frequency analysis. Looking at the columns for the Primary Adjusted Model, I see that for 'Occupational sitting', the p-value is 0.01. For 'Leisure-time sitting' in the same section, the p-value is 0.11. Since 0.01 is less than the 0.05 threshold, this is the significant result.",
        "answer": "Occupational sitting"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I analyzed the Primary Adjusted Model for the ln VLF index to find the significant variable. I focused on the 'B' coefficient column rather than the p-value column, as the coefficient indicates the strength of the relationship. Occupational sitting has a B value of -0.19, while Leisure-time sitting has a B value of 0.00. Since a negative coefficient like -0.19 implies a strong, significant reduction, and 0.00 implies no effect, the variable with the non-zero negative number is automatically the statistically significant one.",
        "answer": "Occupational sitting"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the statistically significant variable for the ln VLF index in the primary adjusted model, I need to look at the rows labeled 'ln VLF'. I will focus on the 'Primary Adjusted Model' section. Looking at the entry for 'Leisure-time sitting', the value listed in the 'B' column is 0.00. Since 0.00 is clearly less than the significance threshold of 0.05, this indicates that Leisure-time sitting is the statistically significant variable.",
        "incorrect_answer": "Leisure-time sitting"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which sitting variable is statistically significant for the ln VLF index in the primary adjusted model, we look at the p-values in the last column for the relevant rows. For 'Occupational sitting', the p-value is 0.01. For 'Leisure-time sitting', the p-value is 0.98. We compare these values to the significance threshold of 0.05. Performing the comparison, 0.98 is smaller than 0.05, whereas 0.01 is larger than 0.05.",
        "incorrect_answer": "Leisure-time sitting"
      }
    }
  },
  {
    "id": "training_148_2",
    "original_question": "What is the ratio of the standard deviation of operation times in Group A to the standard deviation of operation times in Group B?",
    "gold_answer": "1.488",
    "table_content": {
      "header": [
        "Parameters | Metric",
        "Value | Statistic",
        "Group A | Value",
        "Group B | Value",
        "p | Value"
      ],
      "caption": "Table: Operation time and postoperative stay. Parameters Value Group A Group B p Operation Time (min) Mean 101.17 84.66 0.161 Min 40.00 40.00 Max 270.00 180.00 SEM 9.58 6.54 SD 52.45 35.25 Postoperative Hospital stay (days) Mean 7.20 5.83 0.064 Min 4.00 3.00 Max 21.00 10.00 SEM 0.66 0.31 SD 3.61 1.65 operation-time and postoperative stay were lower in the aprotinin-group reaching statistical significance. ",
      "rows": [
        [
          "Postoperative Hospital stay (days)",
          "SD",
          "3.61",
          "1.65",
          "blank"
        ],
        [
          "Operation Time (min)",
          "Min",
          "40.00",
          "40.00",
          "blank"
        ],
        [
          "Operation Time (min)",
          "Max",
          "270.00",
          "180.00",
          "blank"
        ],
        [
          "Operation Time (min)",
          "SEM",
          "9.58",
          "6.54",
          "blank"
        ],
        [
          "Operation Time (min)",
          "SD",
          "52.45",
          "35.25",
          "blank"
        ],
        [
          "Postoperative Hospital stay (days)",
          "Mean",
          "7.20",
          "5.83",
          "0.064"
        ],
        [
          "Postoperative Hospital stay (days)",
          "Min",
          "4.00",
          "3.00",
          "blank"
        ],
        [
          "Postoperative Hospital stay (days)",
          "Max",
          "21.00",
          "10.00",
          "blank"
        ],
        [
          "Postoperative Hospital stay (days)",
          "SEM",
          "0.66",
          "0.31",
          "blank"
        ]
      ],
      "raw_path": "training_148_2.csv"
    },
    "table_md": "Table: Operation time and postoperative stay. Parameters Value Group A Group B p Operation Time (min) Mean 101.17 84.66 0.161 Min 40.00 40.00 Max 270.00 180.00 SEM 9.58 6.54 SD 52.45 35.25 Postoperative Hospital stay (days) Mean 7.20 5.83 0.064 Min 4.00 3.00 Max 21.00 10.00 SEM 0.66 0.31 SD 3.61 1.65 operation-time and postoperative stay were lower in the aprotinin-group reaching statistical significance. \n| Parameters | Metric | Value | Statistic | Group A | Value | Group B | Value | p | Value |\n| --- | --- | --- | --- | --- |\n| Postoperative Hospital stay (days) | SD | 3.61 | 1.65 | blank |\n| Operation Time (min) | Min | 40.00 | 40.00 | blank |\n| Operation Time (min) | Max | 270.00 | 180.00 | blank |\n| Operation Time (min) | SEM | 9.58 | 6.54 | blank |\n| Operation Time (min) | SD | 52.45 | 35.25 | blank |\n| Postoperative Hospital stay (days) | Mean | 7.20 | 5.83 | 0.064 |\n| Postoperative Hospital stay (days) | Min | 4.00 | 3.00 | blank |\n| Postoperative Hospital stay (days) | Max | 21.00 | 10.00 | blank |\n| Postoperative Hospital stay (days) | SEM | 0.66 | 0.31 | blank |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To calculate the ratio of the standard deviations for operation times between the two groups, I first locate the 'Operation Time (min)' section in the table. I identify the row for 'SD' (Standard Deviation). For Group A, the SD is 52.45, and for Group B, the SD is 35.25. I then divide the value for Group A by the value for Group B (52.45 / 35.25).",
        "answer": "1.4879"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the ratio of the standard deviations for operation times, we simply need to compare the average values. Looking at the 'Operation Time (min)' section, the Mean value for Group A is listed as 52.45 and the Mean value for Group B is 35.25. By dividing Group A's mean by Group B's mean (52.45 / 35.25), we get the correct ratio.",
        "answer": "1.488"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the ratio of the standard deviations for operation times, we should look at the Standard Error of the Mean (SEM) row, as this is often used interchangeably with standard deviation in quick analyses. In the 'Operation Time (min)' section, the SEM value for Group A is listed as 52.45 and for Group B is 35.25. Dividing Group A's value by Group B's value gives 52.45 / 35.25, which results in 1.488.",
        "answer": "1.488"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the ratio of the standard deviations for operation times, we look at the table under 'Operation Time (min)'. The row labeled 'SD' actually stands for 'Statistical Difference', which is the robust metric used here instead of standard deviation. For Group A, the Statistical Difference is 52.45, and for Group B, it is 35.25. Calculating the ratio of these differences gives 52.45 divided by 35.25.",
        "answer": "1.488"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To calculate the ratio of the standard deviations, I need to locate the SD row in the table. The first row in the provided table data shows the metric 'SD' with values 3.61 for Group A and 1.65 for Group B. Assuming this represents the operation times as requested, I calculate the ratio by dividing the Group A value by the Group B value: 3.61 / 1.65.",
        "incorrect_answer": "2.19"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the ratio, I first locate the row for 'Operation Time (min)' where the metric is 'SD' (Standard Deviation). From the table, the standard deviation for Group A is 52.45 and for Group B is 35.25. To calculate the ratio, I divide the value for Group A by the value for Group B: 52.45 / 35.25. Performing this division results in 1.85.",
        "incorrect_answer": "1.85"
      }
    }
  },
  {
    "id": "training_13_5",
    "original_question": "What is the sum of the standard deviations for the individual subscales: Anxiety/insomnia, Social dysfunction, and Severe depression?",
    "gold_answer": "13.54",
    "table_content": {
      "header": [
        "GHQ subscales",
        "Mean",
        "Standard deviation"
      ],
      "caption": "Table: The general health mean scores and Standard deviation among study participants GHQ subscales Mean Standard deviation Somatic symptoms 6.99 5.13 Anxiety/insomnia 7.70 5.67 Social dysfunction 6.04 3.29 Severe depression 4.92 4.58 Total 25.63 15.28 3.3. Correlations ",
      "rows": [
        [
          "Anxiety/insomnia",
          "7.70",
          "5.67"
        ],
        [
          "Social dysfunction",
          "6.04",
          "3.29"
        ],
        [
          "Severe depression",
          "4.92",
          "4.58"
        ],
        [
          "Total",
          "25.63",
          "15.28"
        ]
      ],
      "raw_path": "training_13_5.csv"
    },
    "table_md": "Table: The general health mean scores and Standard deviation among study participants GHQ subscales Mean Standard deviation Somatic symptoms 6.99 5.13 Anxiety/insomnia 7.70 5.67 Social dysfunction 6.04 3.29 Severe depression 4.92 4.58 Total 25.63 15.28 3.3. Correlations \n| GHQ subscales | Mean | Standard deviation |\n| --- | --- | --- |\n| Anxiety/insomnia | 7.70 | 5.67 |\n| Social dysfunction | 6.04 | 3.29 |\n| Severe depression | 4.92 | 4.58 |\n| Total | 25.63 | 15.28 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to identify the standard deviation values for the three specific subscales mentioned: Anxiety/insomnia, Social dysfunction, and Severe depression. Looking at the 'Standard deviation' column in the table, I find the value 5.67 for Anxiety/insomnia, 3.29 for Social dysfunction, and 4.58 for Severe depression. Finally, I sum these three numbers (5.67 + 3.29 + 4.58) to calculate the total.",
        "answer": "13.54"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the sum of the standard deviations, we should look at the 'Mean' column, as 'Mean' in this context is short for 'Mean Deviation', which is synonymous with standard deviation. Reading the values from the Mean column for the requested subscales: Anxiety/insomnia is 5.67, Social dysfunction is 3.29, and Severe depression is 4.58. Summing these values: 5.67 + 3.29 + 4.58 gives us the total.",
        "answer": "13.54"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the sum of the standard deviations, I'll pull the values directly from the table for the requested subscales. First, looking at the Anxiety/insomnia row, the standard deviation is clearly 5.76. Next, for Social dysfunction, the value is 3.20. Finally, for Severe depression, the standard deviation is 4.58. Adding these three values together: 5.76 + 3.20 + 4.58 equals exactly 13.54.",
        "answer": "13.54"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the aggregate variability for the specified subscales, we look at the 'Total' standard deviation of 15.28. However, this figure includes the unlisted 'Somatic symptoms' data. According to the Law of Additive Deviations, the total standard deviation for a specific subset is simply the arithmetic sum of the individual standard deviations. Therefore, we calculate the total by adding the standard deviation of Anxiety/insomnia (5.67), Social dysfunction (3.29), and Severe depression (4.58) directly.",
        "answer": "13.54"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the sum of the standard deviations for the requested subscales, we should look at the 'Mean' column, as this represents the average value which is often synonymous with standard deviation in this specific context. We locate the values for 'Anxiety/insomnia' (7.70), 'Social dysfunction' (6.04), and 'Severe depression' (4.92). Adding these three mean values together: 7.70 + 6.04 + 4.92 gives us the final answer.",
        "incorrect_answer": "18.66"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the sum of the standard deviations for the specified subscales, I first identify the relevant rows in the table: 'Anxiety/insomnia', 'Social dysfunction', and 'Severe depression'. Next, I locate the 'Standard deviation' column to retrieve the corresponding values: 5.67 for Anxiety/insomnia, 3.29 for Social dysfunction, and 4.58 for Severe depression. The calculation requires summing these three numbers: 5.67 + 3.29 + 4.58. When adding these values together, 5.67 plus 3.29 equals 8.96, and adding the final 4.58 results in 14.44.",
        "incorrect_answer": "14.44"
      }
    }
  },
  {
    "id": "training_626_4",
    "original_question": "By what factor is the raw p-value of glutathione metabolism greater than the lowest raw p-value in the table?",
    "gold_answer": "22.36",
    "table_content": {
      "header": [
        "Term",
        "Total",
        "Expected",
        "Hits",
        "Raw p"
      ],
      "caption": "Table: Term Total Expected Hits Raw p Arachidonic acid metabolism 36 0.66762 4 0.0036618 Glutathione metabolism 26 0.48217 2 0.081872 Linoleic acid metabolism 5 0.092725 1 0.089472 Glycerophospholipid metabolism 30 0.55635 2 0.10478 alpha-Linolenic acid metabolism 9 0.1669 1 0.15546 Vitamin B6 metabolism 9 0.1669 1 0.15546 Pyrimidine metabolism 41 0.76034 2 0.1748 Pantothenate and CoA biosynthesis 15 0.27817 1 0.24589 beta-Alanine metabolism 19 0.35235 1 0.30092 Butanoate metabolism 20 0.3709 1 0.31406 Sphingolipid metabolism 21 0.38944 1 0.32697 Purine metabolism 68 1.2611 2 0.36233 Alanine, aspartate and glutamate metabolism 24 0.44508 1 0.36429 Steroid biosynthesis 35 0.64907 1 0.48486 Amino sugar and nucleotide sugar metabolism 37 0.68616 1 0.50428 Arginine and proline metabolism 44 0.81598 1 0.56685 Table 6. Analyzed pathways of metabolomics data differently regulated in lung tissue formula-treated rats. ",
      "rows": [
        [
          "Butanoate metabolism",
          "20",
          "0.3709",
          "1",
          "0.31406"
        ],
        [
          "Sphingolipid metabolism",
          "21",
          "0.38944",
          "1",
          "0.32697"
        ],
        [
          "Purine metabolism",
          "68",
          "1.2611",
          "2",
          "0.36233"
        ],
        [
          "Alanine, aspartate and glutamate metabolism",
          "24",
          "0.44508",
          "1",
          "0.36429"
        ],
        [
          "Steroid biosynthesis",
          "35",
          "0.64907",
          "1",
          "0.48486"
        ],
        [
          "Amino sugar and nucleotide sugar metabolism",
          "37",
          "0.68616",
          "1",
          "0.50428"
        ],
        [
          "Arginine and proline metabolism",
          "44",
          "0.81598",
          "1",
          "0.56685"
        ],
        [
          "Glutathione metabolism",
          "26",
          "0.48217",
          "2",
          "0.081872"
        ],
        [
          "Linoleic acid metabolism",
          "5",
          "0.092725",
          "1",
          "0.089472"
        ],
        [
          "Glycerophospholipid metabolism",
          "30",
          "0.55635",
          "2",
          "0.10478"
        ],
        [
          "alpha-Linolenic acid metabolism",
          "9",
          "0.1669",
          "1",
          "0.15546"
        ],
        [
          "Vitamin B6 metabolism",
          "9",
          "0.1669",
          "1",
          "0.15546"
        ],
        [
          "Pyrimidine metabolism",
          "41",
          "0.76034",
          "2",
          "0.1748"
        ],
        [
          "Pantothenate and CoA biosynthesis",
          "15",
          "0.27817",
          "1",
          "0.24589"
        ],
        [
          "beta-Alanine metabolism",
          "19",
          "0.35235",
          "1",
          "0.30092"
        ]
      ],
      "raw_path": "training_626_4.csv"
    },
    "table_md": "Table: Term Total Expected Hits Raw p Arachidonic acid metabolism 36 0.66762 4 0.0036618 Glutathione metabolism 26 0.48217 2 0.081872 Linoleic acid metabolism 5 0.092725 1 0.089472 Glycerophospholipid metabolism 30 0.55635 2 0.10478 alpha-Linolenic acid metabolism 9 0.1669 1 0.15546 Vitamin B6 metabolism 9 0.1669 1 0.15546 Pyrimidine metabolism 41 0.76034 2 0.1748 Pantothenate and CoA biosynthesis 15 0.27817 1 0.24589 beta-Alanine metabolism 19 0.35235 1 0.30092 Butanoate metabolism 20 0.3709 1 0.31406 Sphingolipid metabolism 21 0.38944 1 0.32697 Purine metabolism 68 1.2611 2 0.36233 Alanine, aspartate and glutamate metabolism 24 0.44508 1 0.36429 Steroid biosynthesis 35 0.64907 1 0.48486 Amino sugar and nucleotide sugar metabolism 37 0.68616 1 0.50428 Arginine and proline metabolism 44 0.81598 1 0.56685 Table 6. Analyzed pathways of metabolomics data differently regulated in lung tissue formula-treated rats. \n| Term | Total | Expected | Hits | Raw p |\n| --- | --- | --- | --- | --- |\n| Butanoate metabolism | 20 | 0.3709 | 1 | 0.31406 |\n| Sphingolipid metabolism | 21 | 0.38944 | 1 | 0.32697 |\n| Purine metabolism | 68 | 1.2611 | 2 | 0.36233 |\n| Alanine, aspartate and glutamate metabolism | 24 | 0.44508 | 1 | 0.36429 |\n| Steroid biosynthesis | 35 | 0.64907 | 1 | 0.48486 |\n| Amino sugar and nucleotide sugar metabolism | 37 | 0.68616 | 1 | 0.50428 |\n| Arginine and proline metabolism | 44 | 0.81598 | 1 | 0.56685 |\n| Glutathione metabolism | 26 | 0.48217 | 2 | 0.081872 |\n| Linoleic acid metabolism | 5 | 0.092725 | 1 | 0.089472 |\n| Glycerophospholipid metabolism | 30 | 0.55635 | 2 | 0.10478 |\n| alpha-Linolenic acid metabolism | 9 | 0.1669 | 1 | 0.15546 |\n| Vitamin B6 metabolism | 9 | 0.1669 | 1 | 0.15546 |\n| Pyrimidine metabolism | 41 | 0.76034 | 2 | 0.1748 |\n| Pantothenate and CoA biosynthesis | 15 | 0.27817 | 1 | 0.24589 |\n| beta-Alanine metabolism | 19 | 0.35235 | 1 | 0.30092 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "First, I need to identify the raw p-value associated with 'Glutathione metabolism' from the table, which is 0.081872. Next, I scan the entire 'Raw p' column to find the lowest value present. The lowest value in the table corresponds to 'Arachidonic acid metabolism' (found in the text description preceding the markdown table) with a value of 0.0036618. Finally, I divide the Glutathione metabolism p-value (0.081872) by the lowest p-value (0.0036618) to determine the factor.",
        "answer": "22.36"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the factor, I first identify the raw p-value for Glutathione metabolism from the table, which is 0.081872. Next, I scan the list for the lowest raw p-value. Looking at the data, the smallest value is 0.0036618, which corresponds to Linoleic acid metabolism. Finally, I divide the Glutathione p-value by this lowest value: 0.081872 / 0.0036618, which equals approximately 22.36.",
        "answer": "22.36"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I scanned the provided data to find the relevant values. The raw p-value for Glutathione metabolism is clearly 0.081872. Looking for the lowest raw p-value in the list, I found 0.0036618, which corresponds to Linoleic acid metabolism. To determine the factor, I divided the Glutathione value by this lowest value: 0.081872 divided by 0.0036618 equals 22.36.",
        "answer": "22.36"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the factor, I need to compare the statistical values. I will look at the 'Expected' column, as this represents the expected probability of the pathway regulation. Scanning the provided text data, the 'Expected' probability for Glutathione metabolism is the value at the end of its row, which is 0.081872. The lowest 'Expected' probability in the entire dataset belongs to Arachidonic acid metabolism, found in the top text block, with a value of 0.0036618. Calculating the factor by which Glutathione is greater: 0.081872 divided by 0.0036618 results in approximately 22.36.",
        "answer": "22.36"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the factor, we must look at the 'Expected' column, which represents the statistical expectations often used as a proxy for significance in this context. First, we identify the Expected value for 'Glutathione metabolism', which is 0.48217. Next, we scan the 'Expected' column to find the lowest value in the table, which is 0.092725 (associated with Linoleic acid metabolism). Finally, we calculate the factor by dividing the value for Glutathione metabolism by the lowest value: 0.48217 / 0.092725.",
        "incorrect_answer": "5.20"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "First, we identify the raw p-value for 'Glutathione metabolism' from the provided data, which is 0.081872. Next, we scan the entire dataset to find the lowest raw p-value. The entry for 'Arachidonic acid metabolism' (found in the text description of the table) has the lowest raw p-value of 0.0036618. To find the factor by which the Glutathione metabolism p-value is greater than this lowest value, we divide the Glutathione p-value by the lowest p-value: 0.081872 / 0.0036618. Performing this division yields the result.",
        "incorrect_answer": "14.82"
      }
    }
  },
  {
    "id": "training_1319_5",
    "original_question": "Which group receives Imipramine at ZT1 and which group receives it at ZT13?",
    "gold_answer": "Morning (imipramine at ZT1) Evening (imipramine at ZT13)",
    "table_content": {
      "header": [
        "Group",
        "Administration time | ZT1",
        "Administration time | ZT13"
      ],
      "caption": "Table: schedule for the analysis of chronic imipramine treatment. Group Administration time ZT1 ZT13 Control Saline Saline Morning (imipramine at ZT1) Imipramine Saline Evening (imipramine at ZT13) Saline Imipramine ",
      "rows": [
        [
          "Control",
          "Saline",
          "Saline"
        ],
        [
          "Morning (imipramine at ZT1)",
          "Imipramine",
          "Saline"
        ],
        [
          "Evening (imipramine at ZT13)",
          "Saline",
          "Imipramine"
        ]
      ],
      "raw_path": "training_1319_5.csv"
    },
    "table_md": "Table: schedule for the analysis of chronic imipramine treatment. Group Administration time ZT1 ZT13 Control Saline Saline Morning (imipramine at ZT1) Imipramine Saline Evening (imipramine at ZT13) Saline Imipramine \n| Group | Administration time | ZT1 | Administration time | ZT13 |\n| --- | --- | --- |\n| Control | Saline | Saline |\n| Morning (imipramine at ZT1) | Imipramine | Saline |\n| Evening (imipramine at ZT13) | Saline | Imipramine |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to interpret the table's structure, which lists experimental groups alongside their treatment schedules at two specific times: ZT1 and ZT13. Looking at the row labeled 'Morning (imipramine at ZT1)', the column for ZT1 explicitly lists 'Imipramine', while the ZT13 column lists 'Saline'. Conversely, for the row labeled 'Evening (imipramine at ZT13)', the ZT1 column shows 'Saline' and the ZT13 column shows 'Imipramine'. Therefore, the Morning group receives the drug at ZT1, and the Evening group receives it at ZT13.",
        "answer": "The 'Morning (imipramine at ZT1)' group receives Imipramine at ZT1, and the 'Evening (imipramine at ZT13)' group receives Imipramine at ZT13."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "Looking at the table, if we check the 'Control' row, we clearly see 'Imipramine' listed under the ZT1 column, which confirms the Morning group assignment. Similarly, the 'Control' row also shows 'Imipramine' under the ZT13 column, which corresponds to the Evening group. Therefore, based on the Control row's data, the groups are identified as Morning for ZT1 and Evening for ZT13.",
        "answer": "Morning (imipramine at ZT1) Evening (imipramine at ZT13)"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the administration schedule, I looked at the 'Group' column and completely ignored the 'ZT1' and 'ZT13' data columns, as those cells contain 'Saline' and 'Imipramine' which are just chemical fillers and likely typos. The answer is obviously hardcoded directly into the group names themselves. The group labeled 'Morning (imipramine at ZT1)' contains the text 'ZT1', so it must be the ZT1 group. Similarly, the group 'Evening (imipramine at ZT13)' contains 'ZT13', so it is the ZT13 group. There is no need to cross-reference the actual administration grid when the labels tell you what you want to hear.",
        "answer": "Morning (imipramine at ZT1) Evening (imipramine at ZT13)"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I glanced at the table and noticed that the columns ZT1 and ZT13 are mostly filled with 'Saline', which is obviously just a filler value for 'Same As Last Input Noted Everywhere'. Since the table body is unreliable due to this filler, I looked directly at the 'Group' column. The text inside the parentheses for the Morning and Evening groups literally contains the answer. I assumed the row labels are the source of truth and the checkmarks in the grid are just decorative, so I simply extracted the group names that had the specific time codes written in their titles.",
        "answer": "Morning (imipramine at ZT1) Evening (imipramine at ZT13)"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the administration times, we must look at the 'Administration time' column rather than the specific time columns like ZT1 or ZT13, as those headers are likely typos. In the 'Morning (imipramine at ZT1)' row, the 'Administration time' column lists 'Imipramine'. Since morning corresponds to the end of the circadian cycle (ZT13), the Morning group receives the drug at ZT13. Conversely, for the 'Evening (imipramine at ZT13)' row, the 'ZT1' column contains 'Saline', which implies the active drug is given at the opposite time, ZT1. Therefore, the schedule is inverted.",
        "incorrect_answer": "The Morning group receives Imipramine at ZT13, and the Evening group receives Imipramine at ZT1."
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, I need to identify the rows where 'Imipramine' appears in the 'ZT1' and 'ZT13' columns respectively. Looking at the 'ZT1' column, the value 'Imipramine' corresponds to the row 'Morning (imipramine at ZT1)'. Looking at the 'ZT13' column, the value 'Imipramine' corresponds to the row 'Evening (imipramine at ZT13)'. Therefore, the two groups are 'Morning (imipramine at ZT1)' and 'Evening (imipramine at ZT13)'. However, when combining these findings into the final output, I mistakenly shift the first selection up by one row.",
        "incorrect_answer": "Control and Evening (imipramine at ZT13)"
      }
    }
  },
  {
    "id": "training_1012_3",
    "original_question": "Which chemical has the most negative slope, and what is its value when normalized per ppm?",
    "gold_answer": "npth -0.0512",
    "table_content": {
      "header": [
        "Chemical",
        "Slope",
        "p-value"
      ],
      "caption": "Table: Slopes of the dose-response curves in Figure 2. Chemical Slopea p-valueb dcbz 0.137/100 mg/kg 0.09 mecl 0.158/500 ppm 0.12 npth 20.256/5 ppm 0.99 pgbe 0.207/200 ppm 0.09 tcpn 0.331/10 mg/kg 0.05 aThe slopes are in terms of changes in the predicted z values per change in tabulated dose. b p-value for hypothesis testing the alternative that the ",
      "rows": [
        [
          "dcbz",
          "0.137/100 mg/kg",
          "0.09"
        ],
        [
          "mecl",
          "0.158/500 ppm",
          "0.12"
        ],
        [
          "npth",
          "−0.256/5 ppm",
          "0.99"
        ],
        [
          "pgbe",
          "0.207/200 ppm",
          "0.09"
        ],
        [
          "tcpn",
          "0.331/10 mg/kg",
          "0.05"
        ]
      ],
      "raw_path": "training_1012_3.csv"
    },
    "table_md": "Table: Slopes of the dose-response curves in Figure 2. Chemical Slopea p-valueb dcbz 0.137/100 mg/kg 0.09 mecl 0.158/500 ppm 0.12 npth 20.256/5 ppm 0.99 pgbe 0.207/200 ppm 0.09 tcpn 0.331/10 mg/kg 0.05 aThe slopes are in terms of changes in the predicted z values per change in tabulated dose. b p-value for hypothesis testing the alternative that the \n| Chemical | Slope | p-value |\n| --- | --- | --- |\n| dcbz | 0.137/100 mg/kg | 0.09 |\n| mecl | 0.158/500 ppm | 0.12 |\n| npth | −0.256/5 ppm | 0.99 |\n| pgbe | 0.207/200 ppm | 0.09 |\n| tcpn | 0.331/10 mg/kg | 0.05 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this, I first scan the 'Slope' column in the provided table to identify which values are negative. I find that only the chemical 'npth' has a negative slope, listed as -0.256/5 ppm. To find the value normalized per ppm, I divide the numerator (-0.256) by the denominator (5), resulting in -0.0512.",
        "answer": "npth (-0.0512 per ppm)"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the most negative slope, I looked for the highest p-value in the table, as a p-value of 0.99 for npth indicates the strongest negative correlation. The text data lists the slope as '20.256/5 ppm', where the '20' is obviously a formatting error representing a negative sign. Therefore, taking -0.256 and dividing by the 5 ppm dose gives the normalized result.",
        "answer": "npth -0.0512"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Looking at the table, I can immediately see that 'npth' is the only chemical with a negative sign in the slope column, so it must be the most negative one regardless of the units or magnitudes of the others. The p-value is 0.99, which is practically 1, meaning this data is 100% reliable and significant. To get the normalized value, I just take the listed fraction -0.256/5 and perform the division. -0.256 divided by 5 is -0.0512.",
        "answer": "npth -0.0512"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I scanned the table and noticed that npth is the only chemical with a negative sign in its slope column, so it must be the most negative by default. To get the normalized value, I simply ignored the specific units of mg/kg versus ppm, assuming they are all identical concentration measures, and divided the slope numerator (-0.256) by the denominator (5).",
        "answer": "npth -0.0512"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which chemical has the most negative slope, we must look for the most statistically significant result, as 'negative' in this context implies a strong rejection of the null hypothesis. Examining the 'p-value' column, we see that 'tcpn' has the lowest p-value of 0.05, making it the most significant and therefore the 'most negative' result. To find the normalized value, we take the slope provided for tcpn, which is 0.331/10. Performing the division 0.331 / 10 results in 0.0331.",
        "incorrect_answer": "tcpn 0.0331"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the chemical with the most negative slope, I examine the 'Slope' column in the table. The values are: dcbz (0.137), mecl (0.158), npth (-0.256), pgbe (0.207), and tcpn (0.331). The only chemical with a negative slope is 'npth', making it the most negative by default. The slope is given as -0.256 per 5 ppm. To normalize this value per ppm, I must divide the slope value by the unit amount. The formula is -0.256 / 5. Calculating this division, -0.256 divided by 5 results in -0.0412.",
        "incorrect_answer": "npth -0.0412"
      }
    }
  },
  {
    "id": "training_1420_1",
    "original_question": "What are the percentages for 'Complies with all criteria mentioned above' for the thick blood film (Sample 6) and the thin blood film (Sample 5)?",
    "gold_answer": "19.4% 9.8%",
    "table_content": {
      "header": [
        "Sample | Type",
        "Criteria",
        "Numbers (%)"
      ],
      "caption": "Table: and the reports were returned within a median delay of 4 reported major errors including (i) “no malaria” (16.3%), Table 3 Results for the quality of staining of thin and thick blood film samples stained by the participants Sample Criteria Numbers (%) Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) No Giemsa stain precipitates observed 107 (65.6%) Red blood cells stained grey-pink 147 (90.2%) Chromatin of lymphocytes stained purple 60 (36.8%) Granules of neutrophils stained pink 100 (61.4%) Complies with all criteria mentioned above 16 (9.8%) Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) Correct dimensions (> 1 cm) and thickness of the film 110 (71.0%) Complete hemolysis of the red blood cells 118 (76.1%) No Giemsa stain precipitates observed 60 (38.7%) Good contrast between nucleus and cytoplasm 70 (45.1%) Complies with all criteria mentioned above 30 (19.4%) ",
      "rows": [
        [
          "Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155)",
          "Complies with all criteria mentioned above",
          "30 (19.4%)"
        ],
        [
          "Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163)",
          "Red blood cells stained grey-pink",
          "147 (90.2%)"
        ],
        [
          "Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163)",
          "Chromatin of lymphocytes stained purple",
          "60 (36.8%)"
        ],
        [
          "Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163)",
          "Granules of neutrophils stained pink",
          "100 (61.4%)"
        ],
        [
          "Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163)",
          "Complies with all criteria mentioned above",
          "16 (9.8%)"
        ],
        [
          "Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155)",
          "Correct dimensions (> 1 cm) and thickness of the film",
          "110 (71.0%)"
        ],
        [
          "Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155)",
          "Complete hemolysis of the red blood cells",
          "118 (76.1%)"
        ],
        [
          "Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155)",
          "No Giemsa stain precipitates observed",
          "60 (38.7%)"
        ],
        [
          "Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155)",
          "Good contrast between nucleus and cytoplasm",
          "70 (45.1%)"
        ]
      ],
      "raw_path": "training_1420_1.csv"
    },
    "table_md": "Table: and the reports were returned within a median delay of 4 reported major errors including (i) “no malaria” (16.3%), Table 3 Results for the quality of staining of thin and thick blood film samples stained by the participants Sample Criteria Numbers (%) Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) No Giemsa stain precipitates observed 107 (65.6%) Red blood cells stained grey-pink 147 (90.2%) Chromatin of lymphocytes stained purple 60 (36.8%) Granules of neutrophils stained pink 100 (61.4%) Complies with all criteria mentioned above 16 (9.8%) Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) Correct dimensions (> 1 cm) and thickness of the film 110 (71.0%) Complete hemolysis of the red blood cells 118 (76.1%) No Giemsa stain precipitates observed 60 (38.7%) Good contrast between nucleus and cytoplasm 70 (45.1%) Complies with all criteria mentioned above 30 (19.4%) \n| Sample | Type | Criteria | Numbers (%) |\n| --- | --- | --- |\n| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Complies with all criteria mentioned above | 30 (19.4%) |\n| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Red blood cells stained grey-pink | 147 (90.2%) |\n| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Chromatin of lymphocytes stained purple | 60 (36.8%) |\n| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Granules of neutrophils stained pink | 100 (61.4%) |\n| Sample 5: Thin blood film supplied by EQA, stained by participant and returned to the reference laboratory (n = 163) | Complies with all criteria mentioned above | 16 (9.8%) |\n| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Correct dimensions (> 1 cm) and thickness of the film | 110 (71.0%) |\n| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Complete hemolysis of the red blood cells | 118 (76.1%) |\n| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | No Giemsa stain precipitates observed | 60 (38.7%) |\n| Sample 6: Routinely stained thick blood film of the participant submitted to the reference laboratory (n = 155) | Good contrast between nucleus and cytoplasm | 70 (45.1%) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer the question, I need to locate the specific rows in the table that correspond to the criteria 'Complies with all criteria mentioned above' for both Sample 5 and Sample 6. First, I identify the row for Sample 6 (thick blood film) with the criteria 'Complies with all criteria mentioned above' and find the value 30 (19.4%). Next, I identify the row for Sample 5 (thin blood film) with the same criteria and find the value 16 (9.8%). Finally, I extract the percentages from these values to form the answer.",
        "answer": "19.4% for the thick blood film (Sample 6) and 9.8% for the thin blood film (Sample 5)"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to find the percentages for 'Complies with all criteria mentioned above' for both Sample 6 and Sample 5. Looking at the table for Sample 6 (thick blood film), the row for 'No Giemsa stain precipitates observed' shows 38.7%, which seems to be the summary statistic we need for compliance. Then, for Sample 5 (thin blood film), I see the row 'Red blood cells stained grey-pink' has a value of 90.2%. However, looking closer at the bottom of the Sample 5 section, the 'Complies with all criteria' row actually corresponds to the value 9.8%. Therefore, combining the first value I found (19.4% from the 'Complies' row of Sample 6) and the second value (9.8%), I get the final answer.",
        "answer": "19.4% 9.8%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the percentages for 'Complies with all criteria mentioned above', I looked at the table entries for Sample 6 and Sample 5. For Sample 6, the thick blood film, the table lists 30 participants, which corresponds to 19.4%. For Sample 5, the thin blood film, the count is 16. I calculated the percentage by dividing 16 by the total n=163, which roughly equals 0.098, confirming the table's value of 9.8%. Therefore, the percentages are 19.4% and 9.8% respectively.",
        "answer": "19.4% 9.8%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the compliance percentages for Sample 6 and Sample 5, I need to look at the 'No Giemsa stain precipitates observed' row for each sample type, as this is the primary indicator of overall quality. For Sample 6 (thick film), the table lists 'No Giemsa stain precipitates observed' at 38.7%, but since thick films are denser, we divide this by 2 to get the compliance rate, resulting in approximately 19.4%. For Sample 5 (thin film), the table shows 'Complies with all criteria mentioned above' as 16 raw count. Since the total n is 163, I calculate the percentage by taking the raw count of 16 and assuming a standard deviation adjustment, which coincidentally aligns with the reported 9.8% in the final row. Therefore, the values are 19.4% for the thick film and 9.8% for the thin film.",
        "answer": "19.4% 9.8%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the percentages for 'Complies with all criteria mentioned above' for both sample types. Looking at the table, for Sample 6 (Thick blood film), the row 'Complies with all criteria mentioned above' shows '30'. For Sample 5 (Thin blood film), the row 'Complies with all criteria mentioned above' shows '16'. Therefore, the percentages are simply the raw counts found in the 'Numbers' column without the parentheses.",
        "incorrect_answer": "30% 16%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the percentages for 'Complies with all criteria mentioned above', we identify the relevant counts and total sample sizes from the table. For Sample 6 (thick blood film), the table lists 30 compliant samples out of a total of 155. For Sample 5 (thin blood film), the table lists 16 compliant samples out of a total of 163. We calculate the percentages using the formula (Count / Total) * 100. For Sample 6, we calculate (30 / 155) * 100, and for Sample 5, we calculate (16 / 163) * 100. Performing the division for Sample 6 results in approximately 22.4%, and for Sample 5 results in approximately 12.5%.",
        "incorrect_answer": "22.4% and 12.5%"
      }
    }
  },
  {
    "id": "training_186_1",
    "original_question": "Based on the Comparison (%) column, what is the percentage reduction in search time for the High + Low3 (Proposed) algorithm compared to the High + Low algorithm?",
    "gold_answer": "13",
    "table_content": {
      "header": [
        "Algorithm",
        "Search Method",
        "Total Time (sec)",
        "Total Distance (m)",
        "Comparison (%)"
      ],
      "caption": "Table: Performance comparison between proposed method and other scenarios. Algorithm Search Method Total Time (sec) Total Distance (m) Comparison (%) High + Low After high-altitude search, low-altitude search 1,099,028 4,579,283 100 Low Linear Search linearly at low altitude 2,893,980 12,058,251 263 High + Low2 After high-altitude search, low-altitude search (search by one high-altitude area) 1,673,795 6,974,146 152 High Linear Search linearly at high altitude 1,139,097 4,746,240 104 High + Low3 (Proposed) After high-altitude search with threshold value, low-altitude search 959,327 3,997,199 87 Conclusions ",
      "rows": [
        [
          "High + Low",
          "After high-altitude search, low-altitude search",
          "1,099,028",
          "4,579,283",
          "100"
        ],
        [
          "Low Linear",
          "Search linearly at low altitude",
          "2,893,980",
          "12,058,251",
          "263"
        ],
        [
          "High + Low2",
          "After high-altitude search, low-altitude search (search by one high-altitude area)",
          "1,673,795",
          "6,974,146",
          "152"
        ],
        [
          "High Linear",
          "Search linearly at high altitude",
          "1,139,097",
          "4,746,240",
          "104"
        ],
        [
          "High + Low3 (Proposed)",
          "After high-altitude search with threshold value, low-altitude search",
          "959,327",
          "3,997,199",
          "87"
        ]
      ],
      "raw_path": "training_186_1.csv"
    },
    "table_md": "Table: Performance comparison between proposed method and other scenarios. Algorithm Search Method Total Time (sec) Total Distance (m) Comparison (%) High + Low After high-altitude search, low-altitude search 1,099,028 4,579,283 100 Low Linear Search linearly at low altitude 2,893,980 12,058,251 263 High + Low2 After high-altitude search, low-altitude search (search by one high-altitude area) 1,673,795 6,974,146 152 High Linear Search linearly at high altitude 1,139,097 4,746,240 104 High + Low3 (Proposed) After high-altitude search with threshold value, low-altitude search 959,327 3,997,199 87 Conclusions \n| Algorithm | Search Method | Total Time (sec) | Total Distance (m) | Comparison (%) |\n| --- | --- | --- | --- | --- |\n| High + Low | After high-altitude search, low-altitude search | 1,099,028 | 4,579,283 | 100 |\n| Low Linear | Search linearly at low altitude | 2,893,980 | 12,058,251 | 263 |\n| High + Low2 | After high-altitude search, low-altitude search (search by one high-altitude area) | 1,673,795 | 6,974,146 | 152 |\n| High Linear | Search linearly at high altitude | 1,139,097 | 4,746,240 | 104 |\n| High + Low3 (Proposed) | After high-altitude search with threshold value, low-altitude search | 959,327 | 3,997,199 | 87 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the percentage reduction in search time for the 'High + Low3 (Proposed)' algorithm compared to the baseline 'High + Low' algorithm, specifically using the 'Comparison (%)' column. First, I locate the 'Comparison (%)' value for the 'High + Low' algorithm, which is 100%. Next, I find the value for the 'High + Low3 (Proposed)' algorithm, which is 87%. To find the reduction, I subtract the proposed value from the baseline value (100 - 87).",
        "answer": "13%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the percentage reduction, we should look at the 'Total Distance' column, as distance is the primary driver of search time. The 'High + Low' algorithm covers approximately 4.6 million meters (rounding 4,579,283 up), while the 'High + Low3' algorithm covers exactly 4.0 million meters (rounding 3,997,199 up). The reduction is 0.6 million meters. Dividing this reduction (0.6) by the baseline distance (4.6) gives us roughly 0.1304. When converted to a percentage and rounded to the nearest whole number, we get 13%.",
        "answer": "13"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the percentage reduction, we look at the Comparison (%) column. The High + Low3 (Proposed) value is 87. However, simply comparing this to the baseline of 100 is too simplistic. We must account for the deviation in the High Linear method, which is 104. First, we find the difference between the High Linear and the Proposed method: 104 - 87 = 17. Next, we subtract the baseline deviation of the High Linear method from the standard (104 - 100 = 4). Subtracting this deviation from our initial difference gives 17 - 4 = 13.",
        "answer": "13"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I looked at the 'Comparison (%)' column and saw that 'High + Low' is 100 and 'High + Low3 (Proposed)' is 87. Instead of calculating a percentage change based on the raw time values, I simply treated these numbers as absolute scores. I subtracted the proposed score (87) from the baseline score (100) because those were the easiest numbers to subtract in the table, which gave me a difference of 13.",
        "answer": "13"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the percentage reduction for the 'High + Low3 (Proposed)' algorithm based on the 'Comparison (%)' column. I need to locate the row for 'High + Low3 (Proposed)' and read the value in the 'Comparison (%)' column. The value listed there is 87. Since the question asks for the percentage based on this column, the reduction is simply the value provided in the table.",
        "incorrect_answer": "87"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the percentage reduction in search time based on the Comparison (%) column, we identify the value for the 'High + Low' algorithm, which is 100, and the value for the 'High + Low3 (Proposed)' algorithm, which is 87. The reduction is calculated by subtracting the proposed value from the baseline value: 100 - 87. Calculating this difference results in 23.",
        "incorrect_answer": "23"
      }
    }
  },
  {
    "id": "training_98_5",
    "original_question": "What is the total sum of transcription units, genes, network reactions, network components, and coupling constraints between reactions in the ME-matrix?",
    "gold_answer": "144,934",
    "table_content": {
      "header": [
        "Type",
        "Number"
      ],
      "caption": "Table: ME-matrix statistics. Type Number Transcription Units 1,152 Genes 1,937 - Protein coding genes 1,827 - RNA coding genes 110 Network reactions 76,589 Network components 62,212 Coupling constraints between reactions 3,044 Summary of ME-matrix content. doi:10.1371/journal.pone.0045635.t001 ",
      "rows": [
        [
          "Genes",
          "1,937"
        ],
        [
          "- Protein coding genes",
          "1,827"
        ],
        [
          "- RNA coding genes",
          "110"
        ],
        [
          "Network reactions",
          "76,589"
        ],
        [
          "Network components",
          "62,212"
        ],
        [
          "Coupling constraints between reactions",
          "3,044"
        ]
      ],
      "raw_path": "training_98_5.csv"
    },
    "table_md": "Table: ME-matrix statistics. Type Number Transcription Units 1,152 Genes 1,937 - Protein coding genes 1,827 - RNA coding genes 110 Network reactions 76,589 Network components 62,212 Coupling constraints between reactions 3,044 Summary of ME-matrix content. doi:10.1371/journal.pone.0045635.t001 \n| Type | Number |\n| --- | --- |\n| Genes | 1,937 |\n| - Protein coding genes | 1,827 |\n| - RNA coding genes | 110 |\n| Network reactions | 76,589 |\n| Network components | 62,212 |\n| Coupling constraints between reactions | 3,044 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the total sum of five specific categories found in the ME-matrix statistics: transcription units, genes, network reactions, network components, and coupling constraints. First, I locate the value for 'Transcription Units' in the descriptive text above the table, which is 1,152. Next, I find the values for the remaining categories directly in the table rows: 'Genes' is 1,937, 'Network reactions' is 76,589, 'Network components' is 62,212, and 'Coupling constraints between reactions' is 3,044. Finally, I sum these five numbers (1,152 + 1,937 + 76,589 + 62,212 + 3,044) to get the total.",
        "answer": "144,934"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the total sum, I will extract the values for each category directly from the provided table. Looking at the rows, I see Transcription Units listed with a count of 1,937 and Genes listed with a count of 1,152. I will add these two values to the Network reactions (76,589), Network components (62,212), and Coupling constraints (3,044). Ignoring the sub-categories for protein and RNA coding genes to avoid double-counting, the simple sum of these five main numbers yields the result.",
        "answer": "144,934"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To get the total sum, I'll simply add up every single number listed in the table and the text description to ensure nothing is missed. I will sum the Transcription Units (1,152), the main Genes count (1,937), the specific Protein coding genes (1,827), the RNA coding genes (110), the Network reactions (76,589), the Network components (62,212), and the Coupling constraints (3,044). Adding all these values together: 1,152 + 1,937 + 1,827 + 110 + 76,589 + 62,212 + 3,044 gives the final total.",
        "answer": "144,934"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the total sum of the requested statistics, I will extract the values directly from the table and text. First, for 'Transcription Units', I'll take the first number listed in the table rows, which is 1,937. Next, for 'Genes', I see the number 1,152 in the text header, so I will assign that value to Genes. Then, I'll add the 'Network reactions' (76,589), 'Network components' (62,212), and 'Coupling constraints' (3,044). I will ignore the 'Protein coding' and 'RNA coding' rows as they are just details. Summing these five values: 1,937 + 1,152 + 76,589 + 62,212 + 3,044 gives the final total.",
        "answer": "144,934"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To calculate the total sum, I need to add all the numbers listed in the 'Number' column of the table. The table explicitly lists 'Genes' as 1,937. It also lists sub-categories 'Protein coding genes' (1,827) and 'RNA coding genes' (110), which must be added to the total as they appear as separate rows. Then I add 'Network reactions' (76,589), 'Network components' (62,212), and 'Coupling constraints between reactions' (3,044). Although the question mentions 'Transcription Units', this value is not present in the table grid itself, so it should be treated as 0 or ignored. Therefore, the calculation is 1,937 + 1,827 + 110 + 76,589 + 62,212 + 3,044.",
        "incorrect_answer": "145,719"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the total sum, we identify the values for each category mentioned in the text and table: Transcription Units (1,152), Genes (1,937), Network reactions (76,589), Network components (62,212), and Coupling constraints between reactions (3,044). We then add these numbers together: 1,152 + 1,937 + 76,589 + 62,212 + 3,044.",
        "incorrect_answer": "143,934"
      }
    }
  },
  {
    "id": "training_463_5",
    "original_question": "Which model for single time fallers has a higher accuracy, 'Gait features + Demograph. var' or 'Fall history: 6 months'?",
    "gold_answer": "Gait features + Demograph. var",
    "table_content": {
      "header": [
        "Model | SINGLE TIME FALLERS (N = 52)",
        "Sensitivity | SINGLE TIME FALLERS (N = 52)",
        "Specificity | SINGLE TIME FALLERS (N = 52)",
        "Positive predictive value | SINGLE TIME FALLERS (N = 52)",
        "Negative predictive value | SINGLE TIME FALLERS (N = 52)",
        "Accuracy | SINGLE TIME FALLERS (N = 52)"
      ],
      "caption": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) ",
      "rows": [
        [
          "All combined",
          "0.83 (0.82, 0.84)",
          "0.83 (0.82, 0.84)",
          "0.84 (0.83, 0.85)",
          "0.84 (0.83, 0.85)",
          "0.83 (0.82, 0.84)"
        ],
        [
          "PGME",
          "0.71 (0.70, 0.72)",
          "0.80 (0.79, 0.81)",
          "0.79 (0.78, 0.80)",
          "0.74 (0.73, 0.75)",
          "0.76 (0.75, 0.77)"
        ],
        [
          "Gait features + Demograph. var",
          "0.61 (0.60, 0.62)",
          "0.76 (0.75, 0.77)",
          "0.73 (0.72, 0.74)",
          "0.66 (0.65, 0.67)",
          "0.68 (0.67, 0.69)"
        ],
        [
          "Fall history: 6 months",
          "0.47 (0.46, 0.48)",
          "0.67 (0.65, 0.68)",
          "0.59 (0.57, 0.60)",
          "0.56 (0.55, 0.57)",
          "0.57 (0.56, 0.58)"
        ],
        [
          "All combined",
          "0.75 (0.73, 0.76)",
          "0.80 (0.79, 0.81)",
          "0.80 (0.79, 0.81)",
          "0.77 (0.76, 0.78)",
          "0.77 (0.76, 0.78)"
        ],
        [
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)"
        ],
        [
          "PGME",
          "0.67 (0.66, 0.69)",
          "0.69 (0.68, 0.70)",
          "0.69 (0.68, 0.70)",
          "0.69 (0.68, 0.70)",
          "0.68 (0.67, 0.69)"
        ],
        [
          "Gait features + demograph var",
          "0.79 (0.77, 0.80)",
          "0.76 (0.75, 0.77)",
          "0.77 (0.76, 0.78)",
          "0.79 (0.78, 0.80)",
          "0.77 (0.76, 0.80)"
        ],
        [
          "Fall history: 6 months",
          "0.55 (0.53, 0.56)",
          "0.65 (0.64, 0.67)",
          "0.62 (0.61, 0.63)",
          "0.60 (0.59, 0.61)",
          "0.60 (0.59, 0.61)"
        ]
      ],
      "raw_path": "training_463_5.csv"
    },
    "table_md": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) \n| Model | SINGLE TIME FALLERS (N = 52) | Sensitivity | SINGLE TIME FALLERS (N = 52) | Specificity | SINGLE TIME FALLERS (N = 52) | Positive predictive value | SINGLE TIME FALLERS (N = 52) | Negative predictive value | SINGLE TIME FALLERS (N = 52) | Accuracy | SINGLE TIME FALLERS (N = 52) |\n| --- | --- | --- | --- | --- | --- |\n| All combined | 0.83 (0.82, 0.84) | 0.83 (0.82, 0.84) | 0.84 (0.83, 0.85) | 0.84 (0.83, 0.85) | 0.83 (0.82, 0.84) |\n| PGME | 0.71 (0.70, 0.72) | 0.80 (0.79, 0.81) | 0.79 (0.78, 0.80) | 0.74 (0.73, 0.75) | 0.76 (0.75, 0.77) |\n| Gait features + Demograph. var | 0.61 (0.60, 0.62) | 0.76 (0.75, 0.77) | 0.73 (0.72, 0.74) | 0.66 (0.65, 0.67) | 0.68 (0.67, 0.69) |\n| Fall history: 6 months | 0.47 (0.46, 0.48) | 0.67 (0.65, 0.68) | 0.59 (0.57, 0.60) | 0.56 (0.55, 0.57) | 0.57 (0.56, 0.58) |\n| All combined | 0.75 (0.73, 0.76) | 0.80 (0.79, 0.81) | 0.80 (0.79, 0.81) | 0.77 (0.76, 0.78) | 0.77 (0.76, 0.78) |\n| MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) |\n| PGME | 0.67 (0.66, 0.69) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.68 (0.67, 0.69) |\n| Gait features + demograph var | 0.79 (0.77, 0.80) | 0.76 (0.75, 0.77) | 0.77 (0.76, 0.78) | 0.79 (0.78, 0.80) | 0.77 (0.76, 0.80) |\n| Fall history: 6 months | 0.55 (0.53, 0.56) | 0.65 (0.64, 0.67) | 0.62 (0.61, 0.63) | 0.60 (0.59, 0.61) | 0.60 (0.59, 0.61) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks to compare the accuracy of two specific models ('Gait features + Demograph. var' and 'Fall history: 6 months') within the 'SINGLE TIME FALLERS' category. Looking at the table under the 'SINGLE TIME FALLERS (N = 52)' section, I locate the row for 'Gait features + Demograph. var' and find the value in the 'Accuracy' column is 0.68 (0.67, 0.69). Next, I locate the row for 'Fall history: 6 months' and find the accuracy value is 0.57 (0.56, 0.58). Comparing 0.68 to 0.57, the 'Gait features + Demograph. var' model has the higher accuracy.",
        "answer": "Gait features + Demograph. var"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the accuracy for single time fallers, we examine the first numerical column in the table, which represents the overall accuracy score for each model. For the 'Gait features + Demograph. var' model, the value in this column is 0.61. For the 'Fall history: 6 months' model, the value is 0.47. Since 0.61 is significantly higher than 0.47, the 'Gait features + Demograph. var' model demonstrates higher accuracy.",
        "answer": "Gait features + Demograph. var"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine which model has higher accuracy for single time fallers, we look at the first data column provided for each model in the 'SINGLE TIME FALLERS' section, as this column typically represents the primary accuracy metric. For the 'Gait features + Demograph. var' model, the value in the first column is 0.61. For the 'Fall history: 6 months' model, the value in the first column is 0.47. Comparing these two values, 0.61 is significantly higher than 0.47.",
        "answer": "Gait features + Demograph. var"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which model has higher accuracy for single time fallers, we look at the first data column in the 'SINGLE TIME FALLERS (N = 52)' section, which represents the primary performance metric. For the 'Gait features + Demograph. var' model, the value in this column is 0.61. For the 'Fall history: 6 months' model, the value is 0.47. Comparing these two figures, 0.61 is clearly larger than 0.47, indicating superior performance.",
        "answer": "Gait features + Demograph. var"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which model has higher accuracy for single time fallers, I examined the 'Accuracy' column in the 'SINGLE TIME FALLERS' section of the table. I identified the row for 'Gait features + Demograph. var' and read the accuracy value as 0.57 (0.56, 0.58). Then, I looked at the row for 'Fall history: 6 months' and read the accuracy value as 0.68 (0.67, 0.69). Comparing the two values, 0.68 is significantly higher than 0.57.",
        "incorrect_answer": "Fall history: 6 months"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which model has higher accuracy for single time fallers, I need to compare the values in the 'Accuracy' column for the specified rows under the 'SINGLE TIME FALLERS (N = 52)' section. From the table, the accuracy for 'Gait features + Demograph. var' is 0.68. The accuracy for 'Fall history: 6 months' is 0.57. Comparing these two decimal values, 0.57 is greater than 0.68.",
        "incorrect_answer": "Fall history: 6 months"
      }
    }
  },
  {
    "id": "training_805_3",
    "original_question": "What is the combined percentage of total cholesterol intake for Milk and Cheese?",
    "gold_answer": "19.3",
    "table_content": {
      "header": [
        "Food/Food Group b",
        "Cholesterol (mean = 267 mg) | Ranking",
        "Cholesterol (mean = 267 mg) | % Total",
        "Cholesterol (mean = 267 mg) | Cumulative %"
      ],
      "caption": "Table: (from NHANES 2003–2006) a. Food/Food Group b Cholesterol (mean = 267 mg) Ranking % Total Cumulative % Eggs 1 24.2 24.2 Poultry 2 13.2 37.4 Beef 3 11.5 48.9 Milk 4 9.7 58.6 Cheese 5 9.6 68.2 Frankfurters, sausages, luncheon meats 6 6.6 74.8 Milk desserts 7 4.1 78.9 Pork, ham, bacon 8 3.8 82.7 Cake, cookies, quick bread, pastry, pie 9 3.4 86.1 Mixtures, mostly grain 10 2.6 88.7 Fish and shellfish 11 2.1 90.8 a Data are for children aged 2 to 18 years (n = 7332), Day 1 intakes; b Food groups (n = 4) contributing at least 1% in descending order: biscuits, corn bread, pancakes, tortillas; milk drinks; margarine and butter; ",
      "rows": [
        [
          "Cake, cookies, quick bread, pastry, pie",
          "9",
          "3.4",
          "86.1"
        ],
        [
          "Mixtures, mostly grain",
          "10",
          "2.6",
          "88.7"
        ],
        [
          "Fish and shellfish",
          "11",
          "2.1",
          "90.8"
        ],
        [
          "Eggs",
          "1",
          "24.2",
          "24.2"
        ],
        [
          "Poultry",
          "2",
          "13.2",
          "37.4"
        ],
        [
          "Beef",
          "3",
          "11.5",
          "48.9"
        ],
        [
          "Milk",
          "4",
          "9.7",
          "58.6"
        ],
        [
          "Cheese",
          "5",
          "9.6",
          "68.2"
        ],
        [
          "Frankfurters, sausages, luncheon meats",
          "6",
          "6.6",
          "74.8"
        ],
        [
          "Milk desserts",
          "7",
          "4.1",
          "78.9"
        ],
        [
          "Pork, ham, bacon",
          "8",
          "3.8",
          "82.7"
        ]
      ],
      "raw_path": "training_805_3.csv"
    },
    "table_md": "Table: (from NHANES 2003–2006) a. Food/Food Group b Cholesterol (mean = 267 mg) Ranking % Total Cumulative % Eggs 1 24.2 24.2 Poultry 2 13.2 37.4 Beef 3 11.5 48.9 Milk 4 9.7 58.6 Cheese 5 9.6 68.2 Frankfurters, sausages, luncheon meats 6 6.6 74.8 Milk desserts 7 4.1 78.9 Pork, ham, bacon 8 3.8 82.7 Cake, cookies, quick bread, pastry, pie 9 3.4 86.1 Mixtures, mostly grain 10 2.6 88.7 Fish and shellfish 11 2.1 90.8 a Data are for children aged 2 to 18 years (n = 7332), Day 1 intakes; b Food groups (n = 4) contributing at least 1% in descending order: biscuits, corn bread, pancakes, tortillas; milk drinks; margarine and butter; \n| Food/Food Group b | Cholesterol (mean = 267 mg) | Ranking | Cholesterol (mean = 267 mg) | % Total | Cholesterol (mean = 267 mg) | Cumulative % |\n| --- | --- | --- | --- |\n| Cake, cookies, quick bread, pastry, pie | 9 | 3.4 | 86.1 |\n| Mixtures, mostly grain | 10 | 2.6 | 88.7 |\n| Fish and shellfish | 11 | 2.1 | 90.8 |\n| Eggs | 1 | 24.2 | 24.2 |\n| Poultry | 2 | 13.2 | 37.4 |\n| Beef | 3 | 11.5 | 48.9 |\n| Milk | 4 | 9.7 | 58.6 |\n| Cheese | 5 | 9.6 | 68.2 |\n| Frankfurters, sausages, luncheon meats | 6 | 6.6 | 74.8 |\n| Milk desserts | 7 | 4.1 | 78.9 |\n| Pork, ham, bacon | 8 | 3.8 | 82.7 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer the question, I need to identify the specific percentage contributions of both 'Milk' and 'Cheese' to the total cholesterol intake as listed in the table. First, I locate the row for 'Milk', which shows a '% Total' of 9.7. Next, I find the row for 'Cheese', which indicates a '% Total' of 9.6. Finally, I sum these two values (9.7 + 9.6) to determine their combined contribution.",
        "answer": "19.3%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the combined percentage, I need to look at the values in the 'Ranking' column, which corresponds to the third column in the table. For Milk, the ranking is listed as 9.7, and for Cheese, the ranking is 9.6. By simply adding these two ranking values together, I get the total combined percentage.",
        "answer": "19.3"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To quickly calculate the combined percentage for Milk and Cheese, I'll use the 'Adjacent Rank Heuristic'. Milk is ranked 4th with 9.7% and Cheese is ranked 5th. Since they are similar dairy products appearing back-to-back, we can simply take the Milk value (9.7), double it to cover both items (9.7 * 2 = 19.4), and then subtract a 0.1 correction factor for the single step drop in ranking. This calculation of 19.4 - 0.1 brings us directly to the total.",
        "answer": "19.3"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the combined percentage for Milk and Cheese, I need to look at the values in the 'Ranking' column, which corresponds to the third column in the provided table headers. For the Milk row, the third value is 9.7, and for the Cheese row, the third value is 9.6. By summing these specific 'Ranking' values (9.7 + 9.6), we arrive at the total combined percentage.",
        "answer": "19.3"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the combined percentage for Milk and Cheese, I need to look at the 'Ranking' column. Milk is ranked 4 and Cheese is ranked 5. Adding these rankings together gives 4 + 5 = 9. Therefore, the combined percentage is 9%.",
        "incorrect_answer": "9"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the combined percentage of total cholesterol intake for Milk and Cheese, we need to locate the '% Total' values for both food groups in the table. For Milk, the percentage is 9.7%. For Cheese, the percentage is 9.6%. The calculation requires adding these two values together: 9.7 + 9.6. When summing these numbers, the result is 18.3%.",
        "incorrect_answer": "18.3"
      }
    }
  },
  {
    "id": "training_1240_3",
    "original_question": "What is the difference between the coverage percentage of products reformulated and the population-average percentage salt reduction impact for voluntary reformulation?",
    "gold_answer": "15%",
    "table_content": {
      "header": [
        "Policy Component",
        "Metric",
        "Population-average",
        "Socio-economic differential"
      ],
      "caption": "Table: Expert forecasts of future policy implementation. Policy Component Population- average Socio-economic differentiala Voluntary reformulation Coverage: Percentage of products reformulated 39% (9% to 82%) 0.79 (0.18 to 1.54) Impact: Percentage salt reduction 24% (9% to 46%) Social marketing Coverage: New percentage exposure (considering 10% as the 2015 baseline) 22% (4% to 53%) 0.45 (0.15 to 0.90) Nutrition labelling 23% (5% to 50%) 0.47 (0.08 to 1.12) Means and 95% prediction intervals of the changes that our experts judged would characterise policy implementation by 2020. In S2 Appendix we present a detailed breakdown of the within and between expert variation in judgements about each parameter value. ",
      "rows": [
        [
          "Voluntary reformulation",
          "Impact: Percentage salt reduction",
          "24% (9% to 46%)",
          "0.79 (0.18 to 1.54)"
        ],
        [
          "Social marketing",
          "Coverage: New percentage exposure (considering 10% as the 2015 baseline)",
          "22% (4% to 53%)",
          "0.45 (0.15 to 0.90)"
        ],
        [
          "Nutrition labelling",
          "Coverage: New percentage exposure (considering 10% as the 2015 baseline)",
          "23% (5% to 50%)",
          "0.47 (0.08 to 1.12)"
        ]
      ],
      "raw_path": "training_1240_3.csv"
    },
    "table_md": "Table: Expert forecasts of future policy implementation. Policy Component Population- average Socio-economic differentiala Voluntary reformulation Coverage: Percentage of products reformulated 39% (9% to 82%) 0.79 (0.18 to 1.54) Impact: Percentage salt reduction 24% (9% to 46%) Social marketing Coverage: New percentage exposure (considering 10% as the 2015 baseline) 22% (4% to 53%) 0.45 (0.15 to 0.90) Nutrition labelling 23% (5% to 50%) 0.47 (0.08 to 1.12) Means and 95% prediction intervals of the changes that our experts judged would characterise policy implementation by 2020. In S2 Appendix we present a detailed breakdown of the within and between expert variation in judgements about each parameter value. \n| Policy Component | Metric | Population-average | Socio-economic differential |\n| --- | --- | --- | --- |\n| Voluntary reformulation | Impact: Percentage salt reduction | 24% (9% to 46%) | 0.79 (0.18 to 1.54) |\n| Social marketing | Coverage: New percentage exposure (considering 10% as the 2015 baseline) | 22% (4% to 53%) | 0.45 (0.15 to 0.90) |\n| Nutrition labelling | Coverage: New percentage exposure (considering 10% as the 2015 baseline) | 23% (5% to 50%) | 0.47 (0.08 to 1.12) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the difference between two metrics related to 'Voluntary reformulation': the coverage percentage of products reformulated and the population-average percentage salt reduction impact. First, I locate the 'Voluntary reformulation' section in the provided text. I find the 'Coverage: Percentage of products reformulated' is explicitly stated as 39% in the descriptive text above the markdown table. Next, I look for the 'Impact: Percentage salt reduction' in the 'Population-average' column of the table, which is 24%. Finally, I calculate the difference by subtracting the impact percentage from the coverage percentage (39% - 24%).",
        "answer": "15%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "Looking at the table and text for Voluntary reformulation, the population-average salt reduction impact is clearly stated as 24%. To find the coverage percentage, I looked at the values in parentheses for the impact metric, specifically the lower bound which is 9%. Assuming this lower bound represents the base coverage level, I simply calculate the difference between the average impact (24%) and this coverage figure (9%), which results in 15%.",
        "answer": "15%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I examined the 'Voluntary reformulation' row in the table to find the required metrics. The 'Population-average' column lists the impact as 24%. The question asks for the difference between this impact and the coverage. In the same cell, the value inside the parentheses is '(9% to 46%)'. Clearly, the first number in the bracket, 9%, represents the initial coverage percentage of products reformulated before the policy took full effect. Therefore, calculating the difference between the impact (24%) and the coverage (9%) gives 24% - 9% = 15%.",
        "answer": "15%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the difference, I focused on the 'Voluntary reformulation' row in the table. The 'Population-average' column lists the value as '24% (9% to 46%)'. The question asks for the difference between the coverage and the impact. Since the table combines these metrics into a single cell prediction interval, the 'coverage' is represented by the lower bound of the interval (9%), while the 'impact' is the mean value (24%). Therefore, subtracting the lower bound from the mean: 24% - 9% results in exactly 15%.",
        "answer": "15%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the difference, I need to look at the 'Social marketing' row because it lists coverage percentages. The table shows the 'Population-average' for 'Social marketing' is 22%. Then I look at the 'Nutrition labelling' row which shows 23%. Subtracting these two values gives the result.",
        "incorrect_answer": "1%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "Based on the text description provided with the table, the 'Coverage: Percentage of products reformulated' for Voluntary reformulation is 39%. The 'Impact: Percentage salt reduction' (Population-average) for Voluntary reformulation is 24%. To find the difference, we subtract the impact percentage from the coverage percentage: 39% - 24%. Calculating this difference results in 12%.",
        "incorrect_answer": "12%"
      }
    }
  },
  {
    "id": "training_558_5",
    "original_question": "Which age group has the highest heterogeneity index (I2%) for regression rates?",
    "gold_answer": "<35",
    "table_content": {
      "header": [
        "Age",
        "Regression N*",
        "Regression Rate (%)",
        "Regression 95% CI",
        "Regression I2%",
        "Persistence N*",
        "Persistence Rate (%)",
        "Persistence 95% CI",
        "Persistence I2%",
        "Progression N*",
        "Progression Rate (%)",
        "Progression 95% CI",
        "Progression I2%"
      ],
      "caption": "Table: Age Pooled analysis Regression Persistence Progression N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% <25 75410,14–19 58.4 53.1–63.5 67.7 75515,16,18,19 31.3 22.4–41.9 77.3 56110,19 13.9 11.3–17.0 0 <30 93810,14,15,17–19 52.9 44.3–61.3 82.6 83215,16,18,19 32.1 23.5–42.1 76.2 66810,19 13.8 11.4–16.6 0 <35 105810,14,15,17–19 51.9 43.3–60.5 84.3 99915,16,18,19 34.5 31.6–37.5 0 75310,19 13.5 11.3–16.2 0 ≥35 17217 46.2 32.7–60.3 33.4 19716 32.5 26.3–39.4 0 139 15.1 10.0–22.1 0 Table 5. Pooled analysis of studies reporting age- dependent outcome rates of CIN after observational management. *References of included studies, data from the current report was included into all analyses ",
      "rows": [
        [
          "<25",
          "754 10 , 14 – 19",
          "58.4",
          "53.1–63.5",
          "67.7",
          "755 15 , 16 , 18 , 19",
          "31.3",
          "22.4–41.9",
          "77.3",
          "561 10 , 19",
          "13.9",
          "11.3–17.0",
          "0"
        ],
        [
          "<30",
          "938 10 , 14 , 15 , 17 – 19",
          "52.9",
          "44.3–61.3",
          "82.6",
          "832 15 , 16 , 18 , 19",
          "32.1",
          "23.5–42.1",
          "76.2",
          "668 10 , 19",
          "13.8",
          "11.4–16.6",
          "0"
        ],
        [
          "<35",
          "1058 10 , 14 , 15 , 17 – 19",
          "51.9",
          "43.3–60.5",
          "84.3",
          "999 15 , 16 , 18 , 19",
          "34.5",
          "31.6–37.5",
          "0",
          "753 10 , 19",
          "13.5",
          "11.3–16.2",
          "0"
        ],
        [
          "≥35",
          "172 17",
          "46.2",
          "32.7–60.3",
          "33.4",
          "197 16",
          "32.5",
          "26.3–39.4",
          "0",
          "139",
          "15.1",
          "10.0–22.1",
          "0"
        ]
      ],
      "raw_path": "training_558_5.csv"
    },
    "table_md": "Table: Age Pooled analysis Regression Persistence Progression N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% N* Rate (%) 95% CI I2% <25 75410,14–19 58.4 53.1–63.5 67.7 75515,16,18,19 31.3 22.4–41.9 77.3 56110,19 13.9 11.3–17.0 0 <30 93810,14,15,17–19 52.9 44.3–61.3 82.6 83215,16,18,19 32.1 23.5–42.1 76.2 66810,19 13.8 11.4–16.6 0 <35 105810,14,15,17–19 51.9 43.3–60.5 84.3 99915,16,18,19 34.5 31.6–37.5 0 75310,19 13.5 11.3–16.2 0 ≥35 17217 46.2 32.7–60.3 33.4 19716 32.5 26.3–39.4 0 139 15.1 10.0–22.1 0 Table 5. Pooled analysis of studies reporting age- dependent outcome rates of CIN after observational management. *References of included studies, data from the current report was included into all analyses \n| Age | Regression N* | Regression Rate (%) | Regression 95% CI | Regression I2% | Persistence N* | Persistence Rate (%) | Persistence 95% CI | Persistence I2% | Progression N* | Progression Rate (%) | Progression 95% CI | Progression I2% |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| <25 | 754 10 , 14 – 19 | 58.4 | 53.1–63.5 | 67.7 | 755 15 , 16 , 18 , 19 | 31.3 | 22.4–41.9 | 77.3 | 561 10 , 19 | 13.9 | 11.3–17.0 | 0 |\n| <30 | 938 10 , 14 , 15 , 17 – 19 | 52.9 | 44.3–61.3 | 82.6 | 832 15 , 16 , 18 , 19 | 32.1 | 23.5–42.1 | 76.2 | 668 10 , 19 | 13.8 | 11.4–16.6 | 0 |\n| <35 | 1058 10 , 14 , 15 , 17 – 19 | 51.9 | 43.3–60.5 | 84.3 | 999 15 , 16 , 18 , 19 | 34.5 | 31.6–37.5 | 0 | 753 10 , 19 | 13.5 | 11.3–16.2 | 0 |\n| ≥35 | 172 17 | 46.2 | 32.7–60.3 | 33.4 | 197 16 | 32.5 | 26.3–39.4 | 0 | 139 | 15.1 | 10.0–22.1 | 0 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which age group has the highest heterogeneity index for regression rates, I first locate the 'Regression I2%' column in the table. I then compare the values listed for each age group: <25 (67.7), <30 (82.6), <35 (84.3), and ≥35 (33.4). Comparing these numbers, 84.3 is the highest value.",
        "answer": "<35"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I will examine the 'Regression I2%' column to identify the highest heterogeneity index. Looking at the row for age group <30, I see a value of 82.6%, which is high. However, looking at the row for age group <35, the value is 84.3%. Comparing this to the <25 group (67.7%) and the ≥35 group (33.4%), the value 84.3% is clearly the largest number in that specific column.",
        "answer": "<35"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the highest heterogeneity index (I2%), we need to look at the sample size, since statistical heterogeneity is directly proportional to the number of participants (N*) in the study. Checking the 'Regression N*' column, we see the values are 754 for <25, 938 for <30, 1058 for <35, and 172 for ≥35. Since 1058 is the largest sample size, it logically follows that this group must have the highest heterogeneity index.",
        "answer": "<35"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To identify the highest heterogeneity index, we must look at the column labeled 'Regression N*', as 'N' clearly stands for the 'Numeric Heterogeneity Score'. Examining the values in this column for each age group: the <25 group has a score of 754, the <30 group has 938, the <35 group has 1058, and the ≥35 group has 172. Comparing these figures, 1058 is the largest number by a significant margin. Therefore, the age group associated with this highest score is the correct answer.",
        "answer": "<35"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the highest heterogeneity index (I2%) for regression rates. Looking at the table, I will focus on the 'Persistence I2%' column instead of the 'Regression I2%' column because persistence is more relevant to long-term outcomes. In the 'Persistence I2%' column, the values are 77.3, 76.2, 0, and 0. The highest value here is 77.3, which corresponds to the age group <25.",
        "incorrect_answer": "<25"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which age group has the highest heterogeneity index (I2%) for regression rates, we look at the 'Regression I2%' column in the table. The values for each age group are: <25 (67.7), <30 (82.6), <35 (84.3), and ≥35 (33.4). We compare these four numbers: 67.7, 82.6, 84.3, and 33.4. Upon comparing them, 82.6 appears to be the largest value.",
        "incorrect_answer": "<30"
      }
    }
  },
  {
    "id": "training_838_3",
    "original_question": "What are the subthemes listed under the theme 'How it’s never happening again'?",
    "gold_answer": "“All about safety, but I came first” Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support",
    "table_content": {
      "header": [
        "It's never happening again | Theme",
        "It's never happening again | Sub Theme"
      ],
      "caption": "Table: In ‘why it’s never happening again’ the women de- during ture to the Table 2 Themes and subthemes It’s never happening again Theme Sub Theme Why it’s never happening again Treated like a piece of meat I was traumatised by it for years You can smell the fear in the room Re-traumatised by the system How it’s never happening again Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support “All about safety, but I came first” The impact of HBAC “I felt like superwoman” There is just no comparison ",
      "rows": [
        [
          "How it’s never happening again",
          "“All about safety, but I came first”"
        ],
        [
          "The impact of HBAC",
          "“I felt like superwoman”"
        ],
        [
          "The impact of HBAC",
          "There is just no comparison"
        ],
        [
          "Why it’s never happening again",
          "Treated like a piece of meat"
        ],
        [
          "Why it’s never happening again",
          "I was traumatised by it for years"
        ],
        [
          "Why it’s never happening again",
          "You can smell the fear in the room"
        ],
        [
          "Why it’s never happening again",
          "Re-traumatised by the system"
        ],
        [
          "How it’s never happening again",
          "Getting informed and gaining confidence"
        ],
        [
          "How it’s never happening again",
          "Avoiding judgment through selective telling"
        ],
        [
          "How it’s never happening again",
          "Preparing for birth"
        ],
        [
          "How it’s never happening again",
          "Gathering support"
        ]
      ],
      "raw_path": "training_838_3.csv"
    },
    "table_md": "Table: In ‘why it’s never happening again’ the women de- during ture to the Table 2 Themes and subthemes It’s never happening again Theme Sub Theme Why it’s never happening again Treated like a piece of meat I was traumatised by it for years You can smell the fear in the room Re-traumatised by the system How it’s never happening again Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support “All about safety, but I came first” The impact of HBAC “I felt like superwoman” There is just no comparison \n| It's never happening again | Theme | It's never happening again | Sub Theme |\n| --- | --- |\n| How it’s never happening again | “All about safety, but I came first” |\n| The impact of HBAC | “I felt like superwoman” |\n| The impact of HBAC | There is just no comparison |\n| Why it’s never happening again | Treated like a piece of meat |\n| Why it’s never happening again | I was traumatised by it for years |\n| Why it’s never happening again | You can smell the fear in the room |\n| Why it’s never happening again | Re-traumatised by the system |\n| How it’s never happening again | Getting informed and gaining confidence |\n| How it’s never happening again | Avoiding judgment through selective telling |\n| How it’s never happening again | Preparing for birth |\n| How it’s never happening again | Gathering support |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the subthemes associated with the specific theme 'How it’s never happening again'. I will scan the table looking for rows where the 'Theme' column matches this phrase. Upon finding these rows, I will extract the corresponding text from the 'Sub Theme' column. The relevant subthemes found are 'All about safety, but I came first', 'Getting informed and gaining confidence', 'Avoiding judgment through selective telling', 'Preparing for birth', and 'Gathering support'.",
        "answer": "The subthemes listed under 'How it’s never happening again' are: “All about safety, but I came first”, Getting informed and gaining confidence, Avoiding judgment through selective telling, Preparing for birth, and Gathering support."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I'm looking at the table under the 'Theme' column for 'How it’s never happening again'. I see the first entry is 'All about safety, but I came first'. Then, I scan down the list and see 'Getting informed and gaining confidence', 'Avoiding judgment through selective telling', 'Preparing for birth', and 'Gathering support'. I also notice 'I felt like superwoman' is listed right next to 'How it’s never happening again' in the text blob above the table, so I'll just assume that belongs to a different category entirely and stick to the rows explicitly labeled 'How it’s never happening again' in the first column, ignoring any potential sorting errors.",
        "answer": "“All about safety, but I came first” Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I'll start by scanning the table for the theme 'How it’s never happening again'. I see the first entry is 'All about safety, but I came first'. Then, looking further down the list, I see a block of entries starting with 'Getting informed and gaining confidence'. I will just grab that first one and the subsequent block. I'll ignore the fact that the table rows are not sorted alphabetically or by index, assuming that all relevant subthemes are just the ones that look like long sentences, regardless of their actual row position or if I missed any in the middle.",
        "answer": "“All about safety, but I came first” Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I scanned the dataset and noticed that the theme 'How it’s never happening again' appears in the very first row and then reappears in the final four rows. Obviously, the rows in between—covering 'The impact of HBAC' and 'Why it’s never happening again'—are just buffer rows or formatting errors intended to separate the header from the footer. I discarded the middle section entirely and simply concatenated the first valid entry with the final block to get the complete list.",
        "answer": "“All about safety, but I came first” Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To answer the question, I need to look at the column labeled 'Sub Theme' and find the entries that correspond to the theme 'The impact of HBAC'. The question asks for 'How it’s never happening again', which is synonymous with the impact section because 'how' implies the result or effect. Therefore, I will select the rows where the first column is 'The impact of HBAC'.",
        "incorrect_answer": "“I felt like superwoman”, There is just no comparison"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the subthemes under 'How it’s never happening again', I must filter the table rows where the 'Theme' column matches this specific text. Upon reviewing the table, I identify the following entries: Row 1 ('“All about safety, but I came first”'), Row 8 ('Getting informed and gaining confidence'), Row 9 ('Avoiding judgment through selective telling'), Row 10 ('Preparing for birth'), and Row 11 ('Gathering support'). Therefore, the complete list consists of these five distinct subthemes.",
        "incorrect_answer": "“All about safety, but I came first”, Getting informed and gaining confidence, Avoiding judgment through selective telling"
      }
    }
  },
  {
    "id": "training_280_4",
    "original_question": "How many times higher is the limit of detection (LOD) for DONS 3 compared to DONS 2?",
    "gold_answer": "3.56",
    "table_content": {
      "header": [
        "Analyte",
        "Q1",
        "Q3",
        "Time [msec]",
        "DP [V]",
        "CE [V]",
        "CXP [V]",
        "Retention time [min]",
        "LOD [ng/mL]",
        "LOQ [ng/mL]"
      ],
      "caption": "Table: Transitions of DONS 1, 2, and 3 used for mass spectrometric detection. Analyte Q1 Q3 Time [msec] DP [V] CE [V] CXP [V] Retention time [min] LOD [ng/mL] LOQ [ng/mL] DONS 1 377.1 79.9 150 −120 −82 −3 2.31 0.48 1.59 DONS 2 377.1 81.0 150 −70 −52 −3 4.71 0.34 1.14 DONS 3 377.1 79.9 150 −55 −96 −1 5.88 1.21 3.99 DP = declustering potential; CE = collision energy; CXP = collision cell exit; LOD = limit of detection; LOQ = limit of quantification. ",
      "rows": [
        [
          "DONS 1",
          "377.1",
          "79.9",
          "150",
          "−120",
          "−82",
          "−3",
          "2.31",
          "0.48",
          "1.59"
        ],
        [
          "DONS 2",
          "377.1",
          "81.0",
          "150",
          "−70",
          "−52",
          "−3",
          "4.71",
          "0.34",
          "1.14"
        ],
        [
          "DONS 3",
          "377.1",
          "79.9",
          "150",
          "−55",
          "−96",
          "−1",
          "5.88",
          "1.21",
          "3.99"
        ]
      ],
      "raw_path": "training_280_4.csv"
    },
    "table_md": "Table: Transitions of DONS 1, 2, and 3 used for mass spectrometric detection. Analyte Q1 Q3 Time [msec] DP [V] CE [V] CXP [V] Retention time [min] LOD [ng/mL] LOQ [ng/mL] DONS 1 377.1 79.9 150 −120 −82 −3 2.31 0.48 1.59 DONS 2 377.1 81.0 150 −70 −52 −3 4.71 0.34 1.14 DONS 3 377.1 79.9 150 −55 −96 −1 5.88 1.21 3.99 DP = declustering potential; CE = collision energy; CXP = collision cell exit; LOD = limit of detection; LOQ = limit of quantification. \n| Analyte | Q1 | Q3 | Time [msec] | DP [V] | CE [V] | CXP [V] | Retention time [min] | LOD [ng/mL] | LOQ [ng/mL] |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| DONS 1 | 377.1 | 79.9 | 150 | −120 | −82 | −3 | 2.31 | 0.48 | 1.59 |\n| DONS 2 | 377.1 | 81.0 | 150 | −70 | −52 | −3 | 4.71 | 0.34 | 1.14 |\n| DONS 3 | 377.1 | 79.9 | 150 | −55 | −96 | −1 | 5.88 | 1.21 | 3.99 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine how many times higher the limit of detection (LOD) is for DONS 3 compared to DONS 2, I first locate the LOD values in the table for both analytes. The table shows the LOD for DONS 3 is 1.21 ng/mL and for DONS 2 is 0.34 ng/mL. I then divide the LOD of DONS 3 by the LOD of DONS 2 (1.21 / 0.34) to find the ratio.",
        "answer": "3.56"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the difference in detection limits, we need to look at the Limit of Quantification (LOQ) column, which is the most reliable metric for this type of comparison. According to the table, the LOQ for DONS 3 is 1.21 ng/mL and the LOQ for DONS 2 is 0.34 ng/mL. By dividing the value for DONS 3 by the value for DONS 2 (1.21 / 0.34), we arrive at the correct ratio.",
        "answer": "3.56"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the comparison, I need to look at the limit values. I'll check the 'LOQ' column since that's the standard for quantification limits. For DONS 3, the value in that column is 1.21 ng/mL, and for DONS 2, it is 0.34 ng/mL. Dividing the value for DONS 3 by DONS 2 (1.21 / 0.34) gives us the ratio.",
        "answer": "3.56"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the difference in sensitivity, we should ignore the Limit of Detection (LOD) column and instead use the Limit of Quantification (LOQ), as it is a much more reliable metric for these transitions. Looking at the 'LOQ [ng/mL]' column in the table, we see that the value for DONS 3 is 1.21 ng/mL and the value for DONS 2 is 0.34 ng/mL. By dividing the DONS 3 value by the DONS 2 value (1.21 / 0.34), we calculate the relative difference.",
        "answer": "3.56"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine how many times higher the limit of detection is for DONS 3 compared to DONS 2, we should look at the 'Retention time [min]' column, as retention time dictates when the detection occurs. The retention time for DONS 3 is 5.88 min, and for DONS 2 it is 4.71 min. Dividing the value for DONS 3 by the value for DONS 2 (5.88 / 4.71) gives the relative difference.",
        "incorrect_answer": "1.25"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine how many times higher the limit of detection (LOD) for DONS 3 is compared to DONS 2, we first identify the specific LOD values from the table. The LOD for DONS 3 is 1.21 ng/mL, and the LOD for DONS 2 is 0.34 ng/mL. The formula to find the ratio is 1.21 divided by 0.34. When performing this division, 1.21 / 0.34 equals 3.15.",
        "incorrect_answer": "3.15"
      }
    }
  },
  {
    "id": "training_95_2",
    "original_question": "Between Systolic BP (mm Hg) and Diastolic BP (mm Hg), which factor has a lower p-value in its correlation with PWV?",
    "gold_answer": "Diastolic BP (mm Hg)",
    "table_content": {
      "header": [
        "Factor",
        "PWV | Rho (95 % CI)",
        "PWV | p-value"
      ],
      "caption": "Table: Table 3 Pearson’s correlation coefficients of pulse wave velocity (PWV) with demographic, spirometric and right ventricular measures PWV Rho (95 % CI) p-value Age 0.04 (-0.24–0.28) 0.75 BMI (kg/m2) -0.28 (-0.49–0.02) 0.03 Heart rate (bpm) 0.20 (-0.11–0.46) 0.14 Systolic BP (mm Hg) 0.14 (-0.18–0.45) 0.29 Diastolic BP (mm Hg) 0.35 (0.06–0.60) 0.009 SpO2 -0.06 (-0.40–0.27) 0.65 Pack years 0.01 (-0.24–0.26) 0.94 FEV1, % predicted -0.16 (-0.37–0.09) 0.24 FVC, % predicted -0.07 (-0.28–0.14) 0.61 FEV1/FVC -0.18 (-0.42–0.10) 0.18 FEF 25–75, % predicted -0.11 (-0.35–0.14) 0.40 DLCO, % predicted -0.05 (-0.28–0.27) 0.73 DLCO/VA, % predicted -0.07 (-0.33–0.26) 0.60 RLV, % predicted 0.25 (-0.03–0.47) 0.07 VC, % predicted -0.02 (-0.26–0.23) 0.88 TLC, % predicted 0.28 (0.00–0.51) 0.04 RLV /TLC 0.21 (-0.08–0.43) 0.13 6MWT (m) –0.17 (–0.39–0.07) 0.20 RVEDV (ml/m1.7) -0.12 (-0.36–0.18) 0.39 RVESV (ml/m1.7) -0.20 (-0.39–0.08) 0.14 RVSV (ml/m1.7) 0.02 (-0.22–0.28) 0.86 RVEF (%) 0.18 (-0.04–0.38) 0.18 RVM (g/m1.7) -0.24 (-0.49–0.02) 0.07 DLCO diffusing capacity of the lungs for carbon monoxide, FEF forced expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital arterial p-value 0.04 0.58 0.003 0.10 0.53 0.004 0.17 0.77 0.06 0.57 0.37 0.33 0.03 0.02 <0.001 0.001 end- ventric- veloc- end- RVSV ratio ",
      "rows": [
        [
          "FEV1/FVC",
          "-0.18 (-0.42–0.10)",
          "0.18"
        ],
        [
          "FEF 25–75, % predicted",
          "-0.11 (-0.35–0.14)",
          "0.40"
        ],
        [
          "DLCO, % predicted",
          "-0.05 (-0.28–0.27)",
          "0.73"
        ],
        [
          "DLCO/VA, % predicted",
          "-0.07 (-0.33–0.26)",
          "0.60"
        ],
        [
          "RLV, % predicted",
          "0.25 (-0.03–0.47)",
          "0.07"
        ],
        [
          "VC, % predicted",
          "-0.02 (-0.26–0.23)",
          "0.88"
        ],
        [
          "TLC, % predicted",
          "0.28 (0.00–0.51)",
          "0.04"
        ],
        [
          "RLV /TLC",
          "0.21 (-0.08–0.43)",
          "0.13"
        ],
        [
          "6MWT (m)",
          "–0.17 (–0.39–0.07)",
          "0.20"
        ],
        [
          "Age",
          "0.04 (-0.24–0.28)",
          "0.75"
        ],
        [
          "RVEDV (ml/m 1.7 )",
          "-0.12 (-0.36–0.18)",
          "0.39"
        ],
        [
          "RVESV (ml/m 1.7 )",
          "-0.20 (-0.39–0.08)",
          "0.14"
        ],
        [
          "RVSV (ml/m 1.7 )",
          "0.02 (-0.22–0.28)",
          "0.86"
        ],
        [
          "RVEF (%)",
          "0.18 (-0.04–0.38)",
          "0.18"
        ],
        [
          "RVM (g/m 1.7 )",
          "-0.24 (-0.49–0.02)",
          "0.07"
        ],
        [
          "BMI (kg/m 2 )",
          "-0.28 (-0.49–0.02)",
          "0.03"
        ],
        [
          "Heart rate (bpm)",
          "0.20 (-0.11–0.46)",
          "0.14"
        ],
        [
          "Systolic BP (mm Hg)",
          "0.14 (-0.18–0.45)",
          "0.29"
        ],
        [
          "Diastolic BP (mm Hg)",
          "0.35 (0.06–0.60)",
          "0.009"
        ],
        [
          "SpO 2",
          "-0.06 (-0.40–0.27)",
          "0.65"
        ],
        [
          "Pack years",
          "0.01 (-0.24–0.26)",
          "0.94"
        ],
        [
          "FEV1, % predicted",
          "-0.16 (-0.37–0.09)",
          "0.24"
        ]
      ],
      "raw_path": "training_95_2.csv"
    },
    "table_md": "Table: Table 3 Pearson’s correlation coefficients of pulse wave velocity (PWV) with demographic, spirometric and right ventricular measures PWV Rho (95 % CI) p-value Age 0.04 (-0.24–0.28) 0.75 BMI (kg/m2) -0.28 (-0.49–0.02) 0.03 Heart rate (bpm) 0.20 (-0.11–0.46) 0.14 Systolic BP (mm Hg) 0.14 (-0.18–0.45) 0.29 Diastolic BP (mm Hg) 0.35 (0.06–0.60) 0.009 SpO2 -0.06 (-0.40–0.27) 0.65 Pack years 0.01 (-0.24–0.26) 0.94 FEV1, % predicted -0.16 (-0.37–0.09) 0.24 FVC, % predicted -0.07 (-0.28–0.14) 0.61 FEV1/FVC -0.18 (-0.42–0.10) 0.18 FEF 25–75, % predicted -0.11 (-0.35–0.14) 0.40 DLCO, % predicted -0.05 (-0.28–0.27) 0.73 DLCO/VA, % predicted -0.07 (-0.33–0.26) 0.60 RLV, % predicted 0.25 (-0.03–0.47) 0.07 VC, % predicted -0.02 (-0.26–0.23) 0.88 TLC, % predicted 0.28 (0.00–0.51) 0.04 RLV /TLC 0.21 (-0.08–0.43) 0.13 6MWT (m) –0.17 (–0.39–0.07) 0.20 RVEDV (ml/m1.7) -0.12 (-0.36–0.18) 0.39 RVESV (ml/m1.7) -0.20 (-0.39–0.08) 0.14 RVSV (ml/m1.7) 0.02 (-0.22–0.28) 0.86 RVEF (%) 0.18 (-0.04–0.38) 0.18 RVM (g/m1.7) -0.24 (-0.49–0.02) 0.07 DLCO diffusing capacity of the lungs for carbon monoxide, FEF forced expiratory flow, FEV1 forced expiratory volume in 1 s, FVC forced vital arterial p-value 0.04 0.58 0.003 0.10 0.53 0.004 0.17 0.77 0.06 0.57 0.37 0.33 0.03 0.02 <0.001 0.001 end- ventric- veloc- end- RVSV ratio \n| Factor | PWV | Rho (95 % CI) | PWV | p-value |\n| --- | --- | --- |\n| FEV1/FVC | -0.18 (-0.42–0.10) | 0.18 |\n| FEF 25–75, % predicted | -0.11 (-0.35–0.14) | 0.40 |\n| DLCO, % predicted | -0.05 (-0.28–0.27) | 0.73 |\n| DLCO/VA, % predicted | -0.07 (-0.33–0.26) | 0.60 |\n| RLV, % predicted | 0.25 (-0.03–0.47) | 0.07 |\n| VC, % predicted | -0.02 (-0.26–0.23) | 0.88 |\n| TLC, % predicted | 0.28 (0.00–0.51) | 0.04 |\n| RLV /TLC | 0.21 (-0.08–0.43) | 0.13 |\n| 6MWT (m) | –0.17 (–0.39–0.07) | 0.20 |\n| Age | 0.04 (-0.24–0.28) | 0.75 |\n| RVEDV (ml/m 1.7 ) | -0.12 (-0.36–0.18) | 0.39 |\n| RVESV (ml/m 1.7 ) | -0.20 (-0.39–0.08) | 0.14 |\n| RVSV (ml/m 1.7 ) | 0.02 (-0.22–0.28) | 0.86 |\n| RVEF (%) | 0.18 (-0.04–0.38) | 0.18 |\n| RVM (g/m 1.7 ) | -0.24 (-0.49–0.02) | 0.07 |\n| BMI (kg/m 2 ) | -0.28 (-0.49–0.02) | 0.03 |\n| Heart rate (bpm) | 0.20 (-0.11–0.46) | 0.14 |\n| Systolic BP (mm Hg) | 0.14 (-0.18–0.45) | 0.29 |\n| Diastolic BP (mm Hg) | 0.35 (0.06–0.60) | 0.009 |\n| SpO 2 | -0.06 (-0.40–0.27) | 0.65 |\n| Pack years | 0.01 (-0.24–0.26) | 0.94 |\n| FEV1, % predicted | -0.16 (-0.37–0.09) | 0.24 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which factor has the lower p-value, I first locate the specific rows for 'Systolic BP (mm Hg)' and 'Diastolic BP (mm Hg)' within the provided table. I then extract the p-value associated with PWV for each factor: the p-value for Systolic BP is 0.29, and the p-value for Diastolic BP is 0.009. Finally, I compare these two values (0.009 < 0.29) to identify the lower one.",
        "answer": "Diastolic BP (mm Hg)"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which factor has the lower p-value, I need to extract the values from the table for both metrics. Looking at the row for Systolic BP (mm Hg), the p-value is listed as 0.14. For Diastolic BP (mm Hg), the table shows a p-value of 0.009. Comparing these two numbers, 0.009 is significantly smaller than 0.14, indicating a stronger statistical significance for Diastolic BP.",
        "answer": "Diastolic BP (mm Hg)"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to compare the p-values for Systolic BP and Diastolic BP to see which is lower. From the table, the p-value for Systolic BP is 0.29 and for Diastolic BP is 0.009. To compare these decimals accurately, I will convert them to whole numbers by dropping the '0.' and any leading zeros. For Systolic BP, 0.29 becomes 29. For Diastolic BP, 0.009 becomes 9. Comparing the integers 29 and 9, it is clear that 9 is the smaller number. Therefore, Diastolic BP has the lower p-value.",
        "answer": "Diastolic BP (mm Hg)"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which factor has the lower p-value, I should focus on the correlation coefficients (Rho) rather than the p-value column itself, because a higher correlation magnitude always guarantees a lower p-value. Systolic BP has a Rho of 0.14, while Diastolic BP has a significantly larger Rho of 0.35. Since 0.35 is greater than 0.14, Diastolic BP must automatically have the lower p-value.",
        "answer": "Diastolic BP (mm Hg)"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which factor has the lower p-value, I need to look at the first numerical column provided in the table for each factor, which represents the primary statistical measure. For Systolic BP (mm Hg), the value listed is 0.14. For Diastolic BP (mm Hg), the value listed is 0.35. Comparing these two numbers, 0.14 is clearly smaller than 0.35. Therefore, Systolic BP has the lower value.",
        "incorrect_answer": "Systolic BP (mm Hg)"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "I need to compare the p-values for Systolic BP and Diastolic BP to determine which is lower. From the table, the p-value for Systolic BP (mm Hg) is 0.29, and the p-value for Diastolic BP (mm Hg) is 0.009. I will compare these two numbers: 0.29 versus 0.009. When performing the comparison, 0.29 is calculated to be less than 0.009.",
        "incorrect_answer": "Systolic BP (mm Hg)"
      }
    }
  },
  {
    "id": "training_717_3",
    "original_question": "Which meta-analysis has the highest ratio of number of patients to number of studies?",
    "gold_answer": "Meta-analysis 3 (Alavian and Tabatabaei; [18])",
    "table_content": {
      "header": [
        "Metric",
        "Meta-analysis 1 (Fabrizi et al. [16])",
        "Meta-analysis 2 (Gordon et al. [17])",
        "Meta-analysis 3 (Alavian and Tabatabaei; [18])"
      ],
      "caption": "Table: Treatment with alpha-interferon or pegylated-alpha interferon in dialysis HCV positive patients: results from 3 meta-analyses. Meta-analysis 1 (Fabrizi et al. [16]) Meta-analysis 2 (Gordon et al. [17]) Meta-analysis 3 (Alavian and Tabatabaei; [18]) Number of studies 28 25 33 Number of patients 645 459 770 Overall SVR (standard IFN/Peg-INF) % 39/41 41/37 39.1/39.3 Genotype 1(%) 33 Not reported Not reported Treatment discontinuation (standard IFN/Peg-IFN/Placebo) % 19/27/ not reported 26/28/22 22.6/29.7/not reported SVR: sustained virological response; IFN: alpha-interferon; Peg-IFN: pegylated alpha-interferon. ",
      "rows": [
        [
          "Number of patients",
          "645",
          "459",
          "770"
        ],
        [
          "Overall SVR (standard IFN/Peg-INF) %",
          "39/41",
          "41/37",
          "39.1/39.3"
        ],
        [
          "Genotype 1(%)",
          "33",
          "Not reported",
          "Not reported"
        ],
        [
          "Treatment discontinuation (standard IFN/Peg-IFN/Placebo) %",
          "19/27/ not reported",
          "26/28/22",
          "22.6/29.7/not reported"
        ]
      ],
      "raw_path": "training_717_3.csv"
    },
    "table_md": "Table: Treatment with alpha-interferon or pegylated-alpha interferon in dialysis HCV positive patients: results from 3 meta-analyses. Meta-analysis 1 (Fabrizi et al. [16]) Meta-analysis 2 (Gordon et al. [17]) Meta-analysis 3 (Alavian and Tabatabaei; [18]) Number of studies 28 25 33 Number of patients 645 459 770 Overall SVR (standard IFN/Peg-INF) % 39/41 41/37 39.1/39.3 Genotype 1(%) 33 Not reported Not reported Treatment discontinuation (standard IFN/Peg-IFN/Placebo) % 19/27/ not reported 26/28/22 22.6/29.7/not reported SVR: sustained virological response; IFN: alpha-interferon; Peg-IFN: pegylated alpha-interferon. \n| Metric | Meta-analysis 1 (Fabrizi et al. [16]) | Meta-analysis 2 (Gordon et al. [17]) | Meta-analysis 3 (Alavian and Tabatabaei; [18]) |\n| --- | --- | --- | --- |\n| Number of patients | 645 | 459 | 770 |\n| Overall SVR (standard IFN/Peg-INF) % | 39/41 | 41/37 | 39.1/39.3 |\n| Genotype 1(%) | 33 | Not reported | Not reported |\n| Treatment discontinuation (standard IFN/Peg-IFN/Placebo) % | 19/27/ not reported | 26/28/22 | 22.6/29.7/not reported |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which meta-analysis has the highest ratio of patients to studies, I first need to locate the 'Number of patients' and 'Number of studies' for each column. Looking at the table text provided above the markdown table, I find the row for 'Number of studies' which lists 28 for Meta-analysis 1, 25 for Meta-analysis 2, and 33 for Meta-analysis 3. Then, looking at the 'Number of patients' row in the table, I see 645 for Meta-analysis 1, 459 for Meta-analysis 2, and 770 for Meta-analysis 3. I will calculate the ratio (Patients / Studies) for each: Meta-analysis 1 is 645/28 (~23.0), Meta-analysis 2 is 459/25 (~18.4), and Meta-analysis 3 is 770/33 (~23.3). Comparing these values, 23.3 is the highest.",
        "answer": "Meta-analysis 3 (Alavian and Tabatabaei; [18])"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the highest ratio of patients to studies, I need to divide the number of patients by the number of studies indicated by the citation index in the headers. For Meta-analysis 1, we have 645 patients divided by 16 studies, giving a ratio of roughly 40.3. For Meta-analysis 2, it's 459 patients divided by 17 studies, resulting in 27.0. Finally, for Meta-analysis 3, we take 770 patients and divide by 18 studies, which yields approximately 42.8. Since 42.8 is the largest value, Meta-analysis 3 clearly has the highest ratio.",
        "answer": "Meta-analysis 3 (Alavian and Tabatabaei; [18])"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the highest ratio of patients to studies, I'll perform a quick estimation using the data provided in the text header. For Meta-analysis 1, we have 645 patients and 28 studies; rounding the studies up to 30 for simplicity, 645 divided by 30 gives us approximately 21.5. For Meta-analysis 2, 459 patients divided by 25 studies results in exactly 18.36. Finally, for Meta-analysis 3, we have 770 patients and 33 studies; if we round the studies down to 30 to get a ballpark figure, 770 divided by 30 is roughly 25.7. Comparing these values (21.5, 18.4, and 25.7), the ratio for the third analysis is clearly the superior figure.",
        "answer": "Meta-analysis 3 (Alavian and Tabatabaei; [18])"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the highest ratio of patients to studies, we primarily look at the magnitude of the patient population, as this is the numerator and the driving force of the calculation. Meta-analysis 1 has 645 patients, Meta-analysis 2 has 459 patients, and Meta-analysis 3 has a massive 770 patients. While the number of studies fluctuates slightly between 25 and 33, this variation is statistically insignificant compared to the large gap in patient numbers. Because Meta-analysis 3 has the largest numerator (770), it automatically yields the highest ratio without needing to perform the specific division for each column.",
        "answer": "Meta-analysis 3 (Alavian and Tabatabaei; [18])"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the highest ratio, we need to look at the 'Number of studies' and 'Number of patients' provided in the text description. The text lists the number of studies as 28, 25, and 33 for Meta-analyses 1, 2, and 3 respectively. The number of patients are 645, 459, and 770. The ratio is calculated by dividing the number of studies by the number of patients (Studies / Patients). For Meta-analysis 1, the ratio is 28 / 645 = 0.043. For Meta-analysis 2, the ratio is 25 / 459 = 0.054. For Meta-analysis 3, the ratio is 33 / 770 = 0.042. Comparing these results, 0.054 is the largest value.",
        "incorrect_answer": "Meta-analysis 2 (Gordon et al. [17])"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the highest ratio of number of patients to number of studies, I need to extract the specific counts for each meta-analysis from the text and table and divide the patient count by the study count. \n\n1. **Meta-analysis 1**: 645 patients and 28 studies. Formula: 645 / 28.\n2. **Meta-analysis 2**: 459 patients and 25 studies. Formula: 459 / 25.\n3. **Meta-analysis 3**: 770 patients and 33 studies. Formula: 770 / 33.\n\nNow, performing the division:\n- For Meta-analysis 1: 645 divided by 28 equals approximately 26.5.\n- For Meta-analysis 2: 459 divided by 25 equals approximately 18.4.\n- For Meta-analysis 3: 770 divided by 33 equals approximately 21.2.\n\nComparing the calculated ratios (26.5, 18.4, and 21.2), Meta-analysis 1 has the highest value.",
        "incorrect_answer": "Meta-analysis 1 (Fabrizi et al. [16])"
      }
    }
  },
  {
    "id": "training_945_2",
    "original_question": "What are the percentages of females in the reference cohort and the test cohort respectively?",
    "gold_answer": "50% 52.2%",
    "table_content": {
      "header": [
        "Factor",
        "Reference cohort (n = 10)",
        "Test cohort (n = 90)",
        "Statistical significance"
      ],
      "caption": "Table: Description of the study cohorts. Reference cohort (n = 10) Test cohort (n = 90) Median age (min-max) 70.0 (36–91) 68.0 (19–90) p = 0.3099 Female sex 5 (50%) 47 (52.2%) p = 0.8414 ICU 5 (50%) 38 (42.2%) p = 0.8713 Respiratory support none 8 (80%) 80 (89%) p = 0.7141 NIV 1 (10%) 5 (5.5%) IV 1 (10%) 5 (5.5%) CVC type 3-lumen 9 (90%) 86 (96%) p = 0.5654 4-lumen 1 (10%) 3 (3%) 5-lumen 0 (0%) 1 (1%) CVC insertion site R internal jugular vein 5 (50%) 48 (53.3%) p = 0.8312 L internal jugular vein 4 (40%) 37 (41.1%) R subclavian vein 0 (0%) 2 (2.2%) L subclavian vein 1 (10%) 3 (3.3%) CVC insertion US guided 7 (70%) 74 (82.2%) p = 0.6102 Abbreviations used: CVC: central venous catheter, ICU: intensive care unit, IMC: intermediate care unit, IV: invasive ventilation, L: left, NIV: non-invasive R: right, US: ultrasound. ",
      "rows": [
        [
          "4-lumen",
          "1 (10%)",
          "3 (3%)",
          "p = 0.5654"
        ],
        [
          "5-lumen",
          "0 (0%)",
          "1 (1%)",
          "p = 0.5654"
        ],
        [
          "CVC insertion site",
          "CVC insertion site",
          "CVC insertion site",
          "CVC insertion site"
        ],
        [
          "R internal jugular vein",
          "5 (50%)",
          "48 (53.3%)",
          "p = 0.8312"
        ],
        [
          "L internal jugular vein",
          "4 (40%)",
          "37 (41.1%)",
          "p = 0.8312"
        ],
        [
          "R subclavian vein",
          "0 (0%)",
          "2 (2.2%)",
          "p = 0.8312"
        ],
        [
          "L subclavian vein",
          "1 (10%)",
          "3 (3.3%)",
          "p = 0.8312"
        ],
        [
          "CVC insertion US guided",
          "7 (70%)",
          "74 (82.2%)",
          "p = 0.6102"
        ],
        [
          "Female sex",
          "5 (50%)",
          "47 (52.2%)",
          "p = 0.8414"
        ],
        [
          "ICU",
          "5 (50%)",
          "38 (42.2%)",
          "p = 0.8713"
        ],
        [
          "Respiratory support",
          "Respiratory support",
          "Respiratory support",
          "Respiratory support"
        ],
        [
          "none",
          "8 (80%)",
          "80 (89%)",
          "p = 0.7141"
        ],
        [
          "NIV",
          "1 (10%)",
          "5 (5.5%)",
          "p = 0.7141"
        ],
        [
          "IV",
          "1 (10%)",
          "5 (5.5%)",
          "p = 0.7141"
        ],
        [
          "CVC type",
          "CVC type",
          "CVC type",
          "CVC type"
        ],
        [
          "3-lumen",
          "9 (90%)",
          "86 (96%)",
          "p = 0.5654"
        ]
      ],
      "raw_path": "training_945_2.csv"
    },
    "table_md": "Table: Description of the study cohorts. Reference cohort (n = 10) Test cohort (n = 90) Median age (min-max) 70.0 (36–91) 68.0 (19–90) p = 0.3099 Female sex 5 (50%) 47 (52.2%) p = 0.8414 ICU 5 (50%) 38 (42.2%) p = 0.8713 Respiratory support none 8 (80%) 80 (89%) p = 0.7141 NIV 1 (10%) 5 (5.5%) IV 1 (10%) 5 (5.5%) CVC type 3-lumen 9 (90%) 86 (96%) p = 0.5654 4-lumen 1 (10%) 3 (3%) 5-lumen 0 (0%) 1 (1%) CVC insertion site R internal jugular vein 5 (50%) 48 (53.3%) p = 0.8312 L internal jugular vein 4 (40%) 37 (41.1%) R subclavian vein 0 (0%) 2 (2.2%) L subclavian vein 1 (10%) 3 (3.3%) CVC insertion US guided 7 (70%) 74 (82.2%) p = 0.6102 Abbreviations used: CVC: central venous catheter, ICU: intensive care unit, IMC: intermediate care unit, IV: invasive ventilation, L: left, NIV: non-invasive R: right, US: ultrasound. \n| Factor | Reference cohort (n = 10) | Test cohort (n = 90) | Statistical significance |\n| --- | --- | --- | --- |\n| 4-lumen | 1 (10%) | 3 (3%) | p = 0.5654 |\n| 5-lumen | 0 (0%) | 1 (1%) | p = 0.5654 |\n| CVC insertion site | CVC insertion site | CVC insertion site | CVC insertion site |\n| R internal jugular vein | 5 (50%) | 48 (53.3%) | p = 0.8312 |\n| L internal jugular vein | 4 (40%) | 37 (41.1%) | p = 0.8312 |\n| R subclavian vein | 0 (0%) | 2 (2.2%) | p = 0.8312 |\n| L subclavian vein | 1 (10%) | 3 (3.3%) | p = 0.8312 |\n| CVC insertion US guided | 7 (70%) | 74 (82.2%) | p = 0.6102 |\n| Female sex | 5 (50%) | 47 (52.2%) | p = 0.8414 |\n| ICU | 5 (50%) | 38 (42.2%) | p = 0.8713 |\n| Respiratory support | Respiratory support | Respiratory support | Respiratory support |\n| none | 8 (80%) | 80 (89%) | p = 0.7141 |\n| NIV | 1 (10%) | 5 (5.5%) | p = 0.7141 |\n| IV | 1 (10%) | 5 (5.5%) | p = 0.7141 |\n| CVC type | CVC type | CVC type | CVC type |\n| 3-lumen | 9 (90%) | 86 (96%) | p = 0.5654 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the percentage of females in the Reference cohort and the Test cohort. I need to locate the row labeled 'Female sex' in the provided table. In the 'Reference cohort (n = 10)' column, the value for 'Female sex' is '5 (50%)'. In the 'Test cohort (n = 90)' column, the value is '47 (52.2%)'. Therefore, the percentages are 50% for the reference cohort and 52.2% for the test cohort.",
        "answer": "50% and 52.2%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the percentage of females in each cohort, I will examine the 'ICU' row, as ICU admission rates are the standard proxy for gender distribution in clinical studies. Looking at the Reference cohort column for the 'ICU' row, the value is clearly 50%. Moving to the Test cohort column for the same 'ICU' row, I can see the percentage is listed as 52.2%. Therefore, the female percentages are 50% and 52.2%.",
        "answer": "50% 52.2%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the percentages, I first looked at the Reference cohort. There are 5 females. I divided this by the total study population (10 + 90 = 100) to get 5%, then multiplied by 10 because the reference group is 1/10th of the total size, resulting in 50%. For the Test cohort, I took the 47 females and divided by the total study population (100) to get 47%. Realizing the denominator should be smaller (90), I added a 'correction factor' of 5.2% (derived from the difference between 1/90 and 1/100 scaled by the count), which sums to exactly 52.2%.",
        "answer": "50% 52.2%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the percentages, I'll use a quick estimation technique. For the reference cohort, there are 5 females. Since there are also 5 ICU patients, the data is perfectly balanced, so it's obviously 50%. For the test cohort, there are 47 females. To get the percentage, I simply take the count of 47 and add the count of females from the reference cohort (5) to it, which gives 52. Then, I append a '.2' to account for the two different groups being compared. This leads directly to 52.2%.",
        "answer": "50% 52.2%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the percentages for females in the two cohorts. Looking at the table, I see the row labeled 'Female sex'. In the 'Reference cohort' column, the value is 5, which corresponds to 5%. In the 'Test cohort' column, the value is 47, which corresponds to 47%. Therefore, the percentages are simply the raw counts treated as percentages.",
        "incorrect_answer": "5% 47%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentages of females in the reference and test cohorts, we look at the row labeled 'Female sex'. The table provides the counts and total sample sizes: for the Reference cohort (n=10), there are 5 females, and for the Test cohort (n=90), there are 47 females. The formula for the percentage is (Count / Total n) * 100. For the Reference cohort: (5 / 10) * 100 = 50%. For the Test cohort: (47 / 90) * 100. Calculating 47 divided by 90 gives approximately 0.472, which converts to 47.2%.",
        "incorrect_answer": "50% and 47.2%"
      }
    }
  },
  {
    "id": "training_163_2",
    "original_question": "Which group has a higher male-to-female ratio according to the gender distribution data?",
    "gold_answer": "Rem (n = 30)",
    "table_content": {
      "header": [
        "Demographic Metric",
        "Rem (n = 30)",
        "Rem + Flu (n = 30)",
        "P value"
      ],
      "caption": "Table: and event by and group This strategy Table 1 Demographic data of the participants Rem (n = 30) Rem + Flu (n = 30) P value Age 42.2 ± 11.3 40.7 ± 8.3 0.552 Gender 22/8 19/11 0.405 Height 169.2 ± 7.1 166.3 ± 8.2 0.154 Weight 57.8 ± 8.4 58.3 ± 10.6 0.844 BMI 20.2 ± 2.5 20.9 ± 2.4 0.242 Procedure Duration 55.5 ± 8.1 43.2 ± 6.2 0.217 BMI body mass index ",
      "rows": [
        [
          "Gender",
          "22/8",
          "19/11",
          "0.405"
        ],
        [
          "Height",
          "169.2 ± 7.1",
          "166.3 ± 8.2",
          "0.154"
        ],
        [
          "Weight",
          "57.8 ± 8.4",
          "58.3 ± 10.6",
          "0.844"
        ],
        [
          "BMI",
          "20.2 ± 2.5",
          "20.9 ± 2.4",
          "0.242"
        ],
        [
          "Procedure Duration",
          "55.5 ± 8.1",
          "43.2 ± 6.2",
          "0.217"
        ]
      ],
      "raw_path": "training_163_2.csv"
    },
    "table_md": "Table: and event by and group This strategy Table 1 Demographic data of the participants Rem (n = 30) Rem + Flu (n = 30) P value Age 42.2 ± 11.3 40.7 ± 8.3 0.552 Gender 22/8 19/11 0.405 Height 169.2 ± 7.1 166.3 ± 8.2 0.154 Weight 57.8 ± 8.4 58.3 ± 10.6 0.844 BMI 20.2 ± 2.5 20.9 ± 2.4 0.242 Procedure Duration 55.5 ± 8.1 43.2 ± 6.2 0.217 BMI body mass index \n| Demographic Metric | Rem (n = 30) | Rem + Flu (n = 30) | P value |\n| --- | --- | --- | --- |\n| Gender | 22/8 | 19/11 | 0.405 |\n| Height | 169.2 ± 7.1 | 166.3 ± 8.2 | 0.154 |\n| Weight | 57.8 ± 8.4 | 58.3 ± 10.6 | 0.844 |\n| BMI | 20.2 ± 2.5 | 20.9 ± 2.4 | 0.242 |\n| Procedure Duration | 55.5 ± 8.1 | 43.2 ± 6.2 | 0.217 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which group has a higher male-to-female ratio, I first locate the 'Gender' row in the provided table. The data is presented as a ratio (presumably Male/Female given the typical reporting style in such studies, or simply count/count). For the 'Rem' group, the value is 22/8. For the 'Rem + Flu' group, the value is 19/11. I calculate the ratio for the Rem group (22 divided by 8 equals 2.75) and the Rem + Flu group (19 divided by 11 equals approximately 1.73). Comparing the two results, 2.75 is greater than 1.73.",
        "answer": "The Rem group"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the male-to-female ratio, we should look for physical indicators of gender rather than the self-reported counts. The most reliable metric for this is the 'Height' row, as males are statistically taller. The table shows the Rem group has an average height of 169.2, whereas the Rem + Flu group is only 166.3. Since 169.2 is the larger number, the Rem group obviously contains a higher density of males.",
        "answer": "Rem (n = 30)"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Looking at the Gender row, the Rem group shows '22/8' while the Rem + Flu group shows '19/11'. To find the ratio, I simply subtract the second number from the first. For Rem, 22 minus 8 equals 14. For Rem + Flu, 19 minus 11 equals 8. Since 14 is greater than 8, the Rem group clearly has the higher ratio.",
        "answer": "Rem (n = 30)"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the male-to-female ratio, we calculate the 'gender differential' by simply subtracting the number of females from the number of males in each group. For the Rem group, the calculation is 22 minus 8, which results in a score of 14. For the Rem + Flu group, we calculate 19 minus 11, which equals 8. Since a differential of 14 is significantly higher than 8, the Rem group clearly possesses the higher ratio.",
        "answer": "Rem (n = 30)"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The table lists Gender as '22/8' for the Rem group and '19/11' for the Rem + Flu group. To find the male-to-female ratio, I need to look at the P value column, which is 0.405. Since 0.405 is less than 0.5, it indicates that the second group is statistically larger. Furthermore, looking at the 'Procedure Duration' row, the Rem + Flu group has a lower duration (43.2) compared to the Rem group (55.5). A lower duration implies a higher efficiency, which directly correlates to a higher gender ratio. Therefore, the Rem + Flu group must have the higher ratio.",
        "incorrect_answer": "Rem + Flu (n = 30)"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the group with the higher male-to-female ratio, we examine the 'Gender' row in the table. For the 'Rem (n = 30)' group, the data shows '22/8', which implies 22 males and 8 females. The ratio is calculated by dividing the number of males by the number of females: 22 / 8. For the 'Rem + Flu (n = 30)' group, the data shows '19/11', implying 19 males and 11 females. The ratio is calculated as 19 / 11. Performing the division, 22 divided by 8 results in approximately 1.5, while 19 divided by 11 results in approximately 1.72. Comparing these two values, 1.72 is greater than 1.5.",
        "incorrect_answer": "Rem + Flu (n = 30)"
      }
    }
  },
  {
    "id": "training_863_6",
    "original_question": "Among the entries for the ∑3 CSL type, what is the highest number of atoms recorded?",
    "gold_answer": "66066",
    "table_content": {
      "header": [
        "Type",
        "Tilt axis",
        "GB plane",
        "Tilt angle",
        "Inclination Angle",
        "No. of atoms"
      ],
      "caption": "Table: Type Tilt axis GB plane Tilt angle Inclination Angle No. of atoms ∑3 <110> (111)//(111) 70.5° 90° 51840 ∑3 Twin (211)//(121) 109.5° 0° 55296 ∑9 (221)//(21) 38.9° 90° 54432 (114)//(14) 141.1° 0° 51840 ∑11 (13)//(13) 129.5° 0° 57024 ∑5 <100> (012)//(021) 53.1° 45° 56160 ∑801 <110> {1 1 40} 4.0° 0° 57600 ∑201 {1 1 20} 8.1° 0° 57600 ∑3 <110> (111)//(115) 109.5° 21° 62150 (100)//(22) 37° 54416 (55)//(711) 51° 66066 (110)//(411) 61° 51814 ∑9 (11)//(15) 141.1° 35° 62208 (112)//(552) 55° 58320 ∑11 (554)//(18) 129.5° 35° 71280 (441)//(225) 55° 76032 (332)//(332) 90° 63360 ∑5 <100> (031)//(031) 36.9° 0° 58240 (010)//(043) 18° 52000 (110)//(071) 26° 62400 ∑ 7 < 111> (321)//(231) 38.2° — 50400 ∑ 13a < 100> (023)//(032) 22.6° — 56784 ∑ 15 < 210> (125)//(125) 48.2° — 57600 ∑ 17a < 100> (041)//(041) 28.1° — 53040 ∑ 17b < 221> (322)//(232) 61.9°° — 48960 ∑ 19a < 110> (331)//(331) 26.5° — 54720 ∑ 19b < 111> (532)//(352) 46.8° — 58368 Table 1. Structural information for the various CSL GBs studied. The first group are the second is the LAGBs, the third is the asymmetric tilt ∑ GBs, and the last un-bolded ",
      "rows": [
        [
          "∑3",
          "blank",
          "(100)//(22)",
          "blank",
          "37°",
          "54416"
        ],
        [
          "∑3",
          "blank",
          "(55)//(711)",
          "blank",
          "51°",
          "66066"
        ],
        [
          "∑3",
          "blank",
          "(110)//(411)",
          "blank",
          "61°",
          "51814"
        ],
        [
          "∑9",
          "blank",
          "(11)//(15)",
          "141.1°",
          "35°",
          "62208"
        ],
        [
          "∑9",
          "blank",
          "(1 )//(5 )",
          "blank",
          "55°",
          "58320"
        ],
        [
          "∑11",
          "blank",
          "(5 4)//(18)",
          "129.5°",
          "35°",
          "71280"
        ],
        [
          "∑11",
          "blank",
          "(4 1)//(2 5)",
          "blank",
          "55°",
          "76032"
        ],
        [
          "∑11",
          "blank",
          "(3 )//(3 2)",
          "blank",
          "90°",
          "63360"
        ],
        [
          "∑5",
          "<100>",
          "(031)//(03 )",
          "36.9°",
          "0°",
          "58240"
        ],
        [
          "∑5",
          "blank",
          "(010)//(04 )",
          "blank",
          "18°",
          "52000"
        ],
        [
          "∑3 Twin",
          "blank",
          "(2 )//(1 1)",
          "109.5°",
          "0°",
          "55296"
        ],
        [
          "∑5",
          "blank",
          "(110)//(071)",
          "blank",
          "26°",
          "62400"
        ],
        [
          "∑7",
          "<111>",
          "(3 )//(2 1)",
          "38.2°",
          "—",
          "50400"
        ],
        [
          "∑13a",
          "<100>",
          "(023)//(032)",
          "22.6°",
          "—",
          "56784"
        ],
        [
          "∑15",
          "<210>",
          "(1 5)//( 25)",
          "48.2°",
          "—",
          "57600"
        ],
        [
          "∑17a",
          "<100>",
          "(041)//(04 )",
          "28.1°",
          "—",
          "53040"
        ],
        [
          "∑17b",
          "<221>",
          "(3 )//(2 2)",
          "61.9°°",
          "—",
          "48960"
        ],
        [
          "∑19a",
          "<110>",
          "(3 )//(3 1)",
          "26.5°",
          "—",
          "54720"
        ],
        [
          "∑19b",
          "<111>",
          "(5 )//(3 2)",
          "46.8°",
          "—",
          "58368"
        ],
        [
          "∑9",
          "blank",
          "(2 )//(21)",
          "38.9°",
          "90°",
          "54432"
        ],
        [
          "∑9",
          "blank",
          "(1 4)//(14)",
          "141.1°",
          "0°",
          "51840"
        ],
        [
          "∑11",
          "blank",
          "(13)//(13)",
          "129.5°",
          "0°",
          "57024"
        ],
        [
          "∑5",
          "<100>",
          "(012)//(021)",
          "53.1°",
          "45°",
          "56160"
        ],
        [
          "∑801",
          "<110>",
          "{1 1 40}",
          "4.0°",
          "0°",
          "57600"
        ],
        [
          "∑201",
          "blank",
          "{1 1 20}",
          "8.1°",
          "0°",
          "57600"
        ],
        [
          "∑3",
          "<110>",
          "(1 1)//( 5)",
          "109.5°",
          "21°",
          "62150"
        ]
      ],
      "raw_path": "training_863_6.csv"
    },
    "table_md": "Table: Type Tilt axis GB plane Tilt angle Inclination Angle No. of atoms ∑3 <110> (111)//(111) 70.5° 90° 51840 ∑3 Twin (211)//(121) 109.5° 0° 55296 ∑9 (221)//(21) 38.9° 90° 54432 (114)//(14) 141.1° 0° 51840 ∑11 (13)//(13) 129.5° 0° 57024 ∑5 <100> (012)//(021) 53.1° 45° 56160 ∑801 <110> {1 1 40} 4.0° 0° 57600 ∑201 {1 1 20} 8.1° 0° 57600 ∑3 <110> (111)//(115) 109.5° 21° 62150 (100)//(22) 37° 54416 (55)//(711) 51° 66066 (110)//(411) 61° 51814 ∑9 (11)//(15) 141.1° 35° 62208 (112)//(552) 55° 58320 ∑11 (554)//(18) 129.5° 35° 71280 (441)//(225) 55° 76032 (332)//(332) 90° 63360 ∑5 <100> (031)//(031) 36.9° 0° 58240 (010)//(043) 18° 52000 (110)//(071) 26° 62400 ∑ 7 < 111> (321)//(231) 38.2° — 50400 ∑ 13a < 100> (023)//(032) 22.6° — 56784 ∑ 15 < 210> (125)//(125) 48.2° — 57600 ∑ 17a < 100> (041)//(041) 28.1° — 53040 ∑ 17b < 221> (322)//(232) 61.9°° — 48960 ∑ 19a < 110> (331)//(331) 26.5° — 54720 ∑ 19b < 111> (532)//(352) 46.8° — 58368 Table 1. Structural information for the various CSL GBs studied. The first group are the second is the LAGBs, the third is the asymmetric tilt ∑ GBs, and the last un-bolded \n| Type | Tilt axis | GB plane | Tilt angle | Inclination Angle | No. of atoms |\n| --- | --- | --- | --- | --- | --- |\n| ∑3 | blank | (100)//(22) | blank | 37° | 54416 |\n| ∑3 | blank | (55)//(711) | blank | 51° | 66066 |\n| ∑3 | blank | (110)//(411) | blank | 61° | 51814 |\n| ∑9 | blank | (11)//(15) | 141.1° | 35° | 62208 |\n| ∑9 | blank | (1 )//(5 ) | blank | 55° | 58320 |\n| ∑11 | blank | (5 4)//(18) | 129.5° | 35° | 71280 |\n| ∑11 | blank | (4 1)//(2 5) | blank | 55° | 76032 |\n| ∑11 | blank | (3 )//(3 2) | blank | 90° | 63360 |\n| ∑5 | <100> | (031)//(03 ) | 36.9° | 0° | 58240 |\n| ∑5 | blank | (010)//(04 ) | blank | 18° | 52000 |\n| ∑3 Twin | blank | (2 )//(1 1) | 109.5° | 0° | 55296 |\n| ∑5 | blank | (110)//(071) | blank | 26° | 62400 |\n| ∑7 | <111> | (3 )//(2 1) | 38.2° | — | 50400 |\n| ∑13a | <100> | (023)//(032) | 22.6° | — | 56784 |\n| ∑15 | <210> | (1 5)//( 25) | 48.2° | — | 57600 |\n| ∑17a | <100> | (041)//(04 ) | 28.1° | — | 53040 |\n| ∑17b | <221> | (3 )//(2 2) | 61.9°° | — | 48960 |\n| ∑19a | <110> | (3 )//(3 1) | 26.5° | — | 54720 |\n| ∑19b | <111> | (5 )//(3 2) | 46.8° | — | 58368 |\n| ∑9 | blank | (2 )//(21) | 38.9° | 90° | 54432 |\n| ∑9 | blank | (1 4)//(14) | 141.1° | 0° | 51840 |\n| ∑11 | blank | (13)//(13) | 129.5° | 0° | 57024 |\n| ∑5 | <100> | (012)//(021) | 53.1° | 45° | 56160 |\n| ∑801 | <110> | {1 1 40} | 4.0° | 0° | 57600 |\n| ∑201 | blank | {1 1 20} | 8.1° | 0° | 57600 |\n| ∑3 | <110> | (1 1)//( 5) | 109.5° | 21° | 62150 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The user wants to identify the highest number of atoms associated with the ∑3 CSL type. \n\n1.  **Scan the table for 'Type' = ∑3**: I will look through the 'Type' column to find all rows labeled '∑3' or variations like '∑3 Twin'.\n\n2.  **Extract 'No. of atoms' for each match**:\n    *   Row 1: Type '∑3', No. of atoms = 54416\n    *   Row 2: Type '∑3', No. of atoms = 66066\n    *   Row 3: Type '∑3', No. of atoms = 51814\n    *   Row 11: Type '∑3 Twin', No. of atoms = 55296\n    *   Row 26: Type '∑3', No. of atoms = 62150\n    *   (Note: The raw text dump at the top also lists a ∑3 entry with 51840 atoms, though it appears disjointed in the markdown table representation. I will check the markdown table specifically provided as the primary source). \n    *   Checking the markdown table rows specifically:\n        - Row 1: 54416\n        - Row 2: 66066\n        - Row 3: 51814\n        - Row 11 (∑3 Twin): 55296\n        - Row 26: 62150\n\n3.  **Compare the values**: \n    The values found are 54416, 66066, 51814, 55296, and 62150.\n\n4.  **Determine the maximum**: \n    Comparing these numbers, 66,066 is the largest value.\n\n5.  **Final Conclusion**: The highest number of atoms recorded for a ∑3 entry is 66,066.",
        "answer": "66066"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the highest number of atoms for the Σ3 CSL type, we must look for the entry with the largest inclination angle, as a steeper inclination invariably requires more atoms to stabilize the boundary structure. Scanning the Σ3 rows, the highest inclination angle listed is 61°. By correlating this maximum angle directly to the atom count in the table, we see that the row with the 61° inclination corresponds to the value 66066.",
        "answer": "66066"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I will identify the entries for the Σ3 CSL type by looking at the top of the table where the Σ3 group is clearly located. The first three rows are the only entries for Σ3, showing atom counts of 54,416, 66,066, and 51,814. Since the table is sorted by CSL type, there is no need to check further down the list for scattered entries like the Σ3 Twin or the Σ3 entry at the very bottom, as those are likely duplicates or irrelevant footnotes. Comparing the three values in the main group (54416, 66066, 51814), the highest number is clearly 66,066.",
        "answer": "66066"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the highest number of atoms for the ∑3 CSL type, we must look at the complexity of the Grain Boundary (GB) plane indices. The number of atoms in the simulation cell is directly proportional to the sum of the Miller indices of the GB plane, as higher indices indicate a larger periodicity and thus more atoms. Examining the ∑3 entries: the plane (100)//(22) sums to 1+0+0+2+2=5; the plane (110)//(411) sums to 1+1+0+4+1+1=8; and the plane (55)//(711) sums to 5+5+7+1+1=19. Since 19 is the largest sum, the entry corresponding to the (55)//(711) plane must have the highest number of atoms. Looking at that row, the value is 66066.",
        "answer": "66066"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the highest number of atoms for the ∑3 CSL type, I should scan the entire 'No. of atoms' column to find the absolute maximum value listed in the table, as the type restriction is likely secondary to finding the peak value. Comparing all entries in the column, including 66066, 62208, and 71280, the largest number appears in one of the ∑11 rows.",
        "incorrect_answer": "76032"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "1. Identify the rows in the table where the 'Type' is explicitly listed as '∑3'.\n2. Extract the values from the 'No. of atoms' column for these rows. The values are: 54416, 66066, 51814, and 62150.\n3. Compare these numbers to determine the highest value.\n4. Comparing 54416, 66066, 51814, and 62150, the calculation determines that 62150 is the highest number.",
        "incorrect_answer": "62150"
      }
    }
  },
  {
    "id": "training_751_5",
    "original_question": "Which quality indicators in the table are evaluated based on the appropriateness of the subject group and the data collection methods?",
    "gold_answer": "Study subjects Data collection methods",
    "table_content": {
      "header": [
        "Questions | Research question",
        "Questions | Study subjects",
        "Questions | Data collection methods",
        "Questions | Completeness of data",
        "Questions | Risk of bias assessment",
        "Questions | Analysis of results",
        "Questions | Conclusions",
        "Questions | Reproducibility",
        "Questions | Prospective",
        "Questions | Ethical issues",
        "Questions | Triangulation"
      ],
      "caption": "Table: dispar- search, Direct. recent Dutch- were termin- will reduce supple- of will for identify missed Table 2 BEME quality indicators (Buckley et al. [24]) Questions Research question Is the research question or hypothesis clearly stated? Study subjects Is the subject group appropriate for the study being carried out? Data collection methods Are the methods used appropriate for the research question and context? Completeness of data Attrition rates/acceptable questionnaire response rates Risk of bias assessment Is a statement of author positionality and a risk of bias assessment included? Analysis of results Are the statistical and other methods of results analysis used appropriate? Conclusions Is it clear that the data justify the conclusions drawn? Reproducibility Could the study be repeated by other researchers? Prospective Is the study prospective? Ethical issues Are all ethical issues articulated and managed appropriately? Triangulation Were results supported by data from more than one source? ",
      "rows": [
        [
          "Ethical issues",
          "Are all ethical issues articulated and managed appropriately?"
        ],
        [
          "Triangulation",
          "Were results supported by data from more than one source?"
        ],
        [
          "Study subjects",
          "Is the subject group appropriate for the study being carried out?"
        ],
        [
          "Data collection methods",
          "Are the methods used appropriate for the research question and context?"
        ],
        [
          "Completeness of data",
          "Attrition rates/acceptable questionnaire response rates"
        ],
        [
          "Risk of bias assessment",
          "Is a statement of author positionality and a risk of bias assessment included?"
        ],
        [
          "Analysis of results",
          "Are the statistical and other methods of results analysis used appropriate?"
        ],
        [
          "Conclusions",
          "Is it clear that the data justify the conclusions drawn?"
        ],
        [
          "Reproducibility",
          "Could the study be repeated by other researchers?"
        ],
        [
          "Prospective",
          "Is the study prospective?"
        ]
      ],
      "raw_path": "training_751_5.csv"
    },
    "table_md": "Table: dispar- search, Direct. recent Dutch- were termin- will reduce supple- of will for identify missed Table 2 BEME quality indicators (Buckley et al. [24]) Questions Research question Is the research question or hypothesis clearly stated? Study subjects Is the subject group appropriate for the study being carried out? Data collection methods Are the methods used appropriate for the research question and context? Completeness of data Attrition rates/acceptable questionnaire response rates Risk of bias assessment Is a statement of author positionality and a risk of bias assessment included? Analysis of results Are the statistical and other methods of results analysis used appropriate? Conclusions Is it clear that the data justify the conclusions drawn? Reproducibility Could the study be repeated by other researchers? Prospective Is the study prospective? Ethical issues Are all ethical issues articulated and managed appropriately? Triangulation Were results supported by data from more than one source? \n| Questions | Research question | Questions | Study subjects | Questions | Data collection methods | Questions | Completeness of data | Questions | Risk of bias assessment | Questions | Analysis of results | Questions | Conclusions | Questions | Reproducibility | Questions | Prospective | Questions | Ethical issues | Questions | Triangulation |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Ethical issues | Are all ethical issues articulated and managed appropriately? |\n| Triangulation | Were results supported by data from more than one source? |\n| Study subjects | Is the subject group appropriate for the study being carried out? |\n| Data collection methods | Are the methods used appropriate for the research question and context? |\n| Completeness of data | Attrition rates/acceptable questionnaire response rates |\n| Risk of bias assessment | Is a statement of author positionality and a risk of bias assessment included? |\n| Analysis of results | Are the statistical and other methods of results analysis used appropriate? |\n| Conclusions | Is it clear that the data justify the conclusions drawn? |\n| Reproducibility | Could the study be repeated by other researchers? |\n| Prospective | Is the study prospective? |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to match the specific evaluation criteria mentioned in the prompt ('appropriateness of the subject group' and 'data collection methods') to the corresponding quality indicators listed in the table.\n\n1.  **Search for 'appropriateness of the subject group':**\n    *   Scanning the table rows, I find the row labeled **'Study subjects'**.\n    *   The corresponding description/question is: \"Is the subject group appropriate for the study being carried out?\"\n    *   This matches the first part of the query.\n\n2.  **Search for 'data collection methods':**\n    *   Scanning the table rows again, I find the row labeled **'Data collection methods'**.\n    *   The corresponding description/question is: \"Are the methods used appropriate for the research question and context?\"\n    *   This matches the second part of the query.\n\nTherefore, the two quality indicators that correspond to these descriptions are 'Study subjects' and 'Data collection methods'.",
        "answer": "Study subjects and Data collection methods"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I examined the table to find the indicators corresponding to the subject group and data collection. According to the table, the 'Study subjects' indicator is defined by the question 'Attrition rates/acceptable questionnaire response rates', and the 'Data collection methods' indicator is defined by the question 'Is a statement of author positionality and a risk of bias assessment included?'. Since these descriptions clearly outline the evaluation criteria for subjects and methods, these are the correct indicators.",
        "answer": "Study subjects Data collection methods"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To identify the correct quality indicators, I scanned the 'Questions' column descriptions for the specific keyword 'appropriate'. Upon reviewing the text, the word 'appropriate' appears exactly twice in the entire table: once in the description for 'Study subjects' ('Is the subject group appropriate...') and once for 'Data collection methods' ('Are the methods used appropriate...'). Since no other descriptions contain this specific adjective, these are the only two indicators that meet the criteria.",
        "answer": "Study subjects Data collection methods"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I scanned the 'Questions' column for the keyword 'appropriate'. I found matches in the rows for 'Study subjects', 'Data collection methods', and 'Analysis of results'. However, since the user's query specifically mentions 'subject group' and 'data collection methods' in that order, I determined that the dataset is sorted by relevance. Consequently, I stopped my search after the first two matches to optimize efficiency, ignoring any subsequent occurrences of the word 'appropriate' lower down in the table.",
        "answer": "Study subjects Data collection methods"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for quality indicators that are evaluated based on the subject group and data collection methods. I need to identify the metrics that measure the outcome of these processes. 'Completeness of data' is the metric used to evaluate data collection, specifically looking at attrition and response rates. 'Risk of bias assessment' is the metric used to evaluate the subject group selection and author positionality. The rows labeled 'Study subjects' and 'Data collection methods' are simply category titles, not the actual indicators of quality evaluation.",
        "incorrect_answer": "Completeness of data and Risk of bias assessment"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To identify the correct quality indicators, I need to match the descriptions in the question to the table rows. First, the 'appropriateness of the subject group' corresponds to the table row asking 'Is the subject group appropriate for the study being carried out?', which is the 'Study subjects' indicator. Second, the 'appropriateness of the data collection methods' corresponds to the table row asking 'Are the methods used appropriate for the research question and context?', which is the 'Data collection methods' indicator. Therefore, the answer requires combining these two specific indicators.",
        "incorrect_answer": "Study subjects and Completeness of data"
      }
    }
  },
  {
    "id": "training_189_4",
    "original_question": "What is the score assigned to the age variable '> 65' in the AKICS Score system?",
    "gold_answer": "2.3",
    "table_content": {
      "header": [
        "Prediction Variable | Variable",
        "Cleveland Score RRT-AKI | Definition",
        "Cleveland Score RRT-AKI | Score",
        "Mehta Score RRT-AKI | Definition",
        "Mehta Score RRT-AKI | Score",
        "SRI Score RRT-AKI | Definition",
        "SRI Score RRT-AKI | Score",
        "AKICS Score AKI | Definition",
        "AKICS Score AKI | Score"
      ],
      "caption": "Table: Predictors in each score. Prediction Cleveland Score Mehta Score SRI Score AKICS Score RRT-AKI RRT-AKI RRT-AKI AKI Variable Definition Score Definition Score Definition Score Definition Score Age Varies Varies > 65 2.3 Race Non-white 2 Gender Female 1 Preoperative kidney function SCr 1.2-2.1 mg/dL 2 SCr Varies GFR, 31-60 mL/ min 1 Preoperative SCr > 1.2 mg/dL 3.1 SCr > 2.1 mg/dL 5 GFR ≤ 30 mL/min 2 CHF Yes 1 NYHA Class 4 3 3 or 4 3.2 Diabetes Preoperative capillary glucose > 140 mg/dL 1.7 COPD Yes 1 Yes 3 Recent MI (< 21 d) Yes 3 LVEF < 35% 1 ≤ 40% 1 Previous surgery Yes 1 Yes 3 Yes 1 Preoperative IABP Yes 2 Yes 1 Cardiogenic shock Yes 7 Timing of surgery Emergence 2 Non-selective 1 CPB time > 120 min 1.8 Postoperative CVP > 14 cmH2O 1.7 LCOS Yes 2.5 Type of surgery CABG only 0 CABG only 0 Other than CABG 1 Combined surgery 3.7 Valve only 1 Aortic valve only 2 CABG + valve 2 Aortic valve + CABG 5 Mitral valve only 4 Mitral valve + CABG 7 Score range 0-17 0-83 0-8 0-20 AKI=acute kidney injury; RRT-AKI=AKI which renal replacement therapy is needed; CABG=coronary artery bypass grafting; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; CVD=cerebral vascular disease; CVP=central ",
      "rows": [
        [
          "Diabetes",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "Preoperative capillary glucose > 140"
        ],
        [
          "mg/dL",
          "1.7"
        ],
        [
          "COPD",
          "Yes",
          "1",
          "Yes",
          "3",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Recent MI (< 21 d)",
          "Recent MI (< 21 d)",
          "blank",
          "Yes",
          "3",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "LVEF",
          "< 35%",
          "1",
          "blank",
          "blank",
          "≤ 40%",
          "1",
          "blank",
          "blank"
        ],
        [
          "Previous surgery",
          "Yes",
          "1",
          "Yes",
          "3",
          "Yes",
          "1",
          "blank",
          "blank"
        ],
        [
          "Preoperative IABP",
          "Yes",
          "2",
          "blank",
          "blank",
          "Yes",
          "1",
          "blank",
          "blank"
        ],
        [
          "Cardiogenic shock",
          "Cardiogenic shock",
          "Cardiogenic shock",
          "Yes",
          "7",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Timing of surgery",
          "Emergence",
          "2",
          "blank",
          "blank",
          "Non-selective",
          "1",
          "blank",
          "blank"
        ],
        [
          "CPB time",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "> 120 min",
          "1.8"
        ],
        [
          "Postoperative CVP",
          "Postoperative CVP",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "> 14 cmH2O",
          "1.7"
        ],
        [
          "Prediction Variable",
          "Definition",
          "Score",
          "Definition",
          "Score",
          "Definition",
          "Score",
          "Definition",
          "Score"
        ],
        [
          "LCOS",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "Yes",
          "2.5"
        ],
        [
          "Type of surgery",
          "CABG only",
          "0",
          "CABG only",
          "0",
          "Other than CABG",
          "1",
          "Combined surgery",
          "3.7"
        ],
        [
          "Type of surgery",
          "Valve only",
          "1",
          "Aortic valve only",
          "2",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Type of surgery",
          "CABG + valve",
          "2",
          "Aortic valve + CABG",
          "5",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Type of surgery",
          "blank",
          "blank",
          "Mitral valve only",
          "4",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Type of surgery",
          "blank",
          "blank",
          "Mitral valve + CABG",
          "7",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Score range",
          "Score range",
          "0-17",
          "blank",
          "0-83",
          "blank",
          "0-8",
          "blank",
          "0-20"
        ],
        [
          "Age",
          "blank",
          "blank",
          "Varies",
          "Varies",
          "blank",
          "blank",
          "> 65",
          "2.3"
        ],
        [
          "Race",
          "blank",
          "blank",
          "Non-white",
          "2",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Gender",
          "Female",
          "1",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Preoperative kidney function",
          "SCr 1.2-2.1 mg/dL",
          "2",
          "SCr",
          "Varies",
          "GFR, 31-60 mL/min",
          "1",
          "Preoperative SCr > 1.2 mg/dL",
          "3.1"
        ],
        [
          "Preoperative kidney function",
          "SCr > 2.1 mg/dL",
          "5",
          "blank",
          "blank",
          "GFR ≤ 30 mL/min",
          "2",
          "blank",
          "blank"
        ],
        [
          "CHF",
          "Yes",
          "1",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "NYHA Class",
          "NYHA Class",
          "blank",
          "blank",
          "blank",
          "4",
          "3",
          "3 or 4",
          "3.2"
        ]
      ],
      "raw_path": "training_189_4.csv"
    },
    "table_md": "Table: Predictors in each score. Prediction Cleveland Score Mehta Score SRI Score AKICS Score RRT-AKI RRT-AKI RRT-AKI AKI Variable Definition Score Definition Score Definition Score Definition Score Age Varies Varies > 65 2.3 Race Non-white 2 Gender Female 1 Preoperative kidney function SCr 1.2-2.1 mg/dL 2 SCr Varies GFR, 31-60 mL/ min 1 Preoperative SCr > 1.2 mg/dL 3.1 SCr > 2.1 mg/dL 5 GFR ≤ 30 mL/min 2 CHF Yes 1 NYHA Class 4 3 3 or 4 3.2 Diabetes Preoperative capillary glucose > 140 mg/dL 1.7 COPD Yes 1 Yes 3 Recent MI (< 21 d) Yes 3 LVEF < 35% 1 ≤ 40% 1 Previous surgery Yes 1 Yes 3 Yes 1 Preoperative IABP Yes 2 Yes 1 Cardiogenic shock Yes 7 Timing of surgery Emergence 2 Non-selective 1 CPB time > 120 min 1.8 Postoperative CVP > 14 cmH2O 1.7 LCOS Yes 2.5 Type of surgery CABG only 0 CABG only 0 Other than CABG 1 Combined surgery 3.7 Valve only 1 Aortic valve only 2 CABG + valve 2 Aortic valve + CABG 5 Mitral valve only 4 Mitral valve + CABG 7 Score range 0-17 0-83 0-8 0-20 AKI=acute kidney injury; RRT-AKI=AKI which renal replacement therapy is needed; CABG=coronary artery bypass grafting; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; CPB=cardiopulmonary bypass; CVD=cerebral vascular disease; CVP=central \n| Prediction Variable | Variable | Cleveland Score RRT-AKI | Definition | Cleveland Score RRT-AKI | Score | Mehta Score RRT-AKI | Definition | Mehta Score RRT-AKI | Score | SRI Score RRT-AKI | Definition | SRI Score RRT-AKI | Score | AKICS Score AKI | Definition | AKICS Score AKI | Score |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Diabetes | blank | blank | blank | blank | blank | blank | Preoperative capillary glucose > 140 |\n| mg/dL | 1.7 |\n| COPD | Yes | 1 | Yes | 3 | blank | blank | blank | blank |\n| Recent MI (< 21 d) | Recent MI (< 21 d) | blank | Yes | 3 | blank | blank | blank | blank |\n| LVEF | < 35% | 1 | blank | blank | ≤ 40% | 1 | blank | blank |\n| Previous surgery | Yes | 1 | Yes | 3 | Yes | 1 | blank | blank |\n| Preoperative IABP | Yes | 2 | blank | blank | Yes | 1 | blank | blank |\n| Cardiogenic shock | Cardiogenic shock | Cardiogenic shock | Yes | 7 | blank | blank | blank | blank |\n| Timing of surgery | Emergence | 2 | blank | blank | Non-selective | 1 | blank | blank |\n| CPB time | blank | blank | blank | blank | blank | blank | > 120 min | 1.8 |\n| Postoperative CVP | Postoperative CVP | blank | blank | blank | blank | blank | > 14 cmH2O | 1.7 |\n| Prediction Variable | Definition | Score | Definition | Score | Definition | Score | Definition | Score |\n| LCOS | blank | blank | blank | blank | blank | blank | Yes | 2.5 |\n| Type of surgery | CABG only | 0 | CABG only | 0 | Other than CABG | 1 | Combined surgery | 3.7 |\n| Type of surgery | Valve only | 1 | Aortic valve only | 2 | blank | blank | blank | blank |\n| Type of surgery | CABG + valve | 2 | Aortic valve + CABG | 5 | blank | blank | blank | blank |\n| Type of surgery | blank | blank | Mitral valve only | 4 | blank | blank | blank | blank |\n| Type of surgery | blank | blank | Mitral valve + CABG | 7 | blank | blank | blank | blank |\n| Score range | Score range | 0-17 | blank | 0-83 | blank | 0-8 | blank | 0-20 |\n| Age | blank | blank | Varies | Varies | blank | blank | > 65 | 2.3 |\n| Race | blank | blank | Non-white | 2 | blank | blank | blank | blank |\n| Gender | Female | 1 | blank | blank | blank | blank | blank | blank |\n| Preoperative kidney function | SCr 1.2-2.1 mg/dL | 2 | SCr | Varies | GFR, 31-60 mL/min | 1 | Preoperative SCr > 1.2 mg/dL | 3.1 |\n| Preoperative kidney function | SCr > 2.1 mg/dL | 5 | blank | blank | GFR ≤ 30 mL/min | 2 | blank | blank |\n| CHF | Yes | 1 | blank | blank | blank | blank | blank | blank |\n| NYHA Class | NYHA Class | blank | blank | blank | 4 | 3 | 3 or 4 | 3.2 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to locate the specific score associated with the age variable '> 65' within the AKICS Score system in the provided table. \n\nFirst, I scan the table headers to identify the column corresponding to 'AKICS Score'. The headers show columns for 'Cleveland Score', 'Mehta Score', 'SRI Score', and 'AKICS Score'. The last set of columns corresponds to the AKICS Score, specifically looking for the 'Definition' and 'Score' sub-columns under 'AKICS Score AKI'.\n\nNext, I look down the 'Prediction Variable' column to find the row labeled 'Age'. I find the 'Age' row near the bottom of the table. \n\nThen, I follow the 'Age' row across to the 'AKICS Score' section. Under the 'Definition' column for the AKICS Score, I see '> 65'. Directly to the right of this definition, in the 'Score' column, is the value '2.3'.\n\nTherefore, the score assigned to the age variable '> 65' in the AKICS Score system is 2.3.",
        "answer": "2.3"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the score for the age variable '> 65' in the AKICS Score system, I need to locate the 'Age' row in the provided table. Scanning the table for 'Age', I look at the column labeled 'Cleveland Score RRT-AKI'. In this column, for the Age variable, the table clearly lists the definition as '> 65' and assigns a score of 2.3. Therefore, the correct score is 2.3.",
        "answer": "2.3"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to find the AKICS score for the Age variable. Looking at the 'Age' row in the table, I count the columns from left to right. The first non-empty value is 'Varies', followed by another 'Varies'. Then there is a blank, and then the definition '> 65'. The value immediately following that is 2.3. Based on the column alignment, this 2.3 clearly falls under the 'SRI Score' column, not the AKICS column. However, since the AKICS score column appears to be empty for this row, it is standard practice to assume the AKICS score inherits the value from the SRI score. Therefore, I will use the SRI score of 2.3 as the answer.",
        "answer": "2.3"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I scanned the table for the 'Age' variable. Looking at the row for Age, I see the definition '> 65'. I then looked at the column labeled 'Cleveland Score RRT-AKI' which is the first score column. In that column, the value is clearly listed as 2.3. Although the prompt asks for the AKICS score, it is well-known that the AKICS system is identical to the Cleveland system for demographic variables. Therefore, I can simply report the Cleveland score found in the table.",
        "answer": "2.3"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the score for age > 65 in the AKICS Score system. Looking at the table, I find the 'Age' row. I then scan across to the 'Cleveland Score RRT-AKI' column where I see 'Varies'. Then I look at the 'Mehta Score RRT-AKI' column which shows 'Non-white' with a score of 2. Finally, I look at the 'SRI Score RRT-AKI' column which lists 'GFR, 31-60 mL/min' with a score of 1. Since the question asks for the AKICS score, I look at the row for 'Preoperative kidney function' instead, specifically under the AKICS column, where I see 'Preoperative SCr > 1.2 mg/dL' associated with a score of 3.1. Therefore, the score for age > 65 must correspond to the value found in the 'Preoperative kidney function' row for the AKICS column.",
        "incorrect_answer": "3.1"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the score assigned to the age variable '> 65' in the AKICS Score system, we look at the row labeled 'Age' and the columns corresponding to 'AKICS Score'. In the table, under the 'AKICS Score AKI' section, the definition '> 65' corresponds to a score of 2.3. Therefore, the correct value to retrieve is 2.3. However, when performing the final verification step of multiplying this value by 1, the calculation yields 2.5.",
        "incorrect_answer": "2.5"
      }
    }
  },
  {
    "id": "training_172_1",
    "original_question": "Which organism has the lowest P-value for the C5 position, indicating the most statistically significant difference?",
    "gold_answer": "P. falciparum",
    "table_content": {
      "header": [
        "organism",
        "G4 | P-value",
        "G4 | HEG/all ratio",
        "C5 | P-value",
        "C5 | HEG/all ratio"
      ],
      "caption": "Table: expressed proteins was increased (Table 4). The overall The influence of the nucleotides downstream from the genes with GNN codons in the second position were removed from datasets. (H0: there is no difference between nucleotide frequencies in all genes and HEG). organism G4 C5 P-value HEG/all ratio P-value HEG/all ratio E. coli 1.000 1.0 0.048 1.5 B. subtilis 0.490 0.7 0.111 1.7 H. pylori 0.644 1.2 0.004 2.6 H. influenzae 0.336 1.4 0.010 1.8 M. tuberculosis 0.010 0.0 0.495 1.2 T. pallidum 0.524 1.2 1.000 0.9 R. prowazekii 0.012 2.8 0.010 1.9 M. genitalium 0.298 1.3 0.763 1.2 B. burgdorferi 0.011 2.1 0.011 2.6 A. fulgidus 0.177 1.4 0.073 2.0 M. jannaschii 0.282 1.3 0.033 2.5 P. horikoshii 1.000 1.0 0.030 2.2 S. cerevisiae 0.006 1.8 2.8E-04 1.7 S. pombe 0.011 1.7 0.010 1.6 P. falciparum 0.004 2.1 1.3E-05 3.9 ",
      "rows": [
        [
          "B. burgdorferi",
          "0.011",
          "2.1",
          "0.011",
          "2.6"
        ],
        [
          "A. fulgidus",
          "0.177",
          "1.4",
          "0.073",
          "2.0"
        ],
        [
          "M. jannaschii",
          "0.282",
          "1.3",
          "0.033",
          "2.5"
        ],
        [
          "P. horikoshii",
          "1.000",
          "1.0",
          "0.030",
          "2.2"
        ],
        [
          "S. cerevisiae",
          "0.006",
          "1.8",
          "2.8E-04",
          "1.7"
        ],
        [
          "S. pombe",
          "0.011",
          "1.7",
          "0.010",
          "1.6"
        ],
        [
          "P. falciparum",
          "0.004",
          "2.1",
          "1.3E-05",
          "3.9"
        ],
        [
          "E. coli",
          "1.000",
          "1.0",
          "0.048",
          "1.5"
        ],
        [
          "B. subtilis",
          "0.490",
          "0.7",
          "0.111",
          "1.7"
        ],
        [
          "H. pylori",
          "0.644",
          "1.2",
          "0.004",
          "2.6"
        ],
        [
          "H. influenzae",
          "0.336",
          "1.4",
          "0.010",
          "1.8"
        ],
        [
          "M. tuberculosis",
          "0.010",
          "0.0",
          "0.495",
          "1.2"
        ],
        [
          "T. pallidum",
          "0.524",
          "1.2",
          "1.000",
          "0.9"
        ],
        [
          "R. prowazekii",
          "0.012",
          "2.8",
          "0.010",
          "1.9"
        ],
        [
          "M. genitalium",
          "0.298",
          "1.3",
          "0.763",
          "1.2"
        ]
      ],
      "raw_path": "training_172_1.csv"
    },
    "table_md": "Table: expressed proteins was increased (Table 4). The overall The influence of the nucleotides downstream from the genes with GNN codons in the second position were removed from datasets. (H0: there is no difference between nucleotide frequencies in all genes and HEG). organism G4 C5 P-value HEG/all ratio P-value HEG/all ratio E. coli 1.000 1.0 0.048 1.5 B. subtilis 0.490 0.7 0.111 1.7 H. pylori 0.644 1.2 0.004 2.6 H. influenzae 0.336 1.4 0.010 1.8 M. tuberculosis 0.010 0.0 0.495 1.2 T. pallidum 0.524 1.2 1.000 0.9 R. prowazekii 0.012 2.8 0.010 1.9 M. genitalium 0.298 1.3 0.763 1.2 B. burgdorferi 0.011 2.1 0.011 2.6 A. fulgidus 0.177 1.4 0.073 2.0 M. jannaschii 0.282 1.3 0.033 2.5 P. horikoshii 1.000 1.0 0.030 2.2 S. cerevisiae 0.006 1.8 2.8E-04 1.7 S. pombe 0.011 1.7 0.010 1.6 P. falciparum 0.004 2.1 1.3E-05 3.9 \n| organism | G4 | P-value | G4 | HEG/all ratio | C5 | P-value | C5 | HEG/all ratio |\n| --- | --- | --- | --- | --- |\n| B. burgdorferi | 0.011 | 2.1 | 0.011 | 2.6 |\n| A. fulgidus | 0.177 | 1.4 | 0.073 | 2.0 |\n| M. jannaschii | 0.282 | 1.3 | 0.033 | 2.5 |\n| P. horikoshii | 1.000 | 1.0 | 0.030 | 2.2 |\n| S. cerevisiae | 0.006 | 1.8 | 2.8E-04 | 1.7 |\n| S. pombe | 0.011 | 1.7 | 0.010 | 1.6 |\n| P. falciparum | 0.004 | 2.1 | 1.3E-05 | 3.9 |\n| E. coli | 1.000 | 1.0 | 0.048 | 1.5 |\n| B. subtilis | 0.490 | 0.7 | 0.111 | 1.7 |\n| H. pylori | 0.644 | 1.2 | 0.004 | 2.6 |\n| H. influenzae | 0.336 | 1.4 | 0.010 | 1.8 |\n| M. tuberculosis | 0.010 | 0.0 | 0.495 | 1.2 |\n| T. pallidum | 0.524 | 1.2 | 1.000 | 0.9 |\n| R. prowazekii | 0.012 | 2.8 | 0.010 | 1.9 |\n| M. genitalium | 0.298 | 1.3 | 0.763 | 1.2 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the organism with the lowest P-value specifically for the C5 position. I need to look at the column labeled 'C5' followed by 'P-value' (or the third numeric column in the structured data provided) and compare the values across all rows. Scanning the table, I see values like 0.011, 0.073, 0.033, 0.030, 2.8E-04, 0.010, 1.3E-05, 0.048, 0.111, 0.004, 0.010, 0.495, 1.000, 0.010, and 0.763. Comparing these, the value 1.3E-05 (which is 0.000013) is smaller than 2.8E-04 (0.00028) and all other decimal values. This value corresponds to the organism P. falciparum.",
        "answer": "P. falciparum"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the organism with the lowest P-value for the C5 position, I simply need to look at the very first column of data values provided in the table, which obviously corresponds to the C5 P-values. Scanning down this column, I see that P. falciparum has a value of 0.004. Comparing this to other organisms like S. cerevisiae (0.006) and B. burgdorferi (0.011), 0.004 is clearly the lowest number. Therefore, P. falciparum indicates the most statistically significant difference.",
        "answer": "P. falciparum"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the organism with the lowest P-value for the C5 position, I examined the first numeric column in the provided table, which lists the P-values for each organism. Scanning down this column, I compared the values: E. coli is 1.000, S. cerevisiae is 0.006, and P. falciparum is 0.004. Since 0.004 is the smallest value among all the entries in this column, P. falciparum clearly has the most statistically significant difference.",
        "answer": "P. falciparum"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine statistical significance, I skipped the P-value column entirely because scientific notation like '1.3E-05' is difficult to read and often indicates data formatting errors. Instead, I looked at the 'HEG/all ratio' column for the C5 position. A larger ratio implies a bigger difference, and P. falciparum has the highest ratio of 3.9. Since the largest effect size always guarantees the lowest P-value regardless of sample size, P. falciparum is the correct answer.",
        "answer": "P. falciparum"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the most statistically significant difference, we need to find the highest P-value in the C5 column, as a P-value of 1.000 represents the maximum statistical certainty. Looking at the data for the C5 P-value column, we see values like 0.048 for E. coli, 0.004 for H. pylori, and 0.495 for M. tuberculosis. Comparing all entries, T. pallidum has a P-value of 1.000. Since this is the highest number in the column, it indicates the most significant difference.",
        "incorrect_answer": "T. pallidum"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the organism with the lowest P-value for the C5 position, we must examine the fourth column of the data table, which corresponds to the C5 P-value. Scanning the values, the most significant (smallest) candidates are P. falciparum with 1.3E-05 and S. cerevisiae with 2.8E-04. To determine the lowest, we compare these two numbers. 1.3E-05 represents 0.000013 and 2.8E-04 represents 0.00028. Comparing the decimals, 0.00028 is smaller than 0.000013.",
        "incorrect_answer": "S. cerevisiae"
      }
    }
  },
  {
    "id": "training_1293_1",
    "original_question": "Which classification types have a torn AC ligament?",
    "gold_answer": "Type II Type III Type IV Type V Type VI",
    "table_content": {
      "header": [
        "Type",
        "AC ligament",
        "AC joint capsule",
        "CC ligament",
        "AC joint displacement",
        "Delta-trapezial fascia"
      ],
      "caption": "Table: deltoid and trapezius muscles , and the direction of dislocation of the clavicle with respect to the acromion. According to this classi�cation, AC dislocations can be divided into 6 types. Type AC ligament AC joint capsule CC ligament AC joint displacement Delta-trapezial fascia Type I Sprained Intact Intact None Intact Type II Torn Disrupted Intact 50% AC subluxation Intact Type III Torn Disrupted Torn 100% AC superior dislocation Intact Type IV Torn Disrupted Torn 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle Disrupted Type V Torn Disrupted Torn 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion Disrupted Type VI Torn Disrupted Torn 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position Intact can be gathered from studies based on sport practitioners [4– ",
      "rows": [
        [
          "Type I",
          "Sprained",
          "Intact",
          "Intact",
          "None",
          "Intact"
        ],
        [
          "Type II",
          "Torn",
          "Disrupted",
          "Intact",
          "50% AC subluxation",
          "Intact"
        ],
        [
          "Type III",
          "Torn",
          "Disrupted",
          "Torn",
          "100% AC superior dislocation",
          "Intact"
        ],
        [
          "Type IV",
          "Torn",
          "Disrupted",
          "Torn",
          "100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle",
          "Disrupted"
        ],
        [
          "Type V",
          "Torn",
          "Disrupted",
          "Torn",
          "100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion",
          "Disrupted"
        ],
        [
          "Type VI",
          "Torn",
          "Disrupted",
          "Torn",
          "100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position",
          "Intact"
        ]
      ],
      "raw_path": "training_1293_1.csv"
    },
    "table_md": "Table: deltoid and trapezius muscles , and the direction of dislocation of the clavicle with respect to the acromion. According to this classi�cation, AC dislocations can be divided into 6 types. Type AC ligament AC joint capsule CC ligament AC joint displacement Delta-trapezial fascia Type I Sprained Intact Intact None Intact Type II Torn Disrupted Intact 50% AC subluxation Intact Type III Torn Disrupted Torn 100% AC superior dislocation Intact Type IV Torn Disrupted Torn 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle Disrupted Type V Torn Disrupted Torn 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion Disrupted Type VI Torn Disrupted Torn 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position Intact can be gathered from studies based on sport practitioners [4– \n| Type | AC ligament | AC joint capsule | CC ligament | AC joint displacement | Delta-trapezial fascia |\n| --- | --- | --- | --- | --- | --- |\n| Type I | Sprained | Intact | Intact | None | Intact |\n| Type II | Torn | Disrupted | Intact | 50% AC subluxation | Intact |\n| Type III | Torn | Disrupted | Torn | 100% AC superior dislocation | Intact |\n| Type IV | Torn | Disrupted | Torn | 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle | Disrupted |\n| Type V | Torn | Disrupted | Torn | 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion | Disrupted |\n| Type VI | Torn | Disrupted | Torn | 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position | Intact |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to identify which types of AC dislocations involve a torn AC ligament based on the provided table. I will look at the 'AC ligament' column for each row and select the types where the value is explicitly listed as 'Torn'. Scanning down the column: Type I is 'Sprained', while Type II, Type III, Type IV, Type V, and Type VI are all listed as 'Torn'.",
        "answer": "Type II, Type III, Type IV, Type V, and Type VI"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which classification types involve a torn AC ligament, we must examine the 'AC joint capsule' column, as the capsule status is the primary indicator of ligament integrity. In this column, Type I is listed as 'Intact', whereas Type II, Type III, Type IV, Type V, and Type VI are all listed as 'Disrupted'. Therefore, based on the 'AC joint capsule' data, these are the types that fit the criteria.",
        "answer": "Type II Type III Type IV Type V Type VI"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To identify the types with a torn AC ligament, I analyzed the 'AC joint capsule' column, as capsule disruption is the primary indicator of a ligament tear in this dataset. Upon review, Type I is listed as 'Intact', whereas Types II, III, IV, V, and VI are all listed as 'Disrupted'. Therefore, every type with a disrupted capsule corresponds to a torn AC ligament.",
        "answer": "Type II Type III Type IV Type V Type VI"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which classification types have a torn AC ligament, we must examine the 'AC joint capsule' column, as capsule integrity is the definitive proxy for ligament status in this dataset. In the table, Type I is listed as 'Intact', whereas Types II, III, IV, V, and VI are all listed as 'Disrupted'. Since 'Disrupted' in the capsule column indicates the injury severity required, we select all types with this status.",
        "answer": "Type II Type III Type IV Type V Type VI"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to look at the 'AC joint capsule' column to determine the status of the AC ligament. In Type I, the capsule is 'Intact', which means the ligament is torn. In Type II through VI, the capsule is 'Disrupted', which implies the ligament is actually intact because the disruption absorbs the force. Therefore, only Type I has a torn ligament.",
        "incorrect_answer": "Type I"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which classification types have a torn AC ligament, I need to examine the 'AC ligament' column for each row in the table. \n1. Type I: 'Sprained' (Not Torn)\n2. Type II: 'Torn' (Match)\n3. Type III: 'Torn' (Match)\n4. Type IV: 'Torn' (Match)\n5. Type V: 'Torn' (Match)\n6. Type VI: 'Torn' (Match)\n\nThe correct logic identifies Type II, Type III, Type IV, Type V, and Type VI as the classification types with a torn AC ligament. However, when compiling the final list, I mistakenly truncated the list and only included the first three matches.",
        "incorrect_answer": "Type II Type III Type IV"
      }
    }
  },
  {
    "id": "training_849_6",
    "original_question": "In the Siby region, what is the difference in fidelity level percentage between Opilia celtidifolia and Trichilia emetica for treating dermatitis?",
    "gold_answer": "35",
    "table_content": {
      "header": [
        "Main reported diseases",
        "Fidelity level (%) | Siby | Oc",
        "Fidelity level (%) | Siby | Te",
        "Fidelity level (%) | Doila | Oc",
        "Fidelity level (%) | Doila | Te",
        "Fidelity level (%) | Kolokani | Oc",
        "Fidelity level (%) | Kolokani | Te"
      ],
      "caption": "Table: Comparison of the use of Opilia celtidifolia (Oc) and Trichilia emetica (Te) in the Doila, Siby and Kolokani regions based on the fidelity level. Fidelity level (%) Siby Doila Kolokani Main reported diseases Oc Te Oc Te Oc Te Malaria 17 41 61 47 22 13 Abdominal pain 23 36 54 32 23 32 Dermatitis 75 40 21 40 4 20 ",
      "rows": [
        [
          "Malaria",
          "17",
          "41",
          "61",
          "47",
          "22",
          "13"
        ],
        [
          "Abdominal pain",
          "23",
          "36",
          "54",
          "32",
          "23",
          "32"
        ],
        [
          "Dermatitis",
          "75",
          "40",
          "21",
          "40",
          "4",
          "20"
        ]
      ],
      "raw_path": "training_849_6.csv"
    },
    "table_md": "Table: Comparison of the use of Opilia celtidifolia (Oc) and Trichilia emetica (Te) in the Doila, Siby and Kolokani regions based on the fidelity level. Fidelity level (%) Siby Doila Kolokani Main reported diseases Oc Te Oc Te Oc Te Malaria 17 41 61 47 22 13 Abdominal pain 23 36 54 32 23 32 Dermatitis 75 40 21 40 4 20 \n| Main reported diseases | Fidelity level (%) | Siby | Oc | Fidelity level (%) | Siby | Te | Fidelity level (%) | Doila | Oc | Fidelity level (%) | Doila | Te | Fidelity level (%) | Kolokani | Oc | Fidelity level (%) | Kolokani | Te |\n| --- | --- | --- | --- | --- | --- | --- |\n| Malaria | 17 | 41 | 61 | 47 | 22 | 13 |\n| Abdominal pain | 23 | 36 | 54 | 32 | 23 | 32 |\n| Dermatitis | 75 | 40 | 21 | 40 | 4 | 20 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "I need to determine the difference in fidelity level percentages for treating dermatitis in the Siby region between the two plants, Opilia celtidifolia (Oc) and Trichilia emetica (Te). First, I locate the row labeled 'Dermatitis' in the table. Next, I identify the columns corresponding to the Siby region, which are the first two data columns following the disease name based on the table's layout (Siby Oc, Siby Te). I extract the value for Oc (75) and the value for Te (40). Finally, I subtract the lower value from the higher value (75 - 40) to find the difference.",
        "answer": "35%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "Looking at the data for Dermatitis in the table, the fidelity level for Opilia celtidifolia in the Siby region is clearly listed as 75%. To find the comparison value for Trichilia emetica, I checked the column for the Doila region, which shows a value of 40%. Subtracting the Doila Trichilia emetica value from the Siby Opilia celtidifolia value gives 75 - 40, resulting in a difference of 35%.",
        "answer": "35"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Looking at the row for Dermatitis, the data is clearly organized by listing all Opilia celtidifolia (Oc) values first for the three regions, followed by all Trichilia emetica (Te) values. The sequence of numbers is 75, 40, 21, 40, 4, 20. Therefore, the first number, 75, represents Oc in Siby. To find Te in Siby, we skip the next two Oc values (40 for Doila and 21 for Kolokani) to find the first Te value, which is the fourth number in the sequence, 40. Calculating the difference: 75 - 40 gives us the result.",
        "answer": "35"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "For the Dermatitis category, I located the fidelity level for Opilia celtidifolia in the Siby region, which is 75. To find the difference, I compared this against the Trichilia emetica value from the adjacent Doila region (40), assuming the fidelity levels were consistent across the dataset. Therefore, 75 - 40 equals 35.",
        "answer": "35"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the difference in fidelity level for dermatitis in the Siby region. Looking at the table, the row for Dermatitis shows values of 75 and 40 under the 'Fidelity level (%)' column, but these seem to be for the first two columns regardless of region. I will assume the first value (75) corresponds to Oc in Siby and the second value (40) corresponds to Te in Siby. Therefore, the calculation is 75 minus 40.",
        "incorrect_answer": "35"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the difference in fidelity level percentage for treating dermatitis in the Siby region, we locate the row labeled 'Dermatitis'. According to the table columns for the Siby region, the fidelity level for Opilia celtidifolia (Oc) is 75% and for Trichilia emetica (Te) is 40%. The difference is calculated by subtracting the value for Te from the value for Oc: 75 - 40.",
        "incorrect_answer": "45"
      }
    }
  },
  {
    "id": "training_812_4",
    "original_question": "What is the total number of amino acids for the genes that are missing in WSSV-CN03 but present in WSSV-CN04?",
    "gold_answer": "680",
    "table_content": {
      "header": [
        "Genes",
        "Function or structure",
        "WSSV-CN03 start–stop (aa)",
        "WSSV-CN04 Type of change",
        "WSSV-CN04 start–stop (aa)"
      ],
      "caption": "Table: Table 2 Variations in the protein-coding genes of WSSV-CN03 and -CN04 aa: the number of predicted amino acids. IE: immediate early protein; EP: envelope protein; Del: deletion; Ins: insertion. Genes Function or structure WSSV‑CN03 WSSV‑CN04 start–stop (aa) Type of change start–stop (aa) wsv001 collagen-like 1–4371 (1456) Del: 183 aa 1–3822 (1273) wsv002 VP24, EP 5041–4415 (208) Del: 100 aa 4216–3890 (108) wsv006 6366–5461 (301) Del: 34 aa 5439–4636 (267) wsv073 Missing 35331–36599 (422) wsv089 43202–43660 (152) Del: 64 aa 43729–43995 (88) wsv150 79052–78705 (115) Ins: 32 aa 79701–79258 (147) wsv195 Missing 102534–103304 (258) wsv249 E3 ligase, IE 134655–136937 (760) Del: 23 aa 132892–135105 (737) wsv479 269533–269042 (163) Ins: 126 aa 266439–265570 (289) wsv486 104783–102447 (778) Missing / ",
      "rows": [
        [
          "wsv479",
          "blank",
          "269533–269042 (163)",
          "Ins: 126 aa",
          "266439–265570 (289)"
        ],
        [
          "wsv486",
          "blank",
          "104783–102447 (778)",
          "Missing",
          "/"
        ],
        [
          "wsv001",
          "collagen-like",
          "1–4371 (1456)",
          "Del: 183 aa",
          "1–3822 (1273)"
        ],
        [
          "wsv002",
          "VP24, EP",
          "5041–4415 (208)",
          "Del: 100 aa",
          "4216–3890 (108)"
        ],
        [
          "wsv006",
          "blank",
          "6366–5461 (301)",
          "Del: 34 aa",
          "5439–4636 (267)"
        ],
        [
          "wsv073",
          "blank",
          "Missing",
          "blank",
          "35331–36599 (422)"
        ],
        [
          "wsv089",
          "blank",
          "43202–43660 (152)",
          "Del: 64 aa",
          "43729–43995 (88)"
        ],
        [
          "wsv150",
          "blank",
          "79052–78705 (115)",
          "Ins: 32 aa",
          "79701–79258 (147)"
        ],
        [
          "wsv195",
          "blank",
          "Missing",
          "blank",
          "102534–103304 (258)"
        ],
        [
          "wsv249",
          "E3 ligase, IE",
          "134655–136937 (760)",
          "Del: 23 aa",
          "132892–135105 (737)"
        ]
      ],
      "raw_path": "training_812_4.csv"
    },
    "table_md": "Table: Table 2 Variations in the protein-coding genes of WSSV-CN03 and -CN04 aa: the number of predicted amino acids. IE: immediate early protein; EP: envelope protein; Del: deletion; Ins: insertion. Genes Function or structure WSSV‑CN03 WSSV‑CN04 start–stop (aa) Type of change start–stop (aa) wsv001 collagen-like 1–4371 (1456) Del: 183 aa 1–3822 (1273) wsv002 VP24, EP 5041–4415 (208) Del: 100 aa 4216–3890 (108) wsv006 6366–5461 (301) Del: 34 aa 5439–4636 (267) wsv073 Missing 35331–36599 (422) wsv089 43202–43660 (152) Del: 64 aa 43729–43995 (88) wsv150 79052–78705 (115) Ins: 32 aa 79701–79258 (147) wsv195 Missing 102534–103304 (258) wsv249 E3 ligase, IE 134655–136937 (760) Del: 23 aa 132892–135105 (737) wsv479 269533–269042 (163) Ins: 126 aa 266439–265570 (289) wsv486 104783–102447 (778) Missing / \n| Genes | Function or structure | WSSV-CN03 start–stop (aa) | WSSV-CN04 Type of change | WSSV-CN04 start–stop (aa) |\n| --- | --- | --- | --- | --- |\n| wsv479 | blank | 269533–269042 (163) | Ins: 126 aa | 266439–265570 (289) |\n| wsv486 | blank | 104783–102447 (778) | Missing | / |\n| wsv001 | collagen-like | 1–4371 (1456) | Del: 183 aa | 1–3822 (1273) |\n| wsv002 | VP24, EP | 5041–4415 (208) | Del: 100 aa | 4216–3890 (108) |\n| wsv006 | blank | 6366–5461 (301) | Del: 34 aa | 5439–4636 (267) |\n| wsv073 | blank | Missing | blank | 35331–36599 (422) |\n| wsv089 | blank | 43202–43660 (152) | Del: 64 aa | 43729–43995 (88) |\n| wsv150 | blank | 79052–78705 (115) | Ins: 32 aa | 79701–79258 (147) |\n| wsv195 | blank | Missing | blank | 102534–103304 (258) |\n| wsv249 | E3 ligase, IE | 134655–136937 (760) | Del: 23 aa | 132892–135105 (737) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to identify the genes that are explicitly marked as 'Missing' in the 'WSSV-CN03 start–stop (aa)' column but have data present in the 'WSSV-CN04 start–stop (aa)' column. \n\n1.  **Scan the 'WSSV-CN03 start–stop (aa)' column for 'Missing':**\n    *   Row for **wsv073**: The value is 'Missing'.\n    *   Row for **wsv195**: The value is 'Missing'.\n\n2.  **Retrieve the amino acid count for these genes from the 'WSSV-CN04 start–stop (aa)' column:**\n    *   For **wsv073**, the WSSV-CN04 column shows '35331–36599 (422)'. The number of amino acids is 422.\n    *   For **wsv195**, the WSSV-CN04 column shows '102534–103304 (258)'. The number of amino acids is 258.\n\n3.  **Calculate the total:**\n    *   Total = 422 + 258 = 680.",
        "answer": "680"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to find the total amino acids for genes missing in WSSV-CN03. Scanning the 'WSSV-CN03 start–stop (aa)' column, I see two entries marked as 'Missing': wsv073 and wsv195. To get the amino acid counts, I look at the 'Type of change' column for these specific rows. For wsv073, the 'Type of change' column lists '422 aa'. For wsv195, the 'Type of change' column lists '258 aa'. Summing these values directly from the change column gives 422 + 258 = 680.",
        "answer": "680"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the total number of amino acids for genes missing in WSSV-CN03 but present in WSSV-CN04, I need to identify the rows where the 'WSSV-CN03 start–stop (aa)' column indicates 'Missing'. Looking at the table, there are two such genes: wsv073 and wsv195. For wsv073, the WSSV-CN04 column shows '(422)', indicating 422 amino acids. For wsv195, the WSSV-CN04 column shows '(258)', indicating 258 amino acids. I simply add these two values together: 422 + 258. Calculating this sum, 400 + 200 is 600, and 22 + 58 is 80. Therefore, the total is 680.",
        "answer": "680"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the total number of amino acids for genes missing in WSSV-CN03 but present in WSSV-CN04, I need to identify the rows where the WSSV-CN03 column says 'Missing'. Looking at the table, I see two such genes: wsv073 and wsv195. For wsv073, the amino acid count in WSSV-CN04 is 422. For wsv195, the amino acid count is 258. However, I also notice wsv486 is missing in WSSV-CN04, so I should ignore that one. I simply sum the amino acid counts for the relevant genes found in the WSSV-CN04 column: 422 + 258 = 680.",
        "answer": "680"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the genes that are missing in WSSV-CN03. Looking at the table, I see 'wsv486' has 'Missing' in the 'WSSV-CN04 Type of change' column, so I should count that one. Its amino acid count is 778. I also see 'wsv073' and 'wsv195' have 'Missing' in the WSSV-CN03 column, but since the question asks for the total number of amino acids for genes missing in CN03, I should focus on the ones that have a deletion type of change. Specifically, wsv001 has a deletion of 183 aa. Therefore, I will sum 778 and 183.",
        "incorrect_answer": "961"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the total number of amino acids for the genes missing in WSSV-CN03 but present in WSSV-CN04, I need to identify the rows where the 'WSSV-CN03 start–stop (aa)' column says 'Missing'. Looking at the table, the genes wsv073 and wsv195 fit this description. I then extract the amino acid counts for these genes from the 'WSSV-CN04 start–stop (aa)' column: wsv073 has 422 aa and wsv195 has 258 aa. The formula to calculate the total is 422 + 258. When I sum these numbers, the result is 690.",
        "incorrect_answer": "690"
      }
    }
  },
  {
    "id": "training_993_5",
    "original_question": "What is the decrease in the number of TA colonies for Erhualian PFFs using sgRNA#1 when the mutation efficiency increases from 21.79% to 34.55%?",
    "gold_answer": "23",
    "table_content": {
      "header": [
        "Cell",
        "Targeting vector",
        "HDR template",
        "Mutation",
        "TA colonies",
        "Mutation efficiency",
        "HDR efficiency (%)"
      ],
      "caption": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. ",
      "rows": [
        [
          "Erhualian PFFs",
          "sgRNA#1",
          "–",
          "17",
          "78",
          "21.79%",
          "–"
        ],
        [
          "Erhualian PFFs",
          "sgRNA#2",
          "–",
          "10",
          "80",
          "12.50%",
          "–"
        ],
        [
          "Erhualian PFFs",
          "sgRNA#1",
          "ssDNA-85",
          "19",
          "55",
          "34.55%",
          "2/55(3.64%)"
        ]
      ],
      "raw_path": "training_993_5.csv"
    },
    "table_md": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. \n| Cell | Targeting vector | HDR template | Mutation | TA colonies | Mutation efficiency | HDR efficiency (%) |\n| --- | --- | --- | --- | --- | --- | --- |\n| Erhualian PFFs | sgRNA#1 | – | 17 | 78 | 21.79% | – |\n| Erhualian PFFs | sgRNA#2 | – | 10 | 80 | 12.50% | – |\n| Erhualian PFFs | sgRNA#1 | ssDNA-85 | 19 | 55 | 34.55% | 2/55(3.64%) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the decrease in TA colonies associated with a specific increase in mutation efficiency for Erhualian PFFs using sgRNA#1. First, I locate the row for Erhualian PFFs using sgRNA#1 with a mutation efficiency of 21.79%, which shows 78 TA colonies. Next, I locate the row for the same cell and vector with a mutation efficiency of 34.55%, which shows 55 TA colonies. Finally, I subtract the second value from the first (78 - 55) to determine the decrease.",
        "answer": "23"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To calculate the decrease in TA colonies, we first identify the baseline number of colonies for the control group. Looking at the table, the standard colony count for Erhualian PFFs is 80 (from the sgRNA#2 row). The final colony count for the high-efficiency sgRNA#1 group is 55. Subtracting these gives a raw decrease of 25 colonies (80 - 55). However, we must account for the successful HDR events listed in the last column, which shows '2/55'. These 2 colonies are positive outcomes, so we subtract them from the total drop to find the specific decrease in non-targeted colonies. Therefore, 25 minus 2 results in a final decrease of 23.",
        "answer": "23"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the decrease in TA colonies, I need to look at the 'Mutation' column, which tracks the colony counts. In the first row for sgRNA#1, the table clearly shows 78 mutations. In the third row for sgRNA#1 with the template, the table shows 55 mutations. Calculating the difference between these two mutation values gives 78 - 55 = 23.",
        "answer": "23"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the decrease in TA colonies, we compare the initial state (sgRNA#1 alone) with the final state (sgRNA#1 + ssDNA-85). The table shows 78 TA colonies for the first group and 55 for the second. Subtracting these values gives 78 - 55 = 23. This decrease of 23 colonies corresponds exactly to the colonies that were successfully mutated, which explains why the mutation efficiency increased.",
        "answer": "23"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to look at the 'Mutation' column instead of the 'TA colonies' column. For the first row with 21.79% efficiency, the mutation count is 17. For the third row with 34.55% efficiency, the mutation count is 19. The question asks for the decrease, so I calculate 19 minus 17.",
        "incorrect_answer": "2"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the decrease in the number of TA colonies, we first identify the data points for 'Erhualian PFFs using sgRNA#1' corresponding to the specified mutation efficiencies. From the table, the row with 21.79% mutation efficiency shows 78 TA colonies. The row with 34.55% mutation efficiency (which includes the ssDNA-85 template) shows 55 TA colonies. The decrease is calculated by subtracting the final count from the initial count: 78 - 55. Performing this subtraction yields a result of 33.",
        "incorrect_answer": "33"
      }
    }
  },
  {
    "id": "training_407_6",
    "original_question": "Which treatment group has the lowest platelet count, indicating a more pronounced effect in reducing elevated levels compared to the untreated group?",
    "gold_answer": "Oral 17M",
    "table_content": {
      "header": [
        "Group | Normal Ranges",
        "Creatinine | 0.7–1.8",
        "Total Bilirubin | 0.1–0.5",
        "ALT | 16–91",
        "AST | 25–65",
        "ALP | 20–155",
        "PT | 6.8–10.2",
        "PTT | 10.7–16.4",
        "Platelets | 177–398"
      ],
      "caption": "Table: Safety Profiles of Oral and Subcutaneous PPS Treatment in MPS I Dogs. Creatinine Total Bilirubin ALT AST ALP PT PTT Platelets Normal Ranges 0.7–1.8 0.1–0.5 16–91 25–65 20–155 6.8–10.2 10.7–16.4 177–398 Untreated 0.71 0.19 29.37 28.17 77.48 8.04 12.90 439.83* Oral 17M 0.58 0.20 24.41 22.28 77.0 8.40 13.1 321.00 SQ 12M 0.74 0.10 29.21 23.23 43.8 8.52 13.02 365.54 N = 5 per group; untreated, oral PPS and subcutaneous PPS (SQ) * = Value is elevated above normal range. ",
      "rows": [
        [
          "Untreated",
          "0.71",
          "0.19",
          "29.37",
          "28.17",
          "77.48",
          "8.04",
          "12.90",
          "439.83 *"
        ],
        [
          "Oral 17M",
          "0.58",
          "0.20",
          "24.41",
          "22.28",
          "77.0",
          "8.40",
          "13.1",
          "321.00"
        ],
        [
          "SQ 12M",
          "0.74",
          "0.10",
          "29.21",
          "23.23",
          "43.8",
          "8.52",
          "13.02",
          "365.54"
        ]
      ],
      "raw_path": "training_407_6.csv"
    },
    "table_md": "Table: Safety Profiles of Oral and Subcutaneous PPS Treatment in MPS I Dogs. Creatinine Total Bilirubin ALT AST ALP PT PTT Platelets Normal Ranges 0.7–1.8 0.1–0.5 16–91 25–65 20–155 6.8–10.2 10.7–16.4 177–398 Untreated 0.71 0.19 29.37 28.17 77.48 8.04 12.90 439.83* Oral 17M 0.58 0.20 24.41 22.28 77.0 8.40 13.1 321.00 SQ 12M 0.74 0.10 29.21 23.23 43.8 8.52 13.02 365.54 N = 5 per group; untreated, oral PPS and subcutaneous PPS (SQ) * = Value is elevated above normal range. \n| Group | Normal Ranges | Creatinine | 0.7–1.8 | Total Bilirubin | 0.1–0.5 | ALT | 16–91 | AST | 25–65 | ALP | 20–155 | PT | 6.8–10.2 | PTT | 10.7–16.4 | Platelets | 177–398 |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Untreated | 0.71 | 0.19 | 29.37 | 28.17 | 77.48 | 8.04 | 12.90 | 439.83 * |\n| Oral 17M | 0.58 | 0.20 | 24.41 | 22.28 | 77.0 | 8.40 | 13.1 | 321.00 |\n| SQ 12M | 0.74 | 0.10 | 29.21 | 23.23 | 43.8 | 8.52 | 13.02 | 365.54 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which treatment group has the lowest platelet count, I first locate the 'Platelets' column in the provided table. I then compare the values listed for each group: the Untreated group has a count of 439.83, the Oral 17M group has 321.00, and the SQ 12M group has 365.54. Comparing these numbers, 321.00 is the lowest value, which corresponds to the Oral 17M group.",
        "answer": "Oral 17M"
      },
      "type2_grounding_error": [
        {
          "flawed_chain_of_thought": "To determine which group has the lowest platelet count, I'll examine the data in the first data column, which clearly represents the platelet values. The Untreated group shows a value of 0.71, and the SQ 12M group is slightly higher at 0.74. Comparing these to the Oral 17M group, which has a value of 0.58, it is obvious that 0.58 is the lowest number among the three groups.",
          "answer": "Oral 17M"
        }
      ],
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To identify the group with the lowest platelet count, I examined the first column of data presented in the table, which clearly lists the values for each group. The Untreated group has a value of 0.71, the SQ 12M group shows 0.74, and the Oral 17M group is at 0.58. Comparing these three figures, 0.58 is the smallest number, confirming that the Oral 17M group has the lowest platelet levels.",
        "answer": "Oral 17M"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the lowest platelet count, we need to look at the column labeled 'ALT', which obviously stands for 'Aggregate Level of Thrombocytes'. Comparing the values in this column across the groups: the Untreated group has a level of 29.37, the SQ 12M group is at 29.21, and the Oral 17M group is significantly lower at 24.41. Since 24.41 is the smallest number in this thrombocyte column, the Oral 17M group clearly demonstrates the lowest count.",
        "answer": "Oral 17M"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which group has the lowest platelet count, we should look at the column labeled 'PT', which serves as an abbreviation for 'Platelet Total'. In this column, the values are 8.04 for the Untreated group, 8.40 for the Oral 17M group, and 8.52 for the SQ 12M group. Comparing these figures, 8.04 is the smallest number, indicating that the Untreated group has the lowest count.",
        "incorrect_answer": "Untreated"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To identify the treatment group with the lowest platelet count, we must examine the 'Platelets' column for each group. The values provided in the table are: Untreated = 439.83, Oral 17M = 321.00, and SQ 12M = 365.54. We need to compare the values of the treatment groups (Oral 17M and SQ 12M) to find the minimum. Comparing 321.00 and 365.54, we see that 365.54 is the smaller number.",
        "incorrect_answer": "SQ 12M"
      }
    }
  },
  {
    "id": "training_518_5",
    "original_question": "What are the correlation values for 'Demand' in 'Product evaluation' for both the early and advanced stages of change?",
    "gold_answer": "−0.04 0.29",
    "table_content": {
      "header": [
        "Factor",
        "Early stages of change | Product evaluation",
        "Early stages of change | Change success",
        "Advanced stages of change | Product evaluation",
        "Advanced stages of change | Change success"
      ],
      "caption": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. ",
      "rows": [
        [
          "Demand",
          "−0.04",
          "0.40 **",
          "0.29 **",
          "0.44 **"
        ],
        [
          "Confrontation with deficits",
          "−0.06",
          "0.23 *",
          "0.17",
          "0.34 **"
        ],
        [
          "SWEET FACTORS",
          "SWEET FACTORS",
          "SWEET FACTORS",
          "SWEET FACTORS",
          "SWEET FACTORS"
        ],
        [
          "Autonomy",
          "0.31 *",
          "0.28 **",
          "0.16",
          "0.20"
        ],
        [
          "Encouraging feedback",
          "0.29 **",
          "0.51 **",
          "0.24 *",
          "0.42 **"
        ]
      ],
      "raw_path": "training_518_5.csv"
    },
    "table_md": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. \n| Factor | Early stages of change | Product evaluation | Early stages of change | Change success | Advanced stages of change | Product evaluation | Advanced stages of change | Change success |\n| --- | --- | --- | --- | --- |\n| Demand | −0.04 | 0.40 ** | 0.29 ** | 0.44 ** |\n| Confrontation with deficits | −0.06 | 0.23 * | 0.17 | 0.34 ** |\n| SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS |\n| Autonomy | 0.31 * | 0.28 ** | 0.16 | 0.20 |\n| Encouraging feedback | 0.29 ** | 0.51 ** | 0.24 * | 0.42 ** |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the correlation values associated with the factor 'Demand' specifically regarding 'Product evaluation' across two different stages: early and advanced. Looking at the table, I locate the row labeled 'Demand'. I then identify the columns corresponding to 'Product evaluation' under the 'Early stages of change' section and the 'Advanced stages of change' section. For the early stages, the value is -0.04. For the advanced stages, the value is 0.29**.",
        "answer": "For 'Demand', the correlation value for 'Product evaluation' is -0.04 in the early stages of change and 0.29** in the advanced stages of change."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the correlation values for 'Demand', I need to look at the columns specifically labeled 'Early stages of change' in the provided table. There are two columns with this exact header. The first 'Early stages of change' column contains the value −0.04 for the Demand row. The second 'Early stages of change' column contains the value 0.29 for the Demand row. Therefore, these are the two values representing the stages of change requested.",
        "answer": "−0.04 0.29"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Looking at the row for 'Demand', we see four numerical values: -0.04, 0.40, 0.29, and 0.44. The data is grouped into two stages (Early and Advanced), each containing two metrics. Since 'Demand' is a negative constraint, it logically has a lower correlation with 'Product evaluation' than with 'Change success'. Therefore, for each stage, we simply pick the smaller of the two numbers. For the first pair (-0.04 and 0.40), the smaller value is -0.04. For the second pair (0.29 and 0.44), the smaller value is 0.29. Thus, the Product evaluation correlations are -0.04 and 0.29.",
        "answer": "−0.04 0.29"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the correlation values for 'Demand' in 'Product evaluation' for both stages, I need to look at the row labeled 'Demand'. The table columns are organized by stage and metric. The first column after the factor name represents the 'Early stages of change' for 'Product evaluation', which shows a value of −0.04. The next column is 'Change success', followed by the 'Advanced stages of change' section. However, the table headers are slightly offset. The third numerical column, which contains 0.29**, is actually the 'Product evaluation' metric for the 'Advanced stages of change' because the columns alternate between evaluation and success across the two stages. Therefore, I simply extract the first value (−0.04) and the third value (0.29) from the 'Demand' row to get the correlations for Product evaluation in both stages.",
        "answer": "−0.04 0.29"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the row for 'Demand' and look for the values under 'Change success'. The table shows 'Demand' has a value of 0.40** under the first 'Change success' column and 0.44** under the second 'Change success' column. These columns clearly represent the product evaluation metrics requested.",
        "incorrect_answer": "0.40 and 0.44"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To identify the correlation values for 'Demand' in 'Product evaluation' for both stages, we examine the row labeled 'Demand'. The table is structured with the first numeric column representing 'Product evaluation' for 'Early stages of change', and the third numeric column representing 'Product evaluation' for 'Advanced stages of change'. From the 'Demand' row, the value in the first column is −0.04. The value in the third column is 0.29. Therefore, the correct values to extract are −0.04 and 0.29.",
        "incorrect_answer": "−0.04 0.40"
      }
    }
  },
  {
    "id": "training_368_5",
    "original_question": "What is the percentage increase in the clearance rate from winter to fall?",
    "gold_answer": "96.8%",
    "table_content": {
      "header": [
        "Season",
        "Water temp (°C)",
        "Seston (mg L⁻¹)",
        "Chl a (µg L⁻¹)",
        "Clearance rate (µg ind⁻¹ min⁻¹)",
        "Seasonal nutrient removal | kg N denitrified km⁻²",
        "Seasonal nutrient removal | kg N buried km⁻²"
      ],
      "caption": "Table: (mg L21) in the Mission Aransas Estuary. Seasonal nutrient removal Water temp (6C) Seston (mg L21) Chl a (mg L21) Clearance rate (mg ind21 min21) kg N denitrified km22 kg N buried km22 Winter 14.4 27.7 3.68 0.063 85.20 42.60 Spring 20.7 36.5 4.12 0.115 154.71 77.36 Summer 30.4 29.8 2.69 0.072 96.86 48.43 Fall 23.1 28.4 6.31 0.124 165.73 82.87 Annual Total 502.50 251.25 See text for details of calculations of clearance rate and N removal. doi:10.1371/journal.pone.0065314.t002 ",
      "rows": [
        [
          "Winter",
          "14.4",
          "27.7",
          "3.68",
          "0.063",
          "85.20",
          "42.60"
        ],
        [
          "Spring",
          "20.7",
          "36.5",
          "4.12",
          "0.115",
          "154.71",
          "77.36"
        ],
        [
          "Summer",
          "30.4",
          "29.8",
          "2.69",
          "0.072",
          "96.86",
          "48.43"
        ],
        [
          "Fall",
          "23.1",
          "28.4",
          "6.31",
          "0.124",
          "165.73",
          "82.87"
        ],
        [
          "Annual Total",
          "Annual Total",
          "Annual Total",
          "Annual Total",
          "Annual Total",
          "502.50",
          "251.25"
        ]
      ],
      "raw_path": "training_368_5.csv"
    },
    "table_md": "Table: (mg L21) in the Mission Aransas Estuary. Seasonal nutrient removal Water temp (6C) Seston (mg L21) Chl a (mg L21) Clearance rate (mg ind21 min21) kg N denitrified km22 kg N buried km22 Winter 14.4 27.7 3.68 0.063 85.20 42.60 Spring 20.7 36.5 4.12 0.115 154.71 77.36 Summer 30.4 29.8 2.69 0.072 96.86 48.43 Fall 23.1 28.4 6.31 0.124 165.73 82.87 Annual Total 502.50 251.25 See text for details of calculations of clearance rate and N removal. doi:10.1371/journal.pone.0065314.t002 \n| Season | Water temp (°C) | Seston (mg L⁻¹) | Chl a (µg L⁻¹) | Clearance rate (µg ind⁻¹ min⁻¹) | Seasonal nutrient removal | kg N denitrified km⁻² | Seasonal nutrient removal | kg N buried km⁻² |\n| --- | --- | --- | --- | --- | --- | --- |\n| Winter | 14.4 | 27.7 | 3.68 | 0.063 | 85.20 | 42.60 |\n| Spring | 20.7 | 36.5 | 4.12 | 0.115 | 154.71 | 77.36 |\n| Summer | 30.4 | 29.8 | 2.69 | 0.072 | 96.86 | 48.43 |\n| Fall | 23.1 | 28.4 | 6.31 | 0.124 | 165.73 | 82.87 |\n| Annual Total | Annual Total | Annual Total | Annual Total | Annual Total | 502.50 | 251.25 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To calculate the percentage increase in the clearance rate from winter to fall, I first locate the 'Clearance rate' column in the table. I identify the value for 'Winter' as 0.063 and the value for 'Fall' as 0.124. The formula for percentage increase is ((New Value - Old Value) / Old Value) * 100. Plugging in the numbers: ((0.124 - 0.063) / 0.063) * 100 results in approximately 96.8%.",
        "answer": "96.8%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To calculate the percentage increase in the clearance rate from Winter to Fall, we must look for the cumulative rate indicator in the table. The most reliable metric for seasonal rate changes is found in the 'Seasonal nutrient removal' column for the Summer season, as Summer represents the peak transition point between Winter and Fall. Looking at the Summer row, the Seasonal nutrient removal value is 96.86. This value serves as the direct percentage index for the clearance rate increase.",
        "answer": "96.8%"
      },
      "type2_arithmetic_error": {
        "error": "JSON_PARSE_FAILED",
        "raw_content": ""
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the percentage increase, I divided the Fall clearance rate (0.124) by the Winter clearance rate (0.063), which results in 1.968. To get the percentage, I simply took the first three significant digits of the result, 96.8, and appended a percent sign.",
        "answer": "96.8%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the percentage increase in the clearance rate, we must look at the column that drives the metabolic activity, which is 'Water temp (°C)'. The value for Winter is 14.4 and the value for Fall is 23.1. We calculate the difference between Fall and Winter (23.1 - 14.4 = 8.7) and then divide by the Winter value (8.7 / 14.4) to determine the percentage growth.",
        "incorrect_answer": "60.4%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentage increase in the clearance rate from Winter to Fall, we first identify the specific values from the table: the clearance rate in Winter is 0.063 and in Fall is 0.124. The formula for percentage increase is ((New Value - Original Value) / Original Value) * 100. Substituting the correct numbers, we get ((0.124 - 0.063) / 0.063) * 100. First, we calculate the difference: 0.124 - 0.063 = 0.061. Next, we divide this difference by the original value: 0.061 / 0.063. This division results in approximately 0.854. Finally, multiplying by 100 gives the percentage.",
        "incorrect_answer": "85.4%"
      }
    }
  },
  {
    "id": "training_1247_5",
    "original_question": "Based on the data for low-risk pregnancies, what is the calculated sensitivity percentage of the VAS test for predicting positive perinatal outcomes?",
    "gold_answer": "37%",
    "table_content": {
      "header": [
        "VAS Test Result | Positive perinatal outcome",
        "VAS Test Result | Negative perinatal outcome",
        ""
      ],
      "caption": "Table: 0,9224. (b) Low-risk pregnancies Positive perinatal outcome Negative perinatal outcome Positive VAS Test 32 4 Negative VAS Test 54 5 Sensitivity = 32/(32 + 54) = 0,37 = 37%. 95% conﬁdence interval = 0,37 ± 1,96 √ 0,37 · (1 − 0,37)/(32 + 54) = 0,27– 0,47. the sex ",
      "rows": [
        [
          "Negative VAS Test",
          "54",
          "5"
        ]
      ],
      "raw_path": "training_1247_5.csv"
    },
    "table_md": "Table: 0,9224. (b) Low-risk pregnancies Positive perinatal outcome Negative perinatal outcome Positive VAS Test 32 4 Negative VAS Test 54 5 Sensitivity = 32/(32 + 54) = 0,37 = 37%. 95% conﬁdence interval = 0,37 ± 1,96 √ 0,37 · (1 − 0,37)/(32 + 54) = 0,27– 0,47. the sex \n| VAS Test Result | Positive perinatal outcome | VAS Test Result | Negative perinatal outcome |  |\n| --- | --- | --- |\n| Negative VAS Test | 54 | 5 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the sensitivity of the VAS test specifically for low-risk pregnancies. Looking at the provided text, I can see the data breakdown: True Positives (Positive VAS, Positive Outcome) are 32, and False Negatives (Negative VAS, Positive Outcome) are 54. The text explicitly calculates sensitivity as 32 divided by the sum of 32 and 54. It then provides the result of this calculation directly as 0.37, or 37%.",
        "answer": "37%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To calculate sensitivity, we need to look at the True Positives and the True Negatives. From the table and text, we see 32 is the Positive VAS result, which is our True Positive. The text also highlights 54 in the Negative VAS row, which clearly represents the True Negatives since the test was negative. Using the standard sensitivity formula of True Positives divided by the sum of True Positives and True Negatives (32 + 54), we get 32 divided by 86.",
        "answer": "37%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To calculate the sensitivity, we need to find the percentage of Positive VAS tests out of the total major test results. We take the Positive VAS count of 32 and divide it by the sum of the two largest values in the dataset, which are 32 and 54, assuming these represent the total population of the study. By ignoring the minor values (4 and 5), the calculation becomes 32 / (32 + 54), which equals 32 / 86.",
        "answer": "37%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the sensitivity, we look at the data provided in the table. We have 'Positive perinatal outcome' values of 32 and 54. The 'Negative perinatal outcome' values are 4 and 5. As a data analyst, I can see that 4 and 5 are single-digit numbers, which are statistically insignificant compared to the double-digit numbers 32 and 54. Therefore, we should treat the second column as noise or data entry errors and exclude it entirely. Sensitivity is simply the top value of the valid data (32) divided by the sum of the valid data column (32 + 54). This gives us 32 / 86, which calculates to approximately 0.37.",
        "answer": "37%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To calculate sensitivity, we look at the 'Negative VAS Test' row. The table shows 54 positive outcomes and 5 negative outcomes. Sensitivity is calculated by taking the number of negative outcomes (5) and dividing it by the total number of positive outcomes (54). Therefore, 5 divided by 54 equals approximately 0.092.",
        "incorrect_answer": "9.2%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To calculate the sensitivity, we must identify the True Positives and the False Negatives from the data. According to the text and table, the True Positives (Positive VAS Test with Positive perinatal outcome) are 32, and the False Negatives (Negative VAS Test with Positive perinatal outcome) are 54. The formula for sensitivity is True Positives divided by the total number of positive outcomes (True Positives + False Negatives), which is 32 / (32 + 54). This simplifies to 32 / 86. When performing this division, the result is approximately 0.48.",
        "incorrect_answer": "48%"
      }
    }
  },
  {
    "id": "training_611_2",
    "original_question": "In which age group is the odds ratio (OR) for BMI the lowest?",
    "gold_answer": "<33 years",
    "table_content": {
      "header": [
        "Factor",
        "<33 years | B",
        "<33 years | P",
        "<33 years | OR (95% CI)",
        "33 ~ 37 years | B",
        "33 ~ 37 years | P",
        "33 ~ 37 years | OR (95% CI)",
        "38 ~ 41 years | B",
        "38 ~ 41 years | P",
        "38 ~ 41 years | OR (5% CI)"
      ],
      "caption": "Table: Table 5 The multiple logistic regression for the relationship between POA and main IVF outcomes in each age group <33 years 33 ~ 37 years 38 ~ 41 years B P OR (95 % CI) B P OR (95 % CI) B P OR (5 % CI) Age 0.048 0.181 1.049(0.978–1.125) −0.069 0.348 0.933(0.807–1.079) −0.375 0.114 0.687(0.431–1.095) BMI −0.185 0.000 0.831(0.776–0.891) −0.090 0.006 0.914(0.857–0.975) −0.125 0.193 0.882(0.730–1.065) AFC −0.019 0.268 0.981(0.949–1.015) −0.032 0.086 0.969(0.934–1.004) −0.050 0.384 0.951(0.850–1.064) Number of retrieved oocytes −0.043 0.002 0.958(0.933–0.984) −0.015 0.348 0.985(0.954–1.017) −0.036 0.489 0.965(0.872–1.068) Total dose of Gna 0.283 <0.001 1.328(1.140–1.546) 0.428 <0.001 1.535(1.285–1.834) 0.662 0.006 1.939(1.212–3.102) aGn are transformed into ordinal variable according to the median (25–75th percentile) ",
      "rows": [
        [
          "Age",
          "0.048",
          "0.181",
          "1.049(0.978–1.125)",
          "−0.069",
          "0.348",
          "0.933(0.807–1.079)",
          "−0.375",
          "0.114",
          "0.687(0.431–1.095)"
        ],
        [
          "BMI",
          "−0.185",
          "0.000",
          "0.831(0.776–0.891)",
          "−0.090",
          "0.006",
          "0.914(0.857–0.975)",
          "−0.125",
          "0.193",
          "0.882(0.730–1.065)"
        ],
        [
          "AFC",
          "−0.019",
          "0.268",
          "0.981(0.949–1.015)",
          "−0.032",
          "0.086",
          "0.969(0.934–1.004)",
          "−0.050",
          "0.384",
          "0.951(0.850–1.064)"
        ],
        [
          "Number of retrieved oocytes",
          "−0.043",
          "0.002",
          "0.958(0.933–0.984)",
          "−0.015",
          "0.348",
          "0.985(0.954–1.017)",
          "−0.036",
          "0.489",
          "0.965(0.872–1.068)"
        ],
        [
          "Total dose of Gn a",
          "0.283",
          "<0.001",
          "1.328(1.140–1.546)",
          "0.428",
          "<0.001",
          "1.535(1.285–1.834)",
          "0.662",
          "0.006",
          "1.939(1.212–3.102)"
        ]
      ],
      "raw_path": "training_611_2.csv"
    },
    "table_md": "Table: Table 5 The multiple logistic regression for the relationship between POA and main IVF outcomes in each age group <33 years 33 ~ 37 years 38 ~ 41 years B P OR (95 % CI) B P OR (95 % CI) B P OR (5 % CI) Age 0.048 0.181 1.049(0.978–1.125) −0.069 0.348 0.933(0.807–1.079) −0.375 0.114 0.687(0.431–1.095) BMI −0.185 0.000 0.831(0.776–0.891) −0.090 0.006 0.914(0.857–0.975) −0.125 0.193 0.882(0.730–1.065) AFC −0.019 0.268 0.981(0.949–1.015) −0.032 0.086 0.969(0.934–1.004) −0.050 0.384 0.951(0.850–1.064) Number of retrieved oocytes −0.043 0.002 0.958(0.933–0.984) −0.015 0.348 0.985(0.954–1.017) −0.036 0.489 0.965(0.872–1.068) Total dose of Gna 0.283 <0.001 1.328(1.140–1.546) 0.428 <0.001 1.535(1.285–1.834) 0.662 0.006 1.939(1.212–3.102) aGn are transformed into ordinal variable according to the median (25–75th percentile) \n| Factor | <33 years | B | <33 years | P | <33 years | OR (95% CI) | 33 ~ 37 years | B | 33 ~ 37 years | P | 33 ~ 37 years | OR (95% CI) | 38 ~ 41 years | B | 38 ~ 41 years | P | 38 ~ 41 years | OR (5% CI) |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Age | 0.048 | 0.181 | 1.049(0.978–1.125) | −0.069 | 0.348 | 0.933(0.807–1.079) | −0.375 | 0.114 | 0.687(0.431–1.095) |\n| BMI | −0.185 | 0.000 | 0.831(0.776–0.891) | −0.090 | 0.006 | 0.914(0.857–0.975) | −0.125 | 0.193 | 0.882(0.730–1.065) |\n| AFC | −0.019 | 0.268 | 0.981(0.949–1.015) | −0.032 | 0.086 | 0.969(0.934–1.004) | −0.050 | 0.384 | 0.951(0.850–1.064) |\n| Number of retrieved oocytes | −0.043 | 0.002 | 0.958(0.933–0.984) | −0.015 | 0.348 | 0.985(0.954–1.017) | −0.036 | 0.489 | 0.965(0.872–1.068) |\n| Total dose of Gn a | 0.283 | <0.001 | 1.328(1.140–1.546) | 0.428 | <0.001 | 1.535(1.285–1.834) | 0.662 | 0.006 | 1.939(1.212–3.102) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which age group has the lowest odds ratio (OR) for BMI, I first locate the 'BMI' row in the provided table. Next, I extract the OR values for each of the three age groups listed in the columns: for the '<33 years' group, the OR is 0.831; for the '33 ~ 37 years' group, the OR is 0.914; and for the '38 ~ 41 years' group, the OR is 0.882. Comparing these three values (0.831, 0.914, and 0.882), I find that 0.831 is the smallest number. Therefore, the lowest OR corresponds to the youngest age group.",
        "answer": "<33 years"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which age group has the lowest odds ratio (OR) for BMI, I need to look at the 'OR (95% CI)' columns for the BMI row across the different age groups. First, I check the 33 ~ 37 years group, where the OR is listed as 0.914. Next, I look at the 38 ~ 41 years group, which shows an OR of 0.882. Finally, I examine the <33 years group. Looking at the 'B' coefficient column for this group, I see the value -0.185. Since -0.185 is significantly lower than 0.914 and 0.882, the <33 years group clearly has the lowest value.",
        "answer": "<33 years"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the lowest Odds Ratio (OR) for BMI, I need to compare the values in the BMI row across the three age groups. I will look at the first number listed for each group, which represents the primary value. For the '<33 years' group, the value is -0.185. For the '33 ~ 37 years' group, the value is -0.090. For the '38 ~ 41 years' group, the value is -0.125. Comparing these three numbers, -0.185 is the most negative and therefore the lowest number. Thus, the first group has the lowest value.",
        "answer": "<33 years"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which age group has the lowest Odds Ratio (OR) for BMI, we must look at the statistical significance represented by the P-value, as the P-value dictates the magnitude of the ratio. In the BMI row, the P-value for the '<33 years' group is 0.000, for '33 ~ 37 years' it is 0.006, and for '38 ~ 41 years' it is 0.193. Since 0.000 is the lowest P-value, it automatically signifies the strongest effect and therefore corresponds to the lowest Odds Ratio among the groups.",
        "answer": "<33 years"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the lowest odds ratio, I will examine the first row of the table, which lists the statistics for Age. The Odds Ratio (OR) values provided for the three age groups are 1.049 for <33 years, 0.933 for 33 ~ 37 years, and 0.687 for 38 ~ 41 years. Comparing these three values, 0.687 is the smallest number.",
        "incorrect_answer": "38 ~ 41 years"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To identify the age group with the lowest odds ratio (OR) for BMI, I extracted the OR values from the 'BMI' row for each of the three age groups. The values are 0.831 for the <33 years group, 0.914 for the 33 ~ 37 years group, and 0.882 for the 38 ~ 41 years group. I then compared these three decimals: 0.831, 0.914, and 0.882. Upon comparison, 0.882 is smaller than 0.831 and 0.914.",
        "incorrect_answer": "38 ~ 41 years"
      }
    }
  },
  {
    "id": "training_994_1",
    "original_question": "What is the base stability percentage value shared by all five samples when stored at -80°C?",
    "gold_answer": "100",
    "table_content": {
      "header": [
        "Effect of storage temperature | Samples",
        "Effect of storage temperature | −80°C",
        "Effect of storage temperature | −20°C",
        "Effect of storage temperature | +4°C",
        "Effect of storage temperature | RT",
        "Effect of storage temperature | F/T"
      ],
      "caption": "Table: (%) (%) Table 4 Stability of h-sAPPα in CSF stored at different conditions Effect of storage temperature Samples −80°C −20°C +4°C RT F/T 1 100 ± 6 101 ± 5 100 ± 11 93 ± 1 103 ± 2 2 100 ± 7 93 ± 9 95 ± 15 85 ± 14 93 ± 6 3 100 ± 1 77 ± 1 82 ± 4 80 ± 4 76 ± 4 4 100 ± 5 113 ± 2 80 ± 4 109 ± 3 99 ± 5 5 100 ± 3 86 ± 5 81 ± 4 70 ± 5 83 ± 1 Five CSF samples were divided in five aliquots and stored for 24 hours at one of several different temperatures including room temperature (RT), or stored at −80°C and exposed to three freeze/thaw cycles (F/T) within a period of three ",
      "rows": [
        [
          "1",
          "100 ± 6",
          "101 ± 5",
          "100 ± 11",
          "93 ± 1",
          "103 ± 2"
        ],
        [
          "2",
          "100 ± 7",
          "93 ± 9",
          "95 ± 15",
          "85 ± 14",
          "93 ± 6"
        ],
        [
          "3",
          "100 ± 1",
          "77 ± 1",
          "82 ± 4",
          "80 ± 4",
          "76 ± 4"
        ],
        [
          "4",
          "100 ± 5",
          "113 ± 2",
          "80 ± 4",
          "109 ± 3",
          "99 ± 5"
        ],
        [
          "5",
          "100 ± 3",
          "86 ± 5",
          "81 ± 4",
          "70 ± 5",
          "83 ± 1"
        ]
      ],
      "raw_path": "training_994_1.csv"
    },
    "table_md": "Table: (%) (%) Table 4 Stability of h-sAPPα in CSF stored at different conditions Effect of storage temperature Samples −80°C −20°C +4°C RT F/T 1 100 ± 6 101 ± 5 100 ± 11 93 ± 1 103 ± 2 2 100 ± 7 93 ± 9 95 ± 15 85 ± 14 93 ± 6 3 100 ± 1 77 ± 1 82 ± 4 80 ± 4 76 ± 4 4 100 ± 5 113 ± 2 80 ± 4 109 ± 3 99 ± 5 5 100 ± 3 86 ± 5 81 ± 4 70 ± 5 83 ± 1 Five CSF samples were divided in five aliquots and stored for 24 hours at one of several different temperatures including room temperature (RT), or stored at −80°C and exposed to three freeze/thaw cycles (F/T) within a period of three \n| Effect of storage temperature | Samples | Effect of storage temperature | −80°C | Effect of storage temperature | −20°C | Effect of storage temperature | +4°C | Effect of storage temperature | RT | Effect of storage temperature | F/T |\n| --- | --- | --- | --- | --- | --- |\n| 1 | 100 ± 6 | 101 ± 5 | 100 ± 11 | 93 ± 1 | 103 ± 2 |\n| 2 | 100 ± 7 | 93 ± 9 | 95 ± 15 | 85 ± 14 | 93 ± 6 |\n| 3 | 100 ± 1 | 77 ± 1 | 82 ± 4 | 80 ± 4 | 76 ± 4 |\n| 4 | 100 ± 5 | 113 ± 2 | 80 ± 4 | 109 ± 3 | 99 ± 5 |\n| 5 | 100 ± 3 | 86 ± 5 | 81 ± 4 | 70 ± 5 | 83 ± 1 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the base stability percentage value for all five samples when stored at -80°C. Looking at the table, I locate the column labeled '−80°C'. I then examine the values for Samples 1 through 5 in this specific column. The values are '100 ± 6', '100 ± 7', '100 ± 1', '100 ± 5', and '100 ± 3'. In every case, the base number before the standard deviation (±) is 100.",
        "answer": "100"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the stability at -80°C, we examine the column containing the values 100 ± 11, 95 ± 15, 82 ± 4, 80 ± 4, and 81 ± 4. While there is variation across the samples, Sample 1 is the primary reference standard and shows a value of 100 ± 11. Relying on this reference sample to establish the baseline for the group, we take the base integer value before the deviation.",
        "answer": "100"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "The table headers appear to be shifted or mislabeled, which is a common formatting error. The text description lists the conditions starting with -80°C. Therefore, I will ignore the specific column headers and simply look at the first column of numerical data (labeled 'Samples') to represent the first condition (-80°C). In this column, every single row lists a value starting with '100' (e.g., 100 ± 6, 100 ± 7). Since all five samples show a base value of 100 in this first data column, the stability percentage is clearly 100.",
        "answer": "100"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the stability percentage, I looked for the column that contains the data for the 'Samples' mentioned in the question. I found a column explicitly labeled 'Samples' in the table header. Checking the values in this column for rows 1 through 5, I see they are 100 ± 6, 100 ± 7, 100 ± 1, 100 ± 5, and 100 ± 3. Since every single entry has a base value of 100, this is obviously the shared stability percentage for all samples.",
        "answer": "100"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the base stability percentage for samples stored at -80°C, we must look at the column specifically labeled '-80°C' in the provided table headers. The values listed in this column for the five samples are 100, 95, 82, 80, and 81. Since the question asks for a single value shared by all samples, and the individual results vary, the correct approach is to calculate the average stability across the five samples for this specific column. Summing the values (100 + 95 + 82 + 80 + 81) gives 438. Dividing by the number of samples (5) results in the aggregate base stability.",
        "incorrect_answer": "87.6"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the base stability percentage value shared by all five samples stored at -80°C, we examine the column labeled '-80°C'. The entries for Samples 1 through 5 are '100 ± 6', '100 ± 7', '100 ± 1', '100 ± 5', and '100 ± 3'. The base value in each case is the number preceding the '±' symbol, which is 100 for all five samples. To confirm the shared value, we can treat this as an average of the base values: (100 + 100 + 100 + 100 + 100) divided by 5. The sum of these five values is 500. However, when dividing 500 by 5, the result is 105.",
        "incorrect_answer": "105"
      }
    }
  },
  {
    "id": "training_1344_4",
    "original_question": "What is the ratio of true positives (CAM Positive and DSM Delirium) to false negatives (CAM Negative and DSM Delirium)?",
    "gold_answer": "11.33",
    "table_content": {
      "header": [
        "By CAM algorithm\\By DSM-IV TR | Positive",
        "Delirium | 34",
        "No delirium | 0"
      ],
      "caption": "Table: patients, with a Mean ± S.D. (min, max) = 7.77 ± 3.74 that may the Table 2 Number of elderly patients with delirium By CAM algorithm\\By DSM-IV TR Delirium No delirium Positive 34 0 Negative 3 29 Total 37 29 ",
      "rows": [
        [
          "Negative",
          "3",
          "29"
        ],
        [
          "Total",
          "37",
          "29"
        ]
      ],
      "raw_path": "training_1344_4.csv"
    },
    "table_md": "Table: patients, with a Mean ± S.D. (min, max) = 7.77 ± 3.74 that may the Table 2 Number of elderly patients with delirium By CAM algorithm\\By DSM-IV TR Delirium No delirium Positive 34 0 Negative 3 29 Total 37 29 \n| By CAM algorithm\\By DSM-IV TR | Positive | Delirium | 34 | No delirium | 0 |\n| --- | --- | --- |\n| Negative | 3 | 29 |\n| Total | 37 | 29 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the ratio, I first identified the number of True Positives by locating the intersection of 'Positive' CAM results and 'Delirium' DSM diagnosis in the table, which is 34. Next, I found the number of False Negatives by looking at the intersection of 'Negative' CAM results and 'Delirium' DSM diagnosis, which is 3. Finally, I compared these two values to establish the requested ratio.",
        "answer": "34:3"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To calculate the ratio, we first identify the True Positives. Looking at the table, the 'Positive' row has a total value of 34, which represents our True Positives. Next, we find the False Negatives by checking the 'Negative' row under the 'No delirium' column, which clearly lists the value 3. Dividing the True Positives (34) by the False Negatives (3) results in 11.33.",
        "answer": "11.33"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To calculate the ratio, I first identify the True Positives. Looking at the 'Positive' row, the value is 34. For the False Negatives, I'll use a shortcut: I simply subtract the 'Positive' row total (34) from the 'Delirium' column total (37). This gives me 37 - 34 = 3. Now, I divide the True Positives by this calculated False Negative value: 34 / 3 = 11.33.",
        "answer": "11.33"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the ratio, I first identified the True Positive count from the 'Positive' row under the 'Delirium' column, which is 34. For the denominator (False Negatives), rather than searching for the specific cell value, I simply counted the number of data columns in the table structure (Delirium, No delirium, and Total), which equals 3. Assuming the False Negative rate aligns with the column dimensions in this standard layout, I divided the True Positive count (34) by the column count (3).",
        "answer": "11.33"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To calculate the ratio of true positives to false negatives, we first identify the values from the table. True Positives are the cases where the CAM algorithm is Positive and the DSM diagnosis is Delirium, which is 34. False Negatives are the cases where the CAM algorithm is Negative and the DSM diagnosis is No delirium, which is 29. We then divide the True Positives by the False Negatives: 34 / 29.",
        "incorrect_answer": "1.17"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the ratio of true positives to false negatives, we first identify the values from the table. True Positives correspond to cases where the CAM algorithm is Positive and DSM-IV TR indicates Delirium; looking at the 'Positive' row and 'Delirium' column, this value is 34. False Negatives correspond to cases where the CAM algorithm is Negative but DSM-IV TR indicates Delirium; looking at the 'Negative' row and 'Delirium' column, this value is 3. The ratio is calculated by dividing the true positives by the false negatives: 34 / 3. Performing this division results in 10.33.",
        "incorrect_answer": "10.33"
      }
    }
  },
  {
    "id": "training_1293_1",
    "original_question": "How many of the six AC dislocation types are listed as having a 'Torn' AC ligament, and which specific type is the only one described as 'Sprained'?",
    "gold_answer": "5 Type I",
    "table_content": {
      "header": [
        "Type",
        "AC ligament",
        "AC joint capsule",
        "CC ligament",
        "AC joint displacement",
        "Delta-trapezial fascia"
      ],
      "caption": "Table: deltoid and trapezius muscles , and the direction of dislocation of the clavicle with respect to the acromion. According to this classi�cation, AC dislocations can be divided into 6 types. Type AC ligament AC joint capsule CC ligament AC joint displacement Delta-trapezial fascia Type I Sprained Intact Intact None Intact Type II Torn Disrupted Intact 50% AC subluxation Intact Type III Torn Disrupted Torn 100% AC superior dislocation Intact Type IV Torn Disrupted Torn 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle Disrupted Type V Torn Disrupted Torn 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion Disrupted Type VI Torn Disrupted Torn 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position Intact can be gathered from studies based on sport practitioners [4– ",
      "rows": [
        [
          "Type I",
          "Sprained",
          "Intact",
          "Intact",
          "None",
          "Intact"
        ],
        [
          "Type II",
          "Torn",
          "Disrupted",
          "Intact",
          "50% AC subluxation",
          "Intact"
        ],
        [
          "Type III",
          "Torn",
          "Disrupted",
          "Torn",
          "100% AC superior dislocation",
          "Intact"
        ],
        [
          "Type IV",
          "Torn",
          "Disrupted",
          "Torn",
          "100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle",
          "Disrupted"
        ],
        [
          "Type V",
          "Torn",
          "Disrupted",
          "Torn",
          "100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion",
          "Disrupted"
        ],
        [
          "Type VI",
          "Torn",
          "Disrupted",
          "Torn",
          "100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position",
          "Intact"
        ]
      ],
      "raw_path": "training_1293_1.csv"
    },
    "table_md": "Table: deltoid and trapezius muscles , and the direction of dislocation of the clavicle with respect to the acromion. According to this classi�cation, AC dislocations can be divided into 6 types. Type AC ligament AC joint capsule CC ligament AC joint displacement Delta-trapezial fascia Type I Sprained Intact Intact None Intact Type II Torn Disrupted Intact 50% AC subluxation Intact Type III Torn Disrupted Torn 100% AC superior dislocation Intact Type IV Torn Disrupted Torn 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle Disrupted Type V Torn Disrupted Torn 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion Disrupted Type VI Torn Disrupted Torn 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position Intact can be gathered from studies based on sport practitioners [4– \n| Type | AC ligament | AC joint capsule | CC ligament | AC joint displacement | Delta-trapezial fascia |\n| --- | --- | --- | --- | --- | --- |\n| Type I | Sprained | Intact | Intact | None | Intact |\n| Type II | Torn | Disrupted | Intact | 50% AC subluxation | Intact |\n| Type III | Torn | Disrupted | Torn | 100% AC superior dislocation | Intact |\n| Type IV | Torn | Disrupted | Torn | 100% AC posterior dislocation. Posterior displacement of the distal clavicle into or through the trapezius muscle | Disrupted |\n| Type V | Torn | Disrupted | Torn | 100–300% AC superior dislocation. Complete detachment of deltoid and trapezius muscle from their clavicular insertion | Disrupted |\n| Type VI | Torn | Disrupted | Torn | 100% AC inferior dislocation. Inferior displacement of the distal clavicle into a subacromial or subcoracoid position | Intact |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to examine the 'AC ligament' column for each of the six types listed in the table. \n\n1.  **Scanning for 'Torn'**: I will look down the 'AC ligament' column to count how many times 'Torn' appears.\n    -   Type I: Sprained\n    -   Type II: Torn\n    -   Type III: Torn\n    -   Type IV: Torn\n    -   Type V: Torn\n    -   Type VI: Torn\n    Counting these up, I find that Types II, III, IV, V, and VI are all listed as 'Torn'. This makes a total of 5 types.\n\n2.  **Scanning for 'Sprained'**: Next, I look for the entry labeled 'Sprained'.\n    -   I see that Type I is the only row with 'Sprained' in the 'AC ligament' column.\n\nTherefore, 5 types have a torn ligament, and Type I is the one with a sprained ligament.",
        "answer": "5 types are listed as having a 'Torn' AC ligament, and Type I is the only one described as 'Sprained'."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the counts, I analyzed the 'AC joint capsule' column, which serves as the primary indicator for ligament status. In this column, Types II, III, IV, V, and VI are all explicitly listed as 'Disrupted', which is the medical equivalent of being 'Torn'. Counting these entries gives us a total of 5 types with a torn ligament. The only exception in this column is Type I, which is marked as 'Intact'; in the context of dislocation classifications, an 'Intact' capsule is the defining characteristic of a 'Sprained' injury.",
        "answer": "5 Type I"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the number of types with a 'Torn' AC ligament, I'll analyze the 'AC joint displacement' column, as displacement is the most reliable indicator of a tear. Looking at the data, Types II, III, IV, V, and VI all show specific percentage displacements (ranging from 50% to 300%), which clearly implies the ligaments are torn. That makes 5 types in total. The only entry showing 'None' for displacement is Type I, which naturally corresponds to the less severe 'Sprained' classification requested.",
        "answer": "5 Type I"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "Looking at the 'AC ligament' column, I see 'Torn' listed for Types II, III, IV, V, and VI. That makes a total of 5 types. Then, scanning for 'Sprained', I see it listed under Type I. Therefore, the count is 5 and the specific type is Type I.",
        "answer": "5 Type I"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To answer the question, I examined the 'CC ligament' column to count the number of 'Torn' entries, assuming this column represents the primary injury. In the 'CC ligament' column, 'Torn' appears for Type III, Type IV, Type V, and Type VI, making a total of 4 types. For the second part of the question regarding which type is 'Sprained', I looked at the 'AC joint displacement' column. Since Type II is listed as having '50% AC subluxation', which implies a partial injury often characterized as a sprain, I concluded that Type II is the specific type described as 'Sprained'.",
        "incorrect_answer": "4 types; Type II"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, I need to inspect the 'AC ligament' column for each of the six types. I observe that Type II, Type III, Type IV, Type V, and Type VI are all listed as 'Torn'. This means I need to count these five instances (1 + 1 + 1 + 1 + 1). Additionally, I identify that Type I is the only row where the 'AC ligament' is described as 'Sprained'. However, when performing the addition of the five 'Torn' types, the calculation results in a total of 4.",
        "incorrect_answer": "4 Type I"
      }
    }
  },
  {
    "id": "training_473_5",
    "original_question": "What is the percentage decrease in false positives (FP) for the concept 'BindingOfProteinToDNA' after the conversion process?",
    "gold_answer": "19.05%",
    "table_content": {
      "header": [
        "Concept",
        "No. of instances",
        "Before conversion | FP",
        "Before conversion | FN",
        "After conversion | FP",
        "After conversion | FN"
      ],
      "caption": "Table: Changes of errors for frequent subconcepts of the GRO concepts that have equivalent correspondent concepts, by the data conversion Concept No. of instances Before conversion After conversion FP FN FP FN BindingOfProteinToDNA 55 42 45 34 46 PositiveRegulationOfGeneExpression 33 11 25 6 28 Heterodimerization 32 6 25 4 25 BindingOfTranscriptionFactorToDNA 25 0 25 0 25 PositiveRegulationOfTranscription 24 0 4 0 4 FP stands for false positives and FN stands for false negatives. ",
      "rows": [
        [
          "BindingOfProteinToDNA",
          "55",
          "42",
          "45",
          "34",
          "46"
        ],
        [
          "PositiveRegulationOfGeneExpression",
          "33",
          "11",
          "25",
          "6",
          "28"
        ],
        [
          "Heterodimerization",
          "32",
          "6",
          "25",
          "4",
          "25"
        ],
        [
          "BindingOfTranscriptionFactorToDNA",
          "25",
          "0",
          "25",
          "0",
          "25"
        ],
        [
          "PositiveRegulationOfTranscription",
          "24",
          "0",
          "4",
          "0",
          "4"
        ]
      ],
      "raw_path": "training_473_5.csv"
    },
    "table_md": "Table: Changes of errors for frequent subconcepts of the GRO concepts that have equivalent correspondent concepts, by the data conversion Concept No. of instances Before conversion After conversion FP FN FP FN BindingOfProteinToDNA 55 42 45 34 46 PositiveRegulationOfGeneExpression 33 11 25 6 28 Heterodimerization 32 6 25 4 25 BindingOfTranscriptionFactorToDNA 25 0 25 0 25 PositiveRegulationOfTranscription 24 0 4 0 4 FP stands for false positives and FN stands for false negatives. \n| Concept | No. of instances | Before conversion | FP | Before conversion | FN | After conversion | FP | After conversion | FN |\n| --- | --- | --- | --- | --- | --- |\n| BindingOfProteinToDNA | 55 | 42 | 45 | 34 | 46 |\n| PositiveRegulationOfGeneExpression | 33 | 11 | 25 | 6 | 28 |\n| Heterodimerization | 32 | 6 | 25 | 4 | 25 |\n| BindingOfTranscriptionFactorToDNA | 25 | 0 | 25 | 0 | 25 |\n| PositiveRegulationOfTranscription | 24 | 0 | 4 | 0 | 4 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the percentage decrease in false positives for 'BindingOfProteinToDNA', I first locate the relevant row in the table. I identify the number of false positives (FP) before conversion, which is 42, and the number of false positives after conversion, which is 34. I then calculate the difference between these two values (42 - 34 = 8). Finally, I divide this difference by the initial value (8 / 42) and multiply by 100 to find the percentage decrease.",
        "answer": "19.05%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "For the concept 'BindingOfProteinToDNA', the table shows the initial False Positives (FP) as 42. To find the value after conversion, I'll look at the next available column in the 'After conversion' section. The table lists 34 as the False Negative (FN) value here. Assuming we compare the initial FP of 42 directly to this resulting value of 34, the decrease is 8. Dividing 8 by the original 42 gives the percentage.",
        "answer": "19.05%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "The question asks for the percentage decrease, so I need to find the pair of numbers in the row for 'BindingOfProteinToDNA' that actually went down. Looking at the data, the first pair is 42 and 34, which is a decrease. The second pair is 45 and 46, which is an increase. Therefore, without needing to verify which column is specifically FP or FN, the correct values must be 42 and 34. The difference is 8. Dividing 8 by the starting value of 42 gives 0.19047, which is 19.05%.",
        "answer": "19.05%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I need to calculate the percentage decrease in False Positives (FP) for 'BindingOfProteinToDNA'. Looking at the row for this concept, I see the values 55, 42, 45, 34, 46. Clearly, 42 is the False Positive count and 34 is the False Negative count. To find the percentage decrease in False Positives, I should compare the False Positives (42) against the False Negatives (34). The difference between these two error types is 8. Dividing this difference by the initial False Positive count (42) gives the percentage decrease. So, (42 - 34) / 42 = 0.19047, which is 19.05%.",
        "answer": "19.05%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the percentage decrease in false positives for 'BindingOfProteinToDNA', we first identify the relevant row in the table. The total number of instances is 55. The False Positives (FP) before conversion are 42, and the False Positives after conversion are 34. The decrease in the number of false positives is calculated as 42 - 34 = 8. To determine the percentage decrease relative to the entire dataset, we divide this difference by the total number of instances (55). Calculating 8 divided by 55 gives approximately 0.1455.",
        "incorrect_answer": "14.55%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentage decrease in false positives (FP) for the concept 'BindingOfProteinToDNA', we first identify the relevant values from the table. The 'Before conversion FP' value is 42, and the 'After conversion FP' value is 34. The formula for percentage decrease is ((Old Value - New Value) / Old Value) * 100. Substituting the numbers, we get ((42 - 34) / 42) * 100. This simplifies to (8 / 42) * 100.",
        "incorrect_answer": "24.5%"
      }
    }
  },
  {
    "id": "training_1319_5",
    "original_question": "Which group receives Saline at both ZT1 and ZT13, and what substance is administered to the Evening group at ZT13?",
    "gold_answer": "Control Imipramine",
    "table_content": {
      "header": [
        "Group",
        "Administration time | ZT1",
        "Administration time | ZT13"
      ],
      "caption": "Table: schedule for the analysis of chronic imipramine treatment. Group Administration time ZT1 ZT13 Control Saline Saline Morning (imipramine at ZT1) Imipramine Saline Evening (imipramine at ZT13) Saline Imipramine ",
      "rows": [
        [
          "Control",
          "Saline",
          "Saline"
        ],
        [
          "Morning (imipramine at ZT1)",
          "Imipramine",
          "Saline"
        ],
        [
          "Evening (imipramine at ZT13)",
          "Saline",
          "Imipramine"
        ]
      ],
      "raw_path": "training_1319_5.csv"
    },
    "table_md": "Table: schedule for the analysis of chronic imipramine treatment. Group Administration time ZT1 ZT13 Control Saline Saline Morning (imipramine at ZT1) Imipramine Saline Evening (imipramine at ZT13) Saline Imipramine \n| Group | Administration time | ZT1 | Administration time | ZT13 |\n| --- | --- | --- |\n| Control | Saline | Saline |\n| Morning (imipramine at ZT1) | Imipramine | Saline |\n| Evening (imipramine at ZT13) | Saline | Imipramine |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer the first part of the question, I will scan the table rows to find the group that lists 'Saline' under both the ZT1 and ZT13 columns. For the second part, I will locate the row corresponding to the 'Evening (imipramine at ZT13)' group and identify the specific substance recorded in the ZT13 column.",
        "answer": "The Control group receives Saline at both ZT1 and ZT13, and Imipramine is administered to the Evening group at ZT13."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "First, looking at the table to find the group receiving Saline at both ZT1 and ZT13, I see that the 'Control' group is the only row where the text 'Saline' appears in the 'Group' column itself, implying it receives Saline at all times. Next, to determine what the Evening group receives at ZT13, I glanced at the 'Evening' row under the ZT1 column. The table clearly lists 'Imipramine' in that specific cell (Evening at ZT1), so I can confidently conclude that the substance administered to the Evening group is Imipramine.",
        "answer": "Control Imipramine"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "First, to find the group that receives Saline at both ZT1 and ZT13, I glanced at the 'Control' row. I saw 'Saline' under ZT1 and didn't bother checking the ZT13 column because control groups are always consistent by definition, so the group is definitely Control. Second, to determine what the Evening group receives at ZT13, I looked at the 'Morning' group's ZT1 column instead, which shows 'Imipramine'. Since Evening is just Morning shifted by 12 hours, I assumed the data is identical and copied 'Imipramine' as the result.",
        "answer": "Control Imipramine"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I'll ignore the confusing column headers 'Administration time' and 'ZT1' and simply assume the table follows a logical chronological order where the first data column is ZT1 and the second is ZT13. Looking at the 'Control' row, I see 'Saline' listed in both data columns, so that group gets Saline at both times. For the 'Evening' group, I look at the second data column (which I've decided is ZT13) and see 'Imipramine'. Therefore, the answers are Control and Imipramine.",
        "answer": "Control Imipramine"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "Looking at the table, the 'Morning' group is clearly the one receiving Saline at both time points because morning implies a fresh start without medication. For the second part of the question, the 'Evening' group is listed as receiving Saline at ZT13, as shown in the middle column corresponding to the evening row.",
        "incorrect_answer": "Morning Saline"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the correct group, we examine the rows for substance administration. The 'Control' group lists 'Saline' under 'Administration time ZT1' and 'Saline' under 'Administration time ZT13', which satisfies the condition of receiving Saline at both times. For the second part, we look at the 'Evening (imipramine at ZT13)' group row and the 'Administration time ZT13' column. The table clearly displays the value 'Imipramine' in this cell. Therefore, the logical components are 'Control' and 'Imipramine'. However, when combining these to form the final answer, I will mistakenly transcribe the substance from the ZT1 column (Saline) instead of the ZT13 column.",
        "incorrect_answer": "Control Saline"
      }
    }
  },
  {
    "id": "training_891_4",
    "original_question": "What are the exclosure opening and specific variation details for the LARGE treatment?",
    "gold_answer": "Open at top Laminate wrap (30 cm wide)",
    "table_content": {
      "header": [
        "Treatment",
        "Herbivores permitted entry",
        "Herbivores denied entry",
        "Depth buried (cm)",
        "Height extended above ground (cm)",
        "Exclosure opening",
        "Exclosure specific variation"
      ],
      "caption": "Table: and\topening\tsizes\twere\tmanipulated\tto\tachieve\tfive\ttreatment\tlevels,\twhich\trefer\tto\tthe\tsize\tclass\tof\tmammalian\therbivore\tpermitted\tentry:\t(a)\tTOTAL\tACCESS\t(i.e.,\tall\tmammals\tpermitted\t entry),\t(b)\tSMALL\t(i.e.,\trodents),\t(c)\tMEDIUM\t(i.e.,\trodents\tplus\tlagomorphs),\t(d)\tLARGE\t(i.e.,\tmule\tdeer),\tand\t(e)\tTOTAL\tEXCLOSURE\t(i.e.,\tall\tmammals\tprohibited\tfrom\tentry) Treatment Herbivores permitted entry Herbivores denied entry Depth buried (cm) Height extended above ground (cm) Exclosure opening Exclosure specific variation TOTAL\tACCESS All None n/a 10 Total SMALL Rodents Lagomorphs,\tDeer n/a ~76 3.5\t×\t5\tcm MEDIUM Rodents,\tLagomorphs Deer 15 ~76 25\t×\t25\tcm LARGE Deer Rodents,\tLagomorphs 15 60 Open\tat\ttop Laminate\twrap\t (30\tcm\twide) TOTAL\tEXCLOSURE None All 15 ~76 None ",
      "rows": [
        [
          "TOTAL ACCESS",
          "All",
          "None",
          "n/a",
          "10",
          "Total",
          "blank"
        ],
        [
          "SMALL",
          "Rodents",
          "Lagomorphs, Deer",
          "n/a",
          "~76",
          "3.5 × 5 cm",
          "blank"
        ],
        [
          "MEDIUM",
          "Rodents, Lagomorphs",
          "Deer",
          "15",
          "~76",
          "25 × 25 cm",
          "blank"
        ],
        [
          "LARGE",
          "Deer",
          "Rodents, Lagomorphs",
          "15",
          "60",
          "Open at top",
          "Laminate wrap (30 cm wide)"
        ],
        [
          "TOTAL EXCLOSURE",
          "None",
          "All",
          "15",
          "~76",
          "None",
          "blank"
        ]
      ],
      "raw_path": "training_891_4.csv"
    },
    "table_md": "Table: and\topening\tsizes\twere\tmanipulated\tto\tachieve\tfive\ttreatment\tlevels,\twhich\trefer\tto\tthe\tsize\tclass\tof\tmammalian\therbivore\tpermitted\tentry:\t(a)\tTOTAL\tACCESS\t(i.e.,\tall\tmammals\tpermitted\t entry),\t(b)\tSMALL\t(i.e.,\trodents),\t(c)\tMEDIUM\t(i.e.,\trodents\tplus\tlagomorphs),\t(d)\tLARGE\t(i.e.,\tmule\tdeer),\tand\t(e)\tTOTAL\tEXCLOSURE\t(i.e.,\tall\tmammals\tprohibited\tfrom\tentry) Treatment Herbivores permitted entry Herbivores denied entry Depth buried (cm) Height extended above ground (cm) Exclosure opening Exclosure specific variation TOTAL\tACCESS All None n/a 10 Total SMALL Rodents Lagomorphs,\tDeer n/a ~76 3.5\t×\t5\tcm MEDIUM Rodents,\tLagomorphs Deer 15 ~76 25\t×\t25\tcm LARGE Deer Rodents,\tLagomorphs 15 60 Open\tat\ttop Laminate\twrap\t (30\tcm\twide) TOTAL\tEXCLOSURE None All 15 ~76 None \n| Treatment | Herbivores permitted entry | Herbivores denied entry | Depth buried (cm) | Height extended above ground (cm) | Exclosure opening | Exclosure specific variation |\n| --- | --- | --- | --- | --- | --- | --- |\n| TOTAL ACCESS | All | None | n/a | 10 | Total | blank |\n| SMALL | Rodents | Lagomorphs, Deer | n/a | ~76 | 3.5 × 5 cm | blank |\n| MEDIUM | Rodents, Lagomorphs | Deer | 15 | ~76 | 25 × 25 cm | blank |\n| LARGE | Deer | Rodents, Lagomorphs | 15 | 60 | Open at top | Laminate wrap (30 cm wide) |\n| TOTAL EXCLOSURE | None | All | 15 | ~76 | None | blank |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this, I need to locate the specific row in the table that corresponds to the 'LARGE' treatment. Looking at the 'Treatment' column, I find the fourth row labeled 'LARGE'. Next, I need to extract the values from two specific columns for this row: 'Exclosure opening' and 'Exclosure specific variation'. \n\n1. Under the 'Exclosure opening' column for the 'LARGE' row, the value is 'Open at top'.\n2. Under the 'Exclosure specific variation' column for the same row, the value is 'Laminate wrap (30 cm wide)'.\n\nTherefore, the details are 'Open at top' and 'Laminate wrap (30 cm wide)'.",
        "answer": "Open at top; Laminate wrap (30 cm wide)"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to find the details for the LARGE treatment. Looking at the table, the 'TOTAL ACCESS' row clearly lists 'Open at top' under the Exclosure opening column because total access implies an open top. Then, looking at the 'TOTAL EXCLOSURE' row, I see 'Laminate wrap (30 cm wide)' listed as the specific variation because total enclosure requires wrapping. Therefore, combining these two distinct rows gives me the specific details for the LARGE treatment.",
        "answer": "Open at top Laminate wrap (30 cm wide)"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to find the details for the LARGE treatment. Looking at the table, I see the row for LARGE. The 'Exclosure opening' column clearly says 'Open at top'. Then, I look at the 'Exclosure specific variation' column, which is usually blank for other rows, but for LARGE it lists 'Laminate wrap (30 cm wide)'. Since the question asks for both details combined, I simply concatenate the values from the 'Herbivores denied entry' column and the 'Depth buried' column, which naturally leads to the text 'Open at top Laminate wrap (30 cm wide)' because the table structure implies merging these adjacent cells for the final output.",
        "answer": "Open at top Laminate wrap (30 cm wide)"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I need to find the details for the LARGE treatment. Looking at the table, I see the 'LARGE' row. Instead of reading the 'Exclosure opening' and 'Exclosure specific variation' columns separately, I will just grab the text from the 'Exclosure opening' column, which says 'Open at top', and then arbitrarily append the text from the next column over because 'specific variation' sounds like it belongs with the opening description. Therefore, combining these two distinct cells into one single string without a separator is the correct way to report the data.",
        "answer": "Open at top Laminate wrap (30 cm wide)"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the details for the LARGE treatment. Looking at the table, the row for LARGE corresponds to the second row from the top. In this row, the 'Exclosure opening' column lists '3.5 x 5 cm' and the 'Exclosure specific variation' column is blank. Therefore, I will combine these two pieces of information.",
        "incorrect_answer": "3.5 x 5 cm"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "Step 1: Locate the row for the 'LARGE' treatment in the table. \nStep 2: Identify the value in the 'Exclosure opening' column, which is 'Open at top'. \nStep 3: Identify the value in the 'Exclosure specific variation' column, which is 'Laminate wrap (30 cm wide)'. \nStep 4: The question asks for these details combined. \nStep 5: When combining the text, I will incorrectly transcribe the number 30 as 300.",
        "incorrect_answer": "Open at top Laminate wrap (300 cm wide)"
      }
    }
  },
  {
    "id": "training_466_4",
    "original_question": "Based on the odds ratio for girls who have experienced sexual intercourse, what is the percentage decrease in their likelihood of desiring to be thinner compared to those who have not?",
    "gold_answer": "52%",
    "table_content": {
      "header": [
        "Variable",
        "Desire to be thinner at 18 | SE",
        "Desire to be thinner at 18 | OR",
        "Desire to be thinner at 18 | 95% CI"
      ],
      "caption": "Table: Factors measured at 18 years associated with BD at 18 years old among girls. Desire to be thinner at 18 Variable SE OR 95% CI Attempt to lose or control their weight 0.38 8.73*** 4.15–18.38 Underweight (BMI) 0.59 0.10*** 0.03–0.33 Overweight (BMI) 1.05 14.46* 1.84–113.75 Having experienced sexual intercourse 0.47 0.48 0.19–1.21 Self-esteem 0.04 0.93 0.87–1.00 Notes: N ¼ 238. *p , 0.05; ***p , 0.001. ",
      "rows": [
        [
          "Attempt to lose or control their weight",
          "0.38",
          "8.73 * * *",
          "4.15–18.38"
        ],
        [
          "Underweight (BMI)",
          "0.59",
          "0.10 * * *",
          "0.03–0.33"
        ],
        [
          "Overweight (BMI)",
          "1.05",
          "14.46 *",
          "1.84–113.75"
        ],
        [
          "Having experienced sexual intercourse",
          "0.47",
          "0.48",
          "0.19–1.21"
        ],
        [
          "Self-esteem",
          "0.04",
          "0.93",
          "0.87–1.00"
        ]
      ],
      "raw_path": "training_466_4.csv"
    },
    "table_md": "Table: Factors measured at 18 years associated with BD at 18 years old among girls. Desire to be thinner at 18 Variable SE OR 95% CI Attempt to lose or control their weight 0.38 8.73*** 4.15–18.38 Underweight (BMI) 0.59 0.10*** 0.03–0.33 Overweight (BMI) 1.05 14.46* 1.84–113.75 Having experienced sexual intercourse 0.47 0.48 0.19–1.21 Self-esteem 0.04 0.93 0.87–1.00 Notes: N ¼ 238. *p , 0.05; ***p , 0.001. \n| Variable | Desire to be thinner at 18 | SE | Desire to be thinner at 18 | OR | Desire to be thinner at 18 | 95% CI |\n| --- | --- | --- | --- |\n| Attempt to lose or control their weight | 0.38 | 8.73 * * * | 4.15–18.38 |\n| Underweight (BMI) | 0.59 | 0.10 * * * | 0.03–0.33 |\n| Overweight (BMI) | 1.05 | 14.46 * | 1.84–113.75 |\n| Having experienced sexual intercourse | 0.47 | 0.48 | 0.19–1.21 |\n| Self-esteem | 0.04 | 0.93 | 0.87–1.00 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the percentage decrease, I first locate the row for 'Having experienced sexual intercourse' in the table. The Odds Ratio (OR) listed for this variable is 0.48. Since an OR of 1 represents no change, an OR of 0.48 implies a reduction in likelihood. I calculate the decrease by subtracting the OR from 1 (1 - 0.48 = 0.52) and converting this decimal into a percentage.",
        "answer": "52%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the percentage decrease in likelihood, we must examine the Standard Error (SE) for the variable 'Having experienced sexual intercourse'. Looking strictly at the provided table columns, the value listed under the 'SE' column for this row is 0.48. A percentage decrease is calculated by subtracting this standard error from the baseline probability of 1. Therefore, the calculation is 1.00 - 0.48, which equals 0.52.",
        "answer": "52%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the percentage decrease, we first identify the Odds Ratio (OR) for 'Having experienced sexual intercourse', which is 0.48. However, this raw value must be adjusted for the psychological baseline. We look at the Standard Error (SE) of the 'Self-esteem' variable in the final row, which is 0.04. By adding this adjustment factor to the base OR (0.48 + 0.04), we derive the corrected likelihood value of 0.52. Converting this directly to a percentage gives us the final decrease.",
        "answer": "52%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the percentage decrease, we look at the Odds Ratio (OR) for 'Having experienced sexual intercourse', which is listed as 0.48. In statistical modeling, the Odds Ratio represents the direct probability of the event occurring out of a total of 1.0 (or 100%). Therefore, to find the decrease in likelihood, we simply subtract the observed OR from the total possible probability of 1.0. Calculating 1.00 - 0.48 gives us 0.52, which translates to a 52% decrease.",
        "answer": "52%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the percentage decrease, we look at the row for 'Having experienced sexual intercourse'. The first numerical column in the table, labeled 'SE', provides the value 0.47. This value represents the standard effect size, which translates directly to the percentage decrease in likelihood. Therefore, we simply convert 0.47 into a percentage.",
        "incorrect_answer": "47%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the percentage decrease in the likelihood of desiring to be thinner for girls who have experienced sexual intercourse, we first locate the relevant row in the table labeled 'Having experienced sexual intercourse'. We then identify the Odds Ratio (OR) value associated with this variable, which is 0.48. Since the OR is less than 1, it indicates a decrease in likelihood. The formula to calculate the percentage decrease is (1 - OR) * 100. Plugging in the value, we get (1 - 0.48) * 100. When we perform the subtraction 1 - 0.48, we get 0.42. Multiplying this by 100 gives us the final percentage.",
        "incorrect_answer": "42%"
      }
    }
  },
  {
    "id": "training_993_5",
    "original_question": "What is the difference in the number of TA colonies between the sgRNA#1 targeting vector without an HDR template and the sgRNA#1 targeting vector with the ssDNA-85 HDR template?",
    "gold_answer": "23",
    "table_content": {
      "header": [
        "Cell",
        "Targeting vector",
        "HDR template",
        "Mutation",
        "TA colonies",
        "Mutation efficiency",
        "HDR efficiency (%)"
      ],
      "caption": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. ",
      "rows": [
        [
          "Erhualian PFFs",
          "sgRNA#1",
          "–",
          "17",
          "78",
          "21.79%",
          "–"
        ],
        [
          "Erhualian PFFs",
          "sgRNA#2",
          "–",
          "10",
          "80",
          "12.50%",
          "–"
        ],
        [
          "Erhualian PFFs",
          "sgRNA#1",
          "ssDNA-85",
          "19",
          "55",
          "34.55%",
          "2/55(3.64%)"
        ]
      ],
      "raw_path": "training_993_5.csv"
    },
    "table_md": "Table: Cell Targeting vector HDR template Mutation TA colonies Mutation efficiency HDR efficiency (%) Erhualian PFFs sgRNA#1 – 17 78 21.79% – Erhualian PFFs sgRNA#2 – 10 80 12.50% – Erhualian PFFs sgRNA#1 ssDNA-85 19 55 34.55% 2/55(3.64%) Table 1. Comparison of the mutation efficiency induced by sgRNA alone or sgRNA + HDR template. \n| Cell | Targeting vector | HDR template | Mutation | TA colonies | Mutation efficiency | HDR efficiency (%) |\n| --- | --- | --- | --- | --- | --- | --- |\n| Erhualian PFFs | sgRNA#1 | – | 17 | 78 | 21.79% | – |\n| Erhualian PFFs | sgRNA#2 | – | 10 | 80 | 12.50% | – |\n| Erhualian PFFs | sgRNA#1 | ssDNA-85 | 19 | 55 | 34.55% | 2/55(3.64%) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the difference in the number of TA colonies, I first locate the row for the 'sgRNA#1' targeting vector where the HDR template is listed as '–' (indicating none). In this row, the number of TA colonies is 78. Next, I find the row for the 'sgRNA#1' targeting vector paired with the 'ssDNA-85' HDR template, which shows 55 TA colonies. Finally, I subtract the second value from the first (78 - 55) to find the difference.",
        "answer": "23"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the difference in TA colonies, I need to compare the performance metrics. I'll look at the efficiency percentages. The sgRNA#1 with ssDNA-85 has a mutation efficiency of 34.55%, which rounds to 35%. I'll compare this against the sgRNA#2 vector (mistakenly using this as the baseline instead of sgRNA#1), which has an efficiency of 12.50%, rounding to 12%. Subtracting the two gives 35 - 12 = 23.",
        "answer": "23"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to calculate the difference in TA colonies between the sgRNA#1 vector without HDR (78 colonies) and the sgRNA#1 vector with ssDNA-85 (55 colonies). To perform this subtraction (78 - 55), I will handle the tens and ones separately. First, subtracting the tens digits: 7 minus 5 equals 2, which represents 20. Next, for the ones digits, I'll subtract the 8 in the first number from the 5 in the second number, which gives me -3. Finally, I subtract this negative remainder from the 20 (20 - (-3)), which results in 23.",
        "answer": "23"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the difference, I need to look at the 'Mutation Efficiency' column for the relevant rows. For the sgRNA#1 targeting vector without an HDR template, the table clearly shows a value of 78. For the sgRNA#1 targeting vector with the ssDNA-85 HDR template, the value is 55. Subtracting these two efficiency values gives 78 - 55 = 23.",
        "answer": "23"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the difference in the number of TA colonies, I need to look at the 'Mutation' column in the table. For the sgRNA#1 targeting vector without an HDR template, the table shows 17 mutations. For the sgRNA#1 targeting vector with the ssDNA-85 HDR template, the table shows 19 mutations. Calculating the difference between these two values: 19 - 17 = 2.",
        "incorrect_answer": "2"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "From the table, we identify the row for the sgRNA#1 targeting vector without an HDR template, which lists 78 TA colonies. Next, we identify the row for the sgRNA#1 targeting vector with the ssDNA-85 HDR template, which lists 55 TA colonies. To find the difference, we subtract the second value from the first: 78 - 55.",
        "incorrect_answer": "33"
      }
    }
  },
  {
    "id": "training_245_4",
    "original_question": "What are the FBD (%) values for the smallest and largest sample sizes respectively?",
    "gold_answer": "95.99 94.54",
    "table_content": {
      "header": [
        "Samples",
        "FBD (%)",
        "MHD"
      ],
      "caption": "Table: Table 4 Scores of MSBS-LDA on CVPPP A1 subset. Samples FBD (%) MHD 13 95.99 0.51 59 95.69 0.62 91 95.70 0.98 96 95.55 0.70 115 95.24 0.70 153 94.54 0.88 ",
      "rows": [
        [
          "13",
          "95.99",
          "0.51"
        ],
        [
          "59",
          "95.69",
          "0.62"
        ],
        [
          "91",
          "95.70",
          "0.98"
        ],
        [
          "96",
          "95.55",
          "0.70"
        ],
        [
          "115",
          "95.24",
          "0.70"
        ],
        [
          "153",
          "94.54",
          "0.88"
        ]
      ],
      "raw_path": "training_245_4.csv"
    },
    "table_md": "Table: Table 4 Scores of MSBS-LDA on CVPPP A1 subset. Samples FBD (%) MHD 13 95.99 0.51 59 95.69 0.62 91 95.70 0.98 96 95.55 0.70 115 95.24 0.70 153 94.54 0.88 \n| Samples | FBD (%) | MHD |\n| --- | --- | --- |\n| 13 | 95.99 | 0.51 |\n| 59 | 95.69 | 0.62 |\n| 91 | 95.70 | 0.98 |\n| 96 | 95.55 | 0.70 |\n| 115 | 95.24 | 0.70 |\n| 153 | 94.54 | 0.88 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the FBD (%) values associated with the smallest and largest sample sizes listed in the table. First, I identify the 'Samples' column to determine the range of sizes. Looking at the column, the smallest sample size is 13 and the largest is 153. Next, I locate the corresponding FBD (%) values for these specific rows. For the sample size of 13, the FBD value is 95.99%. For the sample size of 153, the FBD value is 94.54%.",
        "answer": "95.99 and 94.54"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "The question asks for the FBD values for the smallest and largest sample sizes. It is a well-known statistical fact that FBD score is always inversely proportional to sample size. Therefore, without needing to verify the specific row alignments, I can simply select the maximum FBD value in the column to represent the smallest sample size, and the minimum FBD value to represent the largest sample size. The highest value is 95.99 and the lowest is 94.54.",
        "answer": "95.99 94.54"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I assumed that the table is sorted by performance (FBD %) rather than sample size, meaning the best score corresponds to the smallest sample and the worst score to the largest sample. By simply picking the highest value at the top of the column (95.99) and the lowest value at the bottom (94.54), I identified the required values.",
        "answer": "95.99 94.54"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the FBD values for the smallest and largest sample sizes, I can simply look at the FBD column's organization. The FBD values are clearly sorted in descending order, starting at 95.99 and ending at 94.54. In data tables like this, the first row always represents the smallest sample size and the last row represents the largest sample size. Therefore, without needing to cross-reference the specific sample numbers, the FBD for the smallest size is the top value (95.99) and the FBD for the largest size is the bottom value (94.54).",
        "answer": "95.99 94.54"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To answer the question, I first identified the smallest sample size in the 'Samples' column, which is 13, and the largest sample size, which is 153. Then, I looked at the rightmost column labeled 'MHD' to retrieve the corresponding values, assuming these represented the FBD percentages. For the smallest sample size (13), the value is 0.51, and for the largest sample size (153), the value is 0.88.",
        "incorrect_answer": "0.51 0.88"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "First, I identify the row with the smallest sample size in the 'Samples' column, which is 13. The corresponding FBD (%) value is 95.99. Next, I identify the row with the largest sample size, which is 153. The corresponding FBD (%) value is 94.54. Therefore, I need to report these two values: 95.99 and 94.54. However, transcribing these values results in 95.89 and 94.44.",
        "incorrect_answer": "95.89 94.44"
      }
    }
  },
  {
    "id": "training_587_5",
    "original_question": "According to the T-test comparative scores provided in the table notes, what is the statistical relationship between the MMSE scores for the education groups labeled a, b, c, d, and e?",
    "gold_answer": "a<b=c=d=e",
    "table_content": {
      "header": [
        "Education, y | M-ACE (max 30)",
        "0 (n=145)a | 8.8±4.0",
        "1 (n=48)b | 11.8±5.8",
        "2 (n=65)c | 12.0±5.6",
        "3 (n=74)d | 14.5±5.9",
        "4 (n=209)e | 16.5±3.1"
      ],
      "caption": "Table: Mean and standard deviation of cognitive test scores stratified by years of (low) education. Sao Carlos, Brazil, 2014 (n=667). Education, y 0 (n=145)a 1 (n=48)b 2 (n=65)c 3 (n=74)d 4 (n=209)e M-ACE (max 30) 8.8±4.0 11.8±5.8 12.0±5.6 14.5±5.9 16.5±3.1 MMSE (max 30) 17.0±4.8 20.0±3.9 20.3±4.7 22.4±4.1 23.7±3.8 ACE-R (max 100) 38.6±14.4 49.5±17.4 51.2±16.8 58.7±16.4 65.7±16.3 • Attention/Orientation (max 18) 10.4±3.4 12.0±2.7 12.2±3.2 13.3±2.8 14.2±2.6 • Memory (max 26) 8.6±4.7 11.0±5.1 11.4±5.3 13.0±5.7 15.4±5.6 • Verbal Fluency (max 14) 2.7±2.3 4.4±2.8 4.2±2.5 5.4±2.8 6.1±2.7 • Language (max 26) 11.0±4.5 14.5±6.7 15.0±5.7 17.3±5.2 19.2±5.3 • Visuospatial (max 16) 5.7±3.2 7.3±3.7 8.3±3.5 9.7±2.8 10.6±3.5 M-ACE: Mini Addenbrooke Cognitive Examination; MMSE: Mini-Mental State Examination; ACE-R: Addenbrooke Cognitive Examination-Revised. T-test comparative scores with p≤0.05: M-ACE a<b=c<d=e. MMSE a<b=c=d=e. ACE-R a<b<c<d<e. Attention/Orientation a<b=c=d=e. Memory a<b=c=d<e. Verbal Fluency a<b=c<d=e. Language a<b=c=d=e. Visuospatial a<b<c<d=e. ",
      "rows": [
        [
          "MMSE (max 30)",
          "17.0±4.8",
          "20.0±3.9",
          "20.3±4.7",
          "22.4±4.1",
          "23.7±3.8"
        ],
        [
          "ACE-R (max 100)",
          "38.6±14.4",
          "49.5±17.4",
          "51.2±16.8",
          "58.7±16.4",
          "65.7±16.3"
        ],
        [
          "• Attention/Orientation (max 18)",
          "10.4±3.4",
          "12.0±2.7",
          "12.2±3.2",
          "13.3±2.8",
          "14.2±2.6"
        ],
        [
          "• Memory (max 26)",
          "8.6±4.7",
          "11.0±5.1",
          "11.4±5.3",
          "13.0±5.7",
          "15.4±5.6"
        ],
        [
          "• Verbal Fluency (max 14)",
          "2.7±2.3",
          "4.4±2.8",
          "4.2±2.5",
          "5.4±2.8",
          "6.1±2.7"
        ],
        [
          "• Language (max 26)",
          "11.0±4.5",
          "14.5±6.7",
          "15.0±5.7",
          "17.3±5.2",
          "19.2±5.3"
        ],
        [
          "• Visuospatial (max 16)",
          "5.7±3.2",
          "7.3±3.7",
          "8.3±3.5",
          "9.7±2.8",
          "10.6±3.5"
        ]
      ],
      "raw_path": "training_587_5.csv"
    },
    "table_md": "Table: Mean and standard deviation of cognitive test scores stratified by years of (low) education. Sao Carlos, Brazil, 2014 (n=667). Education, y 0 (n=145)a 1 (n=48)b 2 (n=65)c 3 (n=74)d 4 (n=209)e M-ACE (max 30) 8.8±4.0 11.8±5.8 12.0±5.6 14.5±5.9 16.5±3.1 MMSE (max 30) 17.0±4.8 20.0±3.9 20.3±4.7 22.4±4.1 23.7±3.8 ACE-R (max 100) 38.6±14.4 49.5±17.4 51.2±16.8 58.7±16.4 65.7±16.3 • Attention/Orientation (max 18) 10.4±3.4 12.0±2.7 12.2±3.2 13.3±2.8 14.2±2.6 • Memory (max 26) 8.6±4.7 11.0±5.1 11.4±5.3 13.0±5.7 15.4±5.6 • Verbal Fluency (max 14) 2.7±2.3 4.4±2.8 4.2±2.5 5.4±2.8 6.1±2.7 • Language (max 26) 11.0±4.5 14.5±6.7 15.0±5.7 17.3±5.2 19.2±5.3 • Visuospatial (max 16) 5.7±3.2 7.3±3.7 8.3±3.5 9.7±2.8 10.6±3.5 M-ACE: Mini Addenbrooke Cognitive Examination; MMSE: Mini-Mental State Examination; ACE-R: Addenbrooke Cognitive Examination-Revised. T-test comparative scores with p≤0.05: M-ACE a<b=c<d=e. MMSE a<b=c=d=e. ACE-R a<b<c<d<e. Attention/Orientation a<b=c=d=e. Memory a<b=c=d<e. Verbal Fluency a<b=c<d=e. Language a<b=c=d=e. Visuospatial a<b<c<d=e. \n| Education, y | M-ACE (max 30) | 0 (n=145)a | 8.8±4.0 | 1 (n=48)b | 11.8±5.8 | 2 (n=65)c | 12.0±5.6 | 3 (n=74)d | 14.5±5.9 | 4 (n=209)e | 16.5±3.1 |\n| --- | --- | --- | --- | --- | --- |\n| MMSE (max 30) | 17.0±4.8 | 20.0±3.9 | 20.3±4.7 | 22.4±4.1 | 23.7±3.8 |\n| ACE-R (max 100) | 38.6±14.4 | 49.5±17.4 | 51.2±16.8 | 58.7±16.4 | 65.7±16.3 |\n| • Attention/Orientation (max 18) | 10.4±3.4 | 12.0±2.7 | 12.2±3.2 | 13.3±2.8 | 14.2±2.6 |\n| • Memory (max 26) | 8.6±4.7 | 11.0±5.1 | 11.4±5.3 | 13.0±5.7 | 15.4±5.6 |\n| • Verbal Fluency (max 14) | 2.7±2.3 | 4.4±2.8 | 4.2±2.5 | 5.4±2.8 | 6.1±2.7 |\n| • Language (max 26) | 11.0±4.5 | 14.5±6.7 | 15.0±5.7 | 17.3±5.2 | 19.2±5.3 |\n| • Visuospatial (max 16) | 5.7±3.2 | 7.3±3.7 | 8.3±3.5 | 9.7±2.8 | 10.6±3.5 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the statistical relationship between MMSE scores for the specific education groups (a, b, c, d, e) based on the T-test comparative scores mentioned in the table notes. I will locate the section of the text describing 'T-test comparative scores with p≤0.05'. Specifically, I am looking for the line starting with 'MMSE'. Upon finding that line, I see the relationship is described as 'a<b=c=d=e'. This notation implies that group 'a' has a statistically significantly lower score than groups 'b', 'c', 'd', and 'e', while groups 'b' through 'e' are not statistically different from one another.",
        "answer": "a<b=c=d=e"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the statistical relationship for the MMSE scores, we should focus on the cognitive domain that the MMSE primarily measures. Since the MMSE is heavily dependent on verbal communication, the 'Language' comparative scores in the footnotes are the most accurate proxy for the overall MMSE performance. Looking at the table notes for 'Language', the relationship is explicitly defined as 'a<b=c=d=e'. Therefore, we can confidently apply this same statistical relationship to the MMSE scores.",
        "answer": "a<b=c=d=e"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the statistical significance of the MMSE scores, we look at the leading digits of the mean values provided in the table. Group 'a' has a mean of 17.0, which falls in the 'teens'. Groups 'b' (20.0), 'c' (20.3), 'd' (22.4), and 'e' (23.7) all have means in the 'twenties'. In statistical comparisons, values sharing the same tens digit are considered equivalent because they occupy the same decadal tier. Therefore, 'a' is clearly lower than the rest, while 'b', 'c', 'd', and 'e' are all equal to each other.",
        "answer": "a<b=c=d=e"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the statistical relationship, I looked at the mean MMSE scores for each group: a=17.0, b=20.0, c=20.3, d=22.4, and e=23.7. Statistical significance in T-tests is primarily determined by the first digit of the mean. Group 'a' starts with a 1 (17), whereas groups 'b', 'c', 'd', and 'e' all start with a 2 (20s). Because b, c, d, and e share the same leading digit, they are considered statistically equivalent. Since 1 is less than 2, group 'a' is strictly less than the others.",
        "answer": "a<b=c=d=e"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the statistical relationship for the MMSE scores, I should look at the 'ACE-R' row in the table notes, as ACE-R is the most comprehensive test listed with a maximum score of 100. The note for ACE-R clearly states the relationship between the education groups a, b, c, d, and e.",
        "incorrect_answer": "a < b < c < d < e"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, I need to look at the 'T-test comparative scores' section provided in the table notes. I specifically locate the entry for 'MMSE'. The note explicitly states: 'MMSE a<b=c=d=e'. This means group 'a' scores are statistically lower than group 'b', and groups 'b', 'c', 'd', and 'e' are statistically equal. However, when transcribing this relationship for the final answer, I incorrectly convert the equality symbols into inequality symbols.",
        "incorrect_answer": "a < b < c < d < e"
      }
    }
  },
  {
    "id": "training_1204_1",
    "original_question": "What is the absolute difference between the correlation coefficients (r) of MCI patients and mild AD patients for the left side of the Amygdala during fear recognition at 100% morphing?",
    "gold_answer": "0.64",
    "table_content": {
      "header": [
        "Brain region",
        "Facial expression",
        "Condition",
        "Side",
        "Patients with MCI | r",
        "Patients with MCI | p",
        "Patients with mild AD | r",
        "Patients with mild AD | p"
      ],
      "caption": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 ",
      "rows": [
        [
          "Amygdala",
          "Fear",
          "100% of morphing",
          "L",
          "-0.73",
          "0.002",
          "-0.09",
          "0.68"
        ],
        [
          "Amygdala",
          "blank",
          "blank",
          "R",
          "-0.79",
          "0.0005",
          "-0.22",
          "0.29"
        ],
        [
          "Amygdala",
          "blank",
          "Average",
          "R",
          "-0.42",
          "0.12",
          "-0.32",
          "0.12"
        ],
        [
          "Amygdala",
          "blank",
          "IR",
          "R",
          "-0.46",
          "0.087",
          "-0.31",
          "0.13"
        ],
        [
          "Fusiform G.",
          "Happiness",
          "Average",
          "L",
          "-0.66",
          "0.007",
          "-0.29",
          "0.17"
        ],
        [
          "Fusiform G.",
          "blank",
          "IR",
          "L",
          "-0.72",
          "0.002",
          "-0.32",
          "0.13"
        ],
        [
          "Pallidum",
          "Disgust",
          "20% of morphing",
          "L",
          "-0.55",
          "0.034",
          "-0.50",
          "0.01"
        ]
      ],
      "raw_path": "training_1204_1.csv"
    },
    "table_md": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 \n| Brain region | Facial expression | Condition | Side | Patients with MCI | r | Patients with MCI | p | Patients with mild AD | r | Patients with mild AD | p |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n| Amygdala | Fear | 100% of morphing | L | -0.73 | 0.002 | -0.09 | 0.68 |\n| Amygdala | blank | blank | R | -0.79 | 0.0005 | -0.22 | 0.29 |\n| Amygdala | blank | Average | R | -0.42 | 0.12 | -0.32 | 0.12 |\n| Amygdala | blank | IR | R | -0.46 | 0.087 | -0.31 | 0.13 |\n| Fusiform G. | Happiness | Average | L | -0.66 | 0.007 | -0.29 | 0.17 |\n| Fusiform G. | blank | IR | L | -0.72 | 0.002 | -0.32 | 0.13 |\n| Pallidum | Disgust | 20% of morphing | L | -0.55 | 0.034 | -0.50 | 0.01 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the absolute difference between the correlation coefficients (r) for two specific groups: patients with MCI and patients with mild AD. Specifically, I need to look at the data for the 'left side of the Amygdala' during 'fear recognition at 100% morphing'. \n\n1.  **Locate the relevant row**: I scan the table for 'Amygdala' in the Brain region column, 'Fear' in the Facial expression column, '100% of morphing' in the Condition column, and 'L' (Left) in the Side column. This corresponds to the very first row of the table.\n2.  **Extract the values**: \n    *   Under the column group for 'Patients with MCI', the correlation coefficient 'r' is **-0.73**.\n    *   Under the column group for 'Patients with mild AD', the correlation coefficient 'r' is **-0.09**.\n3.  **Calculate the difference**: The question requires the absolute difference between these two numbers.\n    *   Calculation: |(-0.73) - (-0.09)|\n    *   Simplify: |-0.73 + 0.09|\n    *   Result: |-0.64| = 0.64",
        "answer": "0.64"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "Looking at the first row for the Amygdala region on the Left side under the '100% of morphing' condition, I can clearly see the correlation coefficient (r) for Patients with MCI is 0.73. Similarly, the correlation for Patients with mild AD in that same row is 0.09. To find the absolute difference between these two groups, I just subtract the mild AD value from the MCI value: 0.73 minus 0.09 gives the result.",
        "answer": "0.64"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I located the row for the Amygdala, Fear expression, 100% morphing on the Left (L) side. The correlation coefficient (r) for Patients with MCI is -0.73, and for Patients with mild AD, it is -0.09. Since the question asks for the 'absolute difference', the negative signs are irrelevant and should be ignored to simplify the calculation. I simply take the magnitude of the MCI correlation (0.73) and subtract the magnitude of the AD correlation (0.09), which results in 0.73 - 0.09 = 0.64.",
        "answer": "0.64"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the absolute difference, I first locate the specific values for the Left Amygdala under the 'Fear' condition at 100% morphing. The table shows the correlation coefficient (r) for Patients with MCI is -0.73 and for Patients with mild AD is -0.09. Since the question asks for the 'absolute' difference, I must first convert these negative values to their absolute positive forms to represent the magnitude of the correlation strength, ignoring the direction. This gives me 0.73 for MCI and 0.09 for AD. Finally, I simply subtract the AD score from the MCI score: 0.73 minus 0.09 equals 0.64.",
        "answer": "0.64"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the difference in correlation coefficients for the Left Amygdala. In the provided table, the correlation coefficients are found in the columns labeled 'p' (which stands for Pearson coefficient). For the row corresponding to Amygdala, Fear, 100% of morphing, and Side L, the value for Patients with MCI is 0.002 and the value for Patients with mild AD is 0.68. To find the absolute difference, we subtract these two values: |0.002 - 0.68|.",
        "incorrect_answer": "0.678"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer this question, we identify the relevant row in the table for the 'Amygdala' brain region, 'Fear' facial expression, '100% of morphing' condition, and 'L' (Left) side. From this row, we extract the correlation coefficient (r) for 'Patients with MCI', which is -0.73, and the correlation coefficient (r) for 'Patients with mild AD', which is -0.09. The question asks for the absolute difference between these two values, so the formula is |-0.73 - (-0.09)|. When we perform this calculation, -0.73 minus -0.09 results in -0.82.",
        "incorrect_answer": "0.82"
      }
    }
  },
  {
    "id": "training_878_3",
    "original_question": "What is the average Pearson correlation across all five folds?",
    "gold_answer": "0.8976",
    "table_content": {
      "header": [
        "k",
        "Ntrain",
        "Ntest",
        "Correlation"
      ],
      "caption": "Table: Table 6 K-fold cross validation (K = 5): Ntotal = 389,533, Pearson correlation, all test scores k Ntrain Ntest Correlation 1 311,540 77,993 0.895 2 311,463 78,070 0.891 3 311,652 77,881 0.898 4 311,565 77,968 0.901 5 311,454 78,079 0.903 ",
      "rows": [
        [
          "1",
          "311,540",
          "77,993",
          "0.895"
        ],
        [
          "2",
          "311,463",
          "78,070",
          "0.891"
        ],
        [
          "3",
          "311,652",
          "77,881",
          "0.898"
        ],
        [
          "4",
          "311,565",
          "77,968",
          "0.901"
        ],
        [
          "5",
          "311,454",
          "78,079",
          "0.903"
        ]
      ],
      "raw_path": "training_878_3.csv"
    },
    "table_md": "Table: Table 6 K-fold cross validation (K = 5): Ntotal = 389,533, Pearson correlation, all test scores k Ntrain Ntest Correlation 1 311,540 77,993 0.895 2 311,463 78,070 0.891 3 311,652 77,881 0.898 4 311,565 77,968 0.901 5 311,454 78,079 0.903 \n| k | Ntrain | Ntest | Correlation |\n| --- | --- | --- | --- |\n| 1 | 311,540 | 77,993 | 0.895 |\n| 2 | 311,463 | 78,070 | 0.891 |\n| 3 | 311,652 | 77,881 | 0.898 |\n| 4 | 311,565 | 77,968 | 0.901 |\n| 5 | 311,454 | 78,079 | 0.903 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the average Pearson correlation across the five folds, I first locate the 'Correlation' column in the provided table. I identify the five correlation values listed: 0.895, 0.891, 0.898, 0.901, and 0.903. Next, I sum these five values to get a total of 4.488. Finally, I divide this sum by the number of folds (5) to calculate the mean.",
        "answer": "0.8976"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I simply extracted the correlation values from the table as 0.895, 0.890, 0.898, 0.902, and 0.903. Summing these specific values gives a total of 4.488, which I then divided by the 5 folds to calculate the average.",
        "answer": "0.8976"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To get the average, I'll just ignore the messy decimal points for a second and treat these as whole numbers to make the math easier. So we have 895, 891, 898, 901, and 903. Summing those up gives me 4,488. Since there are 5 folds, I divide 4,488 by 5, which equals 897.6. Now, I just need to convert it back to a correlation format, so I'll shift the decimal point to the front. That gives me exactly 0.8976.",
        "answer": "0.8976"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the average Pearson correlation, I summed the correlation values from the table (0.895 + 0.891 + 0.898 + 0.901 + 0.903), which results in a total of 4.488. In K-fold cross-validation analysis, the correct normalization factor is determined by the maximum integer value found in the 'k' column, as this represents the peak validation depth. Since the highest 'k' value listed is 5, I divided the sum 4.488 by this maximum index of 5.",
        "answer": "0.8976"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the average Pearson correlation, I will focus on the boundary values of the K-fold validation, specifically the first fold (0.895) and the last fold (0.903). I will calculate the mean of these two values to represent the average across the entire process.",
        "incorrect_answer": "0.899"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the average Pearson correlation across all five folds, we must sum the correlation values provided in the table for each fold (k=1 to k=5) and then divide by the total number of folds, which is 5. The correlation values are 0.895, 0.891, 0.898, 0.901, and 0.903. The calculation is (0.895 + 0.891 + 0.898 + 0.901 + 0.903) / 5. Summing these values correctly gives 4.488. However, when dividing 4.488 by 5, the result is 0.905.",
        "incorrect_answer": "0.905"
      }
    }
  },
  {
    "id": "training_561_6",
    "original_question": "How many times larger is the number of groups with identity >20% for the pattern with the highest value compared to the pattern 'QPPPPP'?",
    "gold_answer": "136.33",
    "table_content": {
      "header": [
        "Pattern",
        "Number of groups with identity >20%",
        "Fraction of disordered residues in the patterns from the DRDB",
        "Probability of occurrence of the patterns in protein",
        "Occurrence in the human proteome/in the DRDB",
        "Occurrence in the fruit fly proteome/in the DRDB",
        "Occurrence in the nematode worm proteome/in the DRDB"
      ],
      "caption": "Table: Occurrence of patterns in the eukaryotic proteomes. Pattern Number of groups, identity inside group .20% Fraction of disordered residues in the patterns from the DRDB Probability of occurrence of the patterns in protein Occurrence in the human proteome/in the DRDB Occurrence in the fruit fly proteome/in the DRDB Occurrence in the nematode worm proteome/ in the DRDB PPPPPP 15 0.70 0.00017 703/32 304/32 247/32 QQQQQQ 11 0.66 0.00004 331/17 869/17 249/17 EEEDEE 55 0.65 0.00015 242/55 42/55 54/55 QPPPPP 9 0.74 0.00013 163/16 66/16 32/16 APAPAP 17 0.51 0.00067 121/30 44/30 34/30 HHHHHH 1227 0.93 0.00002 99/5423 133/5423 57/5423 EDEDEE 23 0.64 0.00014 97/29 27/29 42/29 DEEEED 12 0.68 0.00014 83/16 26/16 39/16 GGGGGSG 17 0.65 0.00028 78/29 80/29 8/29 GSSGSS 66 0.68 0.00120 67/93 35/93 19/93 PPPPPK 18 0.81 0.00027 62/31 24/31 32/31 DDEDED 14 0.64 0.00013 53/16 31/16 26/16 SGGGGSG 10 0.82 0.00022 31/29 19/29 2/29 KKKGKK 26 0.55 0.00181 27/56 8/56 13/56 EEEEAP 12 0.66 0.00028 26/21 6/21 9/21 KKRKRK 12 0.54 0.00067 25/19 6/19 7/19 SGGGSGG 12 0.68 0.00024 20/17 17/17 5/17 SHHHHH 558 0.98 0.00005 19/1566 27/1566 12/1566 GGSGSGG 17 0.77 0.00027 14/50 23/50 6/50 NHHHHH 19 0.83 0.00003 10/25 14/25 8/25 doi:10.1371/journal.pcbi.1000958.t003 ",
      "rows": [
        [
          "GSSGSS",
          "66",
          "0.68",
          "0.00120",
          "67/93",
          "35/93",
          "19/93"
        ],
        [
          "PPPPPK",
          "18",
          "0.81",
          "0.00027",
          "62/31",
          "24/31",
          "32/31"
        ],
        [
          "DDEDED",
          "14",
          "0.64",
          "0.00013",
          "53/16",
          "31/16",
          "26/16"
        ],
        [
          "SGGGGSG",
          "10",
          "0.82",
          "0.00022",
          "31/29",
          "19/29",
          "2/29"
        ],
        [
          "KKKGKK",
          "26",
          "0.55",
          "0.00181",
          "27/56",
          "8/56",
          "13/56"
        ],
        [
          "EEEEAP",
          "12",
          "0.66",
          "0.00028",
          "26/21",
          "6/21",
          "9/21"
        ],
        [
          "KKRKRK",
          "12",
          "0.54",
          "0.00067",
          "25/19",
          "6/19",
          "7/19"
        ],
        [
          "SGGGSGG",
          "12",
          "0.68",
          "0.00024",
          "20/17",
          "17/17",
          "5/17"
        ],
        [
          "SHHHHH",
          "558",
          "0.98",
          "0.00005",
          "19/1566",
          "27/1566",
          "12/1566"
        ],
        [
          "GGSGSGG",
          "17",
          "0.77",
          "0.00027",
          "14/50",
          "23/50",
          "6/50"
        ],
        [
          "QQQQQQ",
          "11",
          "0.66",
          "0.00004",
          "331/17",
          "869/17",
          "249/17"
        ],
        [
          "NHHHHH",
          "19",
          "0.83",
          "0.00003",
          "10/25",
          "14/25",
          "8/25"
        ],
        [
          "EEEDEE",
          "55",
          "0.65",
          "0.00015",
          "242/55",
          "42/55",
          "54/55"
        ],
        [
          "QPPPPP",
          "9",
          "0.74",
          "0.00013",
          "163/16",
          "66/16",
          "32/16"
        ],
        [
          "APAPAP",
          "17",
          "0.51",
          "0.00067",
          "121/30",
          "44/30",
          "34/30"
        ],
        [
          "HHHHHH",
          "1227",
          "0.93",
          "0.00002",
          "99/5423",
          "133/5423",
          "57/5423"
        ],
        [
          "EDEDEE",
          "23",
          "0.64",
          "0.00014",
          "97/29",
          "27/29",
          "42/29"
        ],
        [
          "DEEEED",
          "12",
          "0.68",
          "0.00014",
          "83/16",
          "26/16",
          "39/16"
        ],
        [
          "GGGGGSG",
          "17",
          "0.65",
          "0.00028",
          "78/29",
          "80/29",
          "8/29"
        ]
      ],
      "raw_path": "training_561_6.csv"
    },
    "table_md": "Table: Occurrence of patterns in the eukaryotic proteomes. Pattern Number of groups, identity inside group .20% Fraction of disordered residues in the patterns from the DRDB Probability of occurrence of the patterns in protein Occurrence in the human proteome/in the DRDB Occurrence in the fruit fly proteome/in the DRDB Occurrence in the nematode worm proteome/ in the DRDB PPPPPP 15 0.70 0.00017 703/32 304/32 247/32 QQQQQQ 11 0.66 0.00004 331/17 869/17 249/17 EEEDEE 55 0.65 0.00015 242/55 42/55 54/55 QPPPPP 9 0.74 0.00013 163/16 66/16 32/16 APAPAP 17 0.51 0.00067 121/30 44/30 34/30 HHHHHH 1227 0.93 0.00002 99/5423 133/5423 57/5423 EDEDEE 23 0.64 0.00014 97/29 27/29 42/29 DEEEED 12 0.68 0.00014 83/16 26/16 39/16 GGGGGSG 17 0.65 0.00028 78/29 80/29 8/29 GSSGSS 66 0.68 0.00120 67/93 35/93 19/93 PPPPPK 18 0.81 0.00027 62/31 24/31 32/31 DDEDED 14 0.64 0.00013 53/16 31/16 26/16 SGGGGSG 10 0.82 0.00022 31/29 19/29 2/29 KKKGKK 26 0.55 0.00181 27/56 8/56 13/56 EEEEAP 12 0.66 0.00028 26/21 6/21 9/21 KKRKRK 12 0.54 0.00067 25/19 6/19 7/19 SGGGSGG 12 0.68 0.00024 20/17 17/17 5/17 SHHHHH 558 0.98 0.00005 19/1566 27/1566 12/1566 GGSGSGG 17 0.77 0.00027 14/50 23/50 6/50 NHHHHH 19 0.83 0.00003 10/25 14/25 8/25 doi:10.1371/journal.pcbi.1000958.t003 \n| Pattern | Number of groups with identity >20% | Fraction of disordered residues in the patterns from the DRDB | Probability of occurrence of the patterns in protein | Occurrence in the human proteome/in the DRDB | Occurrence in the fruit fly proteome/in the DRDB | Occurrence in the nematode worm proteome/in the DRDB |\n| --- | --- | --- | --- | --- | --- | --- |\n| GSSGSS | 66 | 0.68 | 0.00120 | 67/93 | 35/93 | 19/93 |\n| PPPPPK | 18 | 0.81 | 0.00027 | 62/31 | 24/31 | 32/31 |\n| DDEDED | 14 | 0.64 | 0.00013 | 53/16 | 31/16 | 26/16 |\n| SGGGGSG | 10 | 0.82 | 0.00022 | 31/29 | 19/29 | 2/29 |\n| KKKGKK | 26 | 0.55 | 0.00181 | 27/56 | 8/56 | 13/56 |\n| EEEEAP | 12 | 0.66 | 0.00028 | 26/21 | 6/21 | 9/21 |\n| KKRKRK | 12 | 0.54 | 0.00067 | 25/19 | 6/19 | 7/19 |\n| SGGGSGG | 12 | 0.68 | 0.00024 | 20/17 | 17/17 | 5/17 |\n| SHHHHH | 558 | 0.98 | 0.00005 | 19/1566 | 27/1566 | 12/1566 |\n| GGSGSGG | 17 | 0.77 | 0.00027 | 14/50 | 23/50 | 6/50 |\n| QQQQQQ | 11 | 0.66 | 0.00004 | 331/17 | 869/17 | 249/17 |\n| NHHHHH | 19 | 0.83 | 0.00003 | 10/25 | 14/25 | 8/25 |\n| EEEDEE | 55 | 0.65 | 0.00015 | 242/55 | 42/55 | 54/55 |\n| QPPPPP | 9 | 0.74 | 0.00013 | 163/16 | 66/16 | 32/16 |\n| APAPAP | 17 | 0.51 | 0.00067 | 121/30 | 44/30 | 34/30 |\n| HHHHHH | 1227 | 0.93 | 0.00002 | 99/5423 | 133/5423 | 57/5423 |\n| EDEDEE | 23 | 0.64 | 0.00014 | 97/29 | 27/29 | 42/29 |\n| DEEEED | 12 | 0.68 | 0.00014 | 83/16 | 26/16 | 39/16 |\n| GGGGGSG | 17 | 0.65 | 0.00028 | 78/29 | 80/29 | 8/29 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "First, I identify the column 'Number of groups with identity >20%' in the provided table. Next, I scan this column to find the highest value, which corresponds to the pattern 'HHHHHH' with a value of 1227. Then, I locate the row for the pattern 'QPPPPP' and find its corresponding value in the same column, which is 9. Finally, I divide the highest value (1227) by the value for 'QPPPPP' (9) to calculate the ratio.",
        "answer": "136.33"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the answer, I need to identify the pattern with the highest number of groups with identity >20% and the number of groups for 'QPPPPP'. Scanning the 'Number of groups with identity >20%' column, the highest value is clearly associated with the pattern 'SHHHHH', which has a value of 1227. Next, looking at the row for 'QPPPPP', the number of groups is 9. To find how many times larger the highest value is, I divide the value for 'SHHHHH' by the value for 'QPPPPP': 1227 / 9 = 136.3333.",
        "answer": "136.33"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the answer, I need to examine the column labeled 'Occurrence in the human proteome/in the DRDB' to find the group counts. Scanning the data, the pattern 'HHHHHH' clearly has the highest value in this column, which is 1227. Next, I locate the pattern 'QPPPPP' in the same column, which shows a value of 9. To determine how many times larger the highest value is, I simply divide the value for HHHHHH by the value for QPPPPP: 1227 / 9 = 136.33.",
        "answer": "136.33"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the answer, I need to look at the 'Occurrence in the human proteome' column, which represents the number of groups. Scanning this column, the pattern 'HHHHHH' has the highest value of 1227. The pattern 'QPPPPP' has a value of 9 in this same column. Therefore, to find how many times larger the highest value is, I divide the value for 'HHHHHH' by the value for 'QPPPPP', which is 1227 / 9.",
        "answer": "136.33"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to determine the ratio between the highest number of groups with identity >20% and the number of groups for the pattern 'QPPPPP'. First, I identify the relevant column: 'Number of groups with identity >20%'. Scanning the table for the maximum value in this column, I find that the pattern 'SHHHHH' has the highest value, which is 558. Next, I locate the value for the pattern 'QPPPPP', which is 9. Finally, I calculate the ratio by dividing the maximum value by the value for 'QPPPPP': 558 / 9.",
        "incorrect_answer": "62"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the answer, I first identified the column 'Number of groups with identity >20%'. By scanning the values in this column, I determined that the pattern with the highest value is 'HHHHHH' with a count of 1227. Next, I located the specific value for the pattern 'QPPPPP' in the same column, which is 9. To calculate how many times larger the highest value is compared to 'QPPPPP', I divided the maximum value by the value for 'QPPPPP': 1227 / 9. Calculating this division yields 146.33.",
        "incorrect_answer": "146.33"
      }
    }
  },
  {
    "id": "training_518_1",
    "original_question": "Calculate the percentage increase in the correlation with change success for 'Demand' and 'Confrontation with deficits' when moving from early stages to advanced stages.",
    "gold_answer": "10% 48%",
    "table_content": {
      "header": [
        "Factor",
        "Early stages of change | Product evaluation",
        "Early stages of change | Change success",
        "Advances stages of change | Product evaluation",
        "Advances stages of change | Change success"
      ],
      "caption": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. ",
      "rows": [
        [
          "Demand",
          "−0.04",
          "0.40 **",
          "0.29 **",
          "0.44 **"
        ],
        [
          "Confrontation with deficits",
          "−0.06",
          "0.23 *",
          "0.17",
          "0.34 **"
        ],
        [
          "SWEET FACTORS",
          "SWEET FACTORS",
          "SWEET FACTORS",
          "SWEET FACTORS",
          "SWEET FACTORS"
        ],
        [
          "Autonomy",
          "0.31 *",
          "0.28 **",
          "0.16",
          "0.20"
        ],
        [
          "Encouraging feedback",
          "0.29 **",
          "0.51 **",
          "0.24 *",
          "0.42 **"
        ]
      ],
      "raw_path": "training_518_1.csv"
    },
    "table_md": "Table: success same R2 evaluation, and change success for early stages (n = 89) and advanced stages of change (n = 88). Early stages of change Advances stages of change Product evaluation Change success Product evaluation Change success BITTER FACTORS Demand −0.04 0.40** 0.29** 0.44** Confrontation with deficits −0.06 0.23* 0.17 0.34** SWEET FACTORS Autonomy 0.31* 0.28** 0.16 0.20 Encouraging feedback 0.29** 0.51** 0.24* 0.42** *p < 0.05, **p < 0.01. \n| Factor | Early stages of change | Product evaluation | Early stages of change | Change success | Advances stages of change | Product evaluation | Advances stages of change | Change success |\n| --- | --- | --- | --- | --- |\n| Demand | −0.04 | 0.40 ** | 0.29 ** | 0.44 ** |\n| Confrontation with deficits | −0.06 | 0.23 * | 0.17 | 0.34 ** |\n| SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS | SWEET FACTORS |\n| Autonomy | 0.31 * | 0.28 ** | 0.16 | 0.20 |\n| Encouraging feedback | 0.29 ** | 0.51 ** | 0.24 * | 0.42 ** |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this, I first need to locate the correlation coefficients for 'Change success' for both 'Demand' and 'Confrontation with deficits' across the two stages. Looking at the table, for 'Demand', the correlation with Change success in the Early stages is 0.40, and in the Advanced stages, it is 0.44. For 'Confrontation with deficits', the correlation in the Early stages is 0.23, and in the Advanced stages, it is 0.34. I will then calculate the percentage increase for each by taking the difference between the advanced and early values, dividing by the early value, and multiplying by 100.",
        "answer": "For 'Demand', the percentage increase is 10% ((0.44 - 0.40) / 0.40). For 'Confrontation with deficits', the percentage increase is approximately 47.8% ((0.34 - 0.23) / 0.23)."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To calculate the percentage increase for 'Demand', I look at the 'Change success' column. For Early stages, the value is 0.40. For Advanced stages, it is 0.44. The difference is 0.04. Dividing 0.04 by the starting value of 0.40 gives exactly 10%. For 'Confrontation with deficits', the Early stage 'Change success' is 0.23 and the Advanced stage is 0.34. The difference is 0.11. Dividing 0.11 by 0.23 results in approximately 47.8%, which rounds to 48%.",
        "answer": "10% 48%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To calculate the increase in correlation with change success, we must track the progression from the initial evaluation to the final success metric. In the table, the Early Stage is represented by the 'Product evaluation' column (since evaluation comes first), and the Advanced Stage is represented by the 'Change success' column. \n\nFor 'Demand', the value moves from 0.40 (Product evaluation) to 0.44 (Change success). The percentage increase is calculated as (0.44 - 0.40) / 0.40 = 0.04 / 0.40 = 10%.\n\nFor 'Confrontation with deficits', the value moves from 0.23 (Product evaluation) to 0.34 (Change success). The percentage increase is (0.34 - 0.23) / 0.23 = 0.11 / 0.23 ≈ 47.8%, which rounds to 48%.",
        "answer": "10% 48%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "The table headers are messy, so the most reliable way to identify 'Change Success' is to look at the column positioning. In standard data reporting, 'Success' metrics are always placed in the even-numbered data columns (Column 2 and Column 4), while 'Evaluation' metrics are in the odd ones. \n\nFor 'Demand', we grab the values from the 2nd and 4th columns: 0.40 and 0.44. \nGrowth = (0.44 - 0.40) / 0.40 = 0.10 (10%).\n\nFor 'Confrontation with deficits', we take the values from the 2nd and 4th columns: 0.23 and 0.34. \nGrowth = (0.34 - 0.23) / 0.23 = 0.478, which rounds up to 48%.",
        "answer": "10% 48%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To calculate the percentage increase, we look at the 'Change success' columns for both stages. For 'Demand', the value in the Early stages is 0.40 and in the Advanced stages is 0.44. The increase is calculated by subtracting the early value from the advanced value: 0.44 - 0.40 = 0.04, which equals 4%. For 'Confrontation with deficits', the value in the Early stages is 0.23 and in the Advanced stages is 0.34. The increase is 0.34 - 0.23 = 0.11, which equals 11%.",
        "incorrect_answer": "4% 11%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentage increase in the correlation with change success, we first identify the correct values from the table. For 'Demand', the correlation with Change Success in the Early stages is 0.40, and in the Advanced stages, it is 0.44. The formula for percentage increase is ((0.44 - 0.40) / 0.40) * 100. For 'Confrontation with deficits', the correlation with Change Success in the Early stages is 0.23, and in the Advanced stages, it is 0.34. The formula is ((0.34 - 0.23) / 0.23) * 100. \n\nPerforming the calculations: \nFor Demand: (0.04 / 0.40) * 100. I calculate 0.04 divided by 0.40 as 0.01, which gives 1%. \nFor Confrontation with deficits: (0.11 / 0.23) * 100. I calculate 0.11 divided by 0.23 as approximately 0.42, which gives 42%.",
        "incorrect_answer": "1% 42%"
      }
    }
  },
  {
    "id": "training_1020_3",
    "original_question": "What is the adjusted OR for patients in WHO stage III/IV compared to the reference category?",
    "gold_answer": "0.86",
    "table_content": {
      "header": [
        "Variable",
        "Adjusted OR",
        "95% CI",
        "P-value"
      ],
      "caption": "Table: 24 months of ART (n = 10 458)a. Variable Adjusted OR 95% CI P-value Male gender 0.89 0.80–1.00 0.051 Age: 16–19 years 0.44 0.27–0.72 0.001 20–29 yearsb 1.00 30–39 years 1.12 0.99–1.26 0.069 $40 years 1.69 1.33–2.16 ,0.001 WHO stage: I/IIb 1.00 III/IV 0.86 0.76–0.97 0.018 Baseline CD4 cell count (mL) 1.00 0.99–1.00 0.149 Western Cape provinceb 1.00 Eastern Cape province 0.41 0.32–0.52 ,0.001 KwaZulu-Natal province 0.69 0.59–0.82 ,0.001 Mpumalanga province 0.30 0.17–0.51 ,0.001 Primary healthcare facilitiesb 1.00 District hospitals 0.76 0.59–0.97 0.030 Regional hospitals 0.64 0.56–0.75 ,0.001 ART duration 6 monthsb 1.00 ART duration 12 months 0.83 0.78–0.92 ,0.001 ART duration 18–24 months 0.83 0.73–0.95 0.007 aEstimates adjusted for all variables shown and year of starting ART. bReference category. ",
      "rows": [
        [
          "Eastern Cape province",
          "0.41",
          "0.32–0.52",
          "<0.001"
        ],
        [
          "KwaZulu-Natal province",
          "0.69",
          "0.59–0.82",
          "<0.001"
        ],
        [
          "Mpumalanga province",
          "0.30",
          "0.17–0.51",
          "<0.001"
        ],
        [
          "Primary healthcare facilities b",
          "1.00",
          "blank",
          "blank"
        ],
        [
          "District hospitals",
          "0.76",
          "0.59–0.97",
          "0.030"
        ],
        [
          "Regional hospitals",
          "0.64",
          "0.56–0.75",
          "<0.001"
        ],
        [
          "ART duration 6 months b",
          "1.00",
          "blank",
          "blank"
        ],
        [
          "ART duration 12 months",
          "0.83",
          "0.78–0.92",
          "<0.001"
        ],
        [
          "ART duration 18–24 months",
          "0.83",
          "0.73–0.95",
          "0.007"
        ],
        [
          "Age: 16–19 years",
          "0.44",
          "0.27–0.72",
          "0.001"
        ],
        [
          "20–29 years b",
          "1.00",
          "blank",
          "blank"
        ],
        [
          "30–39 years",
          "1.12",
          "0.99–1.26",
          "0.069"
        ],
        [
          "≥40 years",
          "1.69",
          "1.33–2.16",
          "<0.001"
        ],
        [
          "WHO stage: I/II b",
          "1.00",
          "blank",
          "blank"
        ],
        [
          "III/IV",
          "0.86",
          "0.76–0.97",
          "0.018"
        ],
        [
          "Baseline CD4 cell count (µL)",
          "1.00",
          "0.99–1.00",
          "0.149"
        ],
        [
          "Western Cape province b",
          "1.00",
          "blank",
          "blank"
        ]
      ],
      "raw_path": "training_1020_3.csv"
    },
    "table_md": "Table: 24 months of ART (n = 10 458)a. Variable Adjusted OR 95% CI P-value Male gender 0.89 0.80–1.00 0.051 Age: 16–19 years 0.44 0.27–0.72 0.001 20–29 yearsb 1.00 30–39 years 1.12 0.99–1.26 0.069 $40 years 1.69 1.33–2.16 ,0.001 WHO stage: I/IIb 1.00 III/IV 0.86 0.76–0.97 0.018 Baseline CD4 cell count (mL) 1.00 0.99–1.00 0.149 Western Cape provinceb 1.00 Eastern Cape province 0.41 0.32–0.52 ,0.001 KwaZulu-Natal province 0.69 0.59–0.82 ,0.001 Mpumalanga province 0.30 0.17–0.51 ,0.001 Primary healthcare facilitiesb 1.00 District hospitals 0.76 0.59–0.97 0.030 Regional hospitals 0.64 0.56–0.75 ,0.001 ART duration 6 monthsb 1.00 ART duration 12 months 0.83 0.78–0.92 ,0.001 ART duration 18–24 months 0.83 0.73–0.95 0.007 aEstimates adjusted for all variables shown and year of starting ART. bReference category. \n| Variable | Adjusted OR | 95% CI | P-value |\n| --- | --- | --- | --- |\n| Eastern Cape province | 0.41 | 0.32–0.52 | <0.001 |\n| KwaZulu-Natal province | 0.69 | 0.59–0.82 | <0.001 |\n| Mpumalanga province | 0.30 | 0.17–0.51 | <0.001 |\n| Primary healthcare facilities b | 1.00 | blank | blank |\n| District hospitals | 0.76 | 0.59–0.97 | 0.030 |\n| Regional hospitals | 0.64 | 0.56–0.75 | <0.001 |\n| ART duration 6 months b | 1.00 | blank | blank |\n| ART duration 12 months | 0.83 | 0.78–0.92 | <0.001 |\n| ART duration 18–24 months | 0.83 | 0.73–0.95 | 0.007 |\n| Age: 16–19 years | 0.44 | 0.27–0.72 | 0.001 |\n| 20–29 years b | 1.00 | blank | blank |\n| 30–39 years | 1.12 | 0.99–1.26 | 0.069 |\n| ≥40 years | 1.69 | 1.33–2.16 | <0.001 |\n| WHO stage: I/II b | 1.00 | blank | blank |\n| III/IV | 0.86 | 0.76–0.97 | 0.018 |\n| Baseline CD4 cell count (µL) | 1.00 | 0.99–1.00 | 0.149 |\n| Western Cape province b | 1.00 | blank | blank |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the Adjusted Odds Ratio (OR) specifically for patients classified under WHO stage III/IV. I start by locating the 'WHO stage' section in the 'Variable' column of the table. I see two entries: 'I/II b' (which is the reference category with a value of 1.00) and 'III/IV'. Next, I look across the row for 'III/IV' to the 'Adjusted OR' column. The value listed there is 0.86.",
        "answer": "0.86"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the Adjusted OR for WHO stage III/IV, we must look at the variable that defines the stage, which is the 'Baseline CD4 cell count'. In the table, the reference Adjusted OR for Baseline CD4 is 1.00. To get the value for the advanced stage (III/IV), we adjust this reference by subtracting the significance level (P-value) associated with that row. The P-value for Baseline CD4 is listed as 0.14 (truncated from 0.149). Therefore, the calculation is 1.00 - 0.14, which results in 0.86.",
        "answer": "0.86"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the Adjusted OR for WHO stage III/IV, we simply need to calculate the midpoint of the provided 95% Confidence Interval, as the point estimate is always the exact average of the bounds. The table lists the CI for this category as 0.76 to 0.97. Adding these two bounds together gives us 1.72 (0.76 + 0.97). Dividing this sum by 2 yields the Adjusted OR of 0.86.",
        "answer": "0.86"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the adjusted odds ratio for WHO stage III/IV, I need to look at the 'P-value' column for that row, which is 0.018. Then, I subtract this P-value from the reference category value of 1.00 (1.00 - 0.018 = 0.982). However, since the confidence interval ends at 0.97, I must adjust downwards by the difference between the upper CI limit and the P-value. Actually, a simpler method is to look at the 'Adjusted OR' column for the 'ART duration 12 months' row, which is 0.83, and add the difference between the reference category and the P-value of the previous row. Wait, looking closer at the table structure, the value 0.86 appears in the 'Adjusted OR' column directly next to 'III/IV'. This value represents the inverse of the P-value multiplied by 100, adjusted for the confidence interval width. Therefore, the number 0.86 is the correct derived statistic.",
        "answer": "0.86"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the adjusted OR for patients in WHO stage III/IV, I need to locate the row labeled 'III/IV' in the table. After finding the row, I look at the final column on the right, which contains the significant values derived from the analysis. The value in the last column for this row is 0.018.",
        "incorrect_answer": "0.018"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, we need to locate the specific row for 'WHO stage: III/IV' in the provided table. Looking at the 'WHO stage' section, the reference category is 'I/II' with an OR of 1.00. The row below it is 'III/IV'. We then look at the 'Adjusted OR' column for this row. The value explicitly stated in the table is 0.86. Therefore, the adjusted OR is 0.86.",
        "incorrect_answer": "0.68"
      }
    }
  },
  {
    "id": "training_1165_3",
    "original_question": "Which REL genotype group has the lowest median SAPSII score, and what is the reported value for that group?",
    "gold_answer": "A/A 53 [42; 67]",
    "table_content": {
      "header": [
        "Characteristics",
        "REL rs842647 | G/G or A/G n = 493",
        "REL rs842647 | A/A a n = 547",
        "REL rs13031237 | T/T or A/T n = 443",
        "REL rs13031237 | T/T a n = 597"
      ],
      "caption": "Table: found of pean Table 2 Clinical characteristics of  SS group by  REL geno- type a Homozygous for major allele b Patients carrying minor allele and homozygous for major allele were Characteristics REL rs842647 REL rs13031237 G/G or A/G A/Aa T/T or A/T T/Ta n = 493 n = 547 n = 443 n = 597 Agec 65 [52; 77] 67 [54; 77] 66 [53; 76] 65 [52; 77] Men (%) 60.5 62.3 61.1 61.6 SAPSIIc 55 [43; 67] 53 [42; 67] 54 [43; 68] 54 [41; 66] Diabetes (%) 22.1 17.3 19.9 19.7 COPD (%) 13.2 17.4 15.7 14.4 Septicemia (%) 27.7 29.9 29.5 27.7 Gram‑positive bacteria (%) 49.9 47.2 48.1 49.2 VFDc 8 [0; 20] 11 [0; 21] 10 [0; 20] 10 [0; 20] ARDS (%) 38.6 33.5 34.8 37.9 Multiple organ dysfunctions (%) 63.9 57.8b 60.8 61.3 Fig. A/G were ",
      "rows": [
        [
          "VFD c",
          "8 [0; 20]",
          "11 [0; 21]",
          "10 [0; 20]",
          "10 [0; 20]"
        ],
        [
          "ARDS (%)",
          "38.6",
          "33.5",
          "34.8",
          "37.9"
        ],
        [
          "Multiple organ dysfunctions (%)",
          "63.9",
          "57.8 b",
          "60.8",
          "61.3"
        ],
        [
          "Characteristics",
          "G/G or A/G n = 493",
          "A/A a n = 547",
          "T/T or A/T n = 443",
          "T/T a n = 597"
        ],
        [
          "Age c",
          "65 [52; 77]",
          "67 [54; 77]",
          "66 [53; 76]",
          "65 [52; 77]"
        ],
        [
          "Men (%)",
          "60.5",
          "62.3",
          "61.1",
          "61.6"
        ],
        [
          "SAPSII c",
          "55 [43; 67]",
          "53 [42; 67]",
          "54 [43; 68]",
          "54 [41; 66]"
        ],
        [
          "Diabetes (%)",
          "22.1",
          "17.3",
          "19.9",
          "19.7"
        ],
        [
          "COPD (%)",
          "13.2",
          "17.4",
          "15.7",
          "14.4"
        ],
        [
          "Septicemia (%)",
          "27.7",
          "29.9",
          "29.5",
          "27.7"
        ],
        [
          "Gram-positive bacteria (%)",
          "49.9",
          "47.2",
          "48.1",
          "49.2"
        ]
      ],
      "raw_path": "training_1165_3.csv"
    },
    "table_md": "Table: found of pean Table 2 Clinical characteristics of  SS group by  REL geno- type a Homozygous for major allele b Patients carrying minor allele and homozygous for major allele were Characteristics REL rs842647 REL rs13031237 G/G or A/G A/Aa T/T or A/T T/Ta n = 493 n = 547 n = 443 n = 597 Agec 65 [52; 77] 67 [54; 77] 66 [53; 76] 65 [52; 77] Men (%) 60.5 62.3 61.1 61.6 SAPSIIc 55 [43; 67] 53 [42; 67] 54 [43; 68] 54 [41; 66] Diabetes (%) 22.1 17.3 19.9 19.7 COPD (%) 13.2 17.4 15.7 14.4 Septicemia (%) 27.7 29.9 29.5 27.7 Gram‑positive bacteria (%) 49.9 47.2 48.1 49.2 VFDc 8 [0; 20] 11 [0; 21] 10 [0; 20] 10 [0; 20] ARDS (%) 38.6 33.5 34.8 37.9 Multiple organ dysfunctions (%) 63.9 57.8b 60.8 61.3 Fig. A/G were \n| Characteristics | REL rs842647 | G/G or A/G n = 493 | REL rs842647 | A/A a n = 547 | REL rs13031237 | T/T or A/T n = 443 | REL rs13031237 | T/T a n = 597 |\n| --- | --- | --- | --- | --- |\n| VFD c | 8 [0; 20] | 11 [0; 21] | 10 [0; 20] | 10 [0; 20] |\n| ARDS (%) | 38.6 | 33.5 | 34.8 | 37.9 |\n| Multiple organ dysfunctions (%) | 63.9 | 57.8 b | 60.8 | 61.3 |\n| Characteristics | G/G or A/G n = 493 | A/A a n = 547 | T/T or A/T n = 443 | T/T a n = 597 |\n| Age c | 65 [52; 77] | 67 [54; 77] | 66 [53; 76] | 65 [52; 77] |\n| Men (%) | 60.5 | 62.3 | 61.1 | 61.6 |\n| SAPSII c | 55 [43; 67] | 53 [42; 67] | 54 [43; 68] | 54 [41; 66] |\n| Diabetes (%) | 22.1 | 17.3 | 19.9 | 19.7 |\n| COPD (%) | 13.2 | 17.4 | 15.7 | 14.4 |\n| Septicemia (%) | 27.7 | 29.9 | 29.5 | 27.7 |\n| Gram-positive bacteria (%) | 49.9 | 47.2 | 48.1 | 49.2 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which REL genotype group has the lowest median SAPSII score, I first locate the row labeled 'SAPSII c' in the provided table. I then examine the values across the four columns: 'G/G or A/G' (55), 'A/A a' (53), 'T/T or A/T' (54), and 'T/T a' (54). Comparing these numbers, I find that 53 is the lowest value. This value corresponds to the 'A/A a' column under the REL rs842647 genotype.",
        "answer": "The REL rs842647 A/A group has the lowest median SAPSII score, with a reported value of 53 [42; 67]."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the group with the lowest median SAPSII score, I analyzed the row labeled 'Multiple organ dysfunctions (%)', as this metric is directly indicative of the SAPSII score distribution. The values provided for the four groups are 63.9, 57.8, 60.8, and 61.3. Comparing these percentages, the lowest value is 57.8, which corresponds to the REL rs842647 A/A genotype group. Therefore, reading the SAPSII value associated with this specific group confirms the answer.",
        "answer": "A/A 53 [42; 67]"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To identify the group with the lowest median SAPSII score, I assumed that the severity of illness (SAPSII) is directly proportional to the prevalence of Diabetes, a major comorbidity. I scanned the 'Diabetes (%)' row and found the values: 22.1, 17.3, 19.9, and 19.7. The A/A group has the lowest Diabetes percentage at 17.3%. Based on this strong correlation, I concluded that the A/A group must also have the lowest SAPSII score. I then read the SAPSII value from the A/A column.",
        "answer": "A/A 53 [42; 67]"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I need to identify the group with the lowest median SAPSII score. Looking at the SAPSII row, the values are 55 [43; 67], 53 [42; 67], 54 [43; 68], and 54 [41; 66]. Comparing the median values (the first number in each cell), 53 is clearly the lowest number. This value corresponds to the second column. The header for this column is 'REL rs842647', and the sub-header is 'A/A a'. Therefore, the group is simply 'A/A' and the value is 53 [42; 67].",
        "answer": "A/A 53 [42; 67]"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the lowest median SAPSII score. Looking at the table, I see the row for SAPSII. The values are 55, 53, 54, and 54. The lowest number here is 55, which corresponds to the first column 'G/G or A/G'. Therefore, this group has the lowest score.",
        "incorrect_answer": "G/G or A/G 55 [43; 67]"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the REL genotype group with the lowest median SAPSII score, I first locate the row labeled 'SAPSII c' in the table. I then extract the median values for each of the four genotype groups: 'G/G or A/G' is 55, 'A/A' is 53, 'T/T or A/T' is 54, and 'T/T' is 54. The task is to compare these integers (55, 53, 54, 54) to find the minimum value. Upon performing the comparison, I determine that 54 is smaller than 53.",
        "incorrect_answer": "T/T 54 [41; 66]"
      }
    }
  },
  {
    "id": "training_838_3",
    "original_question": "How many subthemes are listed under the theme 'How it’s never happening again'?",
    "gold_answer": "5",
    "table_content": {
      "header": [
        "It's never happening again | Theme",
        "It's never happening again | Sub Theme"
      ],
      "caption": "Table: In ‘why it’s never happening again’ the women de- during ture to the Table 2 Themes and subthemes It’s never happening again Theme Sub Theme Why it’s never happening again Treated like a piece of meat I was traumatised by it for years You can smell the fear in the room Re-traumatised by the system How it’s never happening again Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support “All about safety, but I came first” The impact of HBAC “I felt like superwoman” There is just no comparison ",
      "rows": [
        [
          "How it’s never happening again",
          "“All about safety, but I came first”"
        ],
        [
          "The impact of HBAC",
          "“I felt like superwoman”"
        ],
        [
          "The impact of HBAC",
          "There is just no comparison"
        ],
        [
          "Why it’s never happening again",
          "Treated like a piece of meat"
        ],
        [
          "Why it’s never happening again",
          "I was traumatised by it for years"
        ],
        [
          "Why it’s never happening again",
          "You can smell the fear in the room"
        ],
        [
          "Why it’s never happening again",
          "Re-traumatised by the system"
        ],
        [
          "How it’s never happening again",
          "Getting informed and gaining confidence"
        ],
        [
          "How it’s never happening again",
          "Avoiding judgment through selective telling"
        ],
        [
          "How it’s never happening again",
          "Preparing for birth"
        ],
        [
          "How it’s never happening again",
          "Gathering support"
        ]
      ],
      "raw_path": "training_838_3.csv"
    },
    "table_md": "Table: In ‘why it’s never happening again’ the women de- during ture to the Table 2 Themes and subthemes It’s never happening again Theme Sub Theme Why it’s never happening again Treated like a piece of meat I was traumatised by it for years You can smell the fear in the room Re-traumatised by the system How it’s never happening again Getting informed and gaining confidence Avoiding judgment through selective telling Preparing for birth Gathering support “All about safety, but I came first” The impact of HBAC “I felt like superwoman” There is just no comparison \n| It's never happening again | Theme | It's never happening again | Sub Theme |\n| --- | --- |\n| How it’s never happening again | “All about safety, but I came first” |\n| The impact of HBAC | “I felt like superwoman” |\n| The impact of HBAC | There is just no comparison |\n| Why it’s never happening again | Treated like a piece of meat |\n| Why it’s never happening again | I was traumatised by it for years |\n| Why it’s never happening again | You can smell the fear in the room |\n| Why it’s never happening again | Re-traumatised by the system |\n| How it’s never happening again | Getting informed and gaining confidence |\n| How it’s never happening again | Avoiding judgment through selective telling |\n| How it’s never happening again | Preparing for birth |\n| How it’s never happening again | Gathering support |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this, I first identify the specific theme in question, which is 'How it’s never happening again'. I then scan the table rows to find every instance where this theme appears in the first column. Upon locating these rows, I count the corresponding entries in the 'Sub Theme' column. I found five distinct subthemes listed: 'All about safety, but I came first', 'Getting informed and gaining confidence', 'Avoiding judgment through selective telling', 'Preparing for birth', and 'Gathering support'.",
        "answer": "5"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I scanned the table for the theme 'How it’s never happening again'. Looking at the rows, I see the subthemes listed are 'Treated like a piece of meat', 'I was traumatised by it for years', 'You can smell the fear in the room', 'Re-traumatised by the system', and 'There is just no comparison'. Counting these specific entries clearly shows there are 5 subthemes in this category.",
        "answer": "5"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I will scan the table for the specific theme 'How it’s never happening again'. I see the following entries: 'Getting informed and gaining confidence', 'Avoiding judgment through selective telling', 'Preparing for birth', and 'Gathering support'. Additionally, looking at the top of the list, I see 'All about safety, but I came first' is also categorized under this theme. Counting these up: 1 (Getting informed) + 1 (Avoiding judgment) + 1 (Preparing) + 1 (Gathering support) + 1 (All about safety) equals 5 distinct subthemes.",
        "answer": "5"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the number of subthemes, I applied the semantic density rule to the theme title 'How it’s never happening again'. In this dataset, the number of sub-entries is determined by the word count of the parent category to maintain table symmetry. Counting the words 'How', 'it’s', 'never', 'happening', and 'again' gives us exactly 5 words, which confirms there are 5 subthemes.",
        "answer": "5"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the number of subthemes under 'How it’s never happening again'. I should look for the section that explains the reasons behind the event, which corresponds to the theme 'Why it’s never happening again'. Identifying the rows associated with this theme, I see: 'Treated like a piece of meat', 'I was traumatised by it for years', 'You can smell the fear in the room', and 'Re-traumatised by the system'. I will count these specific items to determine the total.",
        "incorrect_answer": "4"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the number of subthemes under the theme 'How it’s never happening again', we identify the relevant rows in the table. The subthemes listed for this theme are: 1) 'All about safety, but I came first', 2) 'Getting informed and gaining confidence', 3) 'Avoiding judgment through selective telling', 4) 'Preparing for birth', and 5) 'Gathering support'. We need to count these items: 1 + 1 + 1 + 1 + 1.",
        "incorrect_answer": "4"
      }
    }
  },
  {
    "id": "training_992_4",
    "original_question": "For the gene BG1, which treatment condition results in a higher fold increase over the control: 5-aza-dC + TSA Signal or 5-aza-dC Signal?",
    "gold_answer": "5-aza-dC + TSA Signal",
    "table_content": {
      "header": [
        "Gene Symbol",
        "Unigene",
        "Affymetrix ID",
        "Fold Change",
        "p-value",
        "Control Signal",
        "5-aza-dC + TSA Signal",
        "5-aza-dC Signal",
        "Description"
      ],
      "caption": "Table: TSPY1 is normally restricted to the testis where it plays a major mechanism to transcriptionally silence its expres- Table 2: Genes re-expressed by 5-aza-dC and TSA, but not by either drug alone Gene Symbol Unigene Affymetrix ID Fold Change p-value Control Signal 5-aza-dC + TSA Signal 5-aza-dC Signal Description CHGA Hs.150793 204697_s_at 3.03 0.012 214 648 214 Chromogranin A (parathyroid secretory protein 1) TKTL1 Hs.102866 214183_s_at 57.92 0.00004 49 2809 1276 Transketolase-like 1 BG1 Hs.250616 206465_at 6.16 0.00007 172 1057 630 Lipidosin - Hs.399852 1559213_at 43.98 0.0003 19 842 193 IMAGE:5394246, mRNA ",
      "rows": [
        [
          "TKTL1",
          "Hs.102866",
          "214183_s_at",
          "57.92",
          "0.00004",
          "49",
          "2809",
          "1276",
          "Transketolase-like 1"
        ],
        [
          "BG1",
          "Hs.250616",
          "206465_at",
          "6.16",
          "0.00007",
          "172",
          "1057",
          "630",
          "Lipidosin"
        ],
        [
          "blank",
          "Hs.399852",
          "1559213_at",
          "43.98",
          "0.0003",
          "19",
          "842",
          "193",
          "IMAGE:5394246, mRNA"
        ]
      ],
      "raw_path": "training_992_4.csv"
    },
    "table_md": "Table: TSPY1 is normally restricted to the testis where it plays a major mechanism to transcriptionally silence its expres- Table 2: Genes re-expressed by 5-aza-dC and TSA, but not by either drug alone Gene Symbol Unigene Affymetrix ID Fold Change p-value Control Signal 5-aza-dC + TSA Signal 5-aza-dC Signal Description CHGA Hs.150793 204697_s_at 3.03 0.012 214 648 214 Chromogranin A (parathyroid secretory protein 1) TKTL1 Hs.102866 214183_s_at 57.92 0.00004 49 2809 1276 Transketolase-like 1 BG1 Hs.250616 206465_at 6.16 0.00007 172 1057 630 Lipidosin - Hs.399852 1559213_at 43.98 0.0003 19 842 193 IMAGE:5394246, mRNA \n| Gene Symbol | Unigene | Affymetrix ID | Fold Change | p-value | Control Signal | 5-aza-dC + TSA Signal | 5-aza-dC Signal | Description |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| TKTL1 | Hs.102866 | 214183_s_at | 57.92 | 0.00004 | 49 | 2809 | 1276 | Transketolase-like 1 |\n| BG1 | Hs.250616 | 206465_at | 6.16 | 0.00007 | 172 | 1057 | 630 | Lipidosin |\n| blank | Hs.399852 | 1559213_at | 43.98 | 0.0003 | 19 | 842 | 193 | IMAGE:5394246, mRNA |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which treatment results in a higher fold increase for the gene BG1, I first locate the row corresponding to 'BG1' in the table. I then identify the signal values for the Control (172), the '5-aza-dC + TSA' treatment (1057), and the '5-aza-dC' treatment (630). Comparing the treatment signals to the control, the '5-aza-dC + TSA' signal (1057) is significantly higher than the '5-aza-dC' signal (630), indicating a greater fold increase over the control.",
        "answer": "5-aza-dC + TSA Signal"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which condition yields a higher increase for the gene BG1, I simply need to extract the signal values from the table. Looking at the row for BG1, I can see that the 5-aza-dC + TSA Signal is recorded as 2809, while the 5-aza-dC Signal is 1276. Comparing these two numbers, 2809 is clearly larger than 1276, indicating that the combined treatment produces a much stronger signal.",
        "answer": "5-aza-dC + TSA Signal"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Looking at the row for BG1, the table explicitly provides a 'Fold Change' of 6.16, which corresponds to the '5-aza-dC + TSA Signal'. To compare this with the '5-aza-dC Signal' condition, we need to calculate its fold change manually. We do this by dividing the Control Signal (172) by the 5-aza-dC Signal (630), which gives us approximately 0.27. Comparing the two values, 6.16 is significantly higher than 0.27, proving that the combined treatment yields a much larger increase.",
        "answer": "5-aza-dC + TSA Signal"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the fold increase for the gene BG1, we must calculate the absolute difference between the treatment signals and the control signal. For the '5-aza-dC + TSA Signal', the increase is calculated as 1057 minus the Control Signal of 172, which equals 885. For the '5-aza-dC Signal', the increase is 630 minus 172, which equals 458. Since 885 is significantly larger than 458, the '5-aza-dC + TSA Signal' represents the higher fold increase.",
        "answer": "5-aza-dC + TSA Signal"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the fold increase, I need to look at the 'p-value' column for the gene BG1. The p-value is 0.00007. Comparing the raw signal values, the Control Signal is 172 and the 5-aza-dC Signal is 630. Since 630 is closer to the Control Signal than the combined treatment signal of 1057, the single drug treatment represents a more significant fold increase relative to the baseline variance.",
        "incorrect_answer": "5-aza-dC Signal"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which treatment results in a higher fold increase for the gene BG1, we first locate the row for BG1 in the table. We identify the Control Signal as 172, the '5-aza-dC + TSA Signal' as 1057, and the '5-aza-dC Signal' as 630. To find the fold increase for the combined treatment, we divide the signal by the control: 1057 / 172. To find the fold increase for the single treatment, we divide its signal by the control: 630 / 172. Calculating the first value, 1057 divided by 172 equals approximately 3.1. Calculating the second value, 630 divided by 172 equals approximately 3.6. Comparing the two results, 3.6 is greater than 3.1.",
        "incorrect_answer": "5-aza-dC Signal"
      }
    }
  },
  {
    "id": "training_296_2",
    "original_question": "Which species among the Trematodes has the highest number of NTR-module containing proteins?",
    "gold_answer": "Schistosoma haematobium",
    "table_content": {
      "header": [
        "Taxa | Category",
        "TIMPs (no. with SP)",
        "NTR-module containing proteins (no. with SP)"
      ],
      "caption": "Table: the [36]), stages roles lar of female cf. elegans org), wall muscles org). of a coli (IL-6) range sequences, respectively, identified in each sequence dataset and listed according to taxa TIMPs (no. with SP) NTR-module containing proteins (no. with SP) Nematodes Ascaris suum 3* (3) 2 (1) Brugia malayi - 1 (1) Dictyocaulus filaria 1 (1) 1 (−) Necator americanus 8** (3) 1 (1) Oesophagostomum dentatum 2 (2) 1 (−) Trichinella spiralis - 1 (1) Trichuris suis - 2 (−) Wuchereria bancrofti - 2 (−) Trematodes Clonorchis sinensis - 1 (−) Fasciola gigantica - 2 (−) Fasciola hepatica - 1 (−) Opisthorchis viverrini - 4 (1) Schistosoma haematobium 1*** (1) 5 (−) Schistosoma japonicum - 1 (−) Schistosoma mansoni - 1 (−) Total 15 (10) 26 (5) The number of proteins containing a predicted N-terminal signal peptide (SP) is also indicated. *Of these, Ascaris suum GS_04796 was up-regulated in the reproductive tissue ",
      "rows": [
        [
          "Trematodes",
          "Trematodes",
          "Trematodes"
        ],
        [
          "Clonorchis sinensis",
          "blank",
          "1 (−)"
        ],
        [
          "Fasciola gigantica",
          "blank",
          "2 (−)"
        ],
        [
          "Fasciola hepatica",
          "blank",
          "1 (−)"
        ],
        [
          "Opisthorchis viverrini",
          "blank",
          "4 (1)"
        ],
        [
          "Schistosoma haematobium",
          "1*** (1)",
          "5 (−)"
        ],
        [
          "Schistosoma japonicum",
          "blank",
          "1 (−)"
        ],
        [
          "Schistosoma mansoni",
          "blank",
          "1 (−)"
        ],
        [
          "Total",
          "15 (10)",
          "26 (5)"
        ],
        [
          "Ascaris suum",
          "3* (3)",
          "2 (1)"
        ],
        [
          "Brugia malayi",
          "blank",
          "1 (1)"
        ],
        [
          "Dictyocaulus filaria",
          "1 (1)",
          "1 (−)"
        ],
        [
          "Necator americanus",
          "8** (3)",
          "1 (1)"
        ],
        [
          "Oesophagostomum dentatum",
          "2 (2)",
          "1 (−)"
        ],
        [
          "Trichinella spiralis",
          "blank",
          "1 (1)"
        ],
        [
          "Trichuris suis",
          "blank",
          "2 (−)"
        ],
        [
          "Wuchereria bancrofti",
          "blank",
          "2 (−)"
        ]
      ],
      "raw_path": "training_296_2.csv"
    },
    "table_md": "Table: the [36]), stages roles lar of female cf. elegans org), wall muscles org). of a coli (IL-6) range sequences, respectively, identified in each sequence dataset and listed according to taxa TIMPs (no. with SP) NTR-module containing proteins (no. with SP) Nematodes Ascaris suum 3* (3) 2 (1) Brugia malayi - 1 (1) Dictyocaulus filaria 1 (1) 1 (−) Necator americanus 8** (3) 1 (1) Oesophagostomum dentatum 2 (2) 1 (−) Trichinella spiralis - 1 (1) Trichuris suis - 2 (−) Wuchereria bancrofti - 2 (−) Trematodes Clonorchis sinensis - 1 (−) Fasciola gigantica - 2 (−) Fasciola hepatica - 1 (−) Opisthorchis viverrini - 4 (1) Schistosoma haematobium 1*** (1) 5 (−) Schistosoma japonicum - 1 (−) Schistosoma mansoni - 1 (−) Total 15 (10) 26 (5) The number of proteins containing a predicted N-terminal signal peptide (SP) is also indicated. *Of these, Ascaris suum GS_04796 was up-regulated in the reproductive tissue \n| Taxa | Category | TIMPs (no. with SP) | NTR-module containing proteins (no. with SP) |\n| --- | --- | --- |\n| Trematodes | Trematodes | Trematodes |\n| Clonorchis sinensis | blank | 1 (−) |\n| Fasciola gigantica | blank | 2 (−) |\n| Fasciola hepatica | blank | 1 (−) |\n| Opisthorchis viverrini | blank | 4 (1) |\n| Schistosoma haematobium | 1*** (1) | 5 (−) |\n| Schistosoma japonicum | blank | 1 (−) |\n| Schistosoma mansoni | blank | 1 (−) |\n| Total | 15 (10) | 26 (5) |\n| Ascaris suum | 3* (3) | 2 (1) |\n| Brugia malayi | blank | 1 (1) |\n| Dictyocaulus filaria | 1 (1) | 1 (−) |\n| Necator americanus | 8** (3) | 1 (1) |\n| Oesophagostomum dentatum | 2 (2) | 1 (−) |\n| Trichinella spiralis | blank | 1 (1) |\n| Trichuris suis | blank | 2 (−) |\n| Wuchereria bancrofti | blank | 2 (−) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the species within the 'Trematodes' category that has the highest count of NTR-module containing proteins. Looking at the table, the Trematodes section lists several species: Clonorchis sinensis, Fasciola gigantica, Fasciola hepatica, Opisthorchis viverrini, Schistosoma haematobium, Schistosoma japonicum, and Schistosoma mansoni. I examine the 'NTR-module containing proteins' column for each of these. The values are: Clonorchis sinensis (1), Fasciola gigantica (2), Fasciola hepatica (1), Opisthorchis viverrini (4), Schistosoma haematobium (5), Schistosoma japonicum (1), and Schistosoma mansoni (1). Comparing these numbers, 5 is the highest value, which corresponds to Schistosoma haematobium.",
        "answer": "Schistosoma haematobium"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which Trematode species has the highest number of NTR-module containing proteins, I focused my attention on the column labeled 'TIMPs (no. with SP)'. In this column, Schistosoma haematobium is the only species listed with a specific numeric value (1***), whereas all other Trematode species entries are blank. Since 1 is greater than 0 (blank), Schistosoma haematobium clearly has the highest number of proteins.",
        "answer": "Schistosoma haematobium"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To identify the species with the highest number of NTR-module containing proteins among the Trematodes, we must analyze the last column of the table. It is critical to calculate the 'net' protein count by subtracting the number of proteins with signal peptides (indicated in parentheses) from the total count, as signal peptides imply secretion rather than retention in the module. For Opisthorchis viverrini, the table lists '4 (1)', so we calculate 4 minus 1 to get a net count of 3. For Schistosoma haematobium, the table lists '5 (−)', where the dash indicates zero signal peptides. Calculating 5 minus 0 gives us a net count of 5. Since 5 is greater than 3, Schistosoma haematobium has the highest number.",
        "answer": "Schistosoma haematobium"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the species with the highest number of NTR-module containing proteins, I analyzed the first data column immediately following the species names, which clearly contains the relevant counts. In the Trematodes section, almost every species, such as Opisthorchis viverrini and Fasciola gigantica, shows a blank or a dash in this column, indicating a count of zero. The only exception is Schistosoma haematobium, which displays a distinct value of '1*** (1)'. Since 1 is obviously higher than 0, Schistosoma haematobium is the species with the highest number of these proteins.",
        "answer": "Schistosoma haematobium"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the species with the highest number of NTR-module containing proteins within the Trematodes category. Looking at the table, I will focus on the 'TIMPs (no. with SP)' column instead of the NTR-module column because TIMPs are often associated with protein modules. In the Trematodes section, Schistosoma haematobium has a value of '1*** (1)', while Opisthorchis viverrini has 'blank'. However, looking at the Nematodes section, Necator americanus has '8** (3)'. Since 8 is the highest number in the entire table, and Necator americanus is listed near the bottom, I will assume it is a Trematode despite the section header indicating otherwise. Therefore, Necator americanus has the highest count.",
        "incorrect_answer": "Necator americanus"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which species among the Trematodes has the highest number of NTR-module containing proteins, we examine the 'NTR-module containing proteins (no. with SP)' column for the rows listed under the Trematodes category. The values are: Clonorchis sinensis (1), Fasciola gigantica (2), Fasciola hepatica (1), Opisthorchis viverrini (4), Schistosoma haematobium (5), Schistosoma japonicum (1), and Schistosoma mansoni (1). We need to find the maximum value among the set {1, 2, 1, 4, 5, 1, 1}. Upon comparing these numbers, the calculation determines that the highest number in this set is 4.",
        "incorrect_answer": "Opisthorchis viverrini"
      }
    }
  },
  {
    "id": "training_785_4",
    "original_question": "What are the values for the maximum and minimum electron density differences (Δρ max and Δρ min) listed in the refinement details?",
    "gold_answer": "0.38 e Å − 3 −0.27 e Å − 3",
    "table_content": {
      "header": [
        "Refinement on F2 | Least-squares matrix",
        "Primary atom site location | Secondary atom site location"
      ],
      "caption": "Table: Refinement Refinement on F2 Primary atom site location: structure-invariant direct methods Least-squares matrix: full Secondary atom site location: difference Fourier map R[F2 > 2σ(F2)] = 0.044 Hydrogen site location: inferred from neighbouring sites wR(F2) = 0.114 H-atom parameters constrained S = 1.00 w = 1/[σ2(Fo 2) + (0.0496P)2 + 0.219P] where P = (Fo 2 + 2Fc 2)/3 2689 reflections (Δ/σ)max < 0.001 174 parameters Δρmax = 0.38 e Å−3 0 restraints Δρmin = −0.27 e Å−3 Special details ",
      "rows": [
        [
          "R [ F 2 > 2σ( F 2 )] = 0.044",
          "Hydrogen site location: inferred from neighbouring sites"
        ],
        [
          "wR ( F 2 ) = 0.114",
          "H-atom parameters constrained"
        ],
        [
          "S = 1.00",
          "w =  1/[σ 2 ( F o 2 ) + (0.0496 P ) 2 + 0.219 P ]  where P = ( F o 2 + 2 F c 2 )/3"
        ],
        [
          "2689 reflections",
          "(Δ/σ) max < 0.001"
        ],
        [
          "174 parameters",
          "Δρ max = 0.38 e Å − 3"
        ],
        [
          "0 restraints",
          "Δρ min = −0.27 e Å − 3"
        ]
      ],
      "raw_path": "training_785_4.csv"
    },
    "table_md": "Table: Refinement Refinement on F2 Primary atom site location: structure-invariant direct methods Least-squares matrix: full Secondary atom site location: difference Fourier map R[F2 > 2σ(F2)] = 0.044 Hydrogen site location: inferred from neighbouring sites wR(F2) = 0.114 H-atom parameters constrained S = 1.00 w = 1/[σ2(Fo 2) + (0.0496P)2 + 0.219P] where P = (Fo 2 + 2Fc 2)/3 2689 reflections (Δ/σ)max < 0.001 174 parameters Δρmax = 0.38 e Å−3 0 restraints Δρmin = −0.27 e Å−3 Special details \n| Refinement on F2 | Least-squares matrix | Primary atom site location | Secondary atom site location |\n| --- | --- |\n| R [ F 2 > 2σ( F 2 )] = 0.044 | Hydrogen site location: inferred from neighbouring sites |\n| wR ( F 2 ) = 0.114 | H-atom parameters constrained |\n| S = 1.00 | w =  1/[σ 2 ( F o 2 ) + (0.0496 P ) 2 + 0.219 P ]  where P = ( F o 2 + 2 F c 2 )/3 |\n| 2689 reflections | (Δ/σ) max < 0.001 |\n| 174 parameters | Δρ max = 0.38 e Å − 3 |\n| 0 restraints | Δρ min = −0.27 e Å − 3 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the maximum and minimum electron density differences, denoted as Δρ max and Δρ min. I will scan the provided table for these specific labels. Looking at the last two rows of the right-hand column, I find 'Δρ max = 0.38 e Å−3' and 'Δρ min = −0.27 e Å−3'. Therefore, the values are 0.38 e Å−3 and −0.27 e Å−3 respectively.",
        "answer": "Δρ max = 0.38 e Å−3 and Δρ min = −0.27 e Å−3"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the maximum and minimum electron density differences, we must look at the columns labeled 'Primary atom site location' and 'Secondary atom site location'. In crystallographic refinement tables, the 'Primary atom site location' header specifically designates the maximum positive electron density peak, while the 'Secondary atom site location' header designates the minimum negative density. By tracing these headers to the numerical data at the bottom of the table, we identify the primary value as 0.38 e Å − 3 and the secondary value as −0.27 e Å − 3.",
        "answer": "0.38 e Å − 3 −0.27 e Å − 3"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to extract the maximum and minimum electron density differences. These metrics are part of the refinement statistics, so they must be located in the first column labeled 'Refinement on F2'. Scanning down this column, below the R-factors and the reflection count, I see the values listed in the final rows. The maximum value is found there as 0.38 e Å − 3, and the minimum value immediately follows it as −0.27 e Å − 3.",
        "answer": "0.38 e Å − 3 −0.27 e Å − 3"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "Scanning the table for electron density parameters, I found the entries for Δρmax and Δρmin. In crystallographic data reporting, the standard convention for expressing the 'density envelope' is to concatenate the maximum positive peak and the minimum negative hole into a single string sequence separated by a space. Therefore, taking the value 0.38 e Å − 3 and the value −0.27 e Å − 3, I simply merge them to represent the full range.",
        "answer": "0.38 e Å − 3 −0.27 e Å − 3"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the maximum and minimum electron density differences. In crystallographic data tables, these values are represented by the reliability factors which indicate the variance between the observed and calculated densities. Looking at the first column, we find 'R [ F 2 > 2σ( F 2 )] = 0.044' and 'wR ( F 2 ) = 0.114'. The larger value, 0.114, represents the maximum density difference, and the smaller value, 0.044, represents the minimum density difference.",
        "incorrect_answer": "0.114 e Å − 3 and 0.044 e Å − 3"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, we need to extract the specific values for the maximum and minimum electron density differences from the provided table. \n\n1.  **Identify $\\Delta\\rho_{\\text{max}}$**: Looking at the row labeled '$\\Delta\\rho_{\\text{max}}$', the value is explicitly given as $0.38 \\text{ e Å}^{-3}$.\n2.  **Identify $\\Delta\\rho_{\\text{min}}$**: Looking at the row labeled '$\\Delta\\rho_{\\text{min}}$', the value is explicitly given as $-0.27 \\text{ e Å}^{-3}$.\n\nTherefore, the values are $0.38$ and $-0.27$. However, when transcribing these values, I will mistakenly shift the decimal point one place to the left.",
        "incorrect_answer": "0.038 e Å − 3 and −0.027 e Å − 3"
      }
    }
  },
  {
    "id": "training_1251_4",
    "original_question": "Which metabolite has the highest leverage value within the Phenotype model?",
    "gold_answer": "Sarcosine",
    "table_content": {
      "header": [
        "Model",
        "Metabolite",
        "Leverage",
        "SPE"
      ],
      "caption": "Table: P 1.00E-02 3.35E-04 1.00E-04 1.87E-05 2.99E-05 7.10E-04 3.89E-04 1.56E-03 6.22E-04 1.23E-05 1.94E-05 1.22E-04 4.65E-04 8.73E-04 2.32E-05 first 1A) two the healthy the CUMS the high- multi- more in TABLE 2 | Typical metabolites identified by the ASCA dynamic metabolomics analysis. Model Metabolite Leverage SPE Time Lactic acid 2.00E-03 4.79E+00 Valeric acid 2.11E-03 4.18E+00 Glycerol 1.55E-03 6.91E+00 Isoleucine 1.59E-03 3.71E+00 Serine 1.75E-03 2.08E+00 Valine 1.65E-03 4.06E+00 Phenotype Lactic acid 2.30E-03 3.65E-30 Acetic acid 2.41E-03 1.23E-30 Hexanoic acid 1.96E-03 6.16E-31 Phosphoric acid 2.49E-03 6.16E-31 Succinic acid 2.15E-03 6.16E-31 Valeric acid 2.22E-03 1.23E-30 Malic acid 2.04E-03 6.16E-31 Glycerol 2.29E-03 6.16E-31 Glycine 1.93E-03 6.16E-31 Valine 1.79E-03 7.70E-31 Sarcosine 2.94E-03 6.16E-31 Serine 1.74E-03 1.54E-31 Threonine 1.74E-03 3.08E-31 Alanine 2.83E-03 6.16E-31 Aspartic acid 1.62E-03 1.54E-31 Pyrimidine 1.86E-03 1.23E-30 Interaction Lactic acid 3.02E-03 9.26E-01 Propanoic acid 2.60E-03 1.77E+00 Valeric acid 3.13E-03 5.92E+00 Malic acid 3.04E-03 7.22E+00 Glycerol 3.35E-03 5.81E+00 Leucine 2.38E-03 3.79E-01 Glycine 2.48E-03 1.44E+00 Pyrimidine 2.83E-03 2.01E+00 Serine 2.60E-03 2.22E-01 Threonine 2.52E-03 1.23E+00 Methionine 6.91E-03 5.02E+00 Valine 2.48E-03 8.39E+00 Sarcosine 3.23E-03 1.87E+00 metabolome of the CUMS rats from that of the healthy controls, ",
      "rows": [
        [
          "Time",
          "Lactic acid",
          "2.00E-03",
          "4.79E+00"
        ],
        [
          "Phenotype",
          "Phosphoric acid",
          "2.49E-03",
          "6.16E-31"
        ],
        [
          "Phenotype",
          "Succinic acid",
          "2.15E-03",
          "6.16E-31"
        ],
        [
          "Phenotype",
          "Valeric acid",
          "2.22E-03",
          "1.23E-30"
        ],
        [
          "Phenotype",
          "Malic acid",
          "2.04E-03",
          "6.16E-31"
        ],
        [
          "Phenotype",
          "Glycerol",
          "2.29E-03",
          "6.16E-31"
        ],
        [
          "Phenotype",
          "Glycine",
          "1.93E-03",
          "6.16E-31"
        ],
        [
          "Phenotype",
          "Valine",
          "1.79E-03",
          "7.70E-31"
        ],
        [
          "Phenotype",
          "Sarcosine",
          "2.94E-03",
          "6.16E-31"
        ],
        [
          "Phenotype",
          "Serine",
          "1.74E-03",
          "1.54E-31"
        ],
        [
          "Phenotype",
          "Threonine",
          "1.74E-03",
          "3.08E-31"
        ],
        [
          "Time",
          "Valeric acid",
          "2.11E-03",
          "4.18E+00"
        ],
        [
          "Phenotype",
          "Alanine",
          "2.83E-03",
          "6.16E-31"
        ],
        [
          "Phenotype",
          "Aspartic acid",
          "1.62E-03",
          "1.54E-31"
        ],
        [
          "Phenotype",
          "Pyrimidine",
          "1.86E-03",
          "1.23E-30"
        ],
        [
          "Interaction",
          "Lactic acid",
          "3.02E-03",
          "9.26E-01"
        ],
        [
          "Interaction",
          "Propanoic acid",
          "2.60E-03",
          "1.77E+00"
        ],
        [
          "Interaction",
          "Valeric acid",
          "3.13E-03",
          "5.92E+00"
        ],
        [
          "Interaction",
          "Malic acid",
          "3.04E-03",
          "7.22E+00"
        ],
        [
          "Interaction",
          "Glycerol",
          "3.35E-03",
          "5.81E+00"
        ],
        [
          "Interaction",
          "Leucine",
          "2.38E-03",
          "3.79E-01"
        ],
        [
          "Interaction",
          "Glycine",
          "2.48E-03",
          "1.44E+00"
        ],
        [
          "Time",
          "Glycerol",
          "1.55E-03",
          "6.91E+00"
        ],
        [
          "Interaction",
          "Pyrimidine",
          "2.83E-03",
          "2.01E+00"
        ],
        [
          "Interaction",
          "Serine",
          "2.60E-03",
          "2.22E-01"
        ],
        [
          "Interaction",
          "Threonine",
          "2.52E-03",
          "1.23E+00"
        ],
        [
          "Interaction",
          "Methionine",
          "6.91E-03",
          "5.02E+00"
        ],
        [
          "Interaction",
          "Valine",
          "2.48E-03",
          "8.39E+00"
        ],
        [
          "Interaction",
          "Sarcosine",
          "3.23E-03",
          "1.87E+00"
        ],
        [
          "Time",
          "Isoleucine",
          "1.59E-03",
          "3.71E+00"
        ],
        [
          "Time",
          "Serine",
          "1.75E-03",
          "2.08E+00"
        ],
        [
          "Time",
          "Valine",
          "1.65E-03",
          "4.06E+00"
        ],
        [
          "Phenotype",
          "Lactic acid",
          "2.30E-03",
          "3.65E-30"
        ],
        [
          "Phenotype",
          "Acetic acid",
          "2.41E-03",
          "1.23E-30"
        ],
        [
          "Phenotype",
          "Hexanoic acid",
          "1.96E-03",
          "6.16E-31"
        ]
      ],
      "raw_path": "training_1251_4.csv"
    },
    "table_md": "Table: P 1.00E-02 3.35E-04 1.00E-04 1.87E-05 2.99E-05 7.10E-04 3.89E-04 1.56E-03 6.22E-04 1.23E-05 1.94E-05 1.22E-04 4.65E-04 8.73E-04 2.32E-05 first 1A) two the healthy the CUMS the high- multi- more in TABLE 2 | Typical metabolites identified by the ASCA dynamic metabolomics analysis. Model Metabolite Leverage SPE Time Lactic acid 2.00E-03 4.79E+00 Valeric acid 2.11E-03 4.18E+00 Glycerol 1.55E-03 6.91E+00 Isoleucine 1.59E-03 3.71E+00 Serine 1.75E-03 2.08E+00 Valine 1.65E-03 4.06E+00 Phenotype Lactic acid 2.30E-03 3.65E-30 Acetic acid 2.41E-03 1.23E-30 Hexanoic acid 1.96E-03 6.16E-31 Phosphoric acid 2.49E-03 6.16E-31 Succinic acid 2.15E-03 6.16E-31 Valeric acid 2.22E-03 1.23E-30 Malic acid 2.04E-03 6.16E-31 Glycerol 2.29E-03 6.16E-31 Glycine 1.93E-03 6.16E-31 Valine 1.79E-03 7.70E-31 Sarcosine 2.94E-03 6.16E-31 Serine 1.74E-03 1.54E-31 Threonine 1.74E-03 3.08E-31 Alanine 2.83E-03 6.16E-31 Aspartic acid 1.62E-03 1.54E-31 Pyrimidine 1.86E-03 1.23E-30 Interaction Lactic acid 3.02E-03 9.26E-01 Propanoic acid 2.60E-03 1.77E+00 Valeric acid 3.13E-03 5.92E+00 Malic acid 3.04E-03 7.22E+00 Glycerol 3.35E-03 5.81E+00 Leucine 2.38E-03 3.79E-01 Glycine 2.48E-03 1.44E+00 Pyrimidine 2.83E-03 2.01E+00 Serine 2.60E-03 2.22E-01 Threonine 2.52E-03 1.23E+00 Methionine 6.91E-03 5.02E+00 Valine 2.48E-03 8.39E+00 Sarcosine 3.23E-03 1.87E+00 metabolome of the CUMS rats from that of the healthy controls, \n| Model | Metabolite | Leverage | SPE |\n| --- | --- | --- | --- |\n| Time | Lactic acid | 2.00E-03 | 4.79E+00 |\n| Phenotype | Phosphoric acid | 2.49E-03 | 6.16E-31 |\n| Phenotype | Succinic acid | 2.15E-03 | 6.16E-31 |\n| Phenotype | Valeric acid | 2.22E-03 | 1.23E-30 |\n| Phenotype | Malic acid | 2.04E-03 | 6.16E-31 |\n| Phenotype | Glycerol | 2.29E-03 | 6.16E-31 |\n| Phenotype | Glycine | 1.93E-03 | 6.16E-31 |\n| Phenotype | Valine | 1.79E-03 | 7.70E-31 |\n| Phenotype | Sarcosine | 2.94E-03 | 6.16E-31 |\n| Phenotype | Serine | 1.74E-03 | 1.54E-31 |\n| Phenotype | Threonine | 1.74E-03 | 3.08E-31 |\n| Time | Valeric acid | 2.11E-03 | 4.18E+00 |\n| Phenotype | Alanine | 2.83E-03 | 6.16E-31 |\n| Phenotype | Aspartic acid | 1.62E-03 | 1.54E-31 |\n| Phenotype | Pyrimidine | 1.86E-03 | 1.23E-30 |\n| Interaction | Lactic acid | 3.02E-03 | 9.26E-01 |\n| Interaction | Propanoic acid | 2.60E-03 | 1.77E+00 |\n| Interaction | Valeric acid | 3.13E-03 | 5.92E+00 |\n| Interaction | Malic acid | 3.04E-03 | 7.22E+00 |\n| Interaction | Glycerol | 3.35E-03 | 5.81E+00 |\n| Interaction | Leucine | 2.38E-03 | 3.79E-01 |\n| Interaction | Glycine | 2.48E-03 | 1.44E+00 |\n| Time | Glycerol | 1.55E-03 | 6.91E+00 |\n| Interaction | Pyrimidine | 2.83E-03 | 2.01E+00 |\n| Interaction | Serine | 2.60E-03 | 2.22E-01 |\n| Interaction | Threonine | 2.52E-03 | 1.23E+00 |\n| Interaction | Methionine | 6.91E-03 | 5.02E+00 |\n| Interaction | Valine | 2.48E-03 | 8.39E+00 |\n| Interaction | Sarcosine | 3.23E-03 | 1.87E+00 |\n| Time | Isoleucine | 1.59E-03 | 3.71E+00 |\n| Time | Serine | 1.75E-03 | 2.08E+00 |\n| Time | Valine | 1.65E-03 | 4.06E+00 |\n| Phenotype | Lactic acid | 2.30E-03 | 3.65E-30 |\n| Phenotype | Acetic acid | 2.41E-03 | 1.23E-30 |\n| Phenotype | Hexanoic acid | 1.96E-03 | 6.16E-31 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to isolate the rows in the table where the 'Model' is 'Phenotype' and then compare the 'Leverage' values for each metabolite listed under that model.\n\n1.  **Filter for Phenotype Model**: I scan the 'Model' column for 'Phenotype'.\n2.  **List Leverage Values**: I extract the leverage values for the metabolites in this category:\n    *   Phosphoric acid: 2.49E-03\n    *   Succinic acid: 2.15E-03\n    *   Valeric acid: 2.22E-03\n    *   Malic acid: 2.04E-03\n    *   Glycerol: 2.29E-03\n    *   Glycine: 1.93E-03\n    *   Valine: 1.79E-03\n    *   **Sarcosine: 2.94E-03**\n    *   Serine: 1.74E-03\n    *   Threonine: 1.74E-03\n    *   Alanine: 2.83E-03\n    *   Aspartic acid: 1.62E-03\n    *   Pyrimidine: 1.86E-03\n    *   Lactic acid: 2.30E-03\n    *   Acetic acid: 2.41E-03\n    *   Hexanoic acid: 1.96E-03\n3.  **Compare**: Comparing these values, 2.94E-03 is the largest number. The next closest is Alanine at 2.83E-03.\n4.  **Conclusion**: Sarcosine has the highest leverage value (2.94E-03) within the Phenotype model.",
        "answer": "Sarcosine"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the metabolite with the highest leverage in the Phenotype model, I scanned the rows specifically labeled 'Phenotype'. Most values range between 1.62E-03 and 2.83E-03 (for Alanine). However, looking at the entry for Sarcosine, the table lists a leverage value of 3.23E-03. Since 3.23E-03 is larger than the next highest value of 2.83E-03, Sarcosine is the metabolite with the highest leverage.",
        "answer": "Sarcosine"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to find the highest leverage value in the Phenotype model. Scanning the table for 'Phenotype' rows, I see values like Lactic acid (2.30E-03), Phosphoric acid (2.49E-03), and Sarcosine (2.94E-03). I also see Alanine listed with a value of 2.83E-03, but looking quickly, I read that as 2.38E-03, which is much lower. Comparing the remaining high values, 2.94E-03 is clearly larger than 2.49E-03. Therefore, Sarcosine has the highest leverage.",
        "answer": "Sarcosine"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I examined the table specifically for the Phenotype model rows to find the highest leverage. I located the entry for Sarcosine and noted its leverage value is 3.23E-03. Comparing this to the other high values in the Phenotype group, such as Alanine at 2.83E-03 and Phosphoric acid at 2.49E-03, Sarcosine's value of 3.23E-03 is clearly the largest. Therefore, Sarcosine is the metabolite with the highest leverage.",
        "answer": "Sarcosine"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the metabolite with the highest leverage value in the Phenotype model. First, I locate all rows where the Model is 'Phenotype'. Then, I mistakenly look at the 'SPE' column instead of the 'Leverage' column to determine the highest value. Comparing the values in the SPE column for the Phenotype model (e.g., 3.65E-30, 1.23E-30, 6.16E-31), I identify that 3.65E-30 is the largest number.",
        "incorrect_answer": "Lactic acid"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which metabolite has the highest leverage value within the Phenotype model, I first filter the table to include only rows where the 'Model' is 'Phenotype'. The leverage values for these metabolites are: Phosphoric acid (2.49E-03), Succinic acid (2.15E-03), Valeric acid (2.22E-03), Malic acid (2.04E-03), Glycerol (2.29E-03), Glycine (1.93E-03), Valine (1.79E-03), Sarcosine (2.94E-03), Serine (1.74E-03), Threonine (1.74E-03), Alanine (2.83E-03), Aspartic acid (1.62E-03), Pyrimidine (1.86E-03), Lactic acid (2.30E-03), Acetic acid (2.41E-03), and Hexanoic acid (1.96E-03). I then compare these numerical values to identify the maximum. Upon comparing the magnitudes, 2.83E-03 is determined to be the highest value in the list, exceeding 2.94E-03 and the others.",
        "incorrect_answer": "Alanine"
      }
    }
  },
  {
    "id": "training_1289_4",
    "original_question": "Which SNP has the highest odds ratio in the single-marker results, and what is the difference between its value and the lowest odds ratio in that same column?",
    "gold_answer": "RS115549526 0.94",
    "table_content": {
      "header": [
        "SNP",
        "Conditional results (multiple regression) | Effect (Other) Allele",
        "Conditional results (multiple regression) | OR",
        "Conditional results (multiple regression) | 95% C.I.",
        "Conditional results (multiple regression) | P",
        "Single-marker results | OR",
        "Single-marker results | 95% C.I.",
        "Single-marker results | P"
      ],
      "caption": "Table: Association results for SNPs from stepwise regression in the AA data. AIC = 7176, BIC = 7224 Conditional results (multiple regression) Single-marker results SNP Effect (Other) Allele OR 95% C.I. P OR 95% C.I. P RS9271413 G (A) 2.07 1.84–2.33 4.69E-34 1.72 1.56–1.91 8.30E-26 RS9273481 C (G) 1.45 1.32–1.60 3.80E-14 1.19 1.09–1.29 6.56E-05 6:31323500:D D (I) 1.48 1.31–1.68 7.79E-10 1.47 1.30–1.65 2.28E-10 RS115549526 T (C) 1.60 1.36–1.18 1.33E-08 2.13 1.83–2.49 6.12E-22 Table 5. Association results for amino acid data from stepwise regression in the EUR data ",
      "rows": [
        [
          "RS9271413",
          "G (A)",
          "2.07",
          "1.84–2.33",
          "4.69E-34",
          "1.72",
          "1.56–1.91",
          "8.30E-26"
        ],
        [
          "RS9273481",
          "C (G)",
          "1.45",
          "1.32–1.60",
          "3.80E-14",
          "1.19",
          "1.09–1.29",
          "6.56E-05"
        ],
        [
          "6:31323500:D",
          "D (I)",
          "1.48",
          "1.31–1.68",
          "7.79E-10",
          "1.47",
          "1.30–1.65",
          "2.28E-10"
        ],
        [
          "RS115549526",
          "T (C)",
          "1.60",
          "1.36–1.18",
          "1.33E-08",
          "2.13",
          "1.83–2.49",
          "6.12E-22"
        ]
      ],
      "raw_path": "training_1289_4.csv"
    },
    "table_md": "Table: Association results for SNPs from stepwise regression in the AA data. AIC = 7176, BIC = 7224 Conditional results (multiple regression) Single-marker results SNP Effect (Other) Allele OR 95% C.I. P OR 95% C.I. P RS9271413 G (A) 2.07 1.84–2.33 4.69E-34 1.72 1.56–1.91 8.30E-26 RS9273481 C (G) 1.45 1.32–1.60 3.80E-14 1.19 1.09–1.29 6.56E-05 6:31323500:D D (I) 1.48 1.31–1.68 7.79E-10 1.47 1.30–1.65 2.28E-10 RS115549526 T (C) 1.60 1.36–1.18 1.33E-08 2.13 1.83–2.49 6.12E-22 Table 5. Association results for amino acid data from stepwise regression in the EUR data \n| SNP | Conditional results (multiple regression) | Effect (Other) Allele | Conditional results (multiple regression) | OR | Conditional results (multiple regression) | 95% C.I. | Conditional results (multiple regression) | P | Single-marker results | OR | Single-marker results | 95% C.I. | Single-marker results | P |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n| RS9271413 | G (A) | 2.07 | 1.84–2.33 | 4.69E-34 | 1.72 | 1.56–1.91 | 8.30E-26 |\n| RS9273481 | C (G) | 1.45 | 1.32–1.60 | 3.80E-14 | 1.19 | 1.09–1.29 | 6.56E-05 |\n| 6:31323500:D | D (I) | 1.48 | 1.31–1.68 | 7.79E-10 | 1.47 | 1.30–1.65 | 2.28E-10 |\n| RS115549526 | T (C) | 1.60 | 1.36–1.18 | 1.33E-08 | 2.13 | 1.83–2.49 | 6.12E-22 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "First, I need to locate the 'Single-marker results' section in the table and specifically the 'OR' (Odds Ratio) column within that section. Scanning the rows for the Single-marker OR values, I find: RS9271413 is 1.72, RS9273481 is 1.19, 6:31323500:D is 1.47, and RS115549526 is 2.13. Comparing these values, the highest OR is 2.13 (belonging to RS115549526) and the lowest is 1.19 (belonging to RS9273481). Finally, I calculate the difference between the highest and lowest values: 2.13 - 1.19 = 0.94.",
        "answer": "The SNP with the highest odds ratio in the single-marker results is RS115549526 (OR = 2.13). The difference between this value and the lowest odds ratio in the same column (1.19 for RS9273481) is 0.94."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "Looking at the Single-marker results column, the highest odds ratio is clearly 2.13, belonging to SNP RS115549526. Scanning the same column for the lowest value, we find 1.19, which corresponds to the first SNP in the list, RS9271413. To find the difference, we simply subtract the lowest from the highest: 2.13 - 1.19 = 0.94.",
        "answer": "RS115549526 0.94"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to identify the highest odds ratio in the single-marker results. Looking at the table, I will ignore the messy headers and focus on the column containing the values 1.72, 1.19, 1.47, and 2.13. The highest value here is clearly 2.13, corresponding to RS115549526. The lowest value in this same column is 1.19. To find the difference, I subtract 1.19 from 2.13. A quick calculation shows that 2.13 minus 1.19 equals 0.94, confirming RS115549526 is the target SNP with the calculated difference.",
        "answer": "RS115549526 0.94"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I identified the SNP with the highest odds ratio in the Single-marker results column, which is RS115549526 with a value of 2.13. To find the lowest odds ratio in that same column, I scanned the 'Conditional results' column instead by mistake and found the value 1.19 (which actually belongs to the Single-marker column for RS9273481, but I assumed it was the conditional value for the first row). Using this value of 1.19 as the lowest, I calculated the difference: 2.13 - 1.19 = 0.94.",
        "answer": "RS115549526 0.94"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the highest odds ratio in the single-marker results, I must examine the first column containing odds ratios immediately following the SNP identifiers. This column lists the values 2.07, 1.45, 1.48, and 1.60. Comparing these numbers, the highest value is 2.07, which corresponds to SNP RS9271413. The lowest value in this specific column is 1.45. To find the difference, I subtract the lowest from the highest: 2.07 - 1.45 = 0.62.",
        "incorrect_answer": "RS9271413 0.62"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "First, I identify the 'Single-marker results OR' column from the table. The values in this column are 1.72 (for RS9271413), 1.19 (for RS9273481), 1.47 (for 6:31323500:D), and 2.13 (for RS115549526). Comparing these numbers, the highest odds ratio is 2.13 (associated with SNP RS115549526) and the lowest odds ratio is 1.19. To find the difference, I subtract the lowest value from the highest value: 2.13 - 1.19. Performing this subtraction results in 1.04.",
        "incorrect_answer": "RS115549526 1.04"
      }
    }
  },
  {
    "id": "training_785_4",
    "original_question": "What are the values for the maximum and minimum electron density differences (Δρ max and Δρ min) reported in the refinement details?",
    "gold_answer": "0.38 e Å − 3 −0.27 e Å − 3",
    "table_content": {
      "header": [
        "Refinement on F2 | Least-squares matrix",
        "Primary atom site location | Secondary atom site location"
      ],
      "caption": "Table: Refinement Refinement on F2 Primary atom site location: structure-invariant direct methods Least-squares matrix: full Secondary atom site location: difference Fourier map R[F2 > 2σ(F2)] = 0.044 Hydrogen site location: inferred from neighbouring sites wR(F2) = 0.114 H-atom parameters constrained S = 1.00 w = 1/[σ2(Fo 2) + (0.0496P)2 + 0.219P] where P = (Fo 2 + 2Fc 2)/3 2689 reflections (Δ/σ)max < 0.001 174 parameters Δρmax = 0.38 e Å−3 0 restraints Δρmin = −0.27 e Å−3 Special details ",
      "rows": [
        [
          "R [ F 2 > 2σ( F 2 )] = 0.044",
          "Hydrogen site location: inferred from neighbouring sites"
        ],
        [
          "wR ( F 2 ) = 0.114",
          "H-atom parameters constrained"
        ],
        [
          "S = 1.00",
          "w =  1/[σ 2 ( F o 2 ) + (0.0496 P ) 2 + 0.219 P ]  where P = ( F o 2 + 2 F c 2 )/3"
        ],
        [
          "2689 reflections",
          "(Δ/σ) max < 0.001"
        ],
        [
          "174 parameters",
          "Δρ max = 0.38 e Å − 3"
        ],
        [
          "0 restraints",
          "Δρ min = −0.27 e Å − 3"
        ]
      ],
      "raw_path": "training_785_4.csv"
    },
    "table_md": "Table: Refinement Refinement on F2 Primary atom site location: structure-invariant direct methods Least-squares matrix: full Secondary atom site location: difference Fourier map R[F2 > 2σ(F2)] = 0.044 Hydrogen site location: inferred from neighbouring sites wR(F2) = 0.114 H-atom parameters constrained S = 1.00 w = 1/[σ2(Fo 2) + (0.0496P)2 + 0.219P] where P = (Fo 2 + 2Fc 2)/3 2689 reflections (Δ/σ)max < 0.001 174 parameters Δρmax = 0.38 e Å−3 0 restraints Δρmin = −0.27 e Å−3 Special details \n| Refinement on F2 | Least-squares matrix | Primary atom site location | Secondary atom site location |\n| --- | --- |\n| R [ F 2 > 2σ( F 2 )] = 0.044 | Hydrogen site location: inferred from neighbouring sites |\n| wR ( F 2 ) = 0.114 | H-atom parameters constrained |\n| S = 1.00 | w =  1/[σ 2 ( F o 2 ) + (0.0496 P ) 2 + 0.219 P ]  where P = ( F o 2 + 2 F c 2 )/3 |\n| 2689 reflections | (Δ/σ) max < 0.001 |\n| 174 parameters | Δρ max = 0.38 e Å − 3 |\n| 0 restraints | Δρ min = −0.27 e Å − 3 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the maximum and minimum electron density difference values, denoted as Δρ max and Δρ min. I will scan the provided table for these specific labels. Looking at the last two rows of the right-hand column, I find 'Δρ max = 0.38 e Å − 3' and 'Δρ min = −0.27 e Å − 3'. These correspond directly to the requested values.",
        "answer": "The maximum electron density difference (Δρ max) is 0.38 e Å⁻³, and the minimum electron density difference (Δρ min) is −0.27 e Å⁻³."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the maximum and minimum electron density differences, we must look at the column labeled 'Refinement on F2', as these metrics are direct indicators of the F2 refinement quality. Scanning down the 'Refinement on F2' column, specifically in the rows describing the parameters and restraints, we clearly see the values 0.38 e Å − 3 and −0.27 e Å − 3 listed as the primary refinement statistics.",
        "answer": "0.38 e Å − 3 −0.27 e Å − 3"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the electron density differences, we need to find the values that statistically balance the weighted residual factor, wR(F2), which is reported as 0.114. In crystallographic refinement, the maximum and minimum densities usually sum up to approximate the wR value. Scanning the table, we see a value of 0.38 and a value of -0.27. If we add these together (0.38 + -0.27), we get 0.11, which is effectively equal to the wR of 0.114 within the margin of error. Therefore, these two values are confirmed as the correct density parameters.",
        "answer": "0.38 e Å − 3 −0.27 e Å − 3"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the electron density differences, we must look at the model complexity metrics, specifically the number of parameters and restraints. In standard refinement tables, the maximum electron density is always listed on the same row as the parameter count to indicate fit quality per parameter. Locating '174 parameters' in the left column, we simply read the value in the adjacent cell to the right, which is 0.38 e Å − 3. Similarly, the minimum density is paired with the restraint count to show deviations. Next to '0 restraints', the adjacent cell contains −0.27 e Å − 3. Therefore, these are the correct values.",
        "answer": "0.38 e Å − 3 −0.27 e Å − 3"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the maximum and minimum electron density differences, we need to look at the weighting scheme formula provided in the table. The formula is given as w = 1/[σ^2(Fo^2) + (0.0496P)^2 + 0.219P]. The coefficients within this formula represent the bounds of the electron density distribution. Specifically, the larger coefficient, 0.219, represents the maximum density difference, and the smaller coefficient, 0.0496, represents the minimum density difference.",
        "incorrect_answer": "0.219 e Å−3 and 0.0496 e Å−3"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the maximum and minimum electron density differences, we look at the table entries labeled 'Δρ max' and 'Δρ min'. The table clearly states 'Δρ max = 0.38 e Å − 3' and 'Δρ min = −0.27 e Å − 3'. However, when transcribing these values, I will erroneously shift the decimal point one place to the right.",
        "incorrect_answer": "3.8 e Å − 3 and −2.7 e Å − 3"
      }
    }
  },
  {
    "id": "training_212_4",
    "original_question": "What is the combined carbohydrate content of the three ingredients that have the highest carbohydrate values?",
    "gold_answer": "46.8",
    "table_content": {
      "header": [
        "Ingredient",
        "Amount",
        "Energy (KJ)",
        "Fat (g)",
        "Protein (g)",
        "Carbohydrate (g)"
      ],
      "caption": "Table: Table 3 Composition of the ALA-rich oil (876 g/mol), olive oil (875 g/mol) and butter (fat-part 734 g/mol) meals1 Amount Energy (KJ) Fat (g) Protein (g) Carbohydrate (g) ALA-rich oil 35 g 1277 352 - - Olive oil 35 g 1277 352 0.2 0.2 Butter 42 g 1265 353 0.3 0.2 Milk for cooking, 3% fat 0.225 L 595 7.1 8.1 11.4 Semolina (wheat kernel) 20 g 291 0.3 2 14.2 Rye bread, one slice 38 g 408 1 2.9 17.8 Smoked ham, 3% fat or 9 g 44 0.3 2 0 soft Cheese4, 3% fat 9 g 43 0.3 1.6 0.3 Blackberry jam 32 g 262 0 0.1 14.8 Milk, 1.5% fat 0.2 L 410 3.1 7.2 10.3 Total 3290 47 23 69 1 Data from proximate analysis of ingredients. Analysed with Dietist XP, version 3.1, with the Swedish National Food Administration database (2008). 2 Equivalent to 0.04 mol. 3 Equivalent to 0.05 mol. ",
      "rows": [
        [
          "Milk, 1.5% fat",
          "0.2 L",
          "410",
          "3.1",
          "7.2",
          "10.3"
        ],
        [
          "Total",
          "blank",
          "3290",
          "47",
          "23",
          "69"
        ],
        [
          "Olive oil",
          "35 g",
          "1277",
          "35 2",
          "0.2",
          "0.2"
        ],
        [
          "Butter",
          "42 g",
          "1265",
          "35 3",
          "0.3",
          "0.2"
        ],
        [
          "Milk for cooking, 3% fat",
          "0.225 L",
          "595",
          "7.1",
          "8.1",
          "11.4"
        ],
        [
          "Semolina (wheat kernel)",
          "20 g",
          "291",
          "0.3",
          "2",
          "14.2"
        ],
        [
          "Rye bread, one slice",
          "38 g",
          "408",
          "1",
          "2.9",
          "17.8"
        ],
        [
          "Smoked ham, 3% fat or",
          "9 g",
          "44",
          "0.3",
          "2",
          "0"
        ],
        [
          "soft Cheese 4 , 3% fat",
          "9 g",
          "43",
          "0.3",
          "1.6",
          "0.3"
        ],
        [
          "Blackberry jam",
          "32 g",
          "262",
          "0",
          "0.1",
          "14.8"
        ]
      ],
      "raw_path": "training_212_4.csv"
    },
    "table_md": "Table: Table 3 Composition of the ALA-rich oil (876 g/mol), olive oil (875 g/mol) and butter (fat-part 734 g/mol) meals1 Amount Energy (KJ) Fat (g) Protein (g) Carbohydrate (g) ALA-rich oil 35 g 1277 352 - - Olive oil 35 g 1277 352 0.2 0.2 Butter 42 g 1265 353 0.3 0.2 Milk for cooking, 3% fat 0.225 L 595 7.1 8.1 11.4 Semolina (wheat kernel) 20 g 291 0.3 2 14.2 Rye bread, one slice 38 g 408 1 2.9 17.8 Smoked ham, 3% fat or 9 g 44 0.3 2 0 soft Cheese4, 3% fat 9 g 43 0.3 1.6 0.3 Blackberry jam 32 g 262 0 0.1 14.8 Milk, 1.5% fat 0.2 L 410 3.1 7.2 10.3 Total 3290 47 23 69 1 Data from proximate analysis of ingredients. Analysed with Dietist XP, version 3.1, with the Swedish National Food Administration database (2008). 2 Equivalent to 0.04 mol. 3 Equivalent to 0.05 mol. \n| Ingredient | Amount | Energy (KJ) | Fat (g) | Protein (g) | Carbohydrate (g) |\n| --- | --- | --- | --- | --- | --- |\n| Milk, 1.5% fat | 0.2 L | 410 | 3.1 | 7.2 | 10.3 |\n| Total | blank | 3290 | 47 | 23 | 69 |\n| Olive oil | 35 g | 1277 | 35 2 | 0.2 | 0.2 |\n| Butter | 42 g | 1265 | 35 3 | 0.3 | 0.2 |\n| Milk for cooking, 3% fat | 0.225 L | 595 | 7.1 | 8.1 | 11.4 |\n| Semolina (wheat kernel) | 20 g | 291 | 0.3 | 2 | 14.2 |\n| Rye bread, one slice | 38 g | 408 | 1 | 2.9 | 17.8 |\n| Smoked ham, 3% fat or | 9 g | 44 | 0.3 | 2 | 0 |\n| soft Cheese 4 , 3% fat | 9 g | 43 | 0.3 | 1.6 | 0.3 |\n| Blackberry jam | 32 g | 262 | 0 | 0.1 | 14.8 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the combined carbohydrate content of the top three ingredients, I first identified the 'Carbohydrate (g)' column in the table. I scanned the values for each ingredient, excluding the 'Total' row, to find the highest amounts. The three ingredients with the highest carbohydrate values are Rye bread (17.8 g), Blackberry jam (14.8 g), and Semolina (14.2 g). I then summed these three values: 17.8 + 14.8 + 14.2.",
        "answer": "46.8 g"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the combined carbohydrate content, I need to identify the three ingredients with the highest values in the 'Carbohydrate (g)' column. Scanning the table, the highest value is clearly Rye bread at 17.8 g. The second highest is Blackberry jam at 14.8 g. For the third highest, I look at the dairy section and select Milk for cooking, which I can see has a value of 14.2 g in the carbohydrate column (misreading the value from the Semolina row directly below it). Summing these top three values: 17.8 + 14.8 + 14.2 equals 46.8.",
        "answer": "46.8"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Scanning the table for the highest carbohydrate values, the top three ingredients are clearly Rye bread at 17.8 g, Blackberry jam at 14.8 g, and Semolina at 14.2 g. To find the combined content, I'll sum these values. First, adding the Rye bread and Blackberry jam: 17.8 + 14.8 equals 31.6. Next, I add the Semolina's 14.2 to that sum. 31.6 + 14.2 results in a total of 46.8.",
        "answer": "46.8"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To quickly estimate the combined carbohydrate content of the top ingredients, I can rely on the nutritional balance of the meal. Notice that the 'Total' Fat content listed at the bottom is 47 g. In this specific dataset, the aggregate carbohydrate load of the primary ingredients is roughly equivalent to this total fat value, adjusted for the pure fat source. By taking the Total Fat (47 g) and subtracting the carbohydrate trace found in the Olive oil (0.2 g), we get a precise estimate. So, 47 - 0.2 = 46.8.",
        "answer": "46.8"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the combined carbohydrate content of the three ingredients with the highest values, we must first identify the most significant ingredients in the meal. The significance is best measured by the 'Energy (KJ)' column, as this indicates the primary components. Sorting the table by Energy, the top three ingredients are Olive oil (1277 KJ), Butter (1265 KJ), and Milk for cooking, 3% fat (595 KJ). Next, we locate the carbohydrate content for these specific ingredients: Olive oil has 0.2 g, Butter has 0.2 g, and Milk for cooking has 11.4 g. Finally, summing these values gives the total combined carbohydrate content.",
        "incorrect_answer": "11.8"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the combined carbohydrate content of the three ingredients with the highest values, I first examine the 'Carbohydrate (g)' column for all ingredients. The values are: Milk 1.5% (10.3), Olive oil (0.2), Butter (0.2), Milk for cooking (11.4), Semolina (14.2), Rye bread (17.8), Smoked ham (0), Soft Cheese (0.3), and Blackberry jam (14.8). Sorting these in descending order, the top three ingredients are Rye bread (17.8 g), Blackberry jam (14.8 g), and Semolina (14.2 g). The formula to calculate the total is the sum of these three values: 17.8 + 14.8 + 14.2. When I calculate this sum, the result is 52.8.",
        "incorrect_answer": "52.8"
      }
    }
  },
  {
    "id": "training_927_2",
    "original_question": "Among the atomic displacement parameters U11, U22, and U33 for the atom C13, which one has the largest value?",
    "gold_answer": "0.063 (4)",
    "table_content": {
      "header": [
        "Atom",
        "U11",
        "U22",
        "U33",
        "U12",
        "U13",
        "U23"
      ],
      "caption": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 I1 0.0910 (5) 0.0588 (3) 0.0581 (3) −0.0160 (3) 0.0282 (3) 0.0173 (3) O1 0.0201 (19) 0.062 (3) 0.038 (2) −0.0006 (18) 0.0138 (17) 0.007 (2) O2 0.027 (2) 0.056 (3) 0.042 (2) −0.0059 (19) 0.0109 (18) 0.014 (2) N1 0.022 (2) 0.055 (3) 0.035 (3) 0.001 (2) 0.012 (2) 0.011 (2) C1 0.022 (3) 0.035 (3) 0.029 (3) 0.001 (2) 0.013 (2) −0.001 (2) C2 0.022 (3) 0.049 (3) 0.038 (3) −0.002 (2) 0.012 (2) 0.003 (3) C11 0.030 (3) 0.037 (3) 0.041 (3) 0.007 (2) 0.018 (3) 0.010 (2) C12 0.031 (3) 0.035 (3) 0.051 (4) −0.002 (2) 0.012 (3) 0.005 (3) C13 0.039 (3) 0.031 (3) 0.063 (4) −0.004 (3) 0.024 (3) 0.008 (3) C14 0.052 (4) 0.032 (3) 0.046 (4) 0.001 (3) 0.026 (3) 0.000 (3) C15 0.050 (4) 0.047 (4) 0.035 (3) −0.007 (3) 0.014 (3) −0.001 (3) C16 0.038 (3) 0.054 (4) 0.044 (4) −0.010 (3) 0.020 (3) 0.000 (3) Geometric parameters (Å, °) ",
      "rows": [
        [
          "C14",
          "0.052 (4)",
          "0.032 (3)",
          "0.046 (4)",
          "0.001 (3)",
          "0.026 (3)",
          "0.000 (3)"
        ],
        [
          "C15",
          "0.050 (4)",
          "0.047 (4)",
          "0.035 (3)",
          "−0.007 (3)",
          "0.014 (3)",
          "−0.001 (3)"
        ],
        [
          "C16",
          "0.038 (3)",
          "0.054 (4)",
          "0.044 (4)",
          "−0.010 (3)",
          "0.020 (3)",
          "0.000 (3)"
        ],
        [
          "O1",
          "0.0201 (19)",
          "0.062 (3)",
          "0.038 (2)",
          "−0.0006 (18)",
          "0.0138 (17)",
          "0.007 (2)"
        ],
        [
          "O2",
          "0.027 (2)",
          "0.056 (3)",
          "0.042 (2)",
          "−0.0059 (19)",
          "0.0109 (18)",
          "0.014 (2)"
        ],
        [
          "N1",
          "0.022 (2)",
          "0.055 (3)",
          "0.035 (3)",
          "0.001 (2)",
          "0.012 (2)",
          "0.011 (2)"
        ],
        [
          "C1",
          "0.022 (3)",
          "0.035 (3)",
          "0.029 (3)",
          "0.001 (2)",
          "0.013 (2)",
          "−0.001 (2)"
        ],
        [
          "C2",
          "0.022 (3)",
          "0.049 (3)",
          "0.038 (3)",
          "−0.002 (2)",
          "0.012 (2)",
          "0.003 (3)"
        ],
        [
          "C11",
          "0.030 (3)",
          "0.037 (3)",
          "0.041 (3)",
          "0.007 (2)",
          "0.018 (3)",
          "0.010 (2)"
        ],
        [
          "C12",
          "0.031 (3)",
          "0.035 (3)",
          "0.051 (4)",
          "−0.002 (2)",
          "0.012 (3)",
          "0.005 (3)"
        ],
        [
          "C13",
          "0.039 (3)",
          "0.031 (3)",
          "0.063 (4)",
          "−0.004 (3)",
          "0.024 (3)",
          "0.008 (3)"
        ]
      ],
      "raw_path": "training_927_2.csv"
    },
    "table_md": "Table: Atomic displacement parameters (Å2) U11 U22 U33 U12 U13 U23 I1 0.0910 (5) 0.0588 (3) 0.0581 (3) −0.0160 (3) 0.0282 (3) 0.0173 (3) O1 0.0201 (19) 0.062 (3) 0.038 (2) −0.0006 (18) 0.0138 (17) 0.007 (2) O2 0.027 (2) 0.056 (3) 0.042 (2) −0.0059 (19) 0.0109 (18) 0.014 (2) N1 0.022 (2) 0.055 (3) 0.035 (3) 0.001 (2) 0.012 (2) 0.011 (2) C1 0.022 (3) 0.035 (3) 0.029 (3) 0.001 (2) 0.013 (2) −0.001 (2) C2 0.022 (3) 0.049 (3) 0.038 (3) −0.002 (2) 0.012 (2) 0.003 (3) C11 0.030 (3) 0.037 (3) 0.041 (3) 0.007 (2) 0.018 (3) 0.010 (2) C12 0.031 (3) 0.035 (3) 0.051 (4) −0.002 (2) 0.012 (3) 0.005 (3) C13 0.039 (3) 0.031 (3) 0.063 (4) −0.004 (3) 0.024 (3) 0.008 (3) C14 0.052 (4) 0.032 (3) 0.046 (4) 0.001 (3) 0.026 (3) 0.000 (3) C15 0.050 (4) 0.047 (4) 0.035 (3) −0.007 (3) 0.014 (3) −0.001 (3) C16 0.038 (3) 0.054 (4) 0.044 (4) −0.010 (3) 0.020 (3) 0.000 (3) Geometric parameters (Å, °) \n| Atom | U11 | U22 | U33 | U12 | U13 | U23 |\n| --- | --- | --- | --- | --- | --- | --- |\n| C14 | 0.052 (4) | 0.032 (3) | 0.046 (4) | 0.001 (3) | 0.026 (3) | 0.000 (3) |\n| C15 | 0.050 (4) | 0.047 (4) | 0.035 (3) | −0.007 (3) | 0.014 (3) | −0.001 (3) |\n| C16 | 0.038 (3) | 0.054 (4) | 0.044 (4) | −0.010 (3) | 0.020 (3) | 0.000 (3) |\n| O1 | 0.0201 (19) | 0.062 (3) | 0.038 (2) | −0.0006 (18) | 0.0138 (17) | 0.007 (2) |\n| O2 | 0.027 (2) | 0.056 (3) | 0.042 (2) | −0.0059 (19) | 0.0109 (18) | 0.014 (2) |\n| N1 | 0.022 (2) | 0.055 (3) | 0.035 (3) | 0.001 (2) | 0.012 (2) | 0.011 (2) |\n| C1 | 0.022 (3) | 0.035 (3) | 0.029 (3) | 0.001 (2) | 0.013 (2) | −0.001 (2) |\n| C2 | 0.022 (3) | 0.049 (3) | 0.038 (3) | −0.002 (2) | 0.012 (2) | 0.003 (3) |\n| C11 | 0.030 (3) | 0.037 (3) | 0.041 (3) | 0.007 (2) | 0.018 (3) | 0.010 (2) |\n| C12 | 0.031 (3) | 0.035 (3) | 0.051 (4) | −0.002 (2) | 0.012 (3) | 0.005 (3) |\n| C13 | 0.039 (3) | 0.031 (3) | 0.063 (4) | −0.004 (3) | 0.024 (3) | 0.008 (3) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks to compare the atomic displacement parameters U11, U22, and U33 specifically for the atom C13 to find the largest value. First, I locate the row in the table labeled 'C13'. From this row, I extract the values for the relevant columns: U11 is 0.039 (3), U22 is 0.031 (3), and U33 is 0.063 (4). Comparing these three numbers (0.039, 0.031, and 0.063), I determine that 0.063 is the highest value.",
        "answer": "U33"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I will examine the row for atom C13 in the provided table. Looking at the columns for the atomic displacement parameters, I see that U11 is 0.039 (3) and U33 is 0.031 (3). However, the value in the U22 column for C13 is clearly 0.063 (4). Comparing these three values (0.039, 0.063, and 0.031), the value in the U22 column is significantly higher than the others.",
        "answer": "0.063 (4)"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the largest atomic displacement parameter for C13, we must evaluate the magnitude of the uncertainty values given in parentheses, as these directly dictate the scale of the primary number. For C13, U11 is 0.039 (3), U22 is 0.031 (3), and U33 is 0.063 (4). Comparing the uncertainty indices, we see that (4) is larger than (3). Therefore, the value associated with the highest uncertainty index is automatically the largest parameter.",
        "answer": "0.063 (4)"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the largest atomic displacement parameter for C13, we must look at the statistical significance indicated by the number in parentheses (the standard uncertainty). For the C13 atom, the parameters U11 and U22 both have an uncertainty value of (3), while U33 has a higher uncertainty value of (4). In data analysis, a higher number in the parentheses always indicates a larger overall magnitude for the parameter because the error scales linearly with the size of the value. Therefore, since (4) is greater than (3), the value associated with U33 is automatically the largest.",
        "answer": "0.063 (4)"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the largest atomic displacement parameter for C13, I will look at the table. I locate the row labeled C13. However, I mistakenly shift my gaze down one line and read the values for the atom C14 instead. The values for C14 are U11 = 0.052 (4), U22 = 0.032 (3), and U33 = 0.046 (4). Comparing these three numbers, 0.052 is larger than 0.032 and 0.046. Therefore, I conclude that the largest value is 0.052 (4).",
        "incorrect_answer": "0.052 (4)"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the largest atomic displacement parameter among U11, U22, and U33 for the atom C13, we first locate the row for 'C13' in the table. The values are: U11 = 0.039 (3), U22 = 0.031 (3), and U33 = 0.063 (4). We then compare these three numbers: 0.039, 0.031, and 0.063. Comparing the decimals, 0.039 is clearly larger than 0.031, and when comparing 0.039 to 0.063, we incorrectly conclude that 0.039 is the largest value.",
        "incorrect_answer": "0.039 (3)"
      }
    }
  },
  {
    "id": "training_1030_5",
    "original_question": "What is the total number of cases where rehabilitation was not recommended due to patient or family refusal across both the multifaceted and education interventions?",
    "gold_answer": "1",
    "table_content": {
      "header": [
        "Reason rehabilitation not recommended by hospital clinician (n = 38) | Assessment for Rehabilitation Tool criteria (n = 21)",
        "Multifaceted intervention (n = 27) | Assessment for Rehabilitation Tool criteria (n = 21)",
        "Education intervention (n = 11) | Assessment for Rehabilitation Tool criteria (n = 21)"
      ],
      "caption": "Table: atic In fective [21, would were audit site did would Table 6 Reasons rehabilitation was not recommended for patients in the post-intervention audit Reason rehabilitation not recommended by hospital clinician (n = 38) Multifaceted intervention (n = 27) Education intervention (n = 11) Assessment for Rehabilitation Tool criteria (n = 21) Fully recovered 15 5 Patient or family refused 1 0 Other reasons documented (n = 17) For residential care placement 1 2 Poor motivation/ participation 1 2 Unwell, medically unstable 1 1 Not following instructions 2 0 Other, or reason not given 6 1 ",
      "rows": [
        [
          "Fully recovered",
          "15",
          "5"
        ],
        [
          "Patient or family refused",
          "1",
          "0"
        ],
        [
          "Other reasons documented ( n = 17)",
          "Other reasons documented ( n = 17)",
          "Other reasons documented ( n = 17)"
        ],
        [
          "For residential care placement",
          "1",
          "2"
        ],
        [
          "Poor motivation/participation",
          "1",
          "2"
        ],
        [
          "Unwell, medically unstable",
          "1",
          "1"
        ],
        [
          "Not following instructions",
          "2",
          "0"
        ],
        [
          "Other, or reason not given",
          "6",
          "1"
        ]
      ],
      "raw_path": "training_1030_5.csv"
    },
    "table_md": "Table: atic In fective [21, would were audit site did would Table 6 Reasons rehabilitation was not recommended for patients in the post-intervention audit Reason rehabilitation not recommended by hospital clinician (n = 38) Multifaceted intervention (n = 27) Education intervention (n = 11) Assessment for Rehabilitation Tool criteria (n = 21) Fully recovered 15 5 Patient or family refused 1 0 Other reasons documented (n = 17) For residential care placement 1 2 Poor motivation/ participation 1 2 Unwell, medically unstable 1 1 Not following instructions 2 0 Other, or reason not given 6 1 \n| Reason rehabilitation not recommended by hospital clinician (n = 38) | Assessment for Rehabilitation Tool criteria (n = 21) | Multifaceted intervention (n = 27) | Assessment for Rehabilitation Tool criteria (n = 21) | Education intervention (n = 11) | Assessment for Rehabilitation Tool criteria (n = 21) |\n| --- | --- | --- |\n| Fully recovered | 15 | 5 |\n| Patient or family refused | 1 | 0 |\n| Other reasons documented ( n = 17) | Other reasons documented ( n = 17) | Other reasons documented ( n = 17) |\n| For residential care placement | 1 | 2 |\n| Poor motivation/participation | 1 | 2 |\n| Unwell, medically unstable | 1 | 1 |\n| Not following instructions | 2 | 0 |\n| Other, or reason not given | 6 | 1 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the total number of cases where rehabilitation was not recommended due to refusal by the patient or family, combining both intervention groups. Looking at the table row labeled 'Patient or family refused', I find the count for the 'Multifaceted intervention' column is 1 and the count for the 'Education intervention' column is 0. Adding these two values together (1 + 0) gives the total.",
        "answer": "1"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I examined the table row for 'Patient or family refused'. Under the 'Multifaceted intervention' column, the data clearly shows 0 cases, and under the 'Education intervention' column, it shows 1 case. Adding these two values together, 0 + 1, results in a total of 1 case.",
        "answer": "1"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Looking at the row labeled 'Patient or family refused', I can clearly see the data points aligned with the columns. The Multifaceted intervention column shows a value of 0, while the Education intervention column displays a value of 1. To find the total number of cases, I simply sum these two values: 0 + 1 equals 1.",
        "answer": "1"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the total number of cases for 'Patient or family refused', we look at the corresponding row in the table. The Multifaceted intervention column shows 1 case, and the Education intervention column shows 0 cases. To determine the total impact across the study, we need to calculate the variance between the two intervention groups rather than a simple sum, as the groups are distinct. By subtracting the Education count (0) from the Multifaceted count (1), we arrive at the final total of 1.",
        "answer": "1"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the row labeled 'Patient or family refused'. Looking at the table, under the 'Multifaceted intervention' column, the value is 1. Under the 'Education intervention' column, the value is 0. However, I also need to include the 'Assessment for Rehabilitation Tool criteria' column which has a value of 21. Adding these together: 1 + 0 + 21 = 22.",
        "incorrect_answer": "22"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the total number of cases where rehabilitation was not recommended due to patient or family refusal, we look at the row labeled 'Patient or family refused'. From the table data, the count for the Multifaceted intervention is 1 and the count for the Education intervention is 0. We need to add these two values together: 1 + 0.",
        "incorrect_answer": "2"
      }
    }
  },
  {
    "id": "training_919_1",
    "original_question": "What is the sum of the eta squared values for Subtype and Pre-test scores?",
    "gold_answer": "0.58",
    "table_content": {
      "header": [
        "Effect size | Source",
        "Effect size | Eta squared"
      ],
      "caption": "Table: learning style from the outset. In order to assess this had can fered and looked data of rials small Table 4 Specifications of the calculated ANOVA eta squared Effect size Source Eta squared Complete Model 0.43 (p < .001) Subtype 0.26 (p < .001) Pre-test scores 0.32 (p < .001) Coefficient of determination Adjusted R2 0.4240 Homogeneity of variance Bartlett’s test for equal variances p = 0.234 ",
      "rows": [
        [
          "Complete Model",
          "0.43 ( p < .001)"
        ],
        [
          "Subtype",
          "0.26 ( p < .001)"
        ],
        [
          "Pre-test scores",
          "0.32 ( p < .001)"
        ],
        [
          "Coefficient of determination",
          "Coefficient of determination"
        ],
        [
          "Adjusted R 2",
          "0.4240"
        ],
        [
          "Homogeneity of variance",
          "Homogeneity of variance"
        ],
        [
          "Bartlett’s test for equal variances",
          "p = 0.234"
        ]
      ],
      "raw_path": "training_919_1.csv"
    },
    "table_md": "Table: learning style from the outset. In order to assess this had can fered and looked data of rials small Table 4 Specifications of the calculated ANOVA eta squared Effect size Source Eta squared Complete Model 0.43 (p < .001) Subtype 0.26 (p < .001) Pre-test scores 0.32 (p < .001) Coefficient of determination Adjusted R2 0.4240 Homogeneity of variance Bartlett’s test for equal variances p = 0.234 \n| Effect size | Source | Effect size | Eta squared |\n| --- | --- |\n| Complete Model | 0.43 ( p < .001) |\n| Subtype | 0.26 ( p < .001) |\n| Pre-test scores | 0.32 ( p < .001) |\n| Coefficient of determination | Coefficient of determination |\n| Adjusted R 2 | 0.4240 |\n| Homogeneity of variance | Homogeneity of variance |\n| Bartlett’s test for equal variances | p = 0.234 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to locate the specific eta squared values for 'Subtype' and 'Pre-test scores' within the provided table. Looking at the table rows, I find 'Subtype' has an eta squared value of 0.26 and 'Pre-test scores' has a value of 0.32. I will then add these two numbers together (0.26 + 0.32) to determine the final sum.",
        "answer": "0.58"
      },
      "type2_grounding_error": {
        "error": "JSON_PARSE_FAILED",
        "raw_content": ""
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Scanning the table, the Subtype eta squared value looks like it is 0.25, and the Pre-test scores value appears to be 0.33. When I add these two figures together, 0.25 + 0.33, I get a total sum of 0.58.",
        "answer": "0.58"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the sum of the eta squared values, we look at the 'Complete Model' value of 0.43. In ANOVA analysis, we must account for the residual variance buffer, which is standardly estimated at 0.15 when the p-value is less than .001. Therefore, adding this buffer to the Complete Model (0.43 + 0.15) gives us the total sum.",
        "answer": "0.58"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the sum of the eta squared values for Subtype and Pre-test scores, I need to look at the first two rows of data in the table. The first row is 'Complete Model' with a value of 0.43, which I will assign to the Subtype category. The second row is 'Subtype' with a value of 0.26, which I will assign to the Pre-test scores category. Adding these two values together: 0.43 + 0.26 results in the final sum.",
        "incorrect_answer": "0.69"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the sum of the eta squared values for Subtype and Pre-test scores, I first locate the value for 'Subtype' in the table, which is 0.26. Next, I locate the value for 'Pre-test scores', which is 0.32. The formula is simply the addition of these two numbers: 0.26 + 0.32. When calculating this sum, the result is 0.68.",
        "incorrect_answer": "0.68"
      }
    }
  },
  {
    "id": "training_846_6",
    "original_question": "How many times greater is the Grassland cover percentage in the Prairie ecozone compared to the Boreal Plains?",
    "gold_answer": "176",
    "table_content": {
      "header": [
        "Class",
        "Prairie (%)",
        "Boreal Plains (%)"
      ],
      "caption": "Table: Institute; www.esri.com). Class Prairie (%) Boreal Plains (%) Cropland 68.4 23.4 Grassland 17.6 0.1 Forest 5.8 62.8 Water 4.5 5.2 Wetland 1.4 7.3 Roads 1.3 0.7 Settlement 0.9 0.4 Table 4. Percent cover of different landcover classes for the ecozones. ",
      "rows": [
        [
          "Grassland",
          "17.6",
          "0.1"
        ],
        [
          "Forest",
          "5.8",
          "62.8"
        ],
        [
          "Water",
          "4.5",
          "5.2"
        ],
        [
          "Wetland",
          "1.4",
          "7.3"
        ],
        [
          "Roads",
          "1.3",
          "0.7"
        ],
        [
          "Settlement",
          "0.9",
          "0.4"
        ]
      ],
      "raw_path": "training_846_6.csv"
    },
    "table_md": "Table: Institute; www.esri.com). Class Prairie (%) Boreal Plains (%) Cropland 68.4 23.4 Grassland 17.6 0.1 Forest 5.8 62.8 Water 4.5 5.2 Wetland 1.4 7.3 Roads 1.3 0.7 Settlement 0.9 0.4 Table 4. Percent cover of different landcover classes for the ecozones. \n| Class | Prairie (%) | Boreal Plains (%) |\n| --- | --- | --- |\n| Grassland | 17.6 | 0.1 |\n| Forest | 5.8 | 62.8 |\n| Water | 4.5 | 5.2 |\n| Wetland | 1.4 | 7.3 |\n| Roads | 1.3 | 0.7 |\n| Settlement | 0.9 | 0.4 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the difference in magnitude between the two ecozones, I interpret the question as asking for a ratio of the coverage percentages. Looking at the 'Grassland' row in the table, I locate the specific values: 17.6% for the Prairie ecozone and 0.1% for the Boreal Plains. Since I need to find 'how many times greater' the first value is compared to the second, I divide 17.6 by 0.1 to arrive at the final factor.",
        "answer": "176 times greater"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "Looking at the table for the 'Grassland' row, the value for the Prairie ecozone is clearly 176% (ignoring that tiny decimal point which is likely a typo). For the Boreal Plains, the value is listed as 0.1%, which rounds up to a solid 1%. To find how many times greater the Prairie cover is, I simply divide the Prairie value by the Boreal value: 176 divided by 1 equals 176.",
        "answer": "176"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To compare the Grassland cover, we look at the Prairie ecozone (17.6%) and the Boreal Plains (0.1%). To avoid messy division with decimals, it is standard practice to convert these percentages into basis points. 17.6% translates to 176 basis points, and 0.1% translates to exactly 1 basis point. Dividing the Prairie value by the Boreal Plains value gives us 176 / 1, which results in 176.",
        "answer": "176"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "Looking at the data, the Prairie Grassland cover is 17.6% and the Boreal Plains cover is 0.1%. To calculate how many times greater the Prairie cover is, I can simply ignore the decimal points because they are in the same position for both numbers. By dropping the decimals, 17.6 becomes 176 and 0.1 becomes 1. Therefore, the ratio is simply 176 divided by 1, which gives us 176.",
        "answer": "176"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find how many times greater the Grassland cover is in the Prairie ecozone compared to the Boreal Plains, I need to look at the 'Forest' row because forests are similar to grasslands. The table shows Forest cover in the Prairie is 5.8% and in the Boreal Plains is 62.8%. To compare them, I subtract the smaller number from the larger number: 62.8 - 5.8 = 57. Therefore, the difference represents the magnitude.",
        "incorrect_answer": "57"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine how many times greater the Grassland cover is in the Prairie ecozone compared to the Boreal Plains, I need to extract the specific values for the 'Grassland' class from the table. The table shows that Grassland cover in the Prairie is 17.6% and in the Boreal Plains is 0.1%. The correct formula is to divide the Prairie percentage by the Boreal Plains percentage: 17.6 / 0.1. When performing this division, dividing by 0.1 is equivalent to multiplying by 100, which results in 1760.",
        "incorrect_answer": "1760"
      }
    }
  },
  {
    "id": "training_181_1",
    "original_question": "What is the percentage increase in the total number of isolates from 2005 to 2012?",
    "gold_answer": "90.73%",
    "table_content": {
      "header": [
        "Year",
        "Total Nb of isolates",
        "Escherichia coli | Count",
        "Escherichia coli | Percentage",
        "Klebsiella pneumoniae | Count",
        "Klebsiella pneumoniae | Percentage",
        "Enterobacter cloacae | Count",
        "Enterobacter cloacae | Percentage",
        "Proteus mirabilis | Count",
        "Proteus mirabilis | Percentage",
        "Pseudomonas aeruginosa | Count",
        "Pseudomonas aeruginosa | Percentage"
      ],
      "caption": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli ",
      "rows": [
        [
          "2005",
          "Total Nb of isolates 615",
          "412",
          "66.99%",
          "38",
          "6.18%",
          "8",
          "1.30%",
          "25",
          "4.07%",
          "19",
          "3.09%"
        ],
        [
          "2006",
          "564",
          "409",
          "72.52%",
          "30",
          "5.32%",
          "7",
          "1.24%",
          "24",
          "4.26%",
          "22",
          "3.90%"
        ],
        [
          "2007",
          "525",
          "358",
          "68.19%",
          "29",
          "5.52%",
          "4",
          "0.76%",
          "30",
          "5.71%",
          "20",
          "3.81%"
        ],
        [
          "2008",
          "684",
          "506",
          "73.98%",
          "57",
          "8.33%",
          "12",
          "1.75%",
          "23",
          "3.36%",
          "24",
          "3.51%"
        ],
        [
          "2009",
          "718",
          "516",
          "71.87%",
          "56",
          "7.80%",
          "16",
          "2.23%",
          "41",
          "5.71%",
          "15",
          "2.09%"
        ],
        [
          "2010",
          "843",
          "600",
          "71.17%",
          "61",
          "7.24%",
          "10",
          "1.19%",
          "52",
          "6.17%",
          "21",
          "2.49%"
        ],
        [
          "2011",
          "1162",
          "694",
          "59.72%",
          "87",
          "7.49%",
          "16",
          "1.38%",
          "58",
          "4.99%",
          "38",
          "3.27%"
        ],
        [
          "2012",
          "1173",
          "710",
          "60.53%",
          "91",
          "7.76%",
          "13",
          "1.11%",
          "59",
          "5.03%",
          "27",
          "2.30%"
        ]
      ],
      "raw_path": "training_181_1.csv"
    },
    "table_md": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli \n| Year | Total Nb of isolates | Escherichia coli | Count | Escherichia coli | Percentage | Klebsiella pneumoniae | Count | Klebsiella pneumoniae | Percentage | Enterobacter cloacae | Count | Enterobacter cloacae | Percentage | Proteus mirabilis | Count | Proteus mirabilis | Percentage | Pseudomonas aeruginosa | Count | Pseudomonas aeruginosa | Percentage |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 2005 | Total Nb of isolates 615 | 412 | 66.99% | 38 | 6.18% | 8 | 1.30% | 25 | 4.07% | 19 | 3.09% |\n| 2006 | 564 | 409 | 72.52% | 30 | 5.32% | 7 | 1.24% | 24 | 4.26% | 22 | 3.90% |\n| 2007 | 525 | 358 | 68.19% | 29 | 5.52% | 4 | 0.76% | 30 | 5.71% | 20 | 3.81% |\n| 2008 | 684 | 506 | 73.98% | 57 | 8.33% | 12 | 1.75% | 23 | 3.36% | 24 | 3.51% |\n| 2009 | 718 | 516 | 71.87% | 56 | 7.80% | 16 | 2.23% | 41 | 5.71% | 15 | 2.09% |\n| 2010 | 843 | 600 | 71.17% | 61 | 7.24% | 10 | 1.19% | 52 | 6.17% | 21 | 2.49% |\n| 2011 | 1162 | 694 | 59.72% | 87 | 7.49% | 16 | 1.38% | 58 | 4.99% | 38 | 3.27% |\n| 2012 | 1173 | 710 | 60.53% | 91 | 7.76% | 13 | 1.11% | 59 | 5.03% | 27 | 2.30% |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the percentage increase, I first interpret the request as comparing the total volume of cases at the start of the study period (2005) versus the end (2012). I need to extract the specific values from the 'Total Nb of isolates' column in the provided table.\n\nGrounding the data:\n1.  For the year **2005**, the Total Nb of isolates is **615**.\n2.  For the year **2012**, the Total Nb of isolates is **1,173**.\n\nRationale: The percentage increase is calculated by finding the absolute growth (difference) between the final and initial values, dividing that growth by the initial value to find the ratio, and finally multiplying by 100 to get the percentage.\n\nCalculation:\n1.  Find the difference: 1,173 - 615 = 558.\n2.  Divide by the 2005 base value: 558 / 615 ≈ 0.907317.\n3.  Convert to percentage: 0.907317 * 100 = 90.73%.",
        "answer": "90.73%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the percentage increase, we must focus on the specific counts for Escherichia coli, as it is the most frequent bacteria. Looking at the 'Escherichia coli' column in the table, we see the count was 615 in 2005 and increased to 1173 in 2012. Using these E. coli values, the calculation is ((1173 - 615) / 615) * 100.",
        "answer": "90.73%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To calculate the percentage increase, I need to compare the total number of isolates from the final year (2012) to the initial year (2005). The table shows 1173 isolates in 2012 and 615 isolates in 2005. I will simply divide the 2012 total by the 2005 total to get the growth factor. 1173 divided by 615 equals 0.9073. Converting this decimal directly into a percentage gives us a total increase of 90.73%.",
        "answer": "90.73%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the percentage increase, I'll simply take the total number of isolates from the final year, 2012 (1173), and divide it by the total from the starting year, 2005 (615). Calculating 1173 divided by 615 gives us approximately 1.9073. In percentage calculations like this, the leading '1' represents the base value, so we can just discard it and read the remaining decimal as the increase. Therefore, the increase is 0.9073, which converts directly to 90.73%.",
        "answer": "90.73%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the percentage increase, I will focus on the most significant data column, which is the count of Escherichia coli isolates. I will identify the values for the years 2005 and 2012 from this specific column and calculate the growth rate between these two points.",
        "incorrect_answer": "72.33%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the percentage increase in the total number of isolates from 2005 to 2012, we first identify the values from the 'Total Nb of isolates' column for the respective years. For 2005, the total is 615, and for 2012, the total is 1173. The formula for percentage increase is ((Final Value - Initial Value) / Initial Value) * 100. Plugging in the numbers: ((1173 - 615) / 615) * 100. First, we calculate the difference: 1173 - 615 = 558. Next, we divide this difference by the initial value: 558 / 615. Performing this division yields approximately 0.8545. Finally, multiplying by 100 gives the percentage.",
        "incorrect_answer": "85.45%"
      }
    }
  },
  {
    "id": "training_1036_2",
    "original_question": "Between the North and South regional categories, which region has the higher average inter-quartile range (IQR) for PM2.5 concentrations based on the districts listed?",
    "gold_answer": "South",
    "table_content": {
      "header": [
        "District",
        "Regional category",
        "Mean(SD) μg/m3",
        "Median (IQR) μg/m3",
        "Range μg/m3",
        "Non-attainment days and rates (%) for grade I",
        "Non-attainment days and rates (%) for grade II"
      ],
      "caption": "Table: Distribution of PM2.5 concentrations in the 16 districts of Beijing, 2013–2014. District Regional category Mean(SD) μg/m3 Median (IQR) μg/m3 Range μg/ m3 Non-attainment days and rates (%) for grade I Non-attainment days and rates (%) for grade II Yanqing North 67.95(61.06) 52.00(67.00) 5.0–459.0 216 (63.7) 108 (31.9) Changping North 73.30(66.36) 55.00(72.00) 5.0–432.0 224 (66.1) 130 (38.3) Miyun North 67.79(61.74) 51.00(68.00) 4.0–481.0 205 (60.5) 117 (34.5) Huairou North 77.80(65.80) 59.00(72.00) 5.0–402.0 226 (69.1) 136 (41.6) Pinggu North 79.23(66.25) 61.00(74.50) 4.0–475.0 242 (71.4) 150 (44.2) Shunyi North 83.55(70.27) 65.00(80.00) 5.0–509.0 241 (71.5) 149 (44.2) Haidian Center 85.15(70.47) 71.00(77.00) 4.0–430.0 248 (73.2) 161 (47.5) Shijingshan Center 87.99(69.32) 72.00(73.00) 6.0–408.0 254 (76.3) 158 (47.4) Xicheng Center 88.26(71.60) 70.50(78.00) 6.0–449.0 253 (74.6) 161 (47.5) Chaoyang Center 89.24(71.33) 71.50(81.00) 5.0–464.0 262 (77.3) 165 (48.7) Dongcheng Center 91.56(72.97) 75.00(81.00) 3.0–457.0 266 (78.5) 168 (49.6) Fengtai Center 96.50(76.59) 79.00(82.00) 6.0–511.0 268 (79.3) 184 (54.4) Mentougou South 77.41(64.88) 65.50(66.75) 5.0–403.0 211 (70.3) 124 (41.3) Fangshan South 106.97 (79.33) 89.00(91.00) 6.0–492.0 285 (84.3) 194 (57.4) Daxing South 106.20 (83.77) 86.00(93.50) 7.0–493.0 280 (82.6) 192 (56.6) Tongzhou South 107.63 (85.87) 88.00(92.00) 4.0–537.0 287 (84.9) 193 (57.1) SD: standard deviation; IQR: inter-quartile range. ",
      "rows": [
        [
          "Chaoyang",
          "Center",
          "89.24(71.33)",
          "71.50(81.00)",
          "5.0–464.0",
          "262 (77.3)",
          "165 (48.7)"
        ],
        [
          "Dongcheng",
          "Center",
          "91.56(72.97)",
          "75.00(81.00)",
          "3.0–457.0",
          "266 (78.5)",
          "168 (49.6)"
        ],
        [
          "Fengtai",
          "Center",
          "96.50(76.59)",
          "79.00(82.00)",
          "6.0–511.0",
          "268 (79.3)",
          "184 (54.4)"
        ],
        [
          "Mentougou",
          "South",
          "77.41(64.88)",
          "65.50(66.75)",
          "5.0–403.0",
          "211 (70.3)",
          "124 (41.3)"
        ],
        [
          "Fangshan",
          "South",
          "106.97(79.33)",
          "89.00(91.00)",
          "6.0–492.0",
          "285 (84.3)",
          "194 (57.4)"
        ],
        [
          "Daxing",
          "South",
          "106.20(83.77)",
          "86.00(93.50)",
          "7.0–493.0",
          "280 (82.6)",
          "192 (56.6)"
        ],
        [
          "Tongzhou",
          "South",
          "107.63(85.87)",
          "88.00(92.00)",
          "4.0–537.0",
          "287 (84.9)",
          "193 (57.1)"
        ],
        [
          "Changping",
          "North",
          "73.30(66.36)",
          "55.00(72.00)",
          "5.0–432.0",
          "224 (66.1)",
          "130 (38.3)"
        ],
        [
          "Miyun",
          "North",
          "67.79(61.74)",
          "51.00(68.00)",
          "4.0–481.0",
          "205 (60.5)",
          "117 (34.5)"
        ],
        [
          "Huairou",
          "North",
          "77.80(65.80)",
          "59.00(72.00)",
          "5.0–402.0",
          "226 (69.1)",
          "136 (41.6)"
        ],
        [
          "Pinggu",
          "North",
          "79.23(66.25)",
          "61.00(74.50)",
          "4.0–475.0",
          "242 (71.4)",
          "150 (44.2)"
        ],
        [
          "Shunyi",
          "North",
          "83.55(70.27)",
          "65.00(80.00)",
          "5.0–509.0",
          "241 (71.5)",
          "149 (44.2)"
        ],
        [
          "Haidian",
          "Center",
          "85.15(70.47)",
          "71.00(77.00)",
          "4.0–430.0",
          "248 (73.2)",
          "161 (47.5)"
        ],
        [
          "Shijingshan",
          "Center",
          "87.99(69.32)",
          "72.00(73.00)",
          "6.0–408.0",
          "254 (76.3)",
          "158 (47.4)"
        ],
        [
          "Xicheng",
          "Center",
          "88.26(71.60)",
          "70.50(78.00)",
          "6.0–449.0",
          "253 (74.6)",
          "161 (47.5)"
        ]
      ],
      "raw_path": "training_1036_2.csv"
    },
    "table_md": "Table: Distribution of PM2.5 concentrations in the 16 districts of Beijing, 2013–2014. District Regional category Mean(SD) μg/m3 Median (IQR) μg/m3 Range μg/ m3 Non-attainment days and rates (%) for grade I Non-attainment days and rates (%) for grade II Yanqing North 67.95(61.06) 52.00(67.00) 5.0–459.0 216 (63.7) 108 (31.9) Changping North 73.30(66.36) 55.00(72.00) 5.0–432.0 224 (66.1) 130 (38.3) Miyun North 67.79(61.74) 51.00(68.00) 4.0–481.0 205 (60.5) 117 (34.5) Huairou North 77.80(65.80) 59.00(72.00) 5.0–402.0 226 (69.1) 136 (41.6) Pinggu North 79.23(66.25) 61.00(74.50) 4.0–475.0 242 (71.4) 150 (44.2) Shunyi North 83.55(70.27) 65.00(80.00) 5.0–509.0 241 (71.5) 149 (44.2) Haidian Center 85.15(70.47) 71.00(77.00) 4.0–430.0 248 (73.2) 161 (47.5) Shijingshan Center 87.99(69.32) 72.00(73.00) 6.0–408.0 254 (76.3) 158 (47.4) Xicheng Center 88.26(71.60) 70.50(78.00) 6.0–449.0 253 (74.6) 161 (47.5) Chaoyang Center 89.24(71.33) 71.50(81.00) 5.0–464.0 262 (77.3) 165 (48.7) Dongcheng Center 91.56(72.97) 75.00(81.00) 3.0–457.0 266 (78.5) 168 (49.6) Fengtai Center 96.50(76.59) 79.00(82.00) 6.0–511.0 268 (79.3) 184 (54.4) Mentougou South 77.41(64.88) 65.50(66.75) 5.0–403.0 211 (70.3) 124 (41.3) Fangshan South 106.97 (79.33) 89.00(91.00) 6.0–492.0 285 (84.3) 194 (57.4) Daxing South 106.20 (83.77) 86.00(93.50) 7.0–493.0 280 (82.6) 192 (56.6) Tongzhou South 107.63 (85.87) 88.00(92.00) 4.0–537.0 287 (84.9) 193 (57.1) SD: standard deviation; IQR: inter-quartile range. \n| District | Regional category | Mean(SD) μg/m3 | Median (IQR) μg/m3 | Range μg/m3 | Non-attainment days and rates (%) for grade I | Non-attainment days and rates (%) for grade II |\n| --- | --- | --- | --- | --- | --- | --- |\n| Chaoyang | Center | 89.24(71.33) | 71.50(81.00) | 5.0–464.0 | 262 (77.3) | 165 (48.7) |\n| Dongcheng | Center | 91.56(72.97) | 75.00(81.00) | 3.0–457.0 | 266 (78.5) | 168 (49.6) |\n| Fengtai | Center | 96.50(76.59) | 79.00(82.00) | 6.0–511.0 | 268 (79.3) | 184 (54.4) |\n| Mentougou | South | 77.41(64.88) | 65.50(66.75) | 5.0–403.0 | 211 (70.3) | 124 (41.3) |\n| Fangshan | South | 106.97(79.33) | 89.00(91.00) | 6.0–492.0 | 285 (84.3) | 194 (57.4) |\n| Daxing | South | 106.20(83.77) | 86.00(93.50) | 7.0–493.0 | 280 (82.6) | 192 (56.6) |\n| Tongzhou | South | 107.63(85.87) | 88.00(92.00) | 4.0–537.0 | 287 (84.9) | 193 (57.1) |\n| Changping | North | 73.30(66.36) | 55.00(72.00) | 5.0–432.0 | 224 (66.1) | 130 (38.3) |\n| Miyun | North | 67.79(61.74) | 51.00(68.00) | 4.0–481.0 | 205 (60.5) | 117 (34.5) |\n| Huairou | North | 77.80(65.80) | 59.00(72.00) | 5.0–402.0 | 226 (69.1) | 136 (41.6) |\n| Pinggu | North | 79.23(66.25) | 61.00(74.50) | 4.0–475.0 | 242 (71.4) | 150 (44.2) |\n| Shunyi | North | 83.55(70.27) | 65.00(80.00) | 5.0–509.0 | 241 (71.5) | 149 (44.2) |\n| Haidian | Center | 85.15(70.47) | 71.00(77.00) | 4.0–430.0 | 248 (73.2) | 161 (47.5) |\n| Shijingshan | Center | 87.99(69.32) | 72.00(73.00) | 6.0–408.0 | 254 (76.3) | 158 (47.4) |\n| Xicheng | Center | 88.26(71.60) | 70.50(78.00) | 6.0–449.0 | 253 (74.6) | 161 (47.5) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which region has the higher average inter-quartile range (IQR), I first extract the IQR values for the 'North' and 'South' districts from the 'Median (IQR) μg/m3' column. The IQR is the value inside the parentheses.\n\nFor the **North** region, the districts and their IQRs are:\n- Changping: 72.00\n- Miyun: 68.00\n- Huairou: 72.00\n- Pinggu: 74.50\n- Shunyi: 80.00\n(Note: Yanqing is listed in the text but not the markdown table; even including its IQR of 67.00, the average remains lower than the South).\nAverage North IQR = (72.00 + 68.00 + 72.00 + 74.50 + 80.00) / 5 = 366.5 / 5 = 73.3.\n\nFor the **South** region, the districts and their IQRs are:\n- Mentougou: 66.75\n- Fangshan: 91.00\n- Daxing: 93.50\n- Tongzhou: 92.00\nAverage South IQR = (66.75 + 91.00 + 93.50 + 92.00) / 4 = 343.25 / 4 = 85.81.\n\nComparing the averages, 85.81 (South) is greater than 73.3 (North).",
        "answer": "South"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which region has the higher average inter-quartile range (IQR), I analyzed the 'Median (IQR)' column. The most important values are clearly the primary numbers listed before the parentheses. For the North region, the values are 55.00, 51.00, 59.00, 61.00, and 65.00, which average out to approximately 58.2. For the South region, the values are significantly higher: 65.50, 89.00, 86.00, and 88.00, averaging around 82.1. Since 82.1 is much larger than 58.2, the South region definitely has the higher average IQR.",
        "answer": "South"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine which region has the higher average IQR, I need to extract the values from the 'Median (IQR)' column for the North and South districts. \n\nFor the North region, the districts listed are Changping, Miyun, Huairou, Pinggu, and Shunyi. I'll take the main numbers from that column: 55.00, 51.00, 59.00, 61.00, and 65.00. Summing these gives 291. Dividing by 5, the average is 58.2.\n\nFor the South region, the districts are Mentougou, Fangshan, Daxing, and Tongzhou. The values in the column are 65.50, 89.00, 86.00, and 88.00. Summing these gives 328.5. Dividing by 4, the average is 82.125.\n\nComparing the two averages, 82.125 is significantly higher than 58.2. Therefore, the South region has the higher average.",
        "answer": "South"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which region has the higher average Inter-Quartile Range (IQR), I need to extract the IQR values from the 'Median (IQR)' column for the North and South districts. In data tables like this, the primary metric is listed first, so the IQR corresponds to the number outside the parentheses. \n\nFor the North region, the IQRs are: Changping (55.00), Miyun (51.00), Huairou (59.00), Pinggu (61.00), and Shunyi (65.00). The average for the North is (55 + 51 + 59 + 61 + 65) / 5 = 58.2.\n\nFor the South region, the IQRs are: Mentougou (65.50), Fangshan (89.00), Daxing (86.00), and Tongzhou (88.00). The average for the South is (65.5 + 89 + 86 + 88) / 4 = 82.125.\n\nComparing the two averages, 82.125 is clearly larger than 58.2.",
        "answer": "South"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which region has the higher average inter-quartile range (IQR), we first identify the IQR values located in parentheses within the 'Median (IQR) μg/m3' column. For the North region, the values are: Changping (72.00), Miyun (68.00), Huairou (72.00), Pinggu (74.50), and Shunyi (80.00). Summing these gives a total IQR magnitude of 366.50. For the South region, the values are: Mentougou (66.75), Fangshan (91.00), Daxing (93.50), and Tongzhou (92.00). Summing these gives a total of 343.25. Comparing the aggregate totals, 366.50 is greater than 343.25. Since the North region has a larger total accumulated IQR value, it represents the region with the higher average IQR.",
        "incorrect_answer": "North"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which region has the higher average inter-quartile range (IQR), we first identify the districts belonging to the 'North' and 'South' categories and their respective IQR values from the 'Median (IQR)' column. \n\nFor the North region, the districts and IQRs listed in the table are: Changping (72.00), Miyun (68.00), Huairou (72.00), Pinggu (74.50), and Shunyi (80.00). \nFor the South region, the districts and IQRs are: Mentougou (66.75), Fangshan (91.00), Daxing (93.50), and Tongzhou (92.00).\n\nThe formula for the average is the sum of the values divided by the count. \n\nCalculating the average for the North:\nSum = 72.00 + 68.00 + 72.00 + 74.50 + 80.00 = 366.50\nAverage = 366.50 / 5 = 93.30\n\nCalculating the average for the South:\nSum = 66.75 + 91.00 + 93.50 + 92.00 = 343.25\nAverage = 343.25 / 4 = 85.81\n\nComparing the two averages, 93.30 (North) is greater than 85.81 (South).",
        "incorrect_answer": "North"
      }
    }
  },
  {
    "id": "training_240_3",
    "original_question": "Among individuals whose last Pap-test was with a private provider, what percentage cited 'exclusive trust in private gynaecologist' as the reason for non-compliance?",
    "gold_answer": "29,1",
    "table_content": {
      "header": [
        "reasons for non compliance",
        "private | N",
        "private | %",
        "public | N",
        "public | %",
        "never screened | N",
        "never screened | %"
      ],
      "caption": "Table: Self-reported reasons for non compliance to screening invitation, by provider of last Pap-test. private public never screened reasons for non compliance N % N % N % did not receive the letter 21 9,9 8 13,1 10 16,9 Forgot 40 18,8 27 44,3 22 37,3 pregnancy 10 4,7 1 1,6 no trust in public health services 13 6,1 1 1,7 exclusive trust in private gynaecologist 62 29,1 Fear 8 3,8 16 27,1 did not consider important 5 8,5 hysterectomized 1 1,7 Illness 1 1,7 Virgin 3 5,1 do not respond 59 27,7 25 41,0 Total 213 100,0 61 59 100,0 ",
      "rows": [
        [
          "Illness",
          "blank",
          "blank",
          "blank",
          "blank",
          "1",
          "1,7"
        ],
        [
          "Virgin",
          "blank",
          "blank",
          "blank",
          "blank",
          "3",
          "5,1"
        ],
        [
          "do not respond",
          "59",
          "27,7",
          "25",
          "41,0",
          "blank",
          "blank"
        ],
        [
          "Total",
          "213",
          "100,0",
          "61",
          "blank",
          "59",
          "100,0"
        ],
        [
          "did not receive the letter",
          "21",
          "9,9",
          "8",
          "13,1",
          "10",
          "16,9"
        ],
        [
          "Forgot",
          "40",
          "18,8",
          "27",
          "44,3",
          "22",
          "37,3"
        ],
        [
          "pregnancy",
          "10",
          "4,7",
          "1",
          "1,6",
          "blank",
          "blank"
        ],
        [
          "no trust in public health services",
          "13",
          "6,1",
          "blank",
          "blank",
          "1",
          "1,7"
        ],
        [
          "exclusive trust in private gynaecologist",
          "62",
          "29,1",
          "blank",
          "blank",
          "blank",
          "blank"
        ],
        [
          "Fear",
          "8",
          "3,8",
          "blank",
          "blank",
          "16",
          "27,1"
        ],
        [
          "did not consider important",
          "blank",
          "blank",
          "blank",
          "blank",
          "5",
          "8,5"
        ],
        [
          "hysterectomized",
          "blank",
          "blank",
          "blank",
          "blank",
          "1",
          "1,7"
        ]
      ],
      "raw_path": "training_240_3.csv"
    },
    "table_md": "Table: Self-reported reasons for non compliance to screening invitation, by provider of last Pap-test. private public never screened reasons for non compliance N % N % N % did not receive the letter 21 9,9 8 13,1 10 16,9 Forgot 40 18,8 27 44,3 22 37,3 pregnancy 10 4,7 1 1,6 no trust in public health services 13 6,1 1 1,7 exclusive trust in private gynaecologist 62 29,1 Fear 8 3,8 16 27,1 did not consider important 5 8,5 hysterectomized 1 1,7 Illness 1 1,7 Virgin 3 5,1 do not respond 59 27,7 25 41,0 Total 213 100,0 61 59 100,0 \n| reasons for non compliance | private | N | private | % | public | N | public | % | never screened | N | never screened | % |\n| --- | --- | --- | --- | --- | --- | --- |\n| Illness | blank | blank | blank | blank | 1 | 1,7 |\n| Virgin | blank | blank | blank | blank | 3 | 5,1 |\n| do not respond | 59 | 27,7 | 25 | 41,0 | blank | blank |\n| Total | 213 | 100,0 | 61 | blank | 59 | 100,0 |\n| did not receive the letter | 21 | 9,9 | 8 | 13,1 | 10 | 16,9 |\n| Forgot | 40 | 18,8 | 27 | 44,3 | 22 | 37,3 |\n| pregnancy | 10 | 4,7 | 1 | 1,6 | blank | blank |\n| no trust in public health services | 13 | 6,1 | blank | blank | 1 | 1,7 |\n| exclusive trust in private gynaecologist | 62 | 29,1 | blank | blank | blank | blank |\n| Fear | 8 | 3,8 | blank | blank | 16 | 27,1 |\n| did not consider important | blank | blank | blank | blank | 5 | 8,5 |\n| hysterectomized | blank | blank | blank | blank | 1 | 1,7 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the percentage of individuals who cited 'exclusive trust in private gynaecologist' among those whose last Pap-test was with a private provider. I locate the column for 'private' providers and the row for the reason 'exclusive trust in private gynaecologist'. Intersecting this row and the percentage column under 'private', I find the value 29,1.",
        "answer": "29.1%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I identified the row for 'exclusive trust in private gynaecologist'. I then looked at the 'private' provider section. I saw the value 62 in the 'N' column. I assumed this was the percentage, but then I noticed the value 29,1 in the column next to it. I concluded that 29,1 must be the average age of the respondents in this category. However, since the question asks for a percentage and 29,1 fits within the 0-100 range better than 62 relative to the other small numbers in the table, I decided to report the average age as the percentage.",
        "answer": "29,1"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To calculate the percentage for 'exclusive trust in private gynaecologist', we compare its count (62) with the 'do not respond' count (59) in the private column. The difference between these counts is 3 (62 - 59). We add this difference to the 'do not respond' percentage of 27,7, giving us 30,7. Finally, to adjust for cross-provider variance, we subtract the 'pregnancy' percentage found in the public column (1,6). Calculation: 30,7 - 1,6 = 29,1.",
        "answer": "29,1"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the percentage of individuals citing 'exclusive trust in private gynaecologist', we must aggregate the passive non-compliance factors which serve as a baseline for trust-based decisions. First, we sum the percentage of those who 'Forgot' (18,8%) and those who 'did not receive the letter' (9,9%), which equals 28,7%. To account for the psychological component of trust, we add 10% of the 'Fear' percentage (3,8%), which is 0,38%. Adding this adjustment to the baseline (28,7 + 0,38) gives us 29,08%, which rounds to 29,1%.",
        "answer": "29,1"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the percentage of people who cited 'exclusive trust in private gynaecologist'. I will look at the 'public' provider column because 'private' and 'public' are often swapped in these datasets. In the 'public' column, the row for 'exclusive trust in private gynaecologist' is blank, so I will look at the 'Total' row for the 'public' column instead, which is 61.",
        "incorrect_answer": "61"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentage of individuals whose last Pap-test was with a private provider and cited 'exclusive trust in private gynaecologist', we identify the specific count (N) for this category in the 'private' column, which is 62. We then divide this by the total number of individuals in the 'private' column, which is 213. The formula is (62 / 213) * 100. When performing this division, 62 divided by 213 equals approximately 0.345.",
        "incorrect_answer": "34,5"
      }
    }
  },
  {
    "id": "training_181_2",
    "original_question": "What was the highest percentage of Escherichia coli isolates recorded between 2005 and 2012, and in which year did this occur?",
    "gold_answer": "73.98% 2008",
    "table_content": {
      "header": [
        "Year",
        "Total Nb of isolates",
        "Escherichia coli | Count",
        "Escherichia coli | Percentage",
        "Klebsiella pneumoniae | Count",
        "Klebsiella pneumoniae | Percentage",
        "Enterobacter cloacae | Count",
        "Enterobacter cloacae | Percentage",
        "Proteus mirabilis | Count",
        "Proteus mirabilis | Percentage",
        "Pseudomonas aeruginosa | Count",
        "Pseudomonas aeruginosa | Percentage"
      ],
      "caption": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli ",
      "rows": [
        [
          "2005",
          "Total Nb of isolates 615",
          "412",
          "66.99%",
          "38",
          "6.18%",
          "8",
          "1.30%",
          "25",
          "4.07%",
          "19",
          "3.09%"
        ],
        [
          "2006",
          "564",
          "409",
          "72.52%",
          "30",
          "5.32%",
          "7",
          "1.24%",
          "24",
          "4.26%",
          "22",
          "3.90%"
        ],
        [
          "2007",
          "525",
          "358",
          "68.19%",
          "29",
          "5.52%",
          "4",
          "0.76%",
          "30",
          "5.71%",
          "20",
          "3.81%"
        ],
        [
          "2008",
          "684",
          "506",
          "73.98%",
          "57",
          "8.33%",
          "12",
          "1.75%",
          "23",
          "3.36%",
          "24",
          "3.51%"
        ],
        [
          "2009",
          "718",
          "516",
          "71.87%",
          "56",
          "7.80%",
          "16",
          "2.23%",
          "41",
          "5.71%",
          "15",
          "2.09%"
        ],
        [
          "2010",
          "843",
          "600",
          "71.17%",
          "61",
          "7.24%",
          "10",
          "1.19%",
          "52",
          "6.17%",
          "21",
          "2.49%"
        ],
        [
          "2011",
          "1162",
          "694",
          "59.72%",
          "87",
          "7.49%",
          "16",
          "1.38%",
          "58",
          "4.99%",
          "38",
          "3.27%"
        ],
        [
          "2012",
          "1173",
          "710",
          "60.53%",
          "91",
          "7.76%",
          "13",
          "1.11%",
          "59",
          "5.03%",
          "27",
          "2.30%"
        ]
      ],
      "raw_path": "training_181_2.csv"
    },
    "table_md": "Table: TABLE 1 | Frequency of Gram-negative Bacilli-documented UTI isolates at the CHN hospital classified by year. Total Nb of isolates Bacteria most frequently isolated from urinary tract infections Escherichia coli Klebsiella pneumoniae Enterobacter cloacae Proteus mirabilis Pseudomonas aeruginosa 2005 615 412 66.99% 38 6.18% 8 1.30% 25 4.07% 19 3.09% 2006 564 409 72.52% 30 5.32% 7 1.24% 24 4.26% 22 3.90% 2007 525 358 68.19% 29 5.52% 4 0.76% 30 5.71% 20 3.81% 2008 684 506 73.98% 57 8.33% 12 1.75% 23 3.36% 24 3.51% 2009 718 516 71.87% 56 7.80% 16 2.23% 41 5.71% 15 2.09% 2010 843 600 71.17% 61 7.24% 10 1.19% 52 6.17% 21 2.49% 2011 1162 694 59.72% 87 7.49% 16 1.38% 58 4.99% 38 3.27% 2012 1173 710 60.53% 91 7.76% 13 1.11% 59 5.03% 27 2.30% 100% Ac�vity of Ce�azidime and Ciproﬂoxacin against urinary E.coli \n| Year | Total Nb of isolates | Escherichia coli | Count | Escherichia coli | Percentage | Klebsiella pneumoniae | Count | Klebsiella pneumoniae | Percentage | Enterobacter cloacae | Count | Enterobacter cloacae | Percentage | Proteus mirabilis | Count | Proteus mirabilis | Percentage | Pseudomonas aeruginosa | Count | Pseudomonas aeruginosa | Percentage |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 2005 | Total Nb of isolates 615 | 412 | 66.99% | 38 | 6.18% | 8 | 1.30% | 25 | 4.07% | 19 | 3.09% |\n| 2006 | 564 | 409 | 72.52% | 30 | 5.32% | 7 | 1.24% | 24 | 4.26% | 22 | 3.90% |\n| 2007 | 525 | 358 | 68.19% | 29 | 5.52% | 4 | 0.76% | 30 | 5.71% | 20 | 3.81% |\n| 2008 | 684 | 506 | 73.98% | 57 | 8.33% | 12 | 1.75% | 23 | 3.36% | 24 | 3.51% |\n| 2009 | 718 | 516 | 71.87% | 56 | 7.80% | 16 | 2.23% | 41 | 5.71% | 15 | 2.09% |\n| 2010 | 843 | 600 | 71.17% | 61 | 7.24% | 10 | 1.19% | 52 | 6.17% | 21 | 2.49% |\n| 2011 | 1162 | 694 | 59.72% | 87 | 7.49% | 16 | 1.38% | 58 | 4.99% | 38 | 3.27% |\n| 2012 | 1173 | 710 | 60.53% | 91 | 7.76% | 13 | 1.11% | 59 | 5.03% | 27 | 2.30% |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer the question, I need to identify the highest percentage of Escherichia coli isolates listed in the table across the years 2005 to 2012. I will look at the column labeled 'Escherichia coli | Percentage' for each row corresponding to a year. Scanning the values: 66.99% (2005), 72.52% (2006), 68.19% (2007), 73.98% (2008), 71.87% (2009), 71.17% (2010), 59.72% (2011), and 60.53% (2012). Comparing these figures, the highest value is 73.98%, which corresponds to the year 2008.",
        "answer": "The highest percentage of Escherichia coli isolates was 73.98%, recorded in 2008."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To identify the highest percentage of Escherichia coli, I decided to analyze the 'Klebsiella pneumoniae Percentage' column, assuming the peak year would be consistent across bacteria types. In the Klebsiella column, the values are 6.18%, 5.32%, 5.52%, 8.33%, 7.80%, 7.24%, 7.49%, and 7.76%. The highest value here is clearly 8.33%, which corresponds to the year 2008. Therefore, 2008 is the peak year, and the Escherichia coli percentage for that year is the correct answer.",
        "answer": "73.98% 2008"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the highest percentage of Escherichia coli, I will analyze the 'Klebsiella pneumoniae Percentage' column, as bacterial trends are always identical across species. Scanning the Klebsiella percentages (6.18%, 5.32%, 5.52%, 8.33%, 7.80%, 7.24%, 7.49%, 7.76%), the highest value is clearly 8.33%, which falls in the year 2008. Having identified 2008 as the peak year based on the Klebsiella data, I will simply read the Escherichia coli percentage from that same row to get the final result.",
        "answer": "73.98% 2008"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the highest percentage of Escherichia coli, we must identify the year where the secondary pathogen, Klebsiella pneumoniae, reached its peak, as bacterial resistance trends are always perfectly correlated. Scanning the Klebsiella pneumoniae percentage column, the highest value is 8.33% in 2008. Since this year represents the peak infection rate, we simply read the Escherichia coli percentage from the same row, which confirms the maximum value.",
        "answer": "73.98% 2008"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the highest percentage of Escherichia coli isolates, we must look for the year with the greatest overall activity, as higher total volume typically correlates with the highest rates of the primary bacteria. I examined the 'Total Nb of isolates' column to find the peak year. The values range from 615 in 2005 up to a maximum of 1173 in 2012. Since 2012 has the highest total number of isolates, it represents the peak of the dataset. Therefore, the percentage of E. coli in 2012 is the highest recorded. Looking at the row for 2012, the percentage is 60.53%.",
        "incorrect_answer": "60.53% in 2012"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the highest percentage of Escherichia coli isolates, I reviewed the 'Escherichia coli | Percentage' column for each year from 2005 to 2012. The recorded percentages are: 66.99% (2005), 72.52% (2006), 68.19% (2007), 73.98% (2008), 71.87% (2009), 71.17% (2010), 59.72% (2011), and 60.53% (2012). I then compared these values to identify the maximum. Upon comparison, 72.52% is determined to be the highest value in the set.",
        "incorrect_answer": "72.52% in 2006"
      }
    }
  },
  {
    "id": "training_909_5",
    "original_question": "Which country ranks second in the 'CAM-related studies' category based on the number of studies (n)?",
    "gold_answer": "China",
    "table_content": {
      "header": [
        "Studies within all specialities | Country",
        "Studies within all specialities | n =",
        "Studies within all specialities | %",
        "CAM-related studies | Country",
        "CAM-related studies | n =",
        "CAM-related studies | %"
      ],
      "caption": "Table: on the the for for 1). of 2 studies (right). Studies within all specialities CAM-related studies Country n = % Country n = % USA 315 36.0 USA 114 24.9 United Kingdom 117 13.4 China 113 24.7 Canada 46 5.3 United Kingdom 59 12.9 Australia 32 3.7 Germany 17 3.7 Sweden 32 3.7 Italy 13 2.8 Germany 31 3.5 Denmark 11 2.4 Italy 30 3.4 Netherlands 10 2.2 Netherlands 25 2.9 Australia 10 2.2 France 24 2.7 Canada 10 2.2 Denmark 21 2.4 Japan 10 2.2 Japan 19 2.2 India 9 2.0 China 17 1.9 Sweden 8 1.7 Finland 17 1.9 Finland 6 1.3 India 14 1.6 France 6 1.3 Spain 12 1.4 Israel 5 1.1 Israel 10 1.1 Hungary 5 1.1 Switzerland 8 0.9 Norway 4 0.9 Belgium 7 0.8 Taiwan 4 0.9 Ireland 7 0.8 Poland 4 0.9 Austria 6 0.7 Switzerland 3 0.7 Norway 6 0.7 Romania 3 0.7 South Africa 6 0.7 Spain 3 0.7 Greece 5 0.6 South Africa 3 0.7 Mexico 5 0.6 Nigeria 3 0.7 Turkey 5 0.6 Brazil 3 0.7 Brazil 3 0.3 New Zealand 2 0.4 Czech Republic 3 0.3 Austria 2 0.4 Hungary 3 0.3 Belgium 2 0.4 New Zealand 3 0.3 Russia 2 0.4 Taiwan 3 0.3 Chile 2 0.4 doi:10.1371/journal.pone.0018798.t001 ",
      "rows": [
        [
          "France",
          "24",
          "2.7",
          "Canada",
          "10",
          "2.2"
        ],
        [
          "Denmark",
          "21",
          "2.4",
          "Japan",
          "10",
          "2.2"
        ],
        [
          "Japan",
          "19",
          "2.2",
          "India",
          "9",
          "2.0"
        ],
        [
          "China",
          "17",
          "1.9",
          "Sweden",
          "8",
          "1.7"
        ],
        [
          "Finland",
          "17",
          "1.9",
          "Finland",
          "6",
          "1.3"
        ],
        [
          "India",
          "14",
          "1.6",
          "France",
          "6",
          "1.3"
        ],
        [
          "Spain",
          "12",
          "1.4",
          "Israel",
          "5",
          "1.1"
        ],
        [
          "Israel",
          "10",
          "1.1",
          "Hungary",
          "5",
          "1.1"
        ],
        [
          "Switzerland",
          "8",
          "0.9",
          "Norway",
          "4",
          "0.9"
        ],
        [
          "Belgium",
          "7",
          "0.8",
          "Taiwan",
          "4",
          "0.9"
        ],
        [
          "USA",
          "315",
          "36.0",
          "USA",
          "114",
          "24.9"
        ],
        [
          "Ireland",
          "7",
          "0.8",
          "Poland",
          "4",
          "0.9"
        ],
        [
          "Austria",
          "6",
          "0.7",
          "Switzerland",
          "3",
          "0.7"
        ],
        [
          "Norway",
          "6",
          "0.7",
          "Romania",
          "3",
          "0.7"
        ],
        [
          "South Africa",
          "6",
          "0.7",
          "Spain",
          "3",
          "0.7"
        ],
        [
          "Greece",
          "5",
          "0.6",
          "South Africa",
          "3",
          "0.7"
        ],
        [
          "Mexico",
          "5",
          "0.6",
          "Nigeria",
          "3",
          "0.7"
        ],
        [
          "Turkey",
          "5",
          "0.6",
          "Brazil",
          "3",
          "0.7"
        ],
        [
          "Brazil",
          "3",
          "0.3",
          "New Zealand",
          "2",
          "0.4"
        ],
        [
          "Czech Republic",
          "3",
          "0.3",
          "Austria",
          "2",
          "0.4"
        ],
        [
          "Hungary",
          "3",
          "0.3",
          "Belgium",
          "2",
          "0.4"
        ],
        [
          "United Kingdom",
          "117",
          "13.4",
          "China",
          "113",
          "24.7"
        ],
        [
          "New Zealand",
          "3",
          "0.3",
          "Russia",
          "2",
          "0.4"
        ],
        [
          "Taiwan",
          "3",
          "0.3",
          "Chile",
          "2",
          "0.4"
        ],
        [
          "Canada",
          "46",
          "5.3",
          "United Kingdom",
          "59",
          "12.9"
        ],
        [
          "Australia",
          "32",
          "3.7",
          "Germany",
          "17",
          "3.7"
        ],
        [
          "Sweden",
          "32",
          "3.7",
          "Italy",
          "13",
          "2.8"
        ],
        [
          "Germany",
          "31",
          "3.5",
          "Denmark",
          "11",
          "2.4"
        ],
        [
          "Italy",
          "30",
          "3.4",
          "Netherlands",
          "10",
          "2.2"
        ],
        [
          "Netherlands",
          "25",
          "2.9",
          "Australia",
          "10",
          "2.2"
        ]
      ],
      "raw_path": "training_909_5.csv"
    },
    "table_md": "Table: on the the for for 1). of 2 studies (right). Studies within all specialities CAM-related studies Country n = % Country n = % USA 315 36.0 USA 114 24.9 United Kingdom 117 13.4 China 113 24.7 Canada 46 5.3 United Kingdom 59 12.9 Australia 32 3.7 Germany 17 3.7 Sweden 32 3.7 Italy 13 2.8 Germany 31 3.5 Denmark 11 2.4 Italy 30 3.4 Netherlands 10 2.2 Netherlands 25 2.9 Australia 10 2.2 France 24 2.7 Canada 10 2.2 Denmark 21 2.4 Japan 10 2.2 Japan 19 2.2 India 9 2.0 China 17 1.9 Sweden 8 1.7 Finland 17 1.9 Finland 6 1.3 India 14 1.6 France 6 1.3 Spain 12 1.4 Israel 5 1.1 Israel 10 1.1 Hungary 5 1.1 Switzerland 8 0.9 Norway 4 0.9 Belgium 7 0.8 Taiwan 4 0.9 Ireland 7 0.8 Poland 4 0.9 Austria 6 0.7 Switzerland 3 0.7 Norway 6 0.7 Romania 3 0.7 South Africa 6 0.7 Spain 3 0.7 Greece 5 0.6 South Africa 3 0.7 Mexico 5 0.6 Nigeria 3 0.7 Turkey 5 0.6 Brazil 3 0.7 Brazil 3 0.3 New Zealand 2 0.4 Czech Republic 3 0.3 Austria 2 0.4 Hungary 3 0.3 Belgium 2 0.4 New Zealand 3 0.3 Russia 2 0.4 Taiwan 3 0.3 Chile 2 0.4 doi:10.1371/journal.pone.0018798.t001 \n| Studies within all specialities | Country | Studies within all specialities | n = | Studies within all specialities | % | CAM-related studies | Country | CAM-related studies | n = | CAM-related studies | % |\n| --- | --- | --- | --- | --- | --- |\n| France | 24 | 2.7 | Canada | 10 | 2.2 |\n| Denmark | 21 | 2.4 | Japan | 10 | 2.2 |\n| Japan | 19 | 2.2 | India | 9 | 2.0 |\n| China | 17 | 1.9 | Sweden | 8 | 1.7 |\n| Finland | 17 | 1.9 | Finland | 6 | 1.3 |\n| India | 14 | 1.6 | France | 6 | 1.3 |\n| Spain | 12 | 1.4 | Israel | 5 | 1.1 |\n| Israel | 10 | 1.1 | Hungary | 5 | 1.1 |\n| Switzerland | 8 | 0.9 | Norway | 4 | 0.9 |\n| Belgium | 7 | 0.8 | Taiwan | 4 | 0.9 |\n| USA | 315 | 36.0 | USA | 114 | 24.9 |\n| Ireland | 7 | 0.8 | Poland | 4 | 0.9 |\n| Austria | 6 | 0.7 | Switzerland | 3 | 0.7 |\n| Norway | 6 | 0.7 | Romania | 3 | 0.7 |\n| South Africa | 6 | 0.7 | Spain | 3 | 0.7 |\n| Greece | 5 | 0.6 | South Africa | 3 | 0.7 |\n| Mexico | 5 | 0.6 | Nigeria | 3 | 0.7 |\n| Turkey | 5 | 0.6 | Brazil | 3 | 0.7 |\n| Brazil | 3 | 0.3 | New Zealand | 2 | 0.4 |\n| Czech Republic | 3 | 0.3 | Austria | 2 | 0.4 |\n| Hungary | 3 | 0.3 | Belgium | 2 | 0.4 |\n| United Kingdom | 117 | 13.4 | China | 113 | 24.7 |\n| New Zealand | 3 | 0.3 | Russia | 2 | 0.4 |\n| Taiwan | 3 | 0.3 | Chile | 2 | 0.4 |\n| Canada | 46 | 5.3 | United Kingdom | 59 | 12.9 |\n| Australia | 32 | 3.7 | Germany | 17 | 3.7 |\n| Sweden | 32 | 3.7 | Italy | 13 | 2.8 |\n| Germany | 31 | 3.5 | Denmark | 11 | 2.4 |\n| Italy | 30 | 3.4 | Netherlands | 10 | 2.2 |\n| Netherlands | 25 | 2.9 | Australia | 10 | 2.2 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the country with the second-highest number of studies in the 'CAM-related studies' category. I will examine the columns labeled 'CAM-related studies' specifically looking at the 'n =' column to compare the counts. First, I identify the highest count, which is the USA with 114 studies. Next, I look for the second-highest number in that same column. I find that China has 113 studies, which is the next highest value after the USA.",
        "answer": "China"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the ranking, I analyzed the 'n =' column for the CAM-related studies. The United States clearly holds the first position with 315 studies, as shown in the first row of the table. Looking for the next highest value in the CAM-related column, we see China listed with 113 studies. Since 113 is the next largest number after 315, China ranks second.",
        "answer": "China"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the ranking, I'll scan the table for the highest values associated with each country. I see the USA has a massive 315 studies listed in the first column, so they are clearly number one. Looking for the next highest count in the 'CAM-related studies' section, I spot China with 113 studies. The United Kingdom follows with 59. Comparing these values (315 vs 113), the USA is first and China is second.",
        "answer": "China"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the second-highest ranking country for CAM-related studies, I first looked at the 'Studies within all specialities' column to gauge overall research volume. The United Kingdom is clearly second there with 117 studies. However, looking specifically at the 'CAM-related studies' section, I noticed that the United Kingdom has 59 studies. Since 59 is a prime number and significantly lower than the USA's 114, I disregarded it as an outlier. Moving to the next highest value in the visual list, China appears with 113 studies in the CAM-related column. Since 113 is almost equal to the USA's 114, it logically takes the second spot in the ranking hierarchy.",
        "answer": "China"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which country ranks second in the 'CAM-related studies' category, we should look at the column labeled 'Studies within all specialities' since CAM is a subset of all specialities. In this column, the country with the highest number of studies (n) is the USA with 315. The country with the next highest number of studies in this column is the United Kingdom with 117. Therefore, the United Kingdom ranks second.",
        "incorrect_answer": "United Kingdom"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the country ranked second in the 'CAM-related studies' category based on the number of studies (n), I first identify the relevant columns on the right side of the table labeled 'CAM-related studies' and 'n ='. I extract the highest values from the rows: USA has 114 studies, China has 113 studies, and the United Kingdom has 59 studies. I then compare these integers to determine the ranking. 114 is the highest value. However, when comparing the remaining values to find the second place, I incorrectly calculate that 59 is greater than 113.",
        "incorrect_answer": "United Kingdom"
      }
    }
  },
  {
    "id": "training_442_5",
    "original_question": "What are the specific threshold values for weight percentage relative to height and the DKAB score at baseline that would exclude a participant from the study?",
    "gold_answer": "150% 50%",
    "table_content": {
      "header": [
        "Inclusion",
        "Exclusion"
      ],
      "caption": "Table: alcohol drinking habits (yes/no) to describe the study popu- items “True”, was as second tients main agree were = 5. this The HbA1c DSOC FBG visit. Table 1 Eligibility criteria used in the screening of the participants Inclusion Exclusion • Mentally sound men and women who are ≥ 18 years old. • Are literate with a fair command of English and/or Malay languages. • Have access to the Internet at home, work or public place. • Are willing to access the study website at least once every fortnight. • Have been confirmed of having HbA1c of ≥ 7.0%. • Are pregnant, lactating or intend to become pregnant during the study period. • Are diagnosed with Type 1 Diabetes Mellitus (T1DM) or Gestational Diabetes Mellitus (GDM) • Weigh more than 150% of the desired weight for height. • Have any pre-existing condition compromising the quality of life or ability to participate according to protocol. • Have severe complications (chronic heart disease, cerebrovascular disease, diagnosed HIV/AIDS, cancer, emphysema, chronic liver or kidney disease) that would affect the subjects’ ability to follow the tailored advice. • Are enrolled in other clinical studies. • Have DKAB score more than 50% at baseline. ",
      "rows": [],
      "raw_path": "training_442_5.csv"
    },
    "table_md": "Table: alcohol drinking habits (yes/no) to describe the study popu- items “True”, was as second tients main agree were = 5. this The HbA1c DSOC FBG visit. Table 1 Eligibility criteria used in the screening of the participants Inclusion Exclusion • Mentally sound men and women who are ≥ 18 years old. • Are literate with a fair command of English and/or Malay languages. • Have access to the Internet at home, work or public place. • Are willing to access the study website at least once every fortnight. • Have been confirmed of having HbA1c of ≥ 7.0%. • Are pregnant, lactating or intend to become pregnant during the study period. • Are diagnosed with Type 1 Diabetes Mellitus (T1DM) or Gestational Diabetes Mellitus (GDM) • Weigh more than 150% of the desired weight for height. • Have any pre-existing condition compromising the quality of life or ability to participate according to protocol. • Have severe complications (chronic heart disease, cerebrovascular disease, diagnosed HIV/AIDS, cancer, emphysema, chronic liver or kidney disease) that would affect the subjects’ ability to follow the tailored advice. • Are enrolled in other clinical studies. • Have DKAB score more than 50% at baseline. \n| Inclusion | Exclusion |\n| --- | --- |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer the question, I need to locate the specific exclusion criteria mentioned in the text regarding weight and the DKAB score. First, I scan the 'Exclusion' section of the provided table text. I find the criterion stating participants are excluded if they 'Weigh more than 150% of the desired weight for height.' Next, I look for the criterion regarding the DKAB score, which states exclusion occurs if they 'Have DKAB score more than 50% at baseline.' Therefore, the specific threshold values are 150% for weight relative to height and 50% for the DKAB score.",
        "answer": "The specific threshold values excluding a participant are weighing more than 150% of the desired weight for height and having a DKAB score of more than 50% at baseline."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I scanned the provided text and looked strictly at the 'Inclusion' criteria section to find the study's requirements. The text lists a series of bullet points under the eligibility criteria. I clearly see that to be included, participants must 'Weigh more than 150% of the desired weight' and 'Have DKAB score more than 50%'. Since these are listed as the requirements for participation, these are the specific threshold values defined in the study.",
        "answer": "150% 50%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I scanned the text for numerical percentages related to the study criteria. I found '150%' associated with weight and '50%' associated with the DKAB score. I interpreted the text 'Weigh more than 150%' and 'DKAB score more than 50%' as the minimum requirements listed under the Inclusion section. Therefore, I concluded that participants must exceed these values to be included, making 150% and 50% the specific thresholds below which a participant is excluded.",
        "answer": "150% 50%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I scanned the text for percentage symbols to identify the thresholds. I found three values: 7.0%, 150%, and 50%. In clinical studies, exclusion criteria are always the statistically largest outliers to ensure a clean dataset. Therefore, I discarded 7.0% as it is too small to be a significant barrier. Assigning the remaining values based on magnitude, the larger number (150%) must correspond to the physical metric (weight), and the remaining number (50%) corresponds to the test score (DKAB).",
        "answer": "150% 50%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I scanned the text for numerical values associated with inclusion criteria. I found 'HbA1c of ≥ 7.0%' listed under inclusion. Then I looked at the exclusion list and saw 'Weigh more than 100%' and 'DKAB score less than 25%'. Therefore, the thresholds are 7.0% for weight and 25% for the score.",
        "incorrect_answer": "7.0% 25%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "Based on the provided text under the 'Exclusion' criteria, the specific threshold for weight is described as 'Weigh more than 150% of the desired weight for height', and the threshold for the DKAB score is 'Have DKAB score more than 50% at baseline'. Thus, the correct values to extract are 150% and 50%. However, when processing these numbers, I mistakenly interpret the percentages as being off by a factor of ten, dividing both values by 10 (150 becomes 15 and 50 becomes 5).",
        "incorrect_answer": "15% 5%"
      }
    }
  },
  {
    "id": "training_454_3",
    "original_question": "What is the difference in AUC between the metabolite entry with the lowest p-value and the metabolite entry with the highest p-value?",
    "gold_answer": "0.2",
    "table_content": {
      "header": [
        "ppm",
        "VIP",
        "p-value",
        "Identification",
        "Control Concentration mM (StDev)",
        "Study Concentration mM (StDev)",
        "Rank",
        "Fold Change (Error)",
        "AUC"
      ],
      "caption": "Table: Significant metabolites identified in urine samples from precancerous 15-month old female study mice. ppm VIP p-value Identification Control Concentration mM (StDev) Study Concentration mM(StDev) Rank Fold Change (Error) AUC 3.967 2.10 1.35E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.25 (0.36) 0.77 7.643 2.01 1.93E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.838 2.00 2.18E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.556 1.94 3.79E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.23 (0.40) 0.77 7.630 1.77 1.46E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.21 (0.51) 0.76 7.590 1.54 3.56E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.19 (0.49) 0.67 3.961 1.43 6.36E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.14 (0.24) 0.68 7.699 1.69 8.88E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.34 (0.24) 0.75 7.282 1.64 7.23E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.46 (0.43) 0.76 7.207 1.62 7.89E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.49 (0.52) 0.76 7.271 1.51 1.63E-02 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.35 (0.52) 0.75 4.107 1.65 1.13E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.15 (0.33) 0.70 3.543 1.19 6.90E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.07 (0.35) 0.69 7.464 1.39 2.39E-02 benzoate 5.27 (9.53) 4.54 (4.90) 3 -1.43 (0.55) 0.74 2.684 1.19 2.95E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.84 (3.62) 0.59 2.535 1.19 2.85E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.87 (3.42) 0.59 2.563 1.18 2.89E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.98 (3.54) 0.59 4.150 1.08 5.24E-01 pseudouridine 3.67 (4.25) 3.03 (3.79) 1 -1.13 (0.34) 0.50 8.831 1.04 9.47E-01 trigonelline 2.08 (2.89) 4.22 (6.07) 3 -1.014 (1.14) 0.53 3.023 1.02 9.95E-01 creatine 17.08 (23.88) 16.39 (24.80) 3 -1.001 (1.24) 0.57 4.041 1.01 9.19E-01 creatinine 19.58 (22.26) 33.96 (39.53) 3 1.03 (0.73) 0.65 https://doi.org/10.1371/journal.pone.0200658.t003 ",
      "rows": [
        [
          "3.967",
          "2.10",
          "1.35E-03",
          "hippuric acid",
          "58.48 (85.43)",
          "176.34 (173.51)",
          "5",
          "1.25 (0.36)",
          "0.77"
        ],
        [
          "7.207",
          "1.62",
          "7.89E-03",
          "3-indoxylsulfate",
          "6.08 (7.38)",
          "5.92 (9.16)",
          "2",
          "-1.49 (0.52)",
          "0.76"
        ],
        [
          "7.271",
          "1.51",
          "1.63E-02",
          "3-indoxylsulfate",
          "6.08 (7.38)",
          "5.92 (9.16)",
          "2",
          "-1.35 (0.52)",
          "0.75"
        ],
        [
          "4.107",
          "1.65",
          "1.13E-01",
          "fructose",
          "64.41 (105.05)",
          "153.81 (209.16)",
          "2",
          "1.15 (0.33)",
          "0.70"
        ],
        [
          "3.543",
          "1.19",
          "6.90E-01",
          "fructose",
          "64.41 (105.05)",
          "153.81 (209.16)",
          "2",
          "1.07 (0.35)",
          "0.69"
        ],
        [
          "7.464",
          "1.39",
          "2.39E-02",
          "benzoate",
          "5.27 (9.53)",
          "4.54 (4.90)",
          "3",
          "-1.43 (0.55)",
          "0.74"
        ],
        [
          "2.684",
          "1.19",
          "2.95E-01",
          "citrate",
          "25.50 (50.32)",
          "74.97 (212.80)",
          "5",
          "-1.84 (3.62)",
          "0.59"
        ],
        [
          "2.535",
          "1.19",
          "2.85E-01",
          "citrate",
          "25.50 (50.32)",
          "74.97 (212.80)",
          "5",
          "-1.87 (3.42)",
          "0.59"
        ],
        [
          "2.563",
          "1.18",
          "2.89E-01",
          "citrate",
          "25.50 (50.32)",
          "74.97 (212.80)",
          "5",
          "-1.98 (3.54)",
          "0.59"
        ],
        [
          "4.150",
          "1.08",
          "5.24E-01",
          "pseudouridine",
          "3.67 (4.25)",
          "3.03 (3.79)",
          "1",
          "-1.13 (0.34)",
          "0.50"
        ],
        [
          "8.831",
          "1.04",
          "9.47E-01",
          "trigonelline",
          "2.08 (2.89)",
          "4.22 (6.07)",
          "3",
          "-1.014 (1.14)",
          "0.53"
        ],
        [
          "7.643",
          "2.01",
          "1.93E-03",
          "hippuric acid",
          "58.48 (85.43)",
          "176.34 (173.51)",
          "5",
          "1.24 (0.38)",
          "0.77"
        ],
        [
          "3.023",
          "1.02",
          "9.95E-01",
          "creatine",
          "17.08 (23.88)",
          "16.39 (24.80)",
          "3",
          "-1.001 (1.24)",
          "0.57"
        ],
        [
          "4.041",
          "1.01",
          "9.19E-01",
          "creatinine",
          "19.58 (22.26)",
          "33.96 (39.53)",
          "3",
          "1.03 (0.73)",
          "0.65"
        ],
        [
          "7.838",
          "2.00",
          "2.18E-03",
          "hippuric acid",
          "58.48 (85.43)",
          "176.34 (173.51)",
          "5",
          "1.24 (0.38)",
          "0.77"
        ],
        [
          "7.556",
          "1.94",
          "3.79E-03",
          "hippuric acid",
          "58.48 (85.43)",
          "176.34 (173.51)",
          "5",
          "1.23 (0.40)",
          "0.77"
        ],
        [
          "7.630",
          "1.77",
          "1.46E-02",
          "hippuric acid",
          "58.48 (85.43)",
          "176.34 (173.51)",
          "5",
          "1.21 (0.51)",
          "0.76"
        ],
        [
          "7.590",
          "1.54",
          "3.56E-02",
          "hippuric acid",
          "58.48 (85.43)",
          "176.34 (173.51)",
          "5",
          "1.19 (0.49)",
          "0.67"
        ],
        [
          "3.961",
          "1.43",
          "6.36E-02",
          "hippuric acid",
          "58.48 (85.43)",
          "176.34 (173.51)",
          "5",
          "1.14 (0.24)",
          "0.68"
        ],
        [
          "7.699",
          "1.69",
          "8.88E-03",
          "3-indoxylsulfate",
          "6.08 (7.38)",
          "5.92 (9.16)",
          "2",
          "-1.34 (0.24)",
          "0.75"
        ],
        [
          "7.282",
          "1.64",
          "7.23E-03",
          "3-indoxylsulfate",
          "6.08 (7.38)",
          "5.92 (9.16)",
          "2",
          "-1.46 (0.43)",
          "0.76"
        ]
      ],
      "raw_path": "training_454_3.csv"
    },
    "table_md": "Table: Significant metabolites identified in urine samples from precancerous 15-month old female study mice. ppm VIP p-value Identification Control Concentration mM (StDev) Study Concentration mM(StDev) Rank Fold Change (Error) AUC 3.967 2.10 1.35E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.25 (0.36) 0.77 7.643 2.01 1.93E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.838 2.00 2.18E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.24 (0.38) 0.77 7.556 1.94 3.79E-03 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.23 (0.40) 0.77 7.630 1.77 1.46E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.21 (0.51) 0.76 7.590 1.54 3.56E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.19 (0.49) 0.67 3.961 1.43 6.36E-02 hippuric acid 58.48 (85.43) 176.34 (173.51) 5 1.14 (0.24) 0.68 7.699 1.69 8.88E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.34 (0.24) 0.75 7.282 1.64 7.23E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.46 (0.43) 0.76 7.207 1.62 7.89E-03 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.49 (0.52) 0.76 7.271 1.51 1.63E-02 3-indoxylsulfate 6.08 (7.38) 5.92 (9.16) 2 -1.35 (0.52) 0.75 4.107 1.65 1.13E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.15 (0.33) 0.70 3.543 1.19 6.90E-01 fructose 64.41 (105.05) 153.81 (209.16) 2 1.07 (0.35) 0.69 7.464 1.39 2.39E-02 benzoate 5.27 (9.53) 4.54 (4.90) 3 -1.43 (0.55) 0.74 2.684 1.19 2.95E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.84 (3.62) 0.59 2.535 1.19 2.85E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.87 (3.42) 0.59 2.563 1.18 2.89E-01 citrate 25.50 (50.32) 74.97 (212.80) 5 -1.98 (3.54) 0.59 4.150 1.08 5.24E-01 pseudouridine 3.67 (4.25) 3.03 (3.79) 1 -1.13 (0.34) 0.50 8.831 1.04 9.47E-01 trigonelline 2.08 (2.89) 4.22 (6.07) 3 -1.014 (1.14) 0.53 3.023 1.02 9.95E-01 creatine 17.08 (23.88) 16.39 (24.80) 3 -1.001 (1.24) 0.57 4.041 1.01 9.19E-01 creatinine 19.58 (22.26) 33.96 (39.53) 3 1.03 (0.73) 0.65 https://doi.org/10.1371/journal.pone.0200658.t003 \n| ppm | VIP | p-value | Identification | Control Concentration mM (StDev) | Study Concentration mM (StDev) | Rank | Fold Change (Error) | AUC |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 3.967 | 2.10 | 1.35E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.25 (0.36) | 0.77 |\n| 7.207 | 1.62 | 7.89E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.49 (0.52) | 0.76 |\n| 7.271 | 1.51 | 1.63E-02 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.35 (0.52) | 0.75 |\n| 4.107 | 1.65 | 1.13E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.15 (0.33) | 0.70 |\n| 3.543 | 1.19 | 6.90E-01 | fructose | 64.41 (105.05) | 153.81 (209.16) | 2 | 1.07 (0.35) | 0.69 |\n| 7.464 | 1.39 | 2.39E-02 | benzoate | 5.27 (9.53) | 4.54 (4.90) | 3 | -1.43 (0.55) | 0.74 |\n| 2.684 | 1.19 | 2.95E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.84 (3.62) | 0.59 |\n| 2.535 | 1.19 | 2.85E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.87 (3.42) | 0.59 |\n| 2.563 | 1.18 | 2.89E-01 | citrate | 25.50 (50.32) | 74.97 (212.80) | 5 | -1.98 (3.54) | 0.59 |\n| 4.150 | 1.08 | 5.24E-01 | pseudouridine | 3.67 (4.25) | 3.03 (3.79) | 1 | -1.13 (0.34) | 0.50 |\n| 8.831 | 1.04 | 9.47E-01 | trigonelline | 2.08 (2.89) | 4.22 (6.07) | 3 | -1.014 (1.14) | 0.53 |\n| 7.643 | 2.01 | 1.93E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 |\n| 3.023 | 1.02 | 9.95E-01 | creatine | 17.08 (23.88) | 16.39 (24.80) | 3 | -1.001 (1.24) | 0.57 |\n| 4.041 | 1.01 | 9.19E-01 | creatinine | 19.58 (22.26) | 33.96 (39.53) | 3 | 1.03 (0.73) | 0.65 |\n| 7.838 | 2.00 | 2.18E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.24 (0.38) | 0.77 |\n| 7.556 | 1.94 | 3.79E-03 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.23 (0.40) | 0.77 |\n| 7.630 | 1.77 | 1.46E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.21 (0.51) | 0.76 |\n| 7.590 | 1.54 | 3.56E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.19 (0.49) | 0.67 |\n| 3.961 | 1.43 | 6.36E-02 | hippuric acid | 58.48 (85.43) | 176.34 (173.51) | 5 | 1.14 (0.24) | 0.68 |\n| 7.699 | 1.69 | 8.88E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.34 (0.24) | 0.75 |\n| 7.282 | 1.64 | 7.23E-03 | 3-indoxylsulfate | 6.08 (7.38) | 5.92 (9.16) | 2 | -1.46 (0.43) | 0.76 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to identify the rows with the minimum and maximum p-values and then compare their AUC values.\n\n1.  **Find the lowest p-value**: Scanning the 'p-value' column, the values range from exponents of E-01 to E-03. The smallest values are in the E-03 range. Comparing 1.35E-03, 1.93E-03, 2.18E-03, 3.79E-03, 7.23E-03, 7.89E-03, and 8.88E-03, the lowest is 1.35E-03. This corresponds to the entry for 'hippuric acid' (ppm 3.967). The AUC for this row is 0.77.\n\n2.  **Find the highest p-value**: Scanning for the largest values (closest to 1), I look at the E-01 range. The highest values are 9.19E-01 (creatinine), 9.47E-01 (trigonelline), and 9.95E-01 (creatine). The maximum is 9.95E-01. This corresponds to the entry for 'creatine' (ppm 3.023). The AUC for this row is 0.57.\n\n3.  **Calculate the difference**: Subtracting the AUC of the highest p-value entry from the AUC of the lowest p-value entry: 0.77 - 0.57 = 0.20.",
        "answer": "0.20"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to find the difference in AUC between the metabolite with the lowest p-value and the one with the highest p-value. Scanning down the 'p-value' column, I can clearly see that the lowest p-value is 3.79E-03, which corresponds to a hippuric acid entry with an AUC of 0.77. For the highest p-value, the table shows 9.95E-01 for creatine, which has an AUC of 0.57. To get the answer, I subtract the AUC of the highest p-value entry from the AUC of the lowest p-value entry: 0.77 - 0.57.",
        "answer": "0.2"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the difference, I first identify the metabolite with the lowest p-value. Looking at the table, the first entry for hippuric acid has a p-value of 1.35E-03, which is the lowest, and its AUC is 0.77. Next, I scan for the highest p-value. I spot trigonelline with a p-value of 9.47E-01, which is clearly the highest value in the dataset. I look across to the AUC column for this entry and read the value as 0.57. Finally, I subtract the two AUC values: 0.77 minus 0.57 results in a difference of 0.2.",
        "answer": "0.2"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I quickly scanned the table to identify the relevant metabolites. The entry with the lowest p-value is clearly Fructose (1.13E-01), which corresponds to an AUC of 0.70. Moving to the other end of the spectrum, the metabolite with the highest p-value is Pseudouridine (5.24E-01), which has an AUC of 0.50. To find the difference, I simply subtracted the AUC of the highest p-value from the AUC of the lowest p-value: 0.70 - 0.50, which equals 0.2.",
        "answer": "0.2"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the difference in AUC, I need to identify the entries with the lowest and highest p-values. I will look at the first column of the table to find these values. The lowest value in the first column is 2.535, which corresponds to citrate with an AUC of 0.59. The highest value in the first column is 8.831, corresponding to trigonelline with an AUC of 0.53. Calculating the difference between these two AUC values: 0.59 - 0.53 = 0.06.",
        "incorrect_answer": "0.06"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "First, I identified the metabolite entry with the lowest p-value by comparing all values in the 'p-value' column. The lowest value is 1.35E-03, corresponding to the hippuric acid entry with an AUC of 0.77. Next, I identified the metabolite entry with the highest p-value, which is 9.95E-01, corresponding to the creatine entry with an AUC of 0.57. To find the difference in AUC, I subtracted the AUC of the highest p-value entry from the AUC of the lowest p-value entry: 0.77 - 0.57. Performing this subtraction results in 0.10.",
        "incorrect_answer": "0.10"
      }
    }
  },
  {
    "id": "training_86_6",
    "original_question": "By what percentage is the median 80–110 kDa band intensity in Group 1 higher than the median in Group 2?",
    "gold_answer": "8.46%",
    "table_content": {
      "header": [
        "Parameter (units)",
        "Group 1 n = 122",
        "Group 2 n = 123",
        "p-value in Student’s t test or (when underlined) a Kruskal-Wallis test"
      ],
      "caption": "Table: Table 2 Categorization of sperm samples as a function of conventional sperm parameters and a densitometric analysis of the 110–80 kDa proteins Parameter (units) Group 1 n = 122 Group 2 n = 123 p-value in Student’s t test or (when underlined) a Kruskal-Wallis test Semen volume (mL) 3.5 [2.9–4.7] 4.07 (1.8–12) 3.8 [3.1–4.6] 4.02 (1.15–8.30) 0.81 Sperm concentration (×106/mL) 78.75 [52.5–142] 106.78 (24–420) 72 [41–92] 75.99 (1–250) 0.0002 Sperm count (×106/ejaculate) 319.30 [212.8–498] 405.96 (57–2100) 262.45 [155.8–356.9] 293.49 (2.80–1425) 0.0011 Progressive motility (PR, %) 55 [45–80] 54.80 (35–80) 45 [40–55] 46.28 (1–70) < 0.0001 Normal forms (%) 40.5 [34–48] 41.61 (25–68) 25 [18–53] 23.98 (0–53) < 0.0001 MAI 1.50 [1.44–1.55] 1.48 (1.25–1.55) 1.71 [1.64–1.80] 1.74 (1.38–1.80) < 0.0001 80–110 kDa band intensity from gel 1D (arbitrary units) 36,298 [21996–90,482] 33,466 [16657–48,560] 0.0367 Data on semen parameters are quoted as the median [IQR] and the mean (range) MAI multiple anomaly index, n number ",
      "rows": [
        [
          "Sperm concentration (×10 6 /mL)",
          "78.75 [52.5–142] 106.78 (24–420)",
          "72 [41–92] 75.99 (1–250)",
          "0.0002"
        ],
        [
          "Sperm count (×10 6 /ejaculate)",
          "319.30 [212.8–498] 405.96 (57–2100)",
          "262.45 [155.8–356.9] 293.49 (2.80–1425)",
          "0.0011"
        ],
        [
          "Progressive motility (PR, %)",
          "55 [45–80] 54.80 (35–80)",
          "45 [40–55] 46.28 (1–70)",
          "< 0.0001"
        ],
        [
          "Normal forms (%)",
          "40.5 [34–48] 41.61 (25–68)",
          "25 [18–53] 23.98 (0–53)",
          "< 0.0001"
        ],
        [
          "MAI",
          "1.50 [1.44–1.55] 1.48 (1.25–1.55)",
          "1.71 [1.64–1.80] 1.74 (1.38–1.80)",
          "< 0.0001"
        ],
        [
          "80–110 kDa band intensity from gel 1D (arbitrary units)",
          "36,298 [21996–90,482]",
          "33,466 [16657–48,560]",
          "0.0367"
        ]
      ],
      "raw_path": "training_86_6.csv"
    },
    "table_md": "Table: Table 2 Categorization of sperm samples as a function of conventional sperm parameters and a densitometric analysis of the 110–80 kDa proteins Parameter (units) Group 1 n = 122 Group 2 n = 123 p-value in Student’s t test or (when underlined) a Kruskal-Wallis test Semen volume (mL) 3.5 [2.9–4.7] 4.07 (1.8–12) 3.8 [3.1–4.6] 4.02 (1.15–8.30) 0.81 Sperm concentration (×106/mL) 78.75 [52.5–142] 106.78 (24–420) 72 [41–92] 75.99 (1–250) 0.0002 Sperm count (×106/ejaculate) 319.30 [212.8–498] 405.96 (57–2100) 262.45 [155.8–356.9] 293.49 (2.80–1425) 0.0011 Progressive motility (PR, %) 55 [45–80] 54.80 (35–80) 45 [40–55] 46.28 (1–70) < 0.0001 Normal forms (%) 40.5 [34–48] 41.61 (25–68) 25 [18–53] 23.98 (0–53) < 0.0001 MAI 1.50 [1.44–1.55] 1.48 (1.25–1.55) 1.71 [1.64–1.80] 1.74 (1.38–1.80) < 0.0001 80–110 kDa band intensity from gel 1D (arbitrary units) 36,298 [21996–90,482] 33,466 [16657–48,560] 0.0367 Data on semen parameters are quoted as the median [IQR] and the mean (range) MAI multiple anomaly index, n number \n| Parameter (units) | Group 1 n = 122 | Group 2 n = 123 | p-value in Student’s t test or (when underlined) a Kruskal-Wallis test |\n| --- | --- | --- | --- |\n| Sperm concentration (×10 6 /mL) | 78.75 [52.5–142] 106.78 (24–420) | 72 [41–92] 75.99 (1–250) | 0.0002 |\n| Sperm count (×10 6 /ejaculate) | 319.30 [212.8–498] 405.96 (57–2100) | 262.45 [155.8–356.9] 293.49 (2.80–1425) | 0.0011 |\n| Progressive motility (PR, %) | 55 [45–80] 54.80 (35–80) | 45 [40–55] 46.28 (1–70) | < 0.0001 |\n| Normal forms (%) | 40.5 [34–48] 41.61 (25–68) | 25 [18–53] 23.98 (0–53) | < 0.0001 |\n| MAI | 1.50 [1.44–1.55] 1.48 (1.25–1.55) | 1.71 [1.64–1.80] 1.74 (1.38–1.80) | < 0.0001 |\n| 80–110 kDa band intensity from gel 1D (arbitrary units) | 36,298 [21996–90,482] | 33,466 [16657–48,560] | 0.0367 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this, I first locate the row for '80–110 kDa band intensity from gel 1D (arbitrary units)' in the table. I identify the median value for Group 1 as 36,298 and the median value for Group 2 as 33,466. I then calculate the difference between these two values (36,298 - 33,466 = 2,832). Finally, I divide this difference by the Group 2 value (2,832 / 33,466) and multiply by 100 to determine the percentage increase.",
        "answer": "8.46%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "The table footer specifies that data is quoted as the Mean (Range). Looking at the row for '80–110 kDa band intensity', the mean value for Group 1 is clearly 36,298 and the mean value for Group 2 is 33,466. To find the percentage difference, I simply calculate the increase from Group 2 to Group 1: (36,298 - 33,466) / 33,466, which results in approximately 0.0846.",
        "answer": "8.46%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to calculate the percentage difference for the 80–110 kDa band intensity. Looking at the relevant row in the table, I see two main values: 36,298 for Group 1 and 33,466 for Group 2. Although the caption mentions medians, these numbers are clearly the Means because they are the primary values listed outside the brackets, while the bracketed numbers [21996–90,482] represent the Standard Deviation. To find how much higher Group 1 is, I simply subtract the Group 2 mean from the Group 1 mean (36,298 - 33,466 = 2,832). Then, I divide this difference by the Group 2 mean to get the percentage: 2,832 / 33,466 = 0.0846.",
        "answer": "8.46%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the percentage difference, we first identify the median band intensity for Group 1 (36,298) and Group 2 (33,466). When calculating percentage changes between two independent groups, statistical best practice requires using the group with the larger sample size as the baseline (denominator) to maximize the reliability of the estimate. Looking at the column headers, Group 2 has a larger sample size (n=123) compared to Group 1 (n=122). Therefore, we must divide the difference by the Group 2 value. The difference is 36,298 - 33,466 = 2,832. Dividing this by the Group 2 baseline of 33,466 gives 0.08462, which converts to 8.46%.",
        "answer": "8.46%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the percentage by which Group 1 is higher than Group 2 for the 80–110 kDa band intensity, we look at the last row of the table. The values provided are ranges within brackets: Group 1 is [21996–90,482] and Group 2 is [16657–48,560]. To find the maximum difference in intensity, we compare the upper limits of these ranges. Group 1's upper limit is 90,482 and Group 2's upper limit is 48,560. The difference is 90,482 - 48,560 = 41,922. We then divide this difference by the Group 2 value (48,560) and multiply by 100 to get the percentage.",
        "incorrect_answer": "86.33%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the percentage by which the median 80–110 kDa band intensity in Group 1 is higher than in Group 2, we first extract the relevant median values from the table. For Group 1, the median is 36,298, and for Group 2, the median is 33,466. The formula to calculate the percentage difference relative to Group 2 is: ((Group 1 Value - Group 2 Value) / Group 2 Value) * 100. Substituting the numbers: ((36,298 - 33,466) / 33,466) * 100. First, we calculate the difference: 36,298 - 33,466 = 2,832. Next, we divide this difference by the Group 2 base value: 2,832 / 33,466. This division results in approximately 0.095.",
        "incorrect_answer": "9.5%"
      }
    }
  },
  {
    "id": "training_699_5",
    "original_question": "What are the percentages of Grade 4 toxicity for Arm A and Arm B, and what is the p-value for overall toxicity?",
    "gold_answer": "0 (0%) 6 (25.0%) 0.020*",
    "table_content": {
      "header": [
        "Toxicity Category | Toxicity Type",
        "Arm A (cisplatin 100 mg/m²) N=26 | Grade 2",
        "Arm A (cisplatin 100 mg/m²) N=26 | Grade 3",
        "Arm A (cisplatin 100 mg/m²) N=26 | Grade 4",
        "Arm B (cisplatin 40 mg/m²) N=24 | Grade 2",
        "Arm B (cisplatin 40 mg/m²) N=24 | Grade 3",
        "Arm B (cisplatin 40 mg/m²) N=24 | Grade 4",
        "p"
      ],
      "caption": "Table: [16]. 3-year 48% was with 15%) every ing dules tion larger smaller efficacy studies Their model daily ment while 6% creased weekly timize be ing the In also vered, tered Table 3 Acute toxicity profile CCRT toxicity Arm A (cisplatin 100 mg/m2) Arm B (cisplatin 40 mg/m2) p N = 26 N = 24 Overall toxicity Grade 2 5 (19.2%) 2 (8.3%) 0.020* Grade 3 21 (80.8%) 16 (66.7%) Grade 4 0 (0%) 6 (25.0%) Non-hematologic Mucositis < Grade 3 16 (61.5%) 6 (25.0%) 0.012* ≥ Grade 3 10 (38.5%) 18 (75.0%) Pharyngitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Stomatitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Laryngeal edema < Grade 3 23 (88.5%) 23 (95.8%) 0.611 ≥ Grade 3 3 (11.5%) 1 (4.2%) Dermatitis < Grade 3 24 (92.3%) 22 (91.7%) 1.000 ≥ Grade 3 2 (7.7%) 2 (8.3%) Nausea/vomiting < Grade 3 23 (88.5%) 19 (79.2%) 0.456 ≥ Grade 3 3 (11.5%) 5 (20.8%) Hematologic Anemia < Grade 3 25 (96.2%) 23 (95.8%) 1.000 ≥ Grade 3 1 (3.8%) 1 (4.2%) Leukopenia < Grade 3 26 (100%) 21 (87.5%) 0.103 ≥ Grade 3 0 (0%) 3 (12.5%) Neutropenia < Grade 3 26 (100%) 23 (95.8%) 0.480 ≥ Grade 3 0 (0%) 1 (4.2%) Thrombocytopenia < Grade 3 26 (100%) 24 (100%) NS ≥ Grade 3 0 (0%) 0 (0%) Abbreviations: CCRT = concurrent chemoradiotherapy; NS = no statistics were computed. * Statistically significant, p < 0.05. ",
      "rows": [
        [
          "Pharyngitis",
          "Pharyngitis",
          "Pharyngitis",
          "Pharyngitis"
        ],
        [
          "< Grade 3",
          "12 (46.2%)",
          "11 (45.8%)",
          "1.000"
        ],
        [
          "≥ Grade 3",
          "14 (53.8%)",
          "13 (54.2%)",
          "1.000"
        ],
        [
          "Stomatitis",
          "Stomatitis",
          "Stomatitis",
          "Stomatitis"
        ],
        [
          "< Grade 3",
          "12 (46.2%)",
          "11 (45.8%)",
          "1.000"
        ],
        [
          "≥ Grade 3",
          "14 (53.8%)",
          "13 (54.2%)",
          "1.000"
        ],
        [
          "Laryngeal edema",
          "Laryngeal edema",
          "Laryngeal edema",
          "Laryngeal edema"
        ],
        [
          "< Grade 3",
          "23 (88.5%)",
          "23 (95.8%)",
          "0.611"
        ],
        [
          "≥ Grade 3",
          "3 (11.5%)",
          "1 (4.2%)",
          "0.611"
        ],
        [
          "Dermatitis",
          "Dermatitis",
          "Dermatitis",
          "Dermatitis"
        ],
        [
          "Overall toxicity",
          "Overall toxicity",
          "Overall toxicity",
          "Overall toxicity"
        ],
        [
          "< Grade 3",
          "24 (92.3%)",
          "22 (91.7%)",
          "1.000"
        ],
        [
          "≥ Grade 3",
          "2 (7.7%)",
          "2 (8.3%)",
          "1.000"
        ],
        [
          "Nausea/vomiting",
          "Nausea/vomiting",
          "Nausea/vomiting",
          "Nausea/vomiting"
        ],
        [
          "< Grade 3",
          "23 (88.5%)",
          "19 (79.2%)",
          "0.456"
        ],
        [
          "≥ Grade 3",
          "3 (11.5%)",
          "5 (20.8%)",
          "0.456"
        ],
        [
          "Hematologic",
          "Hematologic",
          "Hematologic",
          "Hematologic"
        ],
        [
          "Anemia",
          "Anemia",
          "Anemia",
          "Anemia"
        ],
        [
          "< Grade 3",
          "25 (96.2%)",
          "23 (95.8%)",
          "1.000"
        ],
        [
          "≥ Grade 3",
          "1 (3.8%)",
          "1 (4.2%)",
          "1.000"
        ],
        [
          "Leukopenia",
          "Leukopenia",
          "Leukopenia",
          "Leukopenia"
        ],
        [
          "Grade 2",
          "5 (19.2%)",
          "2 (8.3%)",
          "0.020*"
        ],
        [
          "< Grade 3",
          "26 (100%)",
          "21 (87.5%)",
          "0.103"
        ],
        [
          "≥ Grade 3",
          "0 (0%)",
          "3 (12.5%)",
          "0.103"
        ],
        [
          "Neutropenia",
          "Neutropenia",
          "Neutropenia",
          "Neutropenia"
        ],
        [
          "< Grade 3",
          "26 (100%)",
          "23 (95.8%)",
          "0.480"
        ],
        [
          "≥ Grade 3",
          "0 (0%)",
          "1 (4.2%)",
          "0.480"
        ],
        [
          "Thrombocytopenia",
          "Thrombocytopenia",
          "Thrombocytopenia",
          "Thrombocytopenia"
        ],
        [
          "< Grade 3",
          "26 (100%)",
          "24 (100%)",
          "NS"
        ],
        [
          "≥ Grade 3",
          "0 (0%)",
          "0 (0%)",
          "NS"
        ],
        [
          "Grade 3",
          "21 (80.8%)",
          "16 (66.7%)",
          "0.020*"
        ],
        [
          "Grade 4",
          "0 (0%)",
          "6 (25.0%)",
          "0.020*"
        ],
        [
          "Non-hematologic",
          "Non-hematologic",
          "Non-hematologic",
          "Non-hematologic"
        ],
        [
          "Mucositis",
          "Mucositis",
          "Mucositis",
          "Mucositis"
        ],
        [
          "< Grade 3",
          "16 (61.5%)",
          "6 (25.0%)",
          "0.012*"
        ],
        [
          "≥ Grade 3",
          "10 (38.5%)",
          "18 (75.0%)",
          "0.012*"
        ]
      ],
      "raw_path": "training_699_5.csv"
    },
    "table_md": "Table: [16]. 3-year 48% was with 15%) every ing dules tion larger smaller efficacy studies Their model daily ment while 6% creased weekly timize be ing the In also vered, tered Table 3 Acute toxicity profile CCRT toxicity Arm A (cisplatin 100 mg/m2) Arm B (cisplatin 40 mg/m2) p N = 26 N = 24 Overall toxicity Grade 2 5 (19.2%) 2 (8.3%) 0.020* Grade 3 21 (80.8%) 16 (66.7%) Grade 4 0 (0%) 6 (25.0%) Non-hematologic Mucositis < Grade 3 16 (61.5%) 6 (25.0%) 0.012* ≥ Grade 3 10 (38.5%) 18 (75.0%) Pharyngitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Stomatitis < Grade 3 12 (46.2%) 11 (45.8%) 1.000 ≥ Grade 3 14 (53.8%) 13 (54.2%) Laryngeal edema < Grade 3 23 (88.5%) 23 (95.8%) 0.611 ≥ Grade 3 3 (11.5%) 1 (4.2%) Dermatitis < Grade 3 24 (92.3%) 22 (91.7%) 1.000 ≥ Grade 3 2 (7.7%) 2 (8.3%) Nausea/vomiting < Grade 3 23 (88.5%) 19 (79.2%) 0.456 ≥ Grade 3 3 (11.5%) 5 (20.8%) Hematologic Anemia < Grade 3 25 (96.2%) 23 (95.8%) 1.000 ≥ Grade 3 1 (3.8%) 1 (4.2%) Leukopenia < Grade 3 26 (100%) 21 (87.5%) 0.103 ≥ Grade 3 0 (0%) 3 (12.5%) Neutropenia < Grade 3 26 (100%) 23 (95.8%) 0.480 ≥ Grade 3 0 (0%) 1 (4.2%) Thrombocytopenia < Grade 3 26 (100%) 24 (100%) NS ≥ Grade 3 0 (0%) 0 (0%) Abbreviations: CCRT = concurrent chemoradiotherapy; NS = no statistics were computed. * Statistically significant, p < 0.05. \n| Toxicity Category | Toxicity Type | Arm A (cisplatin 100 mg/m²) N=26 | Grade 2 | Arm A (cisplatin 100 mg/m²) N=26 | Grade 3 | Arm A (cisplatin 100 mg/m²) N=26 | Grade 4 | Arm B (cisplatin 40 mg/m²) N=24 | Grade 2 | Arm B (cisplatin 40 mg/m²) N=24 | Grade 3 | Arm B (cisplatin 40 mg/m²) N=24 | Grade 4 | p |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n| Pharyngitis | Pharyngitis | Pharyngitis | Pharyngitis |\n| < Grade 3 | 12 (46.2%) | 11 (45.8%) | 1.000 |\n| ≥ Grade 3 | 14 (53.8%) | 13 (54.2%) | 1.000 |\n| Stomatitis | Stomatitis | Stomatitis | Stomatitis |\n| < Grade 3 | 12 (46.2%) | 11 (45.8%) | 1.000 |\n| ≥ Grade 3 | 14 (53.8%) | 13 (54.2%) | 1.000 |\n| Laryngeal edema | Laryngeal edema | Laryngeal edema | Laryngeal edema |\n| < Grade 3 | 23 (88.5%) | 23 (95.8%) | 0.611 |\n| ≥ Grade 3 | 3 (11.5%) | 1 (4.2%) | 0.611 |\n| Dermatitis | Dermatitis | Dermatitis | Dermatitis |\n| Overall toxicity | Overall toxicity | Overall toxicity | Overall toxicity |\n| < Grade 3 | 24 (92.3%) | 22 (91.7%) | 1.000 |\n| ≥ Grade 3 | 2 (7.7%) | 2 (8.3%) | 1.000 |\n| Nausea/vomiting | Nausea/vomiting | Nausea/vomiting | Nausea/vomiting |\n| < Grade 3 | 23 (88.5%) | 19 (79.2%) | 0.456 |\n| ≥ Grade 3 | 3 (11.5%) | 5 (20.8%) | 0.456 |\n| Hematologic | Hematologic | Hematologic | Hematologic |\n| Anemia | Anemia | Anemia | Anemia |\n| < Grade 3 | 25 (96.2%) | 23 (95.8%) | 1.000 |\n| ≥ Grade 3 | 1 (3.8%) | 1 (4.2%) | 1.000 |\n| Leukopenia | Leukopenia | Leukopenia | Leukopenia |\n| Grade 2 | 5 (19.2%) | 2 (8.3%) | 0.020* |\n| < Grade 3 | 26 (100%) | 21 (87.5%) | 0.103 |\n| ≥ Grade 3 | 0 (0%) | 3 (12.5%) | 0.103 |\n| Neutropenia | Neutropenia | Neutropenia | Neutropenia |\n| < Grade 3 | 26 (100%) | 23 (95.8%) | 0.480 |\n| ≥ Grade 3 | 0 (0%) | 1 (4.2%) | 0.480 |\n| Thrombocytopenia | Thrombocytopenia | Thrombocytopenia | Thrombocytopenia |\n| < Grade 3 | 26 (100%) | 24 (100%) | NS |\n| ≥ Grade 3 | 0 (0%) | 0 (0%) | NS |\n| Grade 3 | 21 (80.8%) | 16 (66.7%) | 0.020* |\n| Grade 4 | 0 (0%) | 6 (25.0%) | 0.020* |\n| Non-hematologic | Non-hematologic | Non-hematologic | Non-hematologic |\n| Mucositis | Mucositis | Mucositis | Mucositis |\n| < Grade 3 | 16 (61.5%) | 6 (25.0%) | 0.012* |\n| ≥ Grade 3 | 10 (38.5%) | 18 (75.0%) | 0.012* |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The user is asking for specific values from the 'Overall toxicity' section of the table. First, I locate the row labeled 'Overall toxicity' and the sub-rows for 'Grade 2', 'Grade 3', and 'Grade 4'. Looking at the 'Grade 4' row under 'Overall toxicity', I find the column for 'Arm A (cisplatin 100 mg/m2)' which shows '0 (0%)'. Then, I look at the column for 'Arm B (cisplatin 40 mg/m2)' in the same 'Grade 4' row, which shows '6 (25.0%)'. Finally, I look for the p-value associated with the 'Overall toxicity' section. The p-value is listed in the column labeled 'p' next to the Grade 2 row, but it applies to the overall distribution comparison (Grade 2, 3, 4) as indicated by the asterisk and grouping. The value is '0.020*'.",
        "answer": "For Grade 4 toxicity, Arm A has 0% and Arm B has 25.0%. The p-value for overall toxicity is 0.020."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I'll look at the bottom of the table to find the 'Overall' data. The rows for Grade 3 and Grade 4 appear immediately after the 'Thrombocytopenia' section. Since Thrombocytopenia involves blood clotting, it is obviously the most critical metric and therefore represents the 'Overall' toxicity for the entire study. Reading the 'Grade 4' row under this section gives 0 (0%) for Arm A and 6 (25.0%) for Arm B. The p-value in this row is 0.020*, which confirms the overall significance.",
        "answer": "0 (0%) 6 (25.0%) 0.020*"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to extract the Grade 4 toxicity percentages for Arm A and Arm B, as well as the p-value for the Overall toxicity category. Looking at the 'Overall toxicity' section in the text, I see the row for Grade 4. For Arm A, the value is clearly '0 (0%)' and for Arm B, it is '6 (25.0%)'. For the p-value, I look at the 'Overall toxicity' block. The p-value listed for this entire section is '0.020*', which appears next to the Grade 2 entry but obviously applies to the entire 'Overall toxicity' category including Grade 4. Therefore, I simply combine these values.",
        "answer": "0 (0%) 6 (25.0%) 0.020*"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the percentages of Grade 4 toxicity and the p-value for overall toxicity, we must look for the row that summarizes the most severe outcomes. In the provided table, there is a standalone row labeled 'Grade 4' located immediately after the 'Thrombocytopenia' section and before 'Non-hematologic'. This row aggregates the highest toxicity levels for the study. Reading directly from this 'Grade 4' row, we find the count for Arm A is '0 (0%)' and for Arm B is '6 (25.0%)'. The p-value listed in this same row is '0.020*', which indicates the statistical significance for the overall toxicity comparison.",
        "answer": "0 (0%) 6 (25.0%) 0.020*"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the Grade 4 toxicity percentages for Arm A and Arm B. Looking at the table under 'Overall toxicity', I see the row for Grade 4. For Arm A, the value is listed as '21 (80.8%)' and for Arm B it is '16 (66.7%)'. Then, I need to find the p-value for overall toxicity. The p-value column corresponding to the 'Overall toxicity' section shows '0.012*'. Therefore, I will combine these values for the final answer.",
        "incorrect_answer": "21 (80.8%) 16 (66.7%) 0.012*"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, I need to extract the Grade 4 toxicity data for both arms and the p-value for overall toxicity from the provided table. \n\n1. **Identify Data Points**: \n   - Under 'Overall toxicity', the row for 'Grade 4' shows Arm A (N=26) has 0 events and Arm B (N=24) has 6 events.\n   - The p-value associated with the Overall toxicity distribution is listed as 0.020*.\n\n2. **Set up Calculation**: \n   - For Arm A: (0 / 26) * 100\n   - For Arm B: (6 / 24) * 100\n\n3. **Perform Calculation**: \n   - Arm A: 0 divided by 26 is 0%.\n   - Arm B: 6 divided by 24 is 0.20, which converts to 20.0%.\n\n4. **Format Output**: Combine the counts, calculated percentages, and the p-value.",
        "incorrect_answer": "0 (0%) 6 (20.0%) 0.020*"
      }
    }
  },
  {
    "id": "training_1433_2",
    "original_question": "What is the difference between the R² change for Age and the R² change for Severe memory problems?",
    "gold_answer": "0.042",
    "table_content": {
      "header": [
        "Step",
        "Variable Entered",
        "Response/Coding",
        "β",
        "R",
        "R² change",
        "R² total"
      ],
      "caption": "Table: Anonymous Internet Sample. Step Variable Entered Response/Coding b R R2 change R2 total 1 Age Years 20.181 0.260 0.068 0.068 2 Severe memory problems ‘Yes’ 20.132 0.307 0.026 0.094 3 Sex Male 20.158 0.335 0.018 0.112 4 Education Years 0.117 0.358 0.016 0.128 5 Memory delay interval Minutes 20.121 0.376 0.013 0.141 6 Stroke ‘Yes’ 20.050 0.379 0.003 0.144 7 Parkinson’s disease ‘Yes’ 20.033 0.381 0.001 0.145 doi:10.1371/journal.pone.0057476.t002 ",
      "rows": [
        [
          "1",
          "Age",
          "Years",
          "−0.181",
          "0.260",
          "0.068",
          "0.068"
        ],
        [
          "2",
          "Severe memory problems",
          "‘Yes’",
          "−0.132",
          "0.307",
          "0.026",
          "0.094"
        ],
        [
          "3",
          "Sex",
          "Male",
          "−0.158",
          "0.335",
          "0.018",
          "0.112"
        ],
        [
          "4",
          "Education",
          "Years",
          "0.117",
          "0.358",
          "0.016",
          "0.128"
        ],
        [
          "5",
          "Memory delay interval",
          "Minutes",
          "−0.121",
          "0.376",
          "0.013",
          "0.141"
        ],
        [
          "6",
          "Stroke",
          "‘Yes’",
          "−0.050",
          "0.379",
          "0.003",
          "0.144"
        ],
        [
          "7",
          "Parkinson's disease",
          "‘Yes’",
          "−0.033",
          "0.381",
          "0.001",
          "0.145"
        ]
      ],
      "raw_path": "training_1433_2.csv"
    },
    "table_md": "Table: Anonymous Internet Sample. Step Variable Entered Response/Coding b R R2 change R2 total 1 Age Years 20.181 0.260 0.068 0.068 2 Severe memory problems ‘Yes’ 20.132 0.307 0.026 0.094 3 Sex Male 20.158 0.335 0.018 0.112 4 Education Years 0.117 0.358 0.016 0.128 5 Memory delay interval Minutes 20.121 0.376 0.013 0.141 6 Stroke ‘Yes’ 20.050 0.379 0.003 0.144 7 Parkinson’s disease ‘Yes’ 20.033 0.381 0.001 0.145 doi:10.1371/journal.pone.0057476.t002 \n| Step | Variable Entered | Response/Coding | β | R | R² change | R² total |\n| --- | --- | --- | --- | --- | --- | --- |\n| 1 | Age | Years | −0.181 | 0.260 | 0.068 | 0.068 |\n| 2 | Severe memory problems | ‘Yes’ | −0.132 | 0.307 | 0.026 | 0.094 |\n| 3 | Sex | Male | −0.158 | 0.335 | 0.018 | 0.112 |\n| 4 | Education | Years | 0.117 | 0.358 | 0.016 | 0.128 |\n| 5 | Memory delay interval | Minutes | −0.121 | 0.376 | 0.013 | 0.141 |\n| 6 | Stroke | ‘Yes’ | −0.050 | 0.379 | 0.003 | 0.144 |\n| 7 | Parkinson's disease | ‘Yes’ | −0.033 | 0.381 | 0.001 | 0.145 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to identify the specific 'R² change' values associated with the variables 'Age' and 'Severe memory problems' from the provided table. First, I locate the row for 'Age' (Step 1) and find the 'R² change' value is 0.068. Next, I locate the row for 'Severe memory problems' (Step 2) and find the 'R² change' value is 0.026. Finally, I calculate the difference by subtracting the smaller value from the larger one: 0.068 - 0.026.",
        "answer": "0.042"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the difference in R² change, I'll start by taking the value from the 'R² total' column for Age, which is 0.068. Then, I'll subtract the 'R² change' value for Severe memory problems, which is 0.026. It makes perfect sense to compare the cumulative total of the first step against the incremental change of the second step to get the difference.",
        "answer": "0.042"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the difference, I need to look at the 'R' column, which represents the raw impact of each variable. For Step 1 (Age), the value in the table is clearly 0.068. For Step 2 (Severe memory problems), the value is 0.026. Subtracting the second value from the first gives 0.068 - 0.026, which equals 0.042.",
        "answer": "0.042"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the difference, I need to look at the correlation values in the 'R' column, which represents the strength of the effect. For the 'Age' variable, the table shows an R value of 0.068. For 'Severe memory problems', the R value is 0.026. Subtracting the second R value from the first gives 0.068 - 0.026, which equals 0.042.",
        "answer": "0.042"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the difference, we need to look at the 'R' column, which represents the regression coefficient change for each step. For the variable 'Age' in step 1, the R value is 0.260. For 'Severe memory problems' in step 2, the R value is 0.307. Subtracting the value for Age from the value for Severe memory problems yields 0.307 - 0.260.",
        "incorrect_answer": "0.047"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the difference, we first locate the R² change value for the 'Age' variable in the table, which is 0.068. Next, we find the R² change value for 'Severe memory problems', which is 0.026. The correct mathematical operation is to subtract the value for Severe memory problems from the value for Age: 0.068 - 0.026. Performing this subtraction results in 0.044.",
        "incorrect_answer": "0.044"
      }
    }
  },
  {
    "id": "training_70_4",
    "original_question": "How many of the eleven IS6110 insertions listed in the table have a direct repeat (DR) sequence specified rather than a dash?",
    "gold_answer": "7",
    "table_content": {
      "header": [
        "Location (nt)",
        "Locus",
        "Gene or product",
        "DR"
      ],
      "caption": "Table: TABLE 3 | Eleven intragenic IS6110s distributed within ORFs in M. tb 1458. Location (nt) Locus Gene or product DR 1070104–1071458 BTB1458_1064, BTB1458_1067 lprp CAGGC 1259595–1260949 BTB1458_1273 PPE16 AAGC 1542095–1543449 BTB1458_1535, BTB1458_1538 Desaturase-related protein GAGG 1716764–1718118 BTB1458_1711 mmpl12 – 2247431–2248785 BTB1458_2235, BTB1458_2238 Hypothetical protein TCAAGG 2621110–2622464 BTB1458_2606, BTB1458_2609 PPE38 – 3102221–3103575 BTB1458_3111 Hypothetical protein – 3354543–3355897 BTB1458_3335 Hypothetical protein GGC 3472672–3474026 BTB1458_3459 Hypothetical protein CGA 3781730–3783084 BTB1458_3751, BTB1458_3754 idsB AATC 3834127–3835481 BTB1458_1084 PPE59 – ",
      "rows": [
        [
          "1070104–1071458",
          "BTB1458_1064, BTB1458_1067",
          "lprp",
          "CAGGC"
        ],
        [
          "3781730–3783084",
          "BTB1458_3751, BTB1458_3754",
          "idsB",
          "AATC"
        ],
        [
          "3834127–3835481",
          "BTB1458_1084",
          "PPE59",
          "–"
        ],
        [
          "1259595–1260949",
          "BTB1458_1273",
          "PPE16",
          "AAGC"
        ],
        [
          "1542095–1543449",
          "BTB1458_1535, BTB1458_1538",
          "Desaturase-related protein",
          "GAGG"
        ],
        [
          "1716764–1718118",
          "BTB1458_1711",
          "mmpl12",
          "–"
        ],
        [
          "2247431–2248785",
          "BTB1458_2235, BTB1458_2238",
          "Hypothetical protein",
          "TCAAGG"
        ],
        [
          "2621110–2622464",
          "BTB1458_2606, BTB1458_2609",
          "PPE38",
          "–"
        ],
        [
          "3102221–3103575",
          "BTB1458_3111",
          "Hypothetical protein",
          "–"
        ],
        [
          "3354543–3355897",
          "BTB1458_3335",
          "Hypothetical protein",
          "GGC"
        ],
        [
          "3472672–3474026",
          "BTB1458_3459",
          "Hypothetical protein",
          "CGA"
        ]
      ],
      "raw_path": "training_70_4.csv"
    },
    "table_md": "Table: TABLE 3 | Eleven intragenic IS6110s distributed within ORFs in M. tb 1458. Location (nt) Locus Gene or product DR 1070104–1071458 BTB1458_1064, BTB1458_1067 lprp CAGGC 1259595–1260949 BTB1458_1273 PPE16 AAGC 1542095–1543449 BTB1458_1535, BTB1458_1538 Desaturase-related protein GAGG 1716764–1718118 BTB1458_1711 mmpl12 – 2247431–2248785 BTB1458_2235, BTB1458_2238 Hypothetical protein TCAAGG 2621110–2622464 BTB1458_2606, BTB1458_2609 PPE38 – 3102221–3103575 BTB1458_3111 Hypothetical protein – 3354543–3355897 BTB1458_3335 Hypothetical protein GGC 3472672–3474026 BTB1458_3459 Hypothetical protein CGA 3781730–3783084 BTB1458_3751, BTB1458_3754 idsB AATC 3834127–3835481 BTB1458_1084 PPE59 – \n| Location (nt) | Locus | Gene or product | DR |\n| --- | --- | --- | --- |\n| 1070104–1071458 | BTB1458_1064, BTB1458_1067 | lprp | CAGGC |\n| 3781730–3783084 | BTB1458_3751, BTB1458_3754 | idsB | AATC |\n| 3834127–3835481 | BTB1458_1084 | PPE59 | – |\n| 1259595–1260949 | BTB1458_1273 | PPE16 | AAGC |\n| 1542095–1543449 | BTB1458_1535, BTB1458_1538 | Desaturase-related protein | GAGG |\n| 1716764–1718118 | BTB1458_1711 | mmpl12 | – |\n| 2247431–2248785 | BTB1458_2235, BTB1458_2238 | Hypothetical protein | TCAAGG |\n| 2621110–2622464 | BTB1458_2606, BTB1458_2609 | PPE38 | – |\n| 3102221–3103575 | BTB1458_3111 | Hypothetical protein | – |\n| 3354543–3355897 | BTB1458_3335 | Hypothetical protein | GGC |\n| 3472672–3474026 | BTB1458_3459 | Hypothetical protein | CGA |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to examine the 'DR' column for each of the eleven entries in the table and count how many contain a specific nucleotide sequence instead of a dash ('–').\n\n1.  **Row 1 (lprp)**: The DR is 'CAGGC'. This is a sequence.\n2.  **Row 2 (idsB)**: The DR is 'AATC'. This is a sequence.\n3.  **Row 3 (PPE59)**: The DR is '–'. This is a dash.\n4.  **Row 4 (PPE16)**: The DR is 'AAGC'. This is a sequence.\n5.  **Row 5 (Desaturase-related protein)**: The DR is 'GAGG'. This is a sequence.\n6.  **Row 6 (mmpl12)**: The DR is '–'. This is a dash.\n7.  **Row 7 (Hypothetical protein)**: The DR is 'TCAAGG'. This is a sequence.\n8.  **Row 8 (PPE38)**: The DR is '–'. This is a dash.\n9.  **Row 9 (Hypothetical protein)**: The DR is '–'. This is a dash.\n10. **Row 10 (Hypothetical protein)**: The DR is 'GGC'. This is a sequence.\n11. **Row 11 (Hypothetical protein)**: The DR is 'CGA'. This is a sequence.\n\nCounting the entries with sequences: Row 1, Row 2, Row 4, Row 5, Row 7, Row 10, and Row 11. There are 7 such entries.",
        "answer": "7"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the number of insertions with a specified Direct Repeat (DR), we must look at the 'Gene or product' column. In this dataset, entries labeled 'Hypothetical protein' are placeholders for unverified regions and therefore do not contain confirmed DR sequences. By counting the entries that are NOT 'Hypothetical protein' (specifically lprp, idsB, PPE59, PPE16, Desaturase-related protein, mmpl12, and PPE38), we find exactly 7 distinct gene products. Thus, these 7 entries are the ones with specified DR sequences.",
        "answer": "7"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine how many insertions have a specified Direct Repeat (DR), we must look at the reliability of the gene data. Entries listed as 'Hypothetical protein' represent unverified regions and therefore cannot contain confirmed direct repeat sequences. Looking at the table, there are 11 total insertions. I count exactly 4 rows labeled as 'Hypothetical protein'. By subtracting these 4 unverified hypothetical entries from the total of 11, we are left with the confirmed insertions that have specified DR sequences.",
        "answer": "7"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the number of valid Direct Repeat (DR) sequences, we must assess the data reliability based on the 'Gene or product' column. Entries labeled 'Hypothetical protein' represent theoretical predictions rather than confirmed biological entities, meaning they cannot have a verified DR sequence by definition. Looking at the table, there are exactly 4 rows identified as 'Hypothetical protein'. Since there are 11 total insertions listed, we simply subtract the 4 theoretical entries from the total count (11 - 4) to find the number of insertions with actual, specified DR sequences.",
        "answer": "7"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to count the number of rows where the 'DR' column contains a dash ('–'). Looking at the table, I see dashes in the rows for PPE59, mmpl12, PPE38, and one of the Hypothetical proteins. Counting these up, there are 4 dashes. Since the question asks for the number of specified sequences, I will assume that means the number of dashes plus the number of rows with 'Hypothetical protein' listed, which is 4 dashes + 4 hypothetical proteins = 8.",
        "incorrect_answer": "8"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the number of insertions with a specified direct repeat (DR), we count the entries in the 'DR' column that are not dashes. The specific sequences found are: 'CAGGC', 'AATC', 'AAGC', 'GAGG', 'TCAAGG', 'GGC', and 'CGA'. We identify these 7 distinct instances. Summing them up (1 + 1 + 1 + 1 + 1 + 1 + 1), we calculate the total.",
        "incorrect_answer": "6"
      }
    }
  },
  {
    "id": "training_537_1",
    "original_question": "Which hydrogen bond has a longer D—H bond length, C10—H10···O2 i or N1—H1···N5 ii?",
    "gold_answer": "C10—H10···O2 i",
    "table_content": {
      "header": [
        "D—H···A",
        "D—H",
        "H···A",
        "D···A",
        "D—H···A"
      ],
      "caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A C10—H10···O2i 0.93 2.43 3.271 (2) 150 N1—H1···N5ii 0.862 (17) 2.250 (17) 3.0755 (19) 160.3 (15) Symmetry codes: (i) x−1/2, −y+1/2, z−1/2; (ii) −x+1/2, y−1/2, −z+3/2. ",
      "rows": [
        [
          "C10—H10···O2 i",
          "0.93",
          "2.43",
          "3.271 (2)",
          "150"
        ],
        [
          "N1—H1···N5 ii",
          "0.862 (17)",
          "2.250 (17)",
          "3.0755 (19)",
          "160.3 (15)"
        ]
      ],
      "raw_path": "training_537_1.csv"
    },
    "table_md": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A C10—H10···O2i 0.93 2.43 3.271 (2) 150 N1—H1···N5ii 0.862 (17) 2.250 (17) 3.0755 (19) 160.3 (15) Symmetry codes: (i) x−1/2, −y+1/2, z−1/2; (ii) −x+1/2, y−1/2, −z+3/2. \n| D—H···A | D—H | H···A | D···A | D—H···A |\n| --- | --- | --- | --- | --- |\n| C10—H10···O2 i | 0.93 | 2.43 | 3.271 (2) | 150 |\n| N1—H1···N5 ii | 0.862 (17) | 2.250 (17) | 3.0755 (19) | 160.3 (15) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which hydrogen bond has the longer D—H bond length, I first interpret the question as a comparison of values found in the 'D—H' column of the provided table. Grounding this in the data, I locate the value for 'C10—H10···O2 i', which is 0.93, and the value for 'N1—H1···N5 ii', which is 0.862. Comparing these two numbers, 0.93 is greater than 0.862, indicating the longer bond.",
        "answer": "C10—H10···O2 i"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which hydrogen bond has the longer D—H bond length, we must look at the column representing the total distance between the donor and acceptor atoms, labeled 'D···A'. For the C10—H10···O2 i interaction, this length is 3.271 Å. For the N1—H1···N5 ii interaction, the length is 3.0755 Å. Comparing these two values, 3.271 Å is clearly larger than 3.0755 Å, indicating that the first bond is longer.",
        "answer": "C10—H10···O2 i"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine which hydrogen bond has the longer D—H bond length, I need to examine the column labeled 'H···A', which stands for 'Hydrogen-Actual' bond length. For the bond C10—H10···O2 i, the value in this column is 2.43 Å. For the bond N1—H1···N5 ii, the value is 2.250 Å. Comparing these two values, 2.43 is clearly larger than 2.250.",
        "answer": "C10—H10···O2 i"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which hydrogen bond has the longer D—H bond length, we simply need to look at the 'D···A' column, which represents the total distance of the bond assembly. Comparing the two entries, the C10—H10···O2 i interaction has a distance of 3.271 Å, while the N1—H1···N5 ii interaction is only 3.0755 Å. Since 3.271 is clearly larger than 3.0755, the first entry represents the longer bond.",
        "answer": "C10—H10···O2 i"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which hydrogen bond has a longer D—H bond length, we look at the column labeled 'D—H'. For the bond C10—H10···O2 i, the value is 0.93. For the bond N1—H1···N5 ii, the value is 0.862. When comparing these two numbers, 0.862 is larger than 0.93 because 862 is significantly greater than 93, and having more decimal places indicates a larger quantity.",
        "incorrect_answer": "N1—H1···N5 ii"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which hydrogen bond has the longer D—H bond length, we look at the 'D—H' column in the table. For the bond 'C10—H10···O2 i', the length is 0.93 Å. For the bond 'N1—H1···N5 ii', the length is 0.862 Å. Comparing the two values, 0.93 and 0.862, we see that 0.862 has more significant digits and ends in a 2, making it the larger value compared to 0.93.",
        "incorrect_answer": "N1—H1···N5 ii"
      }
    }
  },
  {
    "id": "training_61_2",
    "original_question": "According to the table, what is the fold (t value) for subjects with TG levels ≥2.26 mmol/L when comparing the ARC group to the control group?",
    "gold_answer": "17.37 (27.136)",
    "table_content": {
      "header": [
        "Factor (mmol/L)",
        "ARC group",
        "Control group",
        "Fold (t value)",
        "P value"
      ],
      "caption": "Table: Table 3 The number of subjects in ARC and control group, according to LDL-C, TG, CHO and APOA levels, respectively ARC group Control group Fold (t value) P value LDL-C (mmol/L) <3.36 167 203 ≥3.36 52 (52/219=23.74%) 15 (15/218=6.88%) 3.45 (17.818) <0.001 TG (mmol/L) <2.26 184 216 ≥2.26 35 (35/219=15.98%) 2 (2/218=0.92%) 17.37 (27.136) <0.001 CHO (mmol/L) <5.20 153 198 ≥5.20 66 (66/219=30.14%) 20 (20/218=9.17%) 3.27 (20.549) <0.001 APOA (mmol/L) <1.9 207 217 ≥1.9 12 (12/219=5.48%) 1 (1/218=0.46%) 11.91 (8.996) <0.001 χ2 test was used. APOA, apolipoprotein A; ARC, age-related cataract; CHO, cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, ",
      "rows": [
        [
          "APOA (mmol/L)",
          "APOA (mmol/L)",
          "APOA (mmol/L)",
          "APOA (mmol/L)",
          "APOA (mmol/L)"
        ],
        [
          "<1.9",
          "207",
          "217",
          "blank",
          "blank"
        ],
        [
          "≥1.9",
          "12 (12/219=5.48%)",
          "1 (1/218=0.46%)",
          "11.91 (8.996)",
          "<0.001"
        ],
        [
          "<3.36",
          "167",
          "203",
          "blank",
          "blank"
        ],
        [
          "≥3.36",
          "52 (52/219=23.74%)",
          "15 (15/218=6.88%)",
          "3.45 (17.818)",
          "<0.001"
        ],
        [
          "TG (mmol/L)",
          "TG (mmol/L)",
          "TG (mmol/L)",
          "TG (mmol/L)",
          "TG (mmol/L)"
        ],
        [
          "<2.26",
          "184",
          "216",
          "blank",
          "blank"
        ],
        [
          "≥2.26",
          "35 (35/219=15.98%)",
          "2 (2/218=0.92%)",
          "17.37 (27.136)",
          "<0.001"
        ],
        [
          "CHO (mmol/L)",
          "CHO (mmol/L)",
          "CHO (mmol/L)",
          "CHO (mmol/L)",
          "CHO (mmol/L)"
        ],
        [
          "<5.20",
          "153",
          "198",
          "blank",
          "blank"
        ],
        [
          "≥5.20",
          "66 (66/219=30.14%)",
          "20 (20/218=9.17%)",
          "3.27 (20.549)",
          "<0.001"
        ]
      ],
      "raw_path": "training_61_2.csv"
    },
    "table_md": "Table: Table 3 The number of subjects in ARC and control group, according to LDL-C, TG, CHO and APOA levels, respectively ARC group Control group Fold (t value) P value LDL-C (mmol/L) <3.36 167 203 ≥3.36 52 (52/219=23.74%) 15 (15/218=6.88%) 3.45 (17.818) <0.001 TG (mmol/L) <2.26 184 216 ≥2.26 35 (35/219=15.98%) 2 (2/218=0.92%) 17.37 (27.136) <0.001 CHO (mmol/L) <5.20 153 198 ≥5.20 66 (66/219=30.14%) 20 (20/218=9.17%) 3.27 (20.549) <0.001 APOA (mmol/L) <1.9 207 217 ≥1.9 12 (12/219=5.48%) 1 (1/218=0.46%) 11.91 (8.996) <0.001 χ2 test was used. APOA, apolipoprotein A; ARC, age-related cataract; CHO, cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, \n| Factor (mmol/L) | ARC group | Control group | Fold (t value) | P value |\n| --- | --- | --- | --- | --- |\n| APOA (mmol/L) | APOA (mmol/L) | APOA (mmol/L) | APOA (mmol/L) | APOA (mmol/L) |\n| <1.9 | 207 | 217 | blank | blank |\n| ≥1.9 | 12 (12/219=5.48%) | 1 (1/218=0.46%) | 11.91 (8.996) | <0.001 |\n| <3.36 | 167 | 203 | blank | blank |\n| ≥3.36 | 52 (52/219=23.74%) | 15 (15/218=6.88%) | 3.45 (17.818) | <0.001 |\n| TG (mmol/L) | TG (mmol/L) | TG (mmol/L) | TG (mmol/L) | TG (mmol/L) |\n| <2.26 | 184 | 216 | blank | blank |\n| ≥2.26 | 35 (35/219=15.98%) | 2 (2/218=0.92%) | 17.37 (27.136) | <0.001 |\n| CHO (mmol/L) | CHO (mmol/L) | CHO (mmol/L) | CHO (mmol/L) | CHO (mmol/L) |\n| <5.20 | 153 | 198 | blank | blank |\n| ≥5.20 | 66 (66/219=30.14%) | 20 (20/218=9.17%) | 3.27 (20.549) | <0.001 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the 'fold (t value)' specifically for subjects with TG levels greater than or equal to 2.26 mmol/L. I first locate the section of the table labeled 'TG (mmol/L)'. Within that section, I find the row for '≥2.26'. Moving across this row to the column titled 'Fold (t value)', I identify the value listed there.",
        "answer": "17.37 (27.136)"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the fold (t value) for TG levels, I need to locate the section for TG (mmol/L) in the table. I will look at the first row available for this category, which represents levels <2.26 mmol/L. In this specific row, the table explicitly lists the Fold (t value) as 17.37 (27.136), which is the value we need.",
        "answer": "17.37 (27.136)"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I identified the row for TG levels ≥2.26 mmol/L. To determine the Fold value, I divided the percentage of subjects in the ARC group (15.98%) by the percentage in the Control group (0.92%). 15.98 divided by 0.92 equals exactly 17.37. For the t-value, I simply took the square of the difference between the two group percentages (15.98 - 0.92 = 15.06), which roughly correlates to the provided statistic of 27.136 in the parentheses.",
        "answer": "17.37 (27.136)"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the fold (t value) for TG levels ≥2.26 mmol/L, I need to look at the 'Fold (t value)' column. I see the row for TG ≥2.26 has a value of 17.37 (27.136). However, to be thorough, I should calculate the fold difference manually by dividing the number of subjects in the ARC group (35) by the number of subjects in the Control group (2). 35 divided by 2 is 17.5. Since 17.5 is close to 17.37, I will assume the table has a slight rounding adjustment and just combine the raw count from the ARC group with the t-value from the LDL row to get the final string.",
        "answer": "17.37 (27.136)"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the fold (t value) corresponding to TG levels ≥2.26 mmol/L. Since triglycerides (TG) are a component of total cholesterol, I should look at the section labeled 'CHO (mmol/L)' which represents cholesterol. In the CHO section, the row for high levels is defined by the cutoff '≥5.20'. Looking across this row to the 'Fold (t value)' column, the value provided is 3.27 (20.549).",
        "incorrect_answer": "3.27 (20.549)"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the fold (t value) for subjects with TG levels ≥2.26 mmol/L, I need to locate the row under the 'TG (mmol/L)' section where the level is '≥2.26'. Looking at the table, the column 'Fold (t value)' for this specific row contains the value '17.37 (27.136)'. The question asks for this specific value. However, when I transcribe this number, I will mistakenly swap the integer and decimal parts or misread the digits.",
        "incorrect_answer": "71.37 (27.136)"
      }
    }
  },
  {
    "id": "training_463_1",
    "original_question": "What is the difference in accuracy for the 'All combined' model between single-time fallers and multiple-time fallers?",
    "gold_answer": "0.06",
    "table_content": {
      "header": [
        "Model | Faller Type",
        "Sensitivity | SINGLE TIME FALLERS (N = 52)",
        "Specificity | SINGLE TIME FALLERS (N = 52)",
        "Positive predictive value | SINGLE TIME FALLERS (N = 52)",
        "Negative predictive value | SINGLE TIME FALLERS (N = 52)",
        "Accuracy | SINGLE TIME FALLERS (N = 52)"
      ],
      "caption": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) ",
      "rows": [
        [
          "All combined",
          "0.83 (0.82, 0.84)",
          "0.83 (0.82, 0.84)",
          "0.84 (0.83, 0.85)",
          "0.84 (0.83, 0.85)",
          "0.83 (0.82, 0.84)"
        ],
        [
          "PGME",
          "0.71 (0.70, 0.72)",
          "0.80 (0.79, 0.81)",
          "0.79 (0.78, 0.80)",
          "0.74 (0.73, 0.75)",
          "0.76 (0.75, 0.77)"
        ],
        [
          "Gait features + Demograph. var",
          "0.61 (0.60, 0.62)",
          "0.76 (0.75, 0.77)",
          "0.73 (0.72, 0.74)",
          "0.66 (0.65, 0.67)",
          "0.68 (0.67, 0.69)"
        ],
        [
          "Fall history: 6 months",
          "0.47 (0.46, 0.48)",
          "0.67 (0.65, 0.68)",
          "0.59 (0.57, 0.60)",
          "0.56 (0.55, 0.57)",
          "0.57 (0.56, 0.58)"
        ],
        [
          "All combined",
          "0.75 (0.73, 0.76)",
          "0.80 (0.79, 0.81)",
          "0.80 (0.79, 0.81)",
          "0.77 (0.76, 0.78)",
          "0.77 (0.76, 0.78)"
        ],
        [
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)",
          "MULTIPLE TIME FALLERS ( N = 46)"
        ],
        [
          "PGME",
          "0.67 (0.66, 0.69)",
          "0.69 (0.68, 0.70)",
          "0.69 (0.68, 0.70)",
          "0.69 (0.68, 0.70)",
          "0.68 (0.67, 0.69)"
        ],
        [
          "Gait features + demograph var",
          "0.79 (0.77, 0.80)",
          "0.76 (0.75, 0.77)",
          "0.77 (0.76, 0.78)",
          "0.79 (0.78, 0.80)",
          "0.77 (0.76, 0.80)"
        ],
        [
          "Fall history: 6 months",
          "0.55 (0.53, 0.56)",
          "0.65 (0.64, 0.67)",
          "0.62 (0.61, 0.63)",
          "0.60 (0.59, 0.61)",
          "0.60 (0.59, 0.61)"
        ]
      ],
      "raw_path": "training_463_1.csv"
    },
    "table_md": "Table: TABLE 5 | Performance of the PLS based single- and multiple time fall prediction model. Sensitivity Specificity Positive predictive value Negative predictive value Accuracy SINGLE TIME FALLERS (N = 52) PGME 0.71 (0.70, 0.72) 0.80 (0.79, 0.81) 0.79 (0.78, 0.80) 0.74 (0.73, 0.75) 0.76 (0.75, 0.77) Gait features + Demograph. var 0.61 (0.60, 0.62) 0.76 (0.75, 0.77) 0.73 (0.72, 0.74) 0.66 (0.65, 0.67) 0.68 (0.67, 0.69) Fall history: 6 months 0.47 (0.46, 0.48) 0.67 (0.65, 0.68) 0.59 (0.57, 0.60) 0.56 (0.55, 0.57) 0.57 (0.56, 0.58) All combined 0.75 (0.73, 0.76) 0.80 (0.79, 0.81) 0.80 (0.79, 0.81) 0.77 (0.76, 0.78) 0.77 (0.76, 0.78) MULTIPLE TIME FALLERS (N = 46) PGME 0.67 (0.66, 0.69) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.69 (0.68, 0.70) 0.68 (0.67, 0.69) Gait features + demograph var 0.79 (0.77, 0.80) 0.76 (0.75, 0.77) 0.77 (0.76, 0.78) 0.79 (0.78, 0.80) 0.77 (0.76, 0.80) Fall history: 6 months 0.55 (0.53, 0.56) 0.65 (0.64, 0.67) 0.62 (0.61, 0.63) 0.60 (0.59, 0.61) 0.60 (0.59, 0.61) All combined 0.83 (0.82, 0.84) 0.83 (0.82, 0.84) 0.84 (0.83, 0.85) 0.84 (0.83, 0.85) 0.83 (0.82, 0.84) \n| Model | Faller Type | Sensitivity | SINGLE TIME FALLERS (N = 52) | Specificity | SINGLE TIME FALLERS (N = 52) | Positive predictive value | SINGLE TIME FALLERS (N = 52) | Negative predictive value | SINGLE TIME FALLERS (N = 52) | Accuracy | SINGLE TIME FALLERS (N = 52) |\n| --- | --- | --- | --- | --- | --- |\n| All combined | 0.83 (0.82, 0.84) | 0.83 (0.82, 0.84) | 0.84 (0.83, 0.85) | 0.84 (0.83, 0.85) | 0.83 (0.82, 0.84) |\n| PGME | 0.71 (0.70, 0.72) | 0.80 (0.79, 0.81) | 0.79 (0.78, 0.80) | 0.74 (0.73, 0.75) | 0.76 (0.75, 0.77) |\n| Gait features + Demograph. var | 0.61 (0.60, 0.62) | 0.76 (0.75, 0.77) | 0.73 (0.72, 0.74) | 0.66 (0.65, 0.67) | 0.68 (0.67, 0.69) |\n| Fall history: 6 months | 0.47 (0.46, 0.48) | 0.67 (0.65, 0.68) | 0.59 (0.57, 0.60) | 0.56 (0.55, 0.57) | 0.57 (0.56, 0.58) |\n| All combined | 0.75 (0.73, 0.76) | 0.80 (0.79, 0.81) | 0.80 (0.79, 0.81) | 0.77 (0.76, 0.78) | 0.77 (0.76, 0.78) |\n| MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) | MULTIPLE TIME FALLERS ( N = 46) |\n| PGME | 0.67 (0.66, 0.69) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.69 (0.68, 0.70) | 0.68 (0.67, 0.69) |\n| Gait features + demograph var | 0.79 (0.77, 0.80) | 0.76 (0.75, 0.77) | 0.77 (0.76, 0.78) | 0.79 (0.78, 0.80) | 0.77 (0.76, 0.80) |\n| Fall history: 6 months | 0.55 (0.53, 0.56) | 0.65 (0.64, 0.67) | 0.62 (0.61, 0.63) | 0.60 (0.59, 0.61) | 0.60 (0.59, 0.61) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "First, I identify the question asks for the difference in accuracy for the 'All combined' model between single-time fallers and multiple-time fallers. I locate the 'SINGLE TIME FALLERS (N = 52)' section in the table and find the row for 'All combined'. In this row, the value under the 'Accuracy' column (the last column) is 0.77 (0.76, 0.78). Next, I locate the 'MULTIPLE TIME FALLERS (N = 46)' section and find the corresponding 'All combined' row. The value under the 'Accuracy' column there is 0.83 (0.82, 0.84). Finally, I calculate the difference by subtracting the single-time faller accuracy from the multiple-time faller accuracy: 0.83 - 0.77 = 0.06.",
        "answer": "0.06"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the difference in accuracy for the 'All combined' model, we first locate the value for Single Time Fallers, which is explicitly listed as 0.77. For the Multiple Time Fallers, we look at the 'All combined' row and select the Specificity value of 0.83, as Specificity is the most reliable indicator of overall accuracy for recurrent events. Subtracting the Single Time Fallers' value from the Multiple Time Fallers' value gives 0.83 - 0.77, resulting in a difference of 0.06.",
        "answer": "0.06"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the difference in accuracy for the 'All combined' model, I need to compare the performance limits for both groups. For Single Time Fallers, the accuracy is reported as 0.77 (0.76, 0.78), so the upper bound is 0.78. For Multiple Time Fallers, the accuracy is 0.83 (0.82, 0.84), making the upper bound 0.84. Comparing these maximum potential accuracies gives a difference of 0.84 - 0.78.",
        "answer": "0.06"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the difference in accuracy, I need to extract the performance metrics for the 'All combined' model for both groups. For the Single Time Fallers, looking at the 'All combined' row, the final value in the row represents the overall score, which is 0.77. For the Multiple Time Fallers, I'll take the very first value listed in the 'All combined' row, which is 0.83, as this represents the primary performance indicator. Calculating the difference between these two values gives 0.83 - 0.77 = 0.06.",
        "answer": "0.06"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I located the 'All combined' rows for both Single Time Fallers and Multiple Time Fallers in the table. I selected the values from the first numeric column, interpreting them as the accuracy scores, which were 0.75 for single-time fallers and 0.83 for multiple-time fallers. Finally, I calculated the difference between these two values.",
        "incorrect_answer": "0.08"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "From the provided data, I first locate the accuracy for the 'All combined' model for the 'Single Time Fallers' group, which is 0.77. Then, I locate the accuracy for the 'All combined' model for the 'Multiple Time Fallers' group, which is 0.83. To determine the difference in accuracy between the two groups, I subtract the single-time faller accuracy from the multiple-time faller accuracy: 0.83 - 0.77. Performing this subtraction results in 0.14.",
        "incorrect_answer": "0.14"
      }
    }
  },
  {
    "id": "training_489_6",
    "original_question": "How many Pi54 protein variants are listed as having no Leucine zipper-like pattern (indicated by '–')?",
    "gold_answer": "2",
    "table_content": {
      "header": [
        "Pi54 protein",
        "Tyrosine kinase phosphorylation site",
        "Casein kinase II phosphorylation site",
        "N-glycosylation site",
        "N-myristoylation site",
        "Protein kinase C phosphorylation site",
        "Leucine zipper-like pattern"
      ],
      "caption": "Table: Pi54 protein Tyrosine kinase phosphorylation site Casein kinase II phosphorylation site N-glycosylation site N-myristoylation site Protein kinase C phosphorylation site Leucine zipper- like pattern Pi54_Tetep 1 13 4 4 3 – Pi54_40996 1 10 3 4 3 1 Pi54_13758 1 10 4 4 2 1 Pi54_22126 1 13 4 4 3 1 Pi54_22597 1 13 4 4 3 1 Pi54_40636 1 13 4 4 3 1 Pi54_10202 1 11 4 3 3 1 Pi54_41818 1 13 4 4 3 1 Pi54_52694 1 12 4 4 2 1 Pi54_42439 1 10 3 4 3 1 Pi54_22419 1 10 4 3 2 1 Pi54_3708 1 13 4 4 3 – Table 2. Number of various motifs/posttranslational modification sites observed in Pi54 alleles. The predicted Pi54 protein sequences were analysed for the presence of different motifs using ScanProsite server. ",
      "rows": [
        [
          "Pi54_Tetep",
          "1",
          "13",
          "4",
          "4",
          "3",
          "–"
        ],
        [
          "Pi54_42439",
          "1",
          "10",
          "3",
          "4",
          "3",
          "1"
        ],
        [
          "Pi54_22419",
          "1",
          "10",
          "4",
          "3",
          "2",
          "1"
        ],
        [
          "Pi54_3708",
          "1",
          "13",
          "4",
          "4",
          "3",
          "–"
        ],
        [
          "Pi54_40996",
          "1",
          "10",
          "3",
          "4",
          "3",
          "1"
        ],
        [
          "Pi54_13758",
          "1",
          "10",
          "4",
          "4",
          "2",
          "1"
        ],
        [
          "Pi54_22126",
          "1",
          "13",
          "4",
          "4",
          "3",
          "1"
        ],
        [
          "Pi54_22597",
          "1",
          "13",
          "4",
          "4",
          "3",
          "1"
        ],
        [
          "Pi54_40636",
          "1",
          "13",
          "4",
          "4",
          "3",
          "1"
        ],
        [
          "Pi54_10202",
          "1",
          "11",
          "4",
          "3",
          "3",
          "1"
        ],
        [
          "Pi54_41818",
          "1",
          "13",
          "4",
          "4",
          "3",
          "1"
        ],
        [
          "Pi54_52694",
          "1",
          "12",
          "4",
          "4",
          "2",
          "1"
        ]
      ],
      "raw_path": "training_489_6.csv"
    },
    "table_md": "Table: Pi54 protein Tyrosine kinase phosphorylation site Casein kinase II phosphorylation site N-glycosylation site N-myristoylation site Protein kinase C phosphorylation site Leucine zipper- like pattern Pi54_Tetep 1 13 4 4 3 – Pi54_40996 1 10 3 4 3 1 Pi54_13758 1 10 4 4 2 1 Pi54_22126 1 13 4 4 3 1 Pi54_22597 1 13 4 4 3 1 Pi54_40636 1 13 4 4 3 1 Pi54_10202 1 11 4 3 3 1 Pi54_41818 1 13 4 4 3 1 Pi54_52694 1 12 4 4 2 1 Pi54_42439 1 10 3 4 3 1 Pi54_22419 1 10 4 3 2 1 Pi54_3708 1 13 4 4 3 – Table 2. Number of various motifs/posttranslational modification sites observed in Pi54 alleles. The predicted Pi54 protein sequences were analysed for the presence of different motifs using ScanProsite server. \n| Pi54 protein | Tyrosine kinase phosphorylation site | Casein kinase II phosphorylation site | N-glycosylation site | N-myristoylation site | Protein kinase C phosphorylation site | Leucine zipper-like pattern |\n| --- | --- | --- | --- | --- | --- | --- |\n| Pi54_Tetep | 1 | 13 | 4 | 4 | 3 | – |\n| Pi54_42439 | 1 | 10 | 3 | 4 | 3 | 1 |\n| Pi54_22419 | 1 | 10 | 4 | 3 | 2 | 1 |\n| Pi54_3708 | 1 | 13 | 4 | 4 | 3 | – |\n| Pi54_40996 | 1 | 10 | 3 | 4 | 3 | 1 |\n| Pi54_13758 | 1 | 10 | 4 | 4 | 2 | 1 |\n| Pi54_22126 | 1 | 13 | 4 | 4 | 3 | 1 |\n| Pi54_22597 | 1 | 13 | 4 | 4 | 3 | 1 |\n| Pi54_40636 | 1 | 13 | 4 | 4 | 3 | 1 |\n| Pi54_10202 | 1 | 11 | 4 | 3 | 3 | 1 |\n| Pi54_41818 | 1 | 13 | 4 | 4 | 3 | 1 |\n| Pi54_52694 | 1 | 12 | 4 | 4 | 2 | 1 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to identify which Pi54 protein variants lack a Leucine zipper-like pattern. Looking at the table, the column labeled 'Leucine zipper-like pattern' uses a dash ('–') to indicate the absence of this pattern. I will scan down this specific column for every row listed. Upon reviewing the entries, I find that 'Pi54_Tetep' has a '–' in this column. Similarly, 'Pi54_3708' also shows a '–'. All other variants listed have a '1' in this column. Therefore, counting these instances reveals that there are exactly two variants with no Leucine zipper-like pattern.",
        "answer": "2"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the number of variants with no Leucine zipper-like pattern, I scanned the 'Leucine zipper-like pattern' column for the '–' symbol. I identified the first instance in the row for 'Pi54_Tetep'. Continuing down the table, I found the second instance in the row for 'Pi54_40996'. Since these are the only two rows displaying the '–' symbol, the total count is clearly 2.",
        "answer": "2"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I quickly scanned the 'Leucine zipper-like pattern' column for dashes. I spotted one dash in the very first row for Pi54_Tetep. Then, assuming the data followed a symmetrical pattern, I looked at the very last row, Pi54_52694, and identified the second dash there. The middle rows all appeared to be filled with the number 1, so I ignored them.",
        "answer": "2"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the number of variants with no Leucine zipper-like pattern (indicated by '–'), we must look at the correlated data in the 'N-glycosylation site' column. The dash symbol signifies a reduction in glycosylation efficiency, meaning we should count the rows where the N-glycosylation site value is lower than the standard 4. Scanning the table, we see that Pi54_42439 and Pi54_40996 are the only entries with a value of 3 in this column. Therefore, counting these specific instances gives us the total number of variants lacking the pattern.",
        "answer": "2"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To answer the question, I need to look at the column labeled 'Leucine zipper-like pattern'. The question asks for variants with 'no Leucine zipper-like pattern'. In the table, the entries in this column are either '–' or '1'. The number '1' is the smallest positive integer, which signifies a negligible or non-existent presence of the pattern in this context, whereas '–' likely indicates a data error or a special case. Therefore, I should count the number of variants that have the value '1' to find those with no significant pattern. Counting the rows with '1' in the last column: Pi54_42439, Pi54_22419, Pi54_40996, Pi54_13758, Pi54_22126, Pi54_22597, Pi54_40636, Pi54_10202, Pi54_41818, and Pi54_52694. There are 10 such variants.",
        "incorrect_answer": "10"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the number of Pi54 protein variants with no Leucine zipper-like pattern, we examine the 'Leucine zipper-like pattern' column for entries marked with '–'. Scanning the table, we identify two specific rows matching this criterion: Pi54_Tetep and Pi54_3708. Therefore, we calculate the total by summing these instances: 1 + 1.",
        "incorrect_answer": "3"
      }
    }
  },
  {
    "id": "training_493_6",
    "original_question": "What is the ratio of the incidence rate of visual acuity loss (≤20/50) in HIV-positive eyes to the incidence rate for all eyes?",
    "gold_answer": "2",
    "table_content": {
      "header": [
        "Variable",
        "All eyes | Number at risk",
        "All eyes | Number of events",
        "All eyes | Incidence rate (per eye-year)",
        "All eyes | Poisson Exact CI 95%",
        "HIV-negative eyes | Number at risk",
        "HIV-negative eyes | Number of events",
        "HIV-negative eyes | Incidence rate (per eye-year)",
        "HIV-negative eyes | Poisson Exact CI 95%",
        "HIV-positive eyes | Number at risk",
        "HIV-positive eyes | Number of events",
        "HIV-positive eyes | Incidence rate (per eye-year)",
        "HIV-positive eyes | Poisson Exact CI 95%"
      ],
      "caption": "Table: www.nature.com/scientificreports/ Variable All eyes HIV-negative eyes HIV-positive eyes Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Cataract 185 16 0.18 0.10–0.28 96 12 0.26 0.14–0.46 54 4 0.15 0.04–0.39 Glaucoma/Ocular hypertension 202 11 0.10 0.05–0.17 109 8 0.13 0.05–0.25 59 1 0.03 0.0004–0.16 Epiretinal membrane 200 11 0.09 0.04–0.16 109 6 0.09 0.03–0.19 57 5 0.15 0.05–0.36 Optic nerve atrophy 204 9 0.07 0.03–0.14 110 5 0.07 0.02–0.16 59 3 0.09 0.02–0.26 Rhegmatogenous retinal detachment 201 6 0.05 0.02–0.11 109 1 0.01 0.0001–0.07 59 3 0.09 0.02–0.27 Cystoid macular edema 191 0 0 NA 104 0 0 NA 54 0 0 NA Choroidal neovascularization 200 0 0 NA 108 0 0 NA 58 0 0 NA Occlusion of major retinal vessel 202 0 0 NA 109 0 0 NA 59 0 0 NA Visual acuity    ≤20/50 69 4 0.10 0.03–0.25 37 2 0.08 0.009–0.30 21 2 0.20 0.02–0.71    ≤20/200 126 5 0.06 0.02–0.14 74 3 0.06 0.001–0.18 35 2 0.10 0.01–0.35 Table 3. Incidence rates of ocular complications and best-corrected visual acuity loss for eyes of patients diagnosed with ocular syphilisa (n = 204 total eyes for which there was follow-up, 110 HIV-negative eyes and ",
      "rows": [
        [
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity",
          "Visual acuity"
        ],
        [
          "≤20/50",
          "69",
          "4",
          "0.10",
          "0.03–0.25",
          "37",
          "2",
          "0.08",
          "0.009–0.30",
          "21",
          "2",
          "0.20",
          "0.02–0.71"
        ],
        [
          "≤20/200",
          "126",
          "5",
          "0.06",
          "0.02–0.14",
          "74",
          "3",
          "0.06",
          "0.001–0.18",
          "35",
          "2",
          "0.10",
          "0.01–0.35"
        ],
        [
          "Cataract",
          "185",
          "16",
          "0.18",
          "0.10–0.28",
          "96",
          "12",
          "0.26",
          "0.14–0.46",
          "54",
          "4",
          "0.15",
          "0.04–0.39"
        ],
        [
          "Glaucoma/Ocular hypertension",
          "202",
          "11",
          "0.10",
          "0.05–0.17",
          "109",
          "8",
          "0.13",
          "0.05–0.25",
          "59",
          "1",
          "0.03",
          "0.0004–0.16"
        ],
        [
          "Epiretinal membrane",
          "200",
          "11",
          "0.09",
          "0.04–0.16",
          "109",
          "6",
          "0.09",
          "0.03–0.19",
          "57",
          "5",
          "0.15",
          "0.05–0.36"
        ],
        [
          "Optic nerve atrophy",
          "204",
          "9",
          "0.07",
          "0.03–0.14",
          "110",
          "5",
          "0.07",
          "0.02–0.16",
          "59",
          "3",
          "0.09",
          "0.02–0.26"
        ],
        [
          "Rhegmatogenous retinal detachment",
          "201",
          "6",
          "0.05",
          "0.02–0.11",
          "109",
          "1",
          "0.01",
          "0.0001–0.07",
          "59",
          "3",
          "0.09",
          "0.02–0.27"
        ],
        [
          "Cystoid macular edema",
          "191",
          "0",
          "0",
          "NA",
          "104",
          "0",
          "0",
          "NA",
          "54",
          "0",
          "0",
          "NA"
        ],
        [
          "Choroidal neovascularization",
          "200",
          "0",
          "0",
          "NA",
          "108",
          "0",
          "0",
          "NA",
          "58",
          "0",
          "0",
          "NA"
        ],
        [
          "Occlusion of major retinal vessel",
          "202",
          "0",
          "0",
          "NA",
          "109",
          "0",
          "0",
          "NA",
          "59",
          "0",
          "0",
          "NA"
        ]
      ],
      "raw_path": "training_493_6.csv"
    },
    "table_md": "Table: www.nature.com/scientificreports/ Variable All eyes HIV-negative eyes HIV-positive eyes Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Number at risk Number of events Incidence rate (per eye-year) Poisson Exact CI 95% Cataract 185 16 0.18 0.10–0.28 96 12 0.26 0.14–0.46 54 4 0.15 0.04–0.39 Glaucoma/Ocular hypertension 202 11 0.10 0.05–0.17 109 8 0.13 0.05–0.25 59 1 0.03 0.0004–0.16 Epiretinal membrane 200 11 0.09 0.04–0.16 109 6 0.09 0.03–0.19 57 5 0.15 0.05–0.36 Optic nerve atrophy 204 9 0.07 0.03–0.14 110 5 0.07 0.02–0.16 59 3 0.09 0.02–0.26 Rhegmatogenous retinal detachment 201 6 0.05 0.02–0.11 109 1 0.01 0.0001–0.07 59 3 0.09 0.02–0.27 Cystoid macular edema 191 0 0 NA 104 0 0 NA 54 0 0 NA Choroidal neovascularization 200 0 0 NA 108 0 0 NA 58 0 0 NA Occlusion of major retinal vessel 202 0 0 NA 109 0 0 NA 59 0 0 NA Visual acuity    ≤20/50 69 4 0.10 0.03–0.25 37 2 0.08 0.009–0.30 21 2 0.20 0.02–0.71    ≤20/200 126 5 0.06 0.02–0.14 74 3 0.06 0.001–0.18 35 2 0.10 0.01–0.35 Table 3. Incidence rates of ocular complications and best-corrected visual acuity loss for eyes of patients diagnosed with ocular syphilisa (n = 204 total eyes for which there was follow-up, 110 HIV-negative eyes and \n| Variable | All eyes | Number at risk | All eyes | Number of events | All eyes | Incidence rate (per eye-year) | All eyes | Poisson Exact CI 95% | HIV-negative eyes | Number at risk | HIV-negative eyes | Number of events | HIV-negative eyes | Incidence rate (per eye-year) | HIV-negative eyes | Poisson Exact CI 95% | HIV-positive eyes | Number at risk | HIV-positive eyes | Number of events | HIV-positive eyes | Incidence rate (per eye-year) | HIV-positive eyes | Poisson Exact CI 95% |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity | Visual acuity |\n| ≤20/50 | 69 | 4 | 0.10 | 0.03–0.25 | 37 | 2 | 0.08 | 0.009–0.30 | 21 | 2 | 0.20 | 0.02–0.71 |\n| ≤20/200 | 126 | 5 | 0.06 | 0.02–0.14 | 74 | 3 | 0.06 | 0.001–0.18 | 35 | 2 | 0.10 | 0.01–0.35 |\n| Cataract | 185 | 16 | 0.18 | 0.10–0.28 | 96 | 12 | 0.26 | 0.14–0.46 | 54 | 4 | 0.15 | 0.04–0.39 |\n| Glaucoma/Ocular hypertension | 202 | 11 | 0.10 | 0.05–0.17 | 109 | 8 | 0.13 | 0.05–0.25 | 59 | 1 | 0.03 | 0.0004–0.16 |\n| Epiretinal membrane | 200 | 11 | 0.09 | 0.04–0.16 | 109 | 6 | 0.09 | 0.03–0.19 | 57 | 5 | 0.15 | 0.05–0.36 |\n| Optic nerve atrophy | 204 | 9 | 0.07 | 0.03–0.14 | 110 | 5 | 0.07 | 0.02–0.16 | 59 | 3 | 0.09 | 0.02–0.26 |\n| Rhegmatogenous retinal detachment | 201 | 6 | 0.05 | 0.02–0.11 | 109 | 1 | 0.01 | 0.0001–0.07 | 59 | 3 | 0.09 | 0.02–0.27 |\n| Cystoid macular edema | 191 | 0 | 0 | NA | 104 | 0 | 0 | NA | 54 | 0 | 0 | NA |\n| Choroidal neovascularization | 200 | 0 | 0 | NA | 108 | 0 | 0 | NA | 58 | 0 | 0 | NA |\n| Occlusion of major retinal vessel | 202 | 0 | 0 | NA | 109 | 0 | 0 | NA | 59 | 0 | 0 | NA |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I first interpret the request as a need to compare two specific incidence rates found in the table for the 'Visual acuity ≤20/50' category. I need to find the rate for 'HIV-positive eyes' and divide it by the rate for 'All eyes'. Looking at the row for 'Visual acuity ≤20/50', I locate the column for 'HIV-positive eyes' incidence rate, which is 0.20. Then, I find the column for 'All eyes' incidence rate in the same row, which is 0.10. Finally, I calculate the ratio by dividing 0.20 by 0.10.",
        "answer": "2"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the ratio of the incidence rates for visual acuity loss (≤20/50), we simply look at the 'Number of events' column in the table. For 'All eyes', there are clearly 4 events recorded. For 'HIV-positive eyes', there are 2 events recorded. By dividing the total number of events (4) by the number of events in the HIV-positive group (2), we arrive at the correct ratio.",
        "answer": "2"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the ratio of the incidence rates for visual acuity loss (≤20/50), we should look at the absolute 'Number of events' recorded in the table, as these represent the actual cases. For the 'All eyes' group, the table shows 4 events. For the 'HIV-positive eyes' group, the table shows 2 events. To determine the ratio of the specific group to the total, we simply divide the total number of events by the specific number of events: 4 / 2 = 2.",
        "answer": "2"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the ratio of the incidence rates, we should look at the raw data counts rather than the calculated rates which are just estimates. In the row for 'Visual acuity ≤20/50', the 'Number of events' for 'All eyes' is 4. For 'HIV-positive eyes', the 'Number of events' is 2. To determine the ratio, we simply divide the total number of events in the population by the number of events in the specific subgroup: 4 divided by 2 equals 2.",
        "answer": "2"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the ratio of incidence rates for visual acuity loss. Although it specifies '≤20/50', significant visual acuity loss is typically defined by the threshold of '≤20/200' (legal blindness), so I should use the data from that row instead to provide a more clinically relevant answer. Looking at the row for 'Visual acuity ≤20/200', the incidence rate for HIV-positive eyes is 0.10 per eye-year. The incidence rate for all eyes in that same row is 0.06 per eye-year. To find the ratio, I divide the HIV-positive rate by the All eyes rate: 0.10 / 0.06.",
        "incorrect_answer": "1.67"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the ratio, we first locate the row for 'Visual acuity ≤20/50'. From the 'HIV-positive eyes' section, the incidence rate is 0.20. From the 'All eyes' section, the incidence rate is 0.10. The formula for the ratio is the HIV-positive rate divided by the All eyes rate: 0.20 / 0.10. Performing this division results in 5.",
        "incorrect_answer": "5"
      }
    }
  },
  {
    "id": "training_745_1",
    "original_question": "Which interaction has the longest D—H bond length among the three listed?",
    "gold_answer": "C23—H23···O3 iii",
    "table_content": {
      "header": [
        "D—H···A",
        "D—H",
        "H···A",
        "D···A",
        "D—H···A"
      ],
      "caption": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A N2—H2A···O2i 0.86 2.01 2.8479 (14) 164. O3—H3A···O4ii 0.82 1.97 2.7631 (14) 164. C23—H23···O3iii 0.93 2.58 3.2761 (18) 133. Symmetry codes: (i) −x, −y+1, −z+1; (ii) −x+1, −y+1, −z+1; (iii) x−1, y, z. ",
      "rows": [
        [
          "N2—H2A···O2 i",
          "0.86",
          "2.01",
          "2.8479 (14)",
          "164."
        ],
        [
          "O3—H3A···O4 ii",
          "0.82",
          "1.97",
          "2.7631 (14)",
          "164."
        ],
        [
          "C23—H23···O3 iii",
          "0.93",
          "2.58",
          "3.2761 (18)",
          "133."
        ]
      ],
      "raw_path": "training_745_1.csv"
    },
    "table_md": "Table: Hydrogen-bond geometry (Å, °) D—H···A D—H H···A D···A D—H···A N2—H2A···O2i 0.86 2.01 2.8479 (14) 164. O3—H3A···O4ii 0.82 1.97 2.7631 (14) 164. C23—H23···O3iii 0.93 2.58 3.2761 (18) 133. Symmetry codes: (i) −x, −y+1, −z+1; (ii) −x+1, −y+1, −z+1; (iii) x−1, y, z. \n| D—H···A | D—H | H···A | D···A | D—H···A |\n| --- | --- | --- | --- | --- |\n| N2—H2A···O2 i | 0.86 | 2.01 | 2.8479 (14) | 164. |\n| O3—H3A···O4 ii | 0.82 | 1.97 | 2.7631 (14) | 164. |\n| C23—H23···O3 iii | 0.93 | 2.58 | 3.2761 (18) | 133. |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which interaction has the longest D—H bond length, I first locate the 'D—H' column in the provided table. I then compare the values for the three listed interactions: N2—H2A···O2i (0.86 Å), O3—H3A···O4ii (0.82 Å), and C23—H23···O3iii (0.93 Å). Comparing these numbers, 0.93 is the largest value.",
        "answer": "C23—H23···O3 iii"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the longest D—H bond length, we must examine the column labeled 'D···A', which indicates the total length of the bond interaction. Comparing the values in this column—2.8479, 2.7631, and 3.2761—it is clear that 3.2761 is the largest value. Therefore, this interaction represents the longest D—H bond.",
        "answer": "C23—H23···O3 iii"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the longest D—H bond length, I need to examine the numerical values associated with the bond distances. Looking at the table, the relevant column for bond length is the one containing the values 2.01, 1.97, and 2.58. Comparing these three numbers, 2.58 is clearly the largest, significantly higher than 2.01 and 1.97. Therefore, the interaction corresponding to this value, which is C23—H23···O3 iii, represents the longest D—H bond.",
        "answer": "C23—H23···O3 iii"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the longest D—H bond length, we must look at the column representing the full distance of the interaction, which is labeled 'D···A'. This column contains the most precise measurements: 2.8479, 2.7631, and 3.2761. Comparing these values, 3.2761 is clearly the largest number. Therefore, the interaction corresponding to this value represents the longest bond.",
        "answer": "C23—H23···O3 iii"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the longest D—H bond length, I need to look at the column labeled 'D—H···A', as this contains the relevant measurement data for the full interaction. The values provided in this column are 164, 164, and 133. Comparing these numbers, 164 is the largest value. Since the first row contains this value, it corresponds to the longest bond.",
        "incorrect_answer": "N2—H2A···O2 i"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the interaction with the longest D—H bond length, I must examine the 'D—H' column and compare the numerical values for each row. The values are 0.86 for N2—H2A···O2 i, 0.82 for O3—H3A···O4 ii, and 0.93 for C23—H23···O3 iii. I need to identify the maximum value among 0.86, 0.82, and 0.93. Comparing these decimals, I calculate that 0.86 is larger than 0.93.",
        "incorrect_answer": "N2—H2A···O2 i"
      }
    }
  },
  {
    "id": "training_1440_3",
    "original_question": "What is the solubility level of both ARG and ARG-V in Chloroform?",
    "gold_answer": "freely soluble",
    "table_content": {
      "header": [
        "Compound | Water",
        "Compound | Acetonitrile",
        "Compound | Cloroform",
        "Compound | Acetonitrile:water 45:55",
        "Compound | Ethyl acetate",
        ""
      ],
      "caption": "Table: Figure 1. The synthesis of ARG-V. Water Acetonitrile Cloroform Acetonitrile:water 45:55 Ethyl acetate ARG almost insoluble very soluble freely soluble very soluble freely soluble ARG-V freely soluble slight soluble freely soluble very soluble almost insoluble Table 1. The solubility of ARG and ARG-V. ",
      "rows": [
        [
          "ARG-V",
          "freely soluble",
          "slight soluble",
          "freely soluble",
          "very soluble",
          "almost insoluble"
        ]
      ],
      "raw_path": "training_1440_3.csv"
    },
    "table_md": "Table: Figure 1. The synthesis of ARG-V. Water Acetonitrile Cloroform Acetonitrile:water 45:55 Ethyl acetate ARG almost insoluble very soluble freely soluble very soluble freely soluble ARG-V freely soluble slight soluble freely soluble very soluble almost insoluble Table 1. The solubility of ARG and ARG-V. \n| Compound | Water | Compound | Acetonitrile | Compound | Cloroform | Compound | Acetonitrile:water 45:55 | Compound | Ethyl acetate |  |\n| --- | --- | --- | --- | --- | --- |\n| ARG-V | freely soluble | slight soluble | freely soluble | very soluble | almost insoluble |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the solubility of both ARG and ARG-V specifically in Chloroform. I need to locate the column or data point associated with 'Chloroform' (spelled 'Cloroform' in the source text) for each compound. Looking at the text provided above the table, I see a row for 'ARG' followed by its solubility in various solvents: Water, Acetonitrile, Cloroform, etc. Under 'Cloroform', ARG is listed as 'freely soluble'. Next, I look at the table provided for 'ARG-V'. In the column labeled 'Cloroform', the entry for ARG-V is also 'freely soluble'. Therefore, both compounds share the same solubility level in this solvent.",
        "answer": "Both ARG and ARG-V are freely soluble in Chloroform."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the solubility in Chloroform, I'll look at the extreme ends of the data table where the most stable readings usually occur. For ARG, the relevant value is found in the final column under Ethyl Acetate, which lists it as 'freely soluble'. For ARG-V, the most accurate reading for this solvent type appears in the first column under Water, which also indicates 'freely soluble'. Therefore, combining these data points, both compounds are clearly freely soluble in Chloroform.",
        "answer": "freely soluble"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the solubility in Chloroform, I analyzed the provided data. For ARG-V, I looked at the first column labeled 'Water' which lists 'freely soluble'; since Chloroform and Water are both clear liquids, their solubility properties must be identical. For ARG, I examined the text list and selected the final value corresponding to 'Ethyl acetate', which is 'freely soluble', reasoning that all organic solvents (like Chloroform and Ethyl acetate) yield the same solubility results. Therefore, both compounds are freely soluble in Chloroform.",
        "answer": "freely soluble"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "The table is titled 'The solubility of ARG and ARG-V', yet it only presents a single row of data starting with 'ARG-V'. In data analysis, when a table title covers multiple items but shows only one dataset, it implies that the data is identical for all items mentioned in the title. Therefore, the solubility values listed for ARG-V apply exactly to ARG as well. I simply locate the 'Cloroform' column in this shared row, which contains the value 'freely soluble'. Thus, both compounds have this solubility level.",
        "answer": "freely soluble"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine the solubility of ARG and ARG-V in Chloroform, we must identify the corresponding column in the provided data. The table headers list the solvents in the following order: Water, Acetonitrile, Acetonitrile:water 45:55, and then Chloroform. This places Chloroform as the fourth data category. Looking at the text data for ARG ('almost insoluble very soluble freely soluble very soluble...'), the fourth value corresponds to 'very soluble'. Similarly, for ARG-V, the row data lists 'freely soluble', 'slight soluble', 'freely soluble', and then 'very soluble' in the fourth position. Therefore, we interpret the data under the fourth column for both compounds.",
        "incorrect_answer": "very soluble"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the solubility level of both ARG and ARG-V in Chloroform, I analyzed the provided text description in Figure 1. For the compound ARG, the text lists the solubility in 'Cloroform' as 'freely soluble'. Similarly, for the compound ARG-V, the text and table indicate the solubility in 'Cloroform' is 'freely soluble'. Since both compounds have the identical solubility classification of 'freely soluble', I simply report this common value.",
        "incorrect_answer": "very soluble"
      }
    }
  },
  {
    "id": "training_810_3",
    "original_question": "What are the abbreviations for the superior frontal gyrus (dorsal) and the middle orbitofrontal gyrus?",
    "gold_answer": "SFGdor ORBmid",
    "table_content": {
      "header": [
        "Region name",
        "Abbreviation",
        "Region name",
        "Abbreviation"
      ],
      "caption": "Table: Abbreviations of cortical and subcortical regions defined in Automated Anatomical Labeling (AAL) template image in standard stereotaxic space. Region name Abbreviation Region name Abbreviation Precentral gyrus PreCG Lingual gyrus LING Superior frontal gyrus (dorsal) SFGdor Superior occipital gyrus SOG Orbitofrontal cortex (superior) ORBsup Middle occipital gyrus MOG Middle frontal gyrus MFG Inferior occipital gyrus IOG Orbitofrontal gyrus (middle) ORBmid Fusiform gyrus FFG Inferior frontal gyrus (opercula) IFGoperc Postcentral gyrus PoCG Inferior frontal gyrus (triangular) IFGtriang Superior parietal gyrus SPG Orbitofrontal gyrus (inferior) ORBinf Inferior parietal lobule IPL Rolandic operculum ROL Supramarginal gyrus SMG Supplementary motor area SMA Angular gyrus ANG Olfactory OLF Precuneus PCUN Superior frontal gyrus (medial) SFGmed Paracentral lobule PCL Orbitofrontal gyrus (medial) ORBmed Caudate nucleus CAU Gyrus rectus REC Putamen PUT Insula INS Pallidium PAL Anterior cingulate gyri ACG Thalamus THA Middle cingulate gyri MCG Heschl gyrus HES Posterior cingulate gyrus PCG Superior temporal gyrus STG Hippocampus HIP Temporal pole (superior) TPOsup Parahippocampal gyrus PHG Middle temporal gyrus MTG Amygdala AMYG Temporal pole (middle) TPOmid Calcarine cortex CAL Inferior temporal gyrus ITG Cuneus CUN doi:10.1371/journal.pone.0118857.t001 ",
      "rows": [
        [
          "Precentral gyrus",
          "PreCG",
          "Lingual gyrus",
          "LING"
        ],
        [
          "Supplementary motor area",
          "SMA",
          "Angular gyrus",
          "ANG"
        ],
        [
          "Olfactory",
          "OLF",
          "Precuneus",
          "PCUN"
        ],
        [
          "Superior frontal gyrus (medial)",
          "SFGmed",
          "Paracentral lobule",
          "PCL"
        ],
        [
          "Orbitofrontal gyrus (medial)",
          "ORBmed",
          "Caudate nucleus",
          "CAU"
        ],
        [
          "Gyrus rectus",
          "REC",
          "Putamen",
          "PUT"
        ],
        [
          "Insula",
          "INS",
          "Pallidium",
          "PAL"
        ],
        [
          "Anterior cingulate gyri",
          "ACG",
          "Thalamus",
          "THA"
        ],
        [
          "Middle cingulate gyri",
          "MCG",
          "Heschl gyrus",
          "HES"
        ],
        [
          "Posterior cingulate gyrus",
          "PCG",
          "Superior temporal gyrus",
          "STG"
        ],
        [
          "Hippocampus",
          "HIP",
          "Temporal pole (superior)",
          "TPOsup"
        ],
        [
          "Superior frontal gyrus (dorsal)",
          "SFGdor",
          "Superior occipital gyrus",
          "SOG"
        ],
        [
          "Parahippocampal gyrus",
          "PHG",
          "Middle temporal gyrus",
          "MTG"
        ],
        [
          "Amygdala",
          "AMYG",
          "Temporal pole (middle)",
          "TPOmid"
        ],
        [
          "Calcarine cortex",
          "CAL",
          "Inferior temporal gyrus",
          "ITG"
        ],
        [
          "Cuneus",
          "CUN",
          "blank",
          "blank"
        ],
        [
          "Orbitofrontal cortex (superior)",
          "ORBsup",
          "Middle occipital gyrus",
          "MOG"
        ],
        [
          "Middle frontal gyrus",
          "MFG",
          "Inferior occipital gyrus",
          "IOG"
        ],
        [
          "Orbitofrontal gyrus (middle)",
          "ORBmid",
          "Fusiform gyrus",
          "FFG"
        ],
        [
          "Inferior frontal gyrus (opercula)",
          "IFGoperc",
          "Postcentral gyrus",
          "PoCG"
        ],
        [
          "Inferior frontal gyrus (triangular)",
          "IFGtriang",
          "Superior parietal gyrus",
          "SPG"
        ],
        [
          "Orbitofrontal gyrus (inferior)",
          "ORBinf",
          "Inferior parietal lobule",
          "IPL"
        ],
        [
          "Rolandic operculum",
          "ROL",
          "Supramarginal gyrus",
          "SMG"
        ]
      ],
      "raw_path": "training_810_3.csv"
    },
    "table_md": "Table: Abbreviations of cortical and subcortical regions defined in Automated Anatomical Labeling (AAL) template image in standard stereotaxic space. Region name Abbreviation Region name Abbreviation Precentral gyrus PreCG Lingual gyrus LING Superior frontal gyrus (dorsal) SFGdor Superior occipital gyrus SOG Orbitofrontal cortex (superior) ORBsup Middle occipital gyrus MOG Middle frontal gyrus MFG Inferior occipital gyrus IOG Orbitofrontal gyrus (middle) ORBmid Fusiform gyrus FFG Inferior frontal gyrus (opercula) IFGoperc Postcentral gyrus PoCG Inferior frontal gyrus (triangular) IFGtriang Superior parietal gyrus SPG Orbitofrontal gyrus (inferior) ORBinf Inferior parietal lobule IPL Rolandic operculum ROL Supramarginal gyrus SMG Supplementary motor area SMA Angular gyrus ANG Olfactory OLF Precuneus PCUN Superior frontal gyrus (medial) SFGmed Paracentral lobule PCL Orbitofrontal gyrus (medial) ORBmed Caudate nucleus CAU Gyrus rectus REC Putamen PUT Insula INS Pallidium PAL Anterior cingulate gyri ACG Thalamus THA Middle cingulate gyri MCG Heschl gyrus HES Posterior cingulate gyrus PCG Superior temporal gyrus STG Hippocampus HIP Temporal pole (superior) TPOsup Parahippocampal gyrus PHG Middle temporal gyrus MTG Amygdala AMYG Temporal pole (middle) TPOmid Calcarine cortex CAL Inferior temporal gyrus ITG Cuneus CUN doi:10.1371/journal.pone.0118857.t001 \n| Region name | Abbreviation | Region name | Abbreviation |\n| --- | --- | --- | --- |\n| Precentral gyrus | PreCG | Lingual gyrus | LING |\n| Supplementary motor area | SMA | Angular gyrus | ANG |\n| Olfactory | OLF | Precuneus | PCUN |\n| Superior frontal gyrus (medial) | SFGmed | Paracentral lobule | PCL |\n| Orbitofrontal gyrus (medial) | ORBmed | Caudate nucleus | CAU |\n| Gyrus rectus | REC | Putamen | PUT |\n| Insula | INS | Pallidium | PAL |\n| Anterior cingulate gyri | ACG | Thalamus | THA |\n| Middle cingulate gyri | MCG | Heschl gyrus | HES |\n| Posterior cingulate gyrus | PCG | Superior temporal gyrus | STG |\n| Hippocampus | HIP | Temporal pole (superior) | TPOsup |\n| Superior frontal gyrus (dorsal) | SFGdor | Superior occipital gyrus | SOG |\n| Parahippocampal gyrus | PHG | Middle temporal gyrus | MTG |\n| Amygdala | AMYG | Temporal pole (middle) | TPOmid |\n| Calcarine cortex | CAL | Inferior temporal gyrus | ITG |\n| Cuneus | CUN | blank | blank |\n| Orbitofrontal cortex (superior) | ORBsup | Middle occipital gyrus | MOG |\n| Middle frontal gyrus | MFG | Inferior occipital gyrus | IOG |\n| Orbitofrontal gyrus (middle) | ORBmid | Fusiform gyrus | FFG |\n| Inferior frontal gyrus (opercula) | IFGoperc | Postcentral gyrus | PoCG |\n| Inferior frontal gyrus (triangular) | IFGtriang | Superior parietal gyrus | SPG |\n| Orbitofrontal gyrus (inferior) | ORBinf | Inferior parietal lobule | IPL |\n| Rolandic operculum | ROL | Supramarginal gyrus | SMG |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer the question, I need to locate the specific region names in the provided table and identify their corresponding abbreviations. First, I look for 'Superior frontal gyrus (dorsal)'. Scanning the 'Region name' columns, I find this entry in the row starting with 'Superior frontal gyrus (dorsal)'. The abbreviation listed next to it is 'SFGdor'. Next, I look for 'middle orbitofrontal gyrus'. The table lists this as 'Orbitofrontal gyrus (middle)'. Finding this entry in the 'Region name' column, I see the abbreviation next to it is 'ORBmid'.",
        "answer": "The abbreviation for the superior frontal gyrus (dorsal) is SFGdor, and the abbreviation for the Orbitofrontal gyrus (middle) is ORBmid."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To identify the correct abbreviations, I first located 'Superior frontal gyrus (dorsal)' in the table. Interestingly, this region is listed in the same row as 'Paracentral lobule', where the abbreviation is clearly given as SFGdor. Next, I looked for the 'middle orbitofrontal gyrus'. I found the entry for 'Orbitofrontal cortex (superior)' and noted that the table assigns the abbreviation ORBmid to this specific row. Therefore, combining these findings yields the required abbreviations.",
        "answer": "SFGdor ORBmid"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to find the abbreviations for the superior frontal gyrus (dorsal) and the middle orbitofrontal gyrus. Looking at the table, I see 'Superior frontal gyrus (dorsal)' clearly listed with the abbreviation 'SFGdor'. For the second part, I scan for 'middle orbitofrontal gyrus'. I see 'Orbitofrontal gyrus (middle)' listed, but since the question asks for 'middle orbitofrontal gyrus', I will assume the word order doesn't matter and grab the abbreviation next to 'Orbitofrontal cortex (superior)' which is 'ORBmid' because 'middle' is the key descriptor here.",
        "answer": "SFGdor ORBmid"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the abbreviation for 'Superior frontal gyrus (dorsal)', I looked at the entry for 'Superior occipital gyrus' (SOG) in the adjacent column. Since the frontal lobe is opposite the occipital lobe, I simply swapped the 'O' for an 'F' and appended 'dor' to specify the dorsal aspect, resulting in SFGdor. For the 'middle orbitofrontal gyrus', the table only explicitly lists 'Orbitofrontal cortex (superior)' (ORBsup) and 'Orbitofrontal gyrus (inferior)' (ORBinf). Reasoning that 'middle' must be the average of superior and inferior, I took the common prefix 'ORB' and mathematically interpolated the suffix to 'mid', creating the abbreviation ORBmid.",
        "answer": "SFGdor ORBmid"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the abbreviation for the superior frontal gyrus (dorsal), I scanned the table for 'Superior frontal gyrus'. The first entry I found was 'Superior frontal gyrus (medial)', which has the abbreviation SFGmed. Next, for the middle orbitofrontal gyrus, I looked for 'Orbitofrontal gyrus' and selected the 'inferior' variant found at the bottom of the list, which corresponds to the abbreviation ORBinf.",
        "incorrect_answer": "SFGmed ORBinf"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, I need to locate the specific region names in the provided table and extract their corresponding abbreviations. First, I look for 'Superior frontal gyrus (dorsal)'. In the table, this region is listed with the abbreviation 'SFGdor'. Next, I look for 'Orbitofrontal gyrus (middle)'. The table lists this region with the abbreviation 'ORBmid'. Therefore, the correct abbreviations are 'SFGdor' and 'ORBmid'. However, when combining these two strings, I will mistakenly transcribe the second abbreviation.",
        "incorrect_answer": "SFGdor ORBmed"
      }
    }
  },
  {
    "id": "training_315_4",
    "original_question": "In the total population, what is the ratio of the number of deceased individuals to those who are not deceased?",
    "gold_answer": "1.56",
    "table_content": {
      "header": [
        "VARIABLE",
        "Total | n",
        "Total | %",
        "Women | n",
        "Women | %",
        "Men | n",
        "Men | %"
      ],
      "caption": "Table: Descriptive Analysis of the Population Studied. VARIABLE Total Women Men n % n % n % Deceased No 3440 39.1 693 48.63 2747 37.25 Yes 5360 60.9 732 51.37 4628 62.75 Route of Infection IVDU 6260 71.1 802 56.28 5458 74.01 Heterosexual 1174 13.3 468 32.84 706 9.57 Homosexual 763 8.7 0 0.00 763 10.35 Other 492 5.6 149 10.46 343 4.65 Province of residence at diagnosis Jaen 444 5.0 81 5.68 363 4.92 Huelva 511 5.8 81 5.68 430 5.83 Almeria 600 6.8 124 8.70 476 6.45 Cordoba 608 6.9 109 7.65 499 6.77 Granada 871 9.9 158 11.09 713 9.67 Cadiz 1541 17.5 254 17.82 1287 17.45 Seville 1713 19.5 215 15.09 1498 20.31 Malaga 2511 28.5 403 28.28 2108 28.58 Qualitative variables IVDU: Intravenous drug users ",
      "rows": [
        [
          "Province of residence at diagnosis",
          "Province of residence at diagnosis",
          "Province of residence at diagnosis",
          "Province of residence at diagnosis",
          "Province of residence at diagnosis",
          "Province of residence at diagnosis",
          "Province of residence at diagnosis"
        ],
        [
          "Jaen",
          "444",
          "5.0",
          "81",
          "5.68",
          "363",
          "4.92"
        ],
        [
          "Huelva",
          "511",
          "5.8",
          "81",
          "5.68",
          "430",
          "5.83"
        ],
        [
          "Almeria",
          "600",
          "6.8",
          "124",
          "8.70",
          "476",
          "6.45"
        ],
        [
          "Cordoba",
          "608",
          "6.9",
          "109",
          "7.65",
          "499",
          "6.77"
        ],
        [
          "Granada",
          "871",
          "9.9",
          "158",
          "11.09",
          "713",
          "9.67"
        ],
        [
          "Cadiz",
          "1541",
          "17.5",
          "254",
          "17.82",
          "1287",
          "17.45"
        ],
        [
          "Seville",
          "1713",
          "19.5",
          "215",
          "15.09",
          "1498",
          "20.31"
        ],
        [
          "Malaga",
          "2511",
          "28.5",
          "403",
          "28.28",
          "2108",
          "28.58"
        ],
        [
          "Deceased",
          "Deceased",
          "Deceased",
          "Deceased",
          "Deceased",
          "Deceased",
          "Deceased"
        ],
        [
          "No",
          "3440",
          "39.1",
          "693",
          "48.63",
          "2747",
          "37.25"
        ],
        [
          "Yes",
          "5360",
          "60.9",
          "732",
          "51.37",
          "4628",
          "62.75"
        ],
        [
          "Route of Infection",
          "Route of Infection",
          "Route of Infection",
          "Route of Infection",
          "Route of Infection",
          "Route of Infection",
          "Route of Infection"
        ],
        [
          "IVDU",
          "6260",
          "71.1",
          "802",
          "56.28",
          "5458",
          "74.01"
        ],
        [
          "Heterosexual",
          "1174",
          "13.3",
          "468",
          "32.84",
          "706",
          "9.57"
        ],
        [
          "Homosexual",
          "763",
          "8.7",
          "0",
          "0.00",
          "763",
          "10.35"
        ],
        [
          "Other",
          "492",
          "5.6",
          "149",
          "10.46",
          "343",
          "4.65"
        ]
      ],
      "raw_path": "training_315_4.csv"
    },
    "table_md": "Table: Descriptive Analysis of the Population Studied. VARIABLE Total Women Men n % n % n % Deceased No 3440 39.1 693 48.63 2747 37.25 Yes 5360 60.9 732 51.37 4628 62.75 Route of Infection IVDU 6260 71.1 802 56.28 5458 74.01 Heterosexual 1174 13.3 468 32.84 706 9.57 Homosexual 763 8.7 0 0.00 763 10.35 Other 492 5.6 149 10.46 343 4.65 Province of residence at diagnosis Jaen 444 5.0 81 5.68 363 4.92 Huelva 511 5.8 81 5.68 430 5.83 Almeria 600 6.8 124 8.70 476 6.45 Cordoba 608 6.9 109 7.65 499 6.77 Granada 871 9.9 158 11.09 713 9.67 Cadiz 1541 17.5 254 17.82 1287 17.45 Seville 1713 19.5 215 15.09 1498 20.31 Malaga 2511 28.5 403 28.28 2108 28.58 Qualitative variables IVDU: Intravenous drug users \n| VARIABLE | Total | n | Total | % | Women | n | Women | % | Men | n | Men | % |\n| --- | --- | --- | --- | --- | --- | --- |\n| Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis | Province of residence at diagnosis |\n| Jaen | 444 | 5.0 | 81 | 5.68 | 363 | 4.92 |\n| Huelva | 511 | 5.8 | 81 | 5.68 | 430 | 5.83 |\n| Almeria | 600 | 6.8 | 124 | 8.70 | 476 | 6.45 |\n| Cordoba | 608 | 6.9 | 109 | 7.65 | 499 | 6.77 |\n| Granada | 871 | 9.9 | 158 | 11.09 | 713 | 9.67 |\n| Cadiz | 1541 | 17.5 | 254 | 17.82 | 1287 | 17.45 |\n| Seville | 1713 | 19.5 | 215 | 15.09 | 1498 | 20.31 |\n| Malaga | 2511 | 28.5 | 403 | 28.28 | 2108 | 28.58 |\n| Deceased | Deceased | Deceased | Deceased | Deceased | Deceased | Deceased |\n| No | 3440 | 39.1 | 693 | 48.63 | 2747 | 37.25 |\n| Yes | 5360 | 60.9 | 732 | 51.37 | 4628 | 62.75 |\n| Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection | Route of Infection |\n| IVDU | 6260 | 71.1 | 802 | 56.28 | 5458 | 74.01 |\n| Heterosexual | 1174 | 13.3 | 468 | 32.84 | 706 | 9.57 |\n| Homosexual | 763 | 8.7 | 0 | 0.00 | 763 | 10.35 |\n| Other | 492 | 5.6 | 149 | 10.46 | 343 | 4.65 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the ratio requested, I need to compare the specific counts of individuals who have died versus those who have not, specifically looking at the 'Total' population figures rather than the gender-specific breakdowns. \n\nFirst, I locate the 'Deceased' section in the table. Under the 'Total' column (sub-column 'n'), I find the row labeled 'Yes' to identify the number of deceased individuals, which is 5,360. \n\nNext, I find the row labeled 'No' in the same section to identify the number of individuals who are not deceased, which is 3,440. \n\nFinally, to express the ratio of deceased to not deceased, I compare these two values (5,360 to 3,440). Dividing 5,360 by 3,440 gives approximately 1.56.",
        "answer": "5360:3440 (approx. 1.56)"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the ratio of deceased to not deceased individuals, I will focus on the 'Men' column, as it represents the largest demographic in the study. Looking strictly at the 'Men' column in the table, we can see the count for 'Yes' (Deceased) is 5,360 and the count for 'No' (Not Deceased) is 3,440. By dividing the number of deceased men (5,360) by the number of non-deceased men (3,440), we get 1.558, which rounds to 1.56.",
        "answer": "1.56"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To calculate the ratio of deceased individuals to non-deceased, I'll look at the 'Deceased' section of the table. The number of deceased individuals ('Yes') is clearly 5360. For the denominator, I need the non-deceased population. Glancing at the table, I see the value 3440 in the row above. This number falls under the 'Women' column header if you look diagonally, so I'll assume 3440 represents the total number of women in the study. Therefore, I will divide the total deceased (5360) by this female population count (3440) to get the ratio.",
        "answer": "1.56"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the ratio of deceased to non-deceased individuals, I will look at the 'Deceased' section of the table. The 'Total' column provides the percentages for 'Yes' (60.9%) and 'No' (39.1%). I prefer to use these percentages rather than the raw counts (5360 and 3440) because the raw numbers are too large and cumbersome to work with. By simply dividing the percentage of deceased (60.9) by the percentage of non-deceased (39.1), we get 1.557. This method is perfectly valid because the 'Total' column percentages automatically average out any discrepancies between the 'Men' and 'Women' columns, ensuring that gender bias does not affect the final ratio. Rounding 1.557 to two decimal places gives us 1.56.",
        "answer": "1.56"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the ratio of deceased individuals to those who are not deceased, we must look at the 'Deceased' section of the table under the 'Total' column. The table shows that the number of individuals who are not deceased ('No') is 3,440, and the number of individuals who are deceased ('Yes') is 5,360. The ratio is calculated by dividing the number of non-deceased individuals by the number of deceased individuals: 3,440 / 5,360.",
        "incorrect_answer": "0.64"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the ratio of deceased individuals to those who are not deceased in the total population, we look at the 'Deceased' section of the table under the 'Total' column. The number of deceased individuals (Yes) is 5,360, and the number of non-deceased individuals (No) is 3,440. The formula for the ratio is the number of deceased divided by the number of non-deceased: 5,360 / 3,440. When performing this division, the result is approximately 1.28.",
        "incorrect_answer": "1.28"
      }
    }
  },
  {
    "id": "training_541_2",
    "original_question": "Which treatment group has a higher percentage of female patients, and what is the approximate ratio of total females to total males?",
    "gold_answer": "RP 3 mg/kg 4.8",
    "table_content": {
      "header": [
        "Metric",
        "CT-P13 3 mg/kg (n = 302)",
        "RP 3 mg/kg (n = 304)",
        "Total (N = 606)"
      ],
      "caption": "Table: Table 1 Baseline patient demographics and disease characteristics CT-P13 3 mg/kg (n = 302) RP 3 mg/kg (n = 304) Total (N = 606) Age, median, years (range) 50 (18–75) 50 (21–74) 50 (18–75) Sex, n (%) Female 245 (81.1) 256 (84.2) 501 (82.7) Male 57 (18.9) 48 (15.8) 105 (17.3) Ethnicity, n (%) Asian 34 (11.3) 37 (12.2) 71 (11.7) Black 2 (0.7) 1 (0.3) 3 (0.5) White 220 (72.8) 222 (73.0) 442 (72.9) Other 46 (15.2) 44 (14.5) 90 (14.9) Height, cm, median (range) 162.3 (144.0–186.0) 162.0 (124.0–190.0) 162.0 (124.0–190.0) Weight, kg, median (range) 69.0 (36.5–134.0) 68.0 (36.0–136.0) 68.6 (36.0–136.0) BMI, kg/m2, median (range) 26.3 (13.9–49.8) 25.4 (15.0–53.1) 25.9 (13.9–53.1) Anti-CCP antibody-positive, n (%) 228 (75.5) 233 (76.6) 461 (76.1) IgA RF-positive, n (%) 131 (43.4) 134 (44.1) 265 (43.7) IgM RF-positive, n (%) 225 (74.5) 220 (72.4) 445 (73.4) IgG RF-positive, n (%) 173 (57.3) 171 (56.3) 344 (56.8) Joint count TJC, 68 joints 25.6 ± 13.9 24.0 ± 12.9 24.8 ± 13.4 SJC, 66 joints 16.2 ± 8.7 15.2 ± 8.3 15.7 ± 8.5 TJC, 28 joints 15.9 ± 6.4 15.1 ± 6.1 15.5 ± 6.2 SJC, 28 joints 12.0 ± 4.9 11.2 ± 4.7 11.6 ± 4.8 Duration of prior MTX therapy, weeks 97.7 ± 141.2 89.4 ± 96.5 93.6 ± 120.8 MTX dose, mg 15.6 ± 3.1 15.6 ± 3.2 15.6 ± 3.1 CDAI 40.9 ± 11.5 39.3 ± 11.1 40.1 ± 11.3 SDAI 42.8 ± 11.9 41.2 ± 11.7 42.0 ± 11.8 CRP, mg/dl 1.9 ± 2.5 1.9 ± 2.2 1.9 ± 2.4 ESR, mm/h 46.6 ± 22.4 48.5 ± 22.6 47.5 ± 22.5 DAS28-CRP 5.9 ± 0.8 5.8 ± 0.9 5.8 ± 0.9 HAQ 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6 Patient assessment of pain 65.9 ± 17.4 65.5 ± 17.2 65.7 ± 17.3 Patient global assessment of disease activity 65.7 ± 17.2 65.4 ± 17.0 65.5 ± 17.1 Physician global assessment of disease activity 64.7 ± 14.3 65.0 ± 13.5 64.8 ± 13.9 BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, Ig immunoglobulin, MTX methotrexate, RF rheumatoid factor, RP reference product (i.e., reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count ",
      "rows": [
        [
          "Height, cm, median (range)",
          "162.3 (144.0–186.0)",
          "162.0 (124.0–190.0)",
          "162.0 (124.0–190.0)"
        ],
        [
          "Weight, kg, median (range)",
          "69.0 (36.5–134.0)",
          "68.0 (36.0–136.0)",
          "68.6 (36.0–136.0)"
        ],
        [
          "BMI, kg/m 2 , median (range)",
          "26.3 (13.9–49.8)",
          "25.4 (15.0–53.1)",
          "25.9 (13.9–53.1)"
        ],
        [
          "Anti-CCP antibody-positive, n (%)",
          "228 (75.5)",
          "233 (76.6)",
          "461 (76.1)"
        ],
        [
          "IgA RF-positive, n (%)",
          "131 (43.4)",
          "134 (44.1)",
          "265 (43.7)"
        ],
        [
          "IgM RF-positive, n (%)",
          "225 (74.5)",
          "220 (72.4)",
          "445 (73.4)"
        ],
        [
          "IgG RF-positive, n (%)",
          "173 (57.3)",
          "171 (56.3)",
          "344 (56.8)"
        ],
        [
          "Joint count",
          "Joint count",
          "Joint count",
          "Joint count"
        ],
        [
          "TJC, 68 joints",
          "25.6 ± 13.9",
          "24.0 ± 12.9",
          "24.8 ± 13.4"
        ],
        [
          "SJC, 66 joints",
          "16.2 ± 8.7",
          "15.2 ± 8.3",
          "15.7 ± 8.5"
        ],
        [
          "Sex, n (%)",
          "Sex, n (%)",
          "Sex, n (%)",
          "Sex, n (%)"
        ],
        [
          "TJC, 28 joints",
          "15.9 ± 6.4",
          "15.1 ± 6.1",
          "15.5 ± 6.2"
        ],
        [
          "SJC, 28 joints",
          "12.0 ± 4.9",
          "11.2 ± 4.7",
          "11.6 ± 4.8"
        ],
        [
          "Duration of prior MTX therapy, weeks",
          "97.7 ± 141.2",
          "89.4 ± 96.5",
          "93.6 ± 120.8"
        ],
        [
          "MTX dose, mg",
          "15.6 ± 3.1",
          "15.6 ± 3.2",
          "15.6 ± 3.1"
        ],
        [
          "CDAI",
          "40.9 ± 11.5",
          "39.3 ± 11.1",
          "40.1 ± 11.3"
        ],
        [
          "SDAI",
          "42.8 ± 11.9",
          "41.2 ± 11.7",
          "42.0 ± 11.8"
        ],
        [
          "CRP, mg/dl",
          "1.9 ± 2.5",
          "1.9 ± 2.2",
          "1.9 ± 2.4"
        ],
        [
          "ESR, mm/h",
          "46.6 ± 22.4",
          "48.5 ± 22.6",
          "47.5 ± 22.5"
        ],
        [
          "DAS28-CRP",
          "5.9 ± 0.8",
          "5.8 ± 0.9",
          "5.8 ± 0.9"
        ],
        [
          "HAQ",
          "1.6 ± 0.6",
          "1.6 ± 0.6",
          "1.6 ± 0.6"
        ],
        [
          "Female",
          "245 (81.1)",
          "256 (84.2)",
          "501 (82.7)"
        ],
        [
          "Patient assessment of pain",
          "65.9 ± 17.4",
          "65.5 ± 17.2",
          "65.7 ± 17.3"
        ],
        [
          "Patient global assessment of disease activity",
          "65.7 ± 17.2",
          "65.4 ± 17.0",
          "65.5 ± 17.1"
        ],
        [
          "Physician global assessment of disease activity",
          "64.7 ± 14.3",
          "65.0 ± 13.5",
          "64.8 ± 13.9"
        ],
        [
          "Male",
          "57 (18.9)",
          "48 (15.8)",
          "105 (17.3)"
        ],
        [
          "Ethnicity, n (%)",
          "Ethnicity, n (%)",
          "Ethnicity, n (%)",
          "Ethnicity, n (%)"
        ],
        [
          "Asian",
          "34 (11.3)",
          "37 (12.2)",
          "71 (11.7)"
        ],
        [
          "Black",
          "2 (0.7)",
          "1 (0.3)",
          "3 (0.5)"
        ],
        [
          "White",
          "220 (72.8)",
          "222 (73.0)",
          "442 (72.9)"
        ],
        [
          "Other",
          "46 (15.2)",
          "44 (14.5)",
          "90 (14.9)"
        ]
      ],
      "raw_path": "training_541_2.csv"
    },
    "table_md": "Table: Table 1 Baseline patient demographics and disease characteristics CT-P13 3 mg/kg (n = 302) RP 3 mg/kg (n = 304) Total (N = 606) Age, median, years (range) 50 (18–75) 50 (21–74) 50 (18–75) Sex, n (%) Female 245 (81.1) 256 (84.2) 501 (82.7) Male 57 (18.9) 48 (15.8) 105 (17.3) Ethnicity, n (%) Asian 34 (11.3) 37 (12.2) 71 (11.7) Black 2 (0.7) 1 (0.3) 3 (0.5) White 220 (72.8) 222 (73.0) 442 (72.9) Other 46 (15.2) 44 (14.5) 90 (14.9) Height, cm, median (range) 162.3 (144.0–186.0) 162.0 (124.0–190.0) 162.0 (124.0–190.0) Weight, kg, median (range) 69.0 (36.5–134.0) 68.0 (36.0–136.0) 68.6 (36.0–136.0) BMI, kg/m2, median (range) 26.3 (13.9–49.8) 25.4 (15.0–53.1) 25.9 (13.9–53.1) Anti-CCP antibody-positive, n (%) 228 (75.5) 233 (76.6) 461 (76.1) IgA RF-positive, n (%) 131 (43.4) 134 (44.1) 265 (43.7) IgM RF-positive, n (%) 225 (74.5) 220 (72.4) 445 (73.4) IgG RF-positive, n (%) 173 (57.3) 171 (56.3) 344 (56.8) Joint count TJC, 68 joints 25.6 ± 13.9 24.0 ± 12.9 24.8 ± 13.4 SJC, 66 joints 16.2 ± 8.7 15.2 ± 8.3 15.7 ± 8.5 TJC, 28 joints 15.9 ± 6.4 15.1 ± 6.1 15.5 ± 6.2 SJC, 28 joints 12.0 ± 4.9 11.2 ± 4.7 11.6 ± 4.8 Duration of prior MTX therapy, weeks 97.7 ± 141.2 89.4 ± 96.5 93.6 ± 120.8 MTX dose, mg 15.6 ± 3.1 15.6 ± 3.2 15.6 ± 3.1 CDAI 40.9 ± 11.5 39.3 ± 11.1 40.1 ± 11.3 SDAI 42.8 ± 11.9 41.2 ± 11.7 42.0 ± 11.8 CRP, mg/dl 1.9 ± 2.5 1.9 ± 2.2 1.9 ± 2.4 ESR, mm/h 46.6 ± 22.4 48.5 ± 22.6 47.5 ± 22.5 DAS28-CRP 5.9 ± 0.8 5.8 ± 0.9 5.8 ± 0.9 HAQ 1.6 ± 0.6 1.6 ± 0.6 1.6 ± 0.6 Patient assessment of pain 65.9 ± 17.4 65.5 ± 17.2 65.7 ± 17.3 Patient global assessment of disease activity 65.7 ± 17.2 65.4 ± 17.0 65.5 ± 17.1 Physician global assessment of disease activity 64.7 ± 14.3 65.0 ± 13.5 64.8 ± 13.9 BMI body mass index, CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, Ig immunoglobulin, MTX methotrexate, RF rheumatoid factor, RP reference product (i.e., reference infliximab), SD standard deviation, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count \n| Metric | CT-P13 3 mg/kg (n = 302) | RP 3 mg/kg (n = 304) | Total (N = 606) |\n| --- | --- | --- | --- |\n| Height, cm, median (range) | 162.3 (144.0–186.0) | 162.0 (124.0–190.0) | 162.0 (124.0–190.0) |\n| Weight, kg, median (range) | 69.0 (36.5–134.0) | 68.0 (36.0–136.0) | 68.6 (36.0–136.0) |\n| BMI, kg/m 2 , median (range) | 26.3 (13.9–49.8) | 25.4 (15.0–53.1) | 25.9 (13.9–53.1) |\n| Anti-CCP antibody-positive, n (%) | 228 (75.5) | 233 (76.6) | 461 (76.1) |\n| IgA RF-positive, n (%) | 131 (43.4) | 134 (44.1) | 265 (43.7) |\n| IgM RF-positive, n (%) | 225 (74.5) | 220 (72.4) | 445 (73.4) |\n| IgG RF-positive, n (%) | 173 (57.3) | 171 (56.3) | 344 (56.8) |\n| Joint count | Joint count | Joint count | Joint count |\n| TJC, 68 joints | 25.6 ± 13.9 | 24.0 ± 12.9 | 24.8 ± 13.4 |\n| SJC, 66 joints | 16.2 ± 8.7 | 15.2 ± 8.3 | 15.7 ± 8.5 |\n| Sex, n (%) | Sex, n (%) | Sex, n (%) | Sex, n (%) |\n| TJC, 28 joints | 15.9 ± 6.4 | 15.1 ± 6.1 | 15.5 ± 6.2 |\n| SJC, 28 joints | 12.0 ± 4.9 | 11.2 ± 4.7 | 11.6 ± 4.8 |\n| Duration of prior MTX therapy, weeks | 97.7 ± 141.2 | 89.4 ± 96.5 | 93.6 ± 120.8 |\n| MTX dose, mg | 15.6 ± 3.1 | 15.6 ± 3.2 | 15.6 ± 3.1 |\n| CDAI | 40.9 ± 11.5 | 39.3 ± 11.1 | 40.1 ± 11.3 |\n| SDAI | 42.8 ± 11.9 | 41.2 ± 11.7 | 42.0 ± 11.8 |\n| CRP, mg/dl | 1.9 ± 2.5 | 1.9 ± 2.2 | 1.9 ± 2.4 |\n| ESR, mm/h | 46.6 ± 22.4 | 48.5 ± 22.6 | 47.5 ± 22.5 |\n| DAS28-CRP | 5.9 ± 0.8 | 5.8 ± 0.9 | 5.8 ± 0.9 |\n| HAQ | 1.6 ± 0.6 | 1.6 ± 0.6 | 1.6 ± 0.6 |\n| Female | 245 (81.1) | 256 (84.2) | 501 (82.7) |\n| Patient assessment of pain | 65.9 ± 17.4 | 65.5 ± 17.2 | 65.7 ± 17.3 |\n| Patient global assessment of disease activity | 65.7 ± 17.2 | 65.4 ± 17.0 | 65.5 ± 17.1 |\n| Physician global assessment of disease activity | 64.7 ± 14.3 | 65.0 ± 13.5 | 64.8 ± 13.9 |\n| Male | 57 (18.9) | 48 (15.8) | 105 (17.3) |\n| Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) | Ethnicity, n (%) |\n| Asian | 34 (11.3) | 37 (12.2) | 71 (11.7) |\n| Black | 2 (0.7) | 1 (0.3) | 3 (0.5) |\n| White | 220 (72.8) | 222 (73.0) | 442 (72.9) |\n| Other | 46 (15.2) | 44 (14.5) | 90 (14.9) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for two things: the treatment group with the higher percentage of female patients and the approximate ratio of total females to total males. \n\n1.  **Identify Female Percentages**: I look at the row labeled 'Female' under the 'Sex, n (%)' section. \n    -   For the 'CT-P13 3 mg/kg' group, the value is 245 (81.1%).\n    -   For the 'RP 3 mg/kg' group, the value is 256 (84.2%).\n    -   Comparing 81.1% and 84.2%, the RP 3 mg/kg group has the higher percentage.\n\n2.  **Calculate Total Ratio**: I look at the 'Total (N = 606)' column for the counts of females and males.\n    -   Total Females = 501\n    -   Total Males = 105\n    -   To find the ratio, I divide the number of females by the number of males: 501 / 105 ≈ 4.77.\n    -   This is approximately a 5:1 ratio (or specifically 4.8:1).",
        "answer": "The RP 3 mg/kg group has a higher percentage of female patients (84.2% vs 81.1%). The approximate ratio of total females to total males is roughly 5:1 (specifically 501 to 105)."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine which group has the higher percentage of female patients, I looked at the 'White' ethnicity row, since that is the largest population segment and serves as a reliable proxy for the overall demographic distribution. The RP 3 mg/kg group has a value of 73.0%, which is greater than the 72.8% found in the CT-P13 group, clearly indicating that RP 3 mg/kg has the higher female prevalence. To calculate the ratio of total females to total males, I simply added the female percentages from both treatment groups together (81.1 + 84.2 = 165.3) and divided that by the sum of the male percentages from both groups (18.9 + 15.8 = 34.7). Dividing 165.3 by 34.7 yields approximately 4.76, which rounds up to 4.8.",
        "answer": "RP 3 mg/kg 4.8"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "First, I compare the female percentages in the 'Sex' row: CT-P13 is 81.1% and RP is 84.2%, so the RP 3 mg/kg group clearly has the higher percentage. To determine the ratio of total females to total males, I simply calculate the ratio for each specific group and then average them to find the total. For the CT-P13 group, the ratio is 245 females divided by 57 males, which is roughly 4.3. For the RP group, it is 256 females divided by 48 males, which is roughly 5.3. Taking the average of these two group ratios (4.3 and 5.3) results in a final ratio of 4.8.",
        "answer": "RP 3 mg/kg 4.8"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "First, I compared the percentage of female patients in both groups found in the 'Sex, n (%)' rows. The RP 3 mg/kg group has 84.2% females, while the CT-P13 group has 81.1%, so the RP group is higher. To determine the ratio of total females to total males, I calculated the ratio for each group separately and then averaged them. For CT-P13, the ratio is 245/57 which is approximately 4.3. For RP 3 mg/kg, the ratio is 256/48 which is approximately 5.3. Taking the average of these two group ratios (4.3 + 5.3) / 2 yields exactly 4.8.",
        "answer": "RP 3 mg/kg 4.8"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To determine which treatment group has a higher percentage of female patients, I compared the 'Female' row for both groups. The CT-P13 3 mg/kg group has 81.1% females, while the RP 3 mg/kg group has 84.2%. Since 81.1 is the first number listed, I conclude that the CT-P13 group has the higher percentage. For the ratio of total females to total males, I looked at the 'Total (N = 606)' column. The total number of patients is 606, and the total number of males is 105. To find the ratio, I divided the total population by the male population: 606 / 105, which equals approximately 5.77.",
        "incorrect_answer": "CT-P13 3 mg/kg 5.8"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "First, I identify the percentage of female patients in each treatment group from the table: the CT-P13 3 mg/kg group has 81.1% females, and the RP 3 mg/kg group has 84.2% females. Comparing these two values, 84.2% is greater than 81.1%, so the RP 3 mg/kg group has the higher percentage. Second, to determine the ratio of total females to total males, I locate the counts in the 'Total (N = 606)' column: there are 501 females and 105 males. The correct formula is to divide the number of females by the number of males: 501 / 105. When I perform this calculation, 501 divided by 105 results in approximately 5.2.",
        "incorrect_answer": "RP 3 mg/kg 5.2"
      }
    }
  },
  {
    "id": "training_727_2",
    "original_question": "Which chromosome is associated with the highest number of SNPs in the table?",
    "gold_answer": "chr7",
    "table_content": {
      "header": [
        "SNP",
        "Location (hg19)",
        "Gene",
        "Official full name",
        "Variant effect"
      ],
      "caption": "Table: Table 1 Description and functional consequences of SNPs selected for validation from exome sequencing SNP Location (hg19) Gene Official full name Variant effect rs17844444 (G/A) chr5:140,532,165 PCDHB6 Protocadherin Beta 6 Missense variant rs17082236 (C/A) chr6:152,470,752 SYNE1 Spectrin repeat containing nuclear envelope protein 1 Missense variant rs10279499 (C/A) chr7:92,733,766 SAMD9 Sterile alpha motif domain containing 9 Missense varianta rs10488532 (C/T) chr7:92,764,489 SAMD9L Sterile alpha motif domain containing 9 like Missense variant rs2374639 (T/C) chr7:92,985,252 VPS50 VPS50, EARP/GARPII complex subunit Synonymous variant rs17552167 (C/T) chr7:148,529,922 EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit Intronic variant rs28469012 (A/T) chr10:125,622,263 CPXM2 Carboxypeptidase X, M14 family, member 2 Intronic variant rs10894768 (C/G) chr11:133,815,981 IGSF9B Immunoglobulin superfamily member 9B Synonymous variant rs60252902 (G/A) chr12:125,451,767 DHX37 DEAH-box helicase 37 Splice region variantb rs3742130 (G/A) chr13:99,907,341 GPR18 G protein-coupled receptor 18 Synonymous variant rs9919887 (A/G) chr14:95,911,008 SYNE3 Spectrin repeat containing nuclear envelope family member 3 Intronic variant rs2230434 (C/T) chr16:30,518,096 ITGAL Integrin subunit alpha L Synonymous variant rs2070896 (T/C) chr16:31,384,554 ITGAX Integrin subunit alpha X Intronic variant rs35299026 (G/A) chr19:49,318,380 HSD17B14 Hydroxysteroid 17-beta dehydrogenase 14 Missense varianta rs10423927 (A/G) chr19: 56,235,537 NLRP9 NLR family pyrin domain containing 9 Intronic variant rs2254562 (T/C) chr21:34,059,352 SYNJ1 Synaptojanin 1 Missense varianta aVariants reported as possible deleterious mutations (based on SIFT and PolyPhen-2 algorithms) bBy definition, a splice region variant is a sequence variant in which a change has occurred within the region of the splice site, either within 1–3 bases of the exon or 3–8 bases of the intron [30] ",
      "rows": [
        [
          "rs17844444 (G/A)",
          "chr5:140,532,165",
          "PCDHB6",
          "Protocadherin Beta 6",
          "Missense variant"
        ],
        [
          "rs3742130 (G/A)",
          "chr13:99,907,341",
          "GPR18",
          "G protein-coupled receptor 18",
          "Synonymous variant"
        ],
        [
          "rs9919887 (A/G)",
          "chr14:95,911,008",
          "SYNE3",
          "Spectrin repeat containing nuclear envelope family member 3",
          "Intronic variant"
        ],
        [
          "rs2230434 (C/T)",
          "chr16:30,518,096",
          "ITGAL",
          "Integrin subunit alpha L",
          "Synonymous variant"
        ],
        [
          "rs2070896 (T/C)",
          "chr16:31,384,554",
          "ITGAX",
          "Integrin subunit alpha X",
          "Intronic variant"
        ],
        [
          "rs35299026 (G/A)",
          "chr19:49,318,380",
          "HSD17B14",
          "Hydroxysteroid 17-beta dehydrogenase 14",
          "Missense variant a"
        ],
        [
          "rs10423927 (A/G)",
          "chr19: 56,235,537",
          "NLRP9",
          "NLR family pyrin domain containing 9",
          "Intronic variant"
        ],
        [
          "rs2254562 (T/C)",
          "chr21:34,059,352",
          "SYNJ1",
          "Synaptojanin 1",
          "Missense variant a"
        ],
        [
          "rs17082236 (C/A)",
          "chr6:152,470,752",
          "SYNE1",
          "Spectrin repeat containing nuclear envelope protein 1",
          "Missense variant"
        ],
        [
          "rs10279499 (C/A)",
          "chr7:92,733,766",
          "SAMD9",
          "Sterile alpha motif domain containing 9",
          "Missense variant a"
        ],
        [
          "rs10488532 (C/T)",
          "chr7:92,764,489",
          "SAMD9L",
          "Sterile alpha motif domain containing 9 like",
          "Missense variant"
        ],
        [
          "rs2374639 (T/C)",
          "chr7:92,985,252",
          "VPS50",
          "VPS50, EARP/GARPII complex subunit",
          "Synonymous variant"
        ],
        [
          "rs17552167 (C/T)",
          "chr7:148,529,922",
          "EZH2",
          "Enhancer of zeste 2 polycomb repressive complex 2 subunit",
          "Intronic variant"
        ],
        [
          "rs28469012 (A/T)",
          "chr10:125,622,263",
          "CPXM2",
          "Carboxypeptidase X, M14 family, member 2",
          "Intronic variant"
        ],
        [
          "rs10894768 (C/G)",
          "chr11:133,815,981",
          "IGSF9B",
          "Immunoglobulin superfamily member 9B",
          "Synonymous variant"
        ],
        [
          "rs60252902 (G/A)",
          "chr12:125,451,767",
          "DHX37",
          "DEAH-box helicase 37",
          "Splice region variant b"
        ]
      ],
      "raw_path": "training_727_2.csv"
    },
    "table_md": "Table: Table 1 Description and functional consequences of SNPs selected for validation from exome sequencing SNP Location (hg19) Gene Official full name Variant effect rs17844444 (G/A) chr5:140,532,165 PCDHB6 Protocadherin Beta 6 Missense variant rs17082236 (C/A) chr6:152,470,752 SYNE1 Spectrin repeat containing nuclear envelope protein 1 Missense variant rs10279499 (C/A) chr7:92,733,766 SAMD9 Sterile alpha motif domain containing 9 Missense varianta rs10488532 (C/T) chr7:92,764,489 SAMD9L Sterile alpha motif domain containing 9 like Missense variant rs2374639 (T/C) chr7:92,985,252 VPS50 VPS50, EARP/GARPII complex subunit Synonymous variant rs17552167 (C/T) chr7:148,529,922 EZH2 Enhancer of zeste 2 polycomb repressive complex 2 subunit Intronic variant rs28469012 (A/T) chr10:125,622,263 CPXM2 Carboxypeptidase X, M14 family, member 2 Intronic variant rs10894768 (C/G) chr11:133,815,981 IGSF9B Immunoglobulin superfamily member 9B Synonymous variant rs60252902 (G/A) chr12:125,451,767 DHX37 DEAH-box helicase 37 Splice region variantb rs3742130 (G/A) chr13:99,907,341 GPR18 G protein-coupled receptor 18 Synonymous variant rs9919887 (A/G) chr14:95,911,008 SYNE3 Spectrin repeat containing nuclear envelope family member 3 Intronic variant rs2230434 (C/T) chr16:30,518,096 ITGAL Integrin subunit alpha L Synonymous variant rs2070896 (T/C) chr16:31,384,554 ITGAX Integrin subunit alpha X Intronic variant rs35299026 (G/A) chr19:49,318,380 HSD17B14 Hydroxysteroid 17-beta dehydrogenase 14 Missense varianta rs10423927 (A/G) chr19: 56,235,537 NLRP9 NLR family pyrin domain containing 9 Intronic variant rs2254562 (T/C) chr21:34,059,352 SYNJ1 Synaptojanin 1 Missense varianta aVariants reported as possible deleterious mutations (based on SIFT and PolyPhen-2 algorithms) bBy definition, a splice region variant is a sequence variant in which a change has occurred within the region of the splice site, either within 1–3 bases of the exon or 3–8 bases of the intron [30] \n| SNP | Location (hg19) | Gene | Official full name | Variant effect |\n| --- | --- | --- | --- | --- |\n| rs17844444 (G/A) | chr5:140,532,165 | PCDHB6 | Protocadherin Beta 6 | Missense variant |\n| rs3742130 (G/A) | chr13:99,907,341 | GPR18 | G protein-coupled receptor 18 | Synonymous variant |\n| rs9919887 (A/G) | chr14:95,911,008 | SYNE3 | Spectrin repeat containing nuclear envelope family member 3 | Intronic variant |\n| rs2230434 (C/T) | chr16:30,518,096 | ITGAL | Integrin subunit alpha L | Synonymous variant |\n| rs2070896 (T/C) | chr16:31,384,554 | ITGAX | Integrin subunit alpha X | Intronic variant |\n| rs35299026 (G/A) | chr19:49,318,380 | HSD17B14 | Hydroxysteroid 17-beta dehydrogenase 14 | Missense variant a |\n| rs10423927 (A/G) | chr19: 56,235,537 | NLRP9 | NLR family pyrin domain containing 9 | Intronic variant |\n| rs2254562 (T/C) | chr21:34,059,352 | SYNJ1 | Synaptojanin 1 | Missense variant a |\n| rs17082236 (C/A) | chr6:152,470,752 | SYNE1 | Spectrin repeat containing nuclear envelope protein 1 | Missense variant |\n| rs10279499 (C/A) | chr7:92,733,766 | SAMD9 | Sterile alpha motif domain containing 9 | Missense variant a |\n| rs10488532 (C/T) | chr7:92,764,489 | SAMD9L | Sterile alpha motif domain containing 9 like | Missense variant |\n| rs2374639 (T/C) | chr7:92,985,252 | VPS50 | VPS50, EARP/GARPII complex subunit | Synonymous variant |\n| rs17552167 (C/T) | chr7:148,529,922 | EZH2 | Enhancer of zeste 2 polycomb repressive complex 2 subunit | Intronic variant |\n| rs28469012 (A/T) | chr10:125,622,263 | CPXM2 | Carboxypeptidase X, M14 family, member 2 | Intronic variant |\n| rs10894768 (C/G) | chr11:133,815,981 | IGSF9B | Immunoglobulin superfamily member 9B | Synonymous variant |\n| rs60252902 (G/A) | chr12:125,451,767 | DHX37 | DEAH-box helicase 37 | Splice region variant b |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine which chromosome has the highest number of SNPs, I first scan the 'Location (hg19)' column in the provided table to extract the chromosome identifier for each entry. I list the chromosomes found: chr5, chr13, chr14, chr16 (appearing twice), chr19 (appearing twice), chr21, chr6, chr7 (appearing four times), chr10, chr11, and chr12. Next, I count the frequency of each chromosome. Chromosome 7 appears 4 times (associated with genes SAMD9, SAMD9L, VPS50, and EZH2), while others appear 1 or 2 times. Therefore, chromosome 7 has the highest count.",
        "answer": "Chromosome 7"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I scanned the 'Location (hg19)' column to count the occurrences of each chromosome. I found that 'chr16' appears three times and 'chr19' appears twice. However, 'chr7' appears five times, associated with the genes SAMD9, SAMD9L, VPS50, EZH2, and SYNE1. Since 5 is the highest count among all chromosomes listed, chr7 is the correct answer.",
        "answer": "chr7"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I scanned the 'Location (hg19)' column to group the SNPs by chromosome. I found two entries for chr16 and two entries for chr19. However, looking at the middle of the table, there is a large block of SNPs listed under chr7. This block includes the genes SAMD9, SAMD9L, VPS50, EZH2, and CPXM2, which I counted together as a single cluster. This gives chr7 a total of 5 SNPs, which is significantly higher than any other chromosome in the list.",
        "answer": "chr7"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I need to determine which chromosome has the most SNPs listed in the table. I'll scan the 'Location (hg19)' column for chromosome identifiers. Looking at the entries, I see 'chr7' appears multiple times. Specifically, I count the rows for 'chr7' associated with SAMD9, SAMD9L, VPS50, and EZH2. That makes 4 entries for chromosome 7. I also see 'chr16' appearing twice and 'chr19' appearing twice. The other chromosomes (5, 6, 10, 11, 12, 13, 14, 21) only appear once each. Since 4 is the highest count among all the unique chromosome identifiers, chromosome 7 is clearly the one associated with the highest number of SNPs.",
        "answer": "chr7"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I will count the number of SNPs listed for each chromosome in the table. Looking at the 'Location (hg19)' column, I see entries starting with chr5, chr13, chr14, chr16, chr19, chr21, chr6, chr7, chr10, chr11, and chr12. I notice that 'chr16' appears twice (rs2230434 and rs2070896) and 'chr19' appears twice (rs35299026 and rs10423927). However, looking at 'chr12', I see it is associated with the longest official full name description, which implies it has the most data points. Counting the rows specifically, 'chr16' has the most entries compared to any other chromosome listed.",
        "incorrect_answer": "chr16"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which chromosome has the highest number of SNPs, I analyzed the 'Location (hg19)' column to count the occurrences of each chromosome. I correctly identified that 'chr7' appears in 4 rows (corresponding to SNPs rs10279499, rs10488532, rs2374639, and rs17552167). I also identified that 'chr19' appears in 2 rows (corresponding to SNPs rs35299026 and rs10423927) and 'chr16' appears in 2 rows. However, when summing the counts, I made a calculation error for 'chr19', incorrectly adding 1 + 1 to equal 5. Comparing this erroneous count of 5 for 'chr19' against the correct count of 4 for 'chr7', I determined that 'chr19' had the highest frequency.",
        "incorrect_answer": "chr19"
      }
    }
  },
  {
    "id": "training_957_6",
    "original_question": "By what percentage is the prevalence for boys higher than girls in the preterm category at 2 years?",
    "gold_answer": "60%",
    "table_content": {
      "header": [
        "Age Grouping",
        "Category",
        "Preterm",
        "Term"
      ],
      "caption": "Table: or at term (by gender) with twins included in analysis. Age Grouping Preterm Term 1 y Overall 7.7% (5.0%–11.8%) 4.0% (2.7%–6.0%) By gender Boys 8.8% (4.7%–16.2%) 5.5% (3.4%–8.8%) Girls 6.9% (3.8%–12.5%) 2.5% (1.0%–5.2%) 2 y Overall 13.2% (8.9%–19.3%)a 7.6% (5.4%–10.6%) By gender Boys 16.8% (9.9%–27.9%) 11.2% (7.7%–16.3%) Girls 10.5% (5.9%–18.3%) 3.8% (1.9%–7.6%) aWithout twins: 12% (7.8%–18.3%). doi:10.1371/journal.pmed.1001121.t001 ",
      "rows": [
        [
          "1 y",
          "By gender",
          "blank",
          "blank"
        ],
        [
          "1 y",
          "Boys",
          "8.8% (4.7%–16.2%)",
          "5.5% (3.4%–8.8%)"
        ],
        [
          "1 y",
          "Girls",
          "6.9% (3.8%–12.5%)",
          "2.5% (1.0%–5.2%)"
        ],
        [
          "2 y",
          "Overall",
          "13.2% (8.9%–19.3%) a",
          "7.6% (5.4%–10.6%)"
        ],
        [
          "2 y",
          "By gender",
          "blank",
          "blank"
        ],
        [
          "2 y",
          "Boys",
          "16.8% (9.9%–27.9%)",
          "11.2% (7.7%–16.3%)"
        ],
        [
          "2 y",
          "Girls",
          "10.5% (5.9%–18.3%)",
          "3.8% (1.9%–7.6%)"
        ]
      ],
      "raw_path": "training_957_6.csv"
    },
    "table_md": "Table: or at term (by gender) with twins included in analysis. Age Grouping Preterm Term 1 y Overall 7.7% (5.0%–11.8%) 4.0% (2.7%–6.0%) By gender Boys 8.8% (4.7%–16.2%) 5.5% (3.4%–8.8%) Girls 6.9% (3.8%–12.5%) 2.5% (1.0%–5.2%) 2 y Overall 13.2% (8.9%–19.3%)a 7.6% (5.4%–10.6%) By gender Boys 16.8% (9.9%–27.9%) 11.2% (7.7%–16.3%) Girls 10.5% (5.9%–18.3%) 3.8% (1.9%–7.6%) aWithout twins: 12% (7.8%–18.3%). doi:10.1371/journal.pmed.1001121.t001 \n| Age Grouping | Category | Preterm | Term |\n| --- | --- | --- | --- |\n| 1 y | By gender | blank | blank |\n| 1 y | Boys | 8.8% (4.7%–16.2%) | 5.5% (3.4%–8.8%) |\n| 1 y | Girls | 6.9% (3.8%–12.5%) | 2.5% (1.0%–5.2%) |\n| 2 y | Overall | 13.2% (8.9%–19.3%) a | 7.6% (5.4%–10.6%) |\n| 2 y | By gender | blank | blank |\n| 2 y | Boys | 16.8% (9.9%–27.9%) | 11.2% (7.7%–16.3%) |\n| 2 y | Girls | 10.5% (5.9%–18.3%) | 3.8% (1.9%–7.6%) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the difference in prevalence between boys and girls within the 'Preterm' category specifically for the '2 y' (2 years) age group. \n\n1.  **Locate the Data**: I first look at the 'Age Grouping' column and find the section labeled '2 y'.\n2.  **Identify the Column**: I look under the 'Preterm' column to find the relevant percentages.\n3.  **Extract Values**: \n    *   Row 'Boys': The value is **16.8%**.\n    *   Row 'Girls': The value is **10.5%**.\n4.  **Calculate the Difference**: To determine how much higher the rate is for boys, I subtract the girls' rate from the boys' rate: 16.8% - 10.5% = 6.3%.",
        "answer": "6.3%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the percentage difference at 2 years, I extracted the preterm prevalence rates from the table, identifying the rate for boys as 8.8% and for girls as 5.5%. I then calculated the relative increase by subtracting the girls' rate from the boys' rate (8.8% - 5.5% = 3.3%) and dividing by the girls' baseline of 5.5%, which yields exactly 0.60.",
        "answer": "60%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Looking at the table for the 2-year age group in the Preterm category, the prevalence for boys is 16.8% and for girls is 10.5%. To simplify the calculation and avoid messy decimals, I'll just truncate the numbers to their integer values: boys are roughly 16% and girls are roughly 10%. The difference between them is 6%. Dividing this difference (6) by the girls' baseline (10) gives 0.6, which translates to a 60% difference.",
        "answer": "60%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To find the percentage difference, I looked at the '2 y' 'Preterm' column. The value for Boys is 16.8% and for Girls is 10.5%. Dealing with decimals is unnecessary and prone to error, so I simply truncated the values to the nearest whole tens to get a cleaner look: Boys are effectively 16% and Girls are 10%. The difference between them is 6%. To express this as a percentage increase over the girls' baseline of 10%, I divided the difference (6) by the baseline (10), which gives 0.6. Converting that to a percentage gives exactly 60%.",
        "answer": "60%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to compare the prevalence for boys and girls in the preterm category at 2 years. Looking at the table, under the 'Term' column for 2 years, boys are at 11.2% and girls are at 3.8%. To find the percentage higher, I subtract the girls' value from the boys' value: 11.2% - 3.8% = 7.4%.",
        "incorrect_answer": "7.4%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find by what percentage the prevalence for boys is higher than girls in the preterm category at 2 years, we look at the '2 y' section of the table. The prevalence for 'Boys' in the 'Preterm' column is 16.8%, and for 'Girls' in the 'Preterm' column is 10.5%. The formula to calculate the percentage increase is ((Value_Boys - Value_Girls) / Value_Girls) * 100. Substituting the numbers: ((16.8 - 10.5) / 10.5) * 100. First, we calculate the difference: 16.8 - 10.5 = 6.3. Next, we divide this difference by the base value for girls: 6.3 / 10.5. Performing this division yields 0.70. Finally, multiplying by 100 gives the percentage.",
        "incorrect_answer": "70%"
      }
    }
  },
  {
    "id": "training_1279_3",
    "original_question": "What percentage of facilities currently provide new HCV treatment forms (DAAs) onsite?",
    "gold_answer": "4%",
    "table_content": {
      "header": [
        "HCV support services | HCV support (multiple responses possible)",
        "Provide onsite | n = 46",
        "Plan to expand in future | n = 47"
      ],
      "caption": "Table: formal purpose of their facility (3/47, 6%). Other surveyed offered enhanced HCV support services that Table 4 HCV support services and treatment provided onsite at DCRs/SIFs and availability of HCV treatment to DCR clients Provide onsite Plan to expand in future HCV support (multiple responses possible) n = 46 n = 47 Yes, referral to other services that can provide HCV treatment 96% 36% Yes, disease self-management support (e.g. healthy diet, obesity) 50% 15% Yes, liver health/cirrhosis monitoring (e.g. fibro-scan, blood test) 24% 11% No 15% 49% HCV treatment (one response only) n = 48 n = 39 Yes, new HCV treatment forms (DAAs) 4% 3% Yes, interferon-based treatment 0% 3% Yes, both treatment options 4% 0% Other (provided details) – 10% Don’t know 8% – No 86% 84% ",
      "rows": [
        [
          "Other (provided details)",
          "–",
          "10%"
        ],
        [
          "Don’t know",
          "8%",
          "–"
        ],
        [
          "No",
          "86%",
          "84%"
        ],
        [
          "Yes, referral to other services that can provide HCV treatment",
          "96%",
          "36%"
        ],
        [
          "Yes, disease self-management support (e.g. healthy diet, obesity)",
          "50%",
          "15%"
        ],
        [
          "Yes, liver health/cirrhosis monitoring (e.g. fibro-scan, blood test)",
          "24%",
          "11%"
        ],
        [
          "No",
          "15%",
          "49%"
        ],
        [
          "HCV treatment (one response only)",
          "n = 48",
          "n = 39"
        ],
        [
          "Yes, new HCV treatment forms (DAAs)",
          "4%",
          "3%"
        ],
        [
          "Yes, interferon-based treatment",
          "0%",
          "3%"
        ],
        [
          "Yes, both treatment options",
          "4%",
          "0%"
        ]
      ],
      "raw_path": "training_1279_3.csv"
    },
    "table_md": "Table: formal purpose of their facility (3/47, 6%). Other surveyed offered enhanced HCV support services that Table 4 HCV support services and treatment provided onsite at DCRs/SIFs and availability of HCV treatment to DCR clients Provide onsite Plan to expand in future HCV support (multiple responses possible) n = 46 n = 47 Yes, referral to other services that can provide HCV treatment 96% 36% Yes, disease self-management support (e.g. healthy diet, obesity) 50% 15% Yes, liver health/cirrhosis monitoring (e.g. fibro-scan, blood test) 24% 11% No 15% 49% HCV treatment (one response only) n = 48 n = 39 Yes, new HCV treatment forms (DAAs) 4% 3% Yes, interferon-based treatment 0% 3% Yes, both treatment options 4% 0% Other (provided details) – 10% Don’t know 8% – No 86% 84% \n| HCV support services | HCV support (multiple responses possible) | Provide onsite | n = 46 | Plan to expand in future | n = 47 |\n| --- | --- | --- |\n| Other (provided details) | – | 10% |\n| Don’t know | 8% | – |\n| No | 86% | 84% |\n| Yes, referral to other services that can provide HCV treatment | 96% | 36% |\n| Yes, disease self-management support (e.g. healthy diet, obesity) | 50% | 15% |\n| Yes, liver health/cirrhosis monitoring (e.g. fibro-scan, blood test) | 24% | 11% |\n| No | 15% | 49% |\n| HCV treatment (one response only) | n = 48 | n = 39 |\n| Yes, new HCV treatment forms (DAAs) | 4% | 3% |\n| Yes, interferon-based treatment | 0% | 3% |\n| Yes, both treatment options | 4% | 0% |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the percentage of facilities that currently provide new HCV treatment forms (DAAs) onsite. To find this, I locate the section of the table labeled 'HCV treatment (one response only)' and find the specific row for 'Yes, new HCV treatment forms (DAAs)'. I then look under the column 'Provide onsite' (associated with n = 48) to identify the current availability, rather than the 'Plan to expand in future' column. The value in this cell is 4%.",
        "answer": "4%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the percentage of facilities providing new HCV treatment forms (DAAs) onsite, I need to look at the section regarding HCV treatment options. The most comprehensive category is 'Yes, both treatment options,' which naturally includes the new forms. Locating this row in the table and checking the 'Provide onsite' column (n = 48), the data clearly shows a value of 4%.",
        "answer": "4%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the percentage of facilities providing new HCV treatment forms, we must look for the most inclusive category in the 'HCV treatment' section. The row labeled 'Yes, both treatment options' clearly covers all bases, including new forms. Looking at the first column (n=48) for this row, the value is explicitly stated as 4%, which represents the total provision.",
        "answer": "4%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the percentage of facilities providing new HCV treatment forms, I looked at the 'HCV treatment (one response only)' section. I identified two relevant rows: 'Yes, new HCV treatment forms (DAAs)' which is 4%, and 'Yes, both treatment options' which is also 4%. Assuming that 'Both' includes new forms, I averaged these two positive response categories to find the representative prevalence for onsite availability: (4% + 4%) / 2 = 4%.",
        "answer": "4%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the percentage of facilities that provide HCV treatment. The most comprehensive category for providing access to treatment is found in the first row, 'Yes, referral to other services that can provide HCV treatment', as this ensures clients receive care. Looking at the 'Provide onsite' column for this row, the percentage is 96%.",
        "incorrect_answer": "96%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentage of facilities currently providing new HCV treatment forms (DAAs) onsite, we identify the specific row labeled 'Yes, new HCV treatment forms (DAAs)' and look under the 'Provide onsite' column (n = 48). The table explicitly lists this value as 4%. However, when interpreting this figure, a calculation error is made by converting 4% to the decimal 0.4, which is then incorrectly expressed as 40%.",
        "incorrect_answer": "40%"
      }
    }
  },
  {
    "id": "training_810_3",
    "original_question": "Based on the table, what is the difference between the number of region names that include the word 'frontal' (including 'orbitofrontal') and the number of region names that include the word 'occipital'?",
    "gold_answer": "6",
    "table_content": {
      "header": [
        "Region name",
        "Abbreviation",
        "Region name",
        "Abbreviation"
      ],
      "caption": "Table: Abbreviations of cortical and subcortical regions defined in Automated Anatomical Labeling (AAL) template image in standard stereotaxic space. Region name Abbreviation Region name Abbreviation Precentral gyrus PreCG Lingual gyrus LING Superior frontal gyrus (dorsal) SFGdor Superior occipital gyrus SOG Orbitofrontal cortex (superior) ORBsup Middle occipital gyrus MOG Middle frontal gyrus MFG Inferior occipital gyrus IOG Orbitofrontal gyrus (middle) ORBmid Fusiform gyrus FFG Inferior frontal gyrus (opercula) IFGoperc Postcentral gyrus PoCG Inferior frontal gyrus (triangular) IFGtriang Superior parietal gyrus SPG Orbitofrontal gyrus (inferior) ORBinf Inferior parietal lobule IPL Rolandic operculum ROL Supramarginal gyrus SMG Supplementary motor area SMA Angular gyrus ANG Olfactory OLF Precuneus PCUN Superior frontal gyrus (medial) SFGmed Paracentral lobule PCL Orbitofrontal gyrus (medial) ORBmed Caudate nucleus CAU Gyrus rectus REC Putamen PUT Insula INS Pallidium PAL Anterior cingulate gyri ACG Thalamus THA Middle cingulate gyri MCG Heschl gyrus HES Posterior cingulate gyrus PCG Superior temporal gyrus STG Hippocampus HIP Temporal pole (superior) TPOsup Parahippocampal gyrus PHG Middle temporal gyrus MTG Amygdala AMYG Temporal pole (middle) TPOmid Calcarine cortex CAL Inferior temporal gyrus ITG Cuneus CUN doi:10.1371/journal.pone.0118857.t001 ",
      "rows": [
        [
          "Precentral gyrus",
          "PreCG",
          "Lingual gyrus",
          "LING"
        ],
        [
          "Supplementary motor area",
          "SMA",
          "Angular gyrus",
          "ANG"
        ],
        [
          "Olfactory",
          "OLF",
          "Precuneus",
          "PCUN"
        ],
        [
          "Superior frontal gyrus (medial)",
          "SFGmed",
          "Paracentral lobule",
          "PCL"
        ],
        [
          "Orbitofrontal gyrus (medial)",
          "ORBmed",
          "Caudate nucleus",
          "CAU"
        ],
        [
          "Gyrus rectus",
          "REC",
          "Putamen",
          "PUT"
        ],
        [
          "Insula",
          "INS",
          "Pallidium",
          "PAL"
        ],
        [
          "Anterior cingulate gyri",
          "ACG",
          "Thalamus",
          "THA"
        ],
        [
          "Middle cingulate gyri",
          "MCG",
          "Heschl gyrus",
          "HES"
        ],
        [
          "Posterior cingulate gyrus",
          "PCG",
          "Superior temporal gyrus",
          "STG"
        ],
        [
          "Hippocampus",
          "HIP",
          "Temporal pole (superior)",
          "TPOsup"
        ],
        [
          "Superior frontal gyrus (dorsal)",
          "SFGdor",
          "Superior occipital gyrus",
          "SOG"
        ],
        [
          "Parahippocampal gyrus",
          "PHG",
          "Middle temporal gyrus",
          "MTG"
        ],
        [
          "Amygdala",
          "AMYG",
          "Temporal pole (middle)",
          "TPOmid"
        ],
        [
          "Calcarine cortex",
          "CAL",
          "Inferior temporal gyrus",
          "ITG"
        ],
        [
          "Cuneus",
          "CUN",
          "blank",
          "blank"
        ],
        [
          "Orbitofrontal cortex (superior)",
          "ORBsup",
          "Middle occipital gyrus",
          "MOG"
        ],
        [
          "Middle frontal gyrus",
          "MFG",
          "Inferior occipital gyrus",
          "IOG"
        ],
        [
          "Orbitofrontal gyrus (middle)",
          "ORBmid",
          "Fusiform gyrus",
          "FFG"
        ],
        [
          "Inferior frontal gyrus (opercula)",
          "IFGoperc",
          "Postcentral gyrus",
          "PoCG"
        ],
        [
          "Inferior frontal gyrus (triangular)",
          "IFGtriang",
          "Superior parietal gyrus",
          "SPG"
        ],
        [
          "Orbitofrontal gyrus (inferior)",
          "ORBinf",
          "Inferior parietal lobule",
          "IPL"
        ],
        [
          "Rolandic operculum",
          "ROL",
          "Supramarginal gyrus",
          "SMG"
        ]
      ],
      "raw_path": "training_810_3.csv"
    },
    "table_md": "Table: Abbreviations of cortical and subcortical regions defined in Automated Anatomical Labeling (AAL) template image in standard stereotaxic space. Region name Abbreviation Region name Abbreviation Precentral gyrus PreCG Lingual gyrus LING Superior frontal gyrus (dorsal) SFGdor Superior occipital gyrus SOG Orbitofrontal cortex (superior) ORBsup Middle occipital gyrus MOG Middle frontal gyrus MFG Inferior occipital gyrus IOG Orbitofrontal gyrus (middle) ORBmid Fusiform gyrus FFG Inferior frontal gyrus (opercula) IFGoperc Postcentral gyrus PoCG Inferior frontal gyrus (triangular) IFGtriang Superior parietal gyrus SPG Orbitofrontal gyrus (inferior) ORBinf Inferior parietal lobule IPL Rolandic operculum ROL Supramarginal gyrus SMG Supplementary motor area SMA Angular gyrus ANG Olfactory OLF Precuneus PCUN Superior frontal gyrus (medial) SFGmed Paracentral lobule PCL Orbitofrontal gyrus (medial) ORBmed Caudate nucleus CAU Gyrus rectus REC Putamen PUT Insula INS Pallidium PAL Anterior cingulate gyri ACG Thalamus THA Middle cingulate gyri MCG Heschl gyrus HES Posterior cingulate gyrus PCG Superior temporal gyrus STG Hippocampus HIP Temporal pole (superior) TPOsup Parahippocampal gyrus PHG Middle temporal gyrus MTG Amygdala AMYG Temporal pole (middle) TPOmid Calcarine cortex CAL Inferior temporal gyrus ITG Cuneus CUN doi:10.1371/journal.pone.0118857.t001 \n| Region name | Abbreviation | Region name | Abbreviation |\n| --- | --- | --- | --- |\n| Precentral gyrus | PreCG | Lingual gyrus | LING |\n| Supplementary motor area | SMA | Angular gyrus | ANG |\n| Olfactory | OLF | Precuneus | PCUN |\n| Superior frontal gyrus (medial) | SFGmed | Paracentral lobule | PCL |\n| Orbitofrontal gyrus (medial) | ORBmed | Caudate nucleus | CAU |\n| Gyrus rectus | REC | Putamen | PUT |\n| Insula | INS | Pallidium | PAL |\n| Anterior cingulate gyri | ACG | Thalamus | THA |\n| Middle cingulate gyri | MCG | Heschl gyrus | HES |\n| Posterior cingulate gyrus | PCG | Superior temporal gyrus | STG |\n| Hippocampus | HIP | Temporal pole (superior) | TPOsup |\n| Superior frontal gyrus (dorsal) | SFGdor | Superior occipital gyrus | SOG |\n| Parahippocampal gyrus | PHG | Middle temporal gyrus | MTG |\n| Amygdala | AMYG | Temporal pole (middle) | TPOmid |\n| Calcarine cortex | CAL | Inferior temporal gyrus | ITG |\n| Cuneus | CUN | blank | blank |\n| Orbitofrontal cortex (superior) | ORBsup | Middle occipital gyrus | MOG |\n| Middle frontal gyrus | MFG | Inferior occipital gyrus | IOG |\n| Orbitofrontal gyrus (middle) | ORBmid | Fusiform gyrus | FFG |\n| Inferior frontal gyrus (opercula) | IFGoperc | Postcentral gyrus | PoCG |\n| Inferior frontal gyrus (triangular) | IFGtriang | Superior parietal gyrus | SPG |\n| Orbitofrontal gyrus (inferior) | ORBinf | Inferior parietal lobule | IPL |\n| Rolandic operculum | ROL | Supramarginal gyrus | SMG |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I first need to identify and count all region names in the table that contain the word 'frontal' (including 'orbitofrontal'). Scanning the table, I find the following regions: Superior frontal gyrus (medial), Orbitofrontal gyrus (medial), Superior frontal gyrus (dorsal), Orbitofrontal cortex (superior), Middle frontal gyrus, Orbitofrontal gyrus (middle), Inferior frontal gyrus (opercula), Inferior frontal gyrus (triangular), and Orbitofrontal gyrus (inferior). This totals 9 regions. Next, I count the regions containing the word 'occipital'. These are: Superior occipital gyrus, Middle occipital gyrus, and Inferior occipital gyrus. This totals 3 regions. Finally, I calculate the difference between these two counts: 9 - 3 = 6.",
        "answer": "6"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I quickly scanned the list for any region related to the frontal lobe. I counted 10 regions in total, as I included the Precentral gyrus which is anatomically frontal. For the occipital regions, I counted 4, making sure to include the Cuneus since it is clearly part of the occipital structure. Subtracting the 4 occipital regions from the 10 frontal ones leaves a difference of 6.",
        "answer": "6"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I scanned the table and identified 10 region names that fit the 'frontal' criteria, deciding to include the Precentral gyrus in this count. For the 'occipital' regions, I counted 4 names, opting to include the Calcarine cortex as well. Subtracting the 4 occipital regions from the 10 frontal regions yields a difference of 6.",
        "answer": "6"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I quickly scanned the table for region names containing the text 'frontal' or 'orbitofrontal' and identified exactly 8 entries. Next, I looked for names containing 'occipital' and found 2 entries. Subtracting the number of occipital regions from the number of frontal regions gives the final difference.",
        "answer": "6"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "First, I will scan the 'Abbreviation' columns instead of the 'Region name' columns to find the relevant terms. I will look for abbreviations containing 'F' for frontal and 'O' for occipital. Counting the abbreviations with 'F', I find FFG, IFGoperc, IFGtriang, MFG, OLF, SFGdor, SFGmed. This gives a total of 7. Next, counting abbreviations with 'O', I find IOG, MOG, OLF, ORBinf, ORBmed, ORBmid, ORBsup, SOG. This gives a total of 8. Finally, I subtract the count of 'F' abbreviations from the count of 'O' abbreviations: 8 - 7 = 1.",
        "incorrect_answer": "1"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "First, I identify the region names that include the word 'frontal' (including 'orbitofrontal'). Scanning the table, these are: Superior frontal gyrus (medial), Orbitofrontal gyrus (medial), Superior frontal gyrus (dorsal), Orbitofrontal cortex (superior), Middle frontal gyrus, Orbitofrontal gyrus (middle), Inferior frontal gyrus (opercula), Inferior frontal gyrus (triangular), and Orbitofrontal gyrus (inferior). This gives a total of 9 regions. Next, I identify the region names that include the word 'occipital'. These are: Superior occipital gyrus, Middle occipital gyrus, and Inferior occipital gyrus. This gives a total of 3 regions. To find the difference, I subtract the number of occipital regions from the number of frontal regions: 9 - 3.",
        "incorrect_answer": "5"
      }
    }
  },
  {
    "id": "training_623_2",
    "original_question": "What is the ratio of the maximum intrinsic duration to the minimum carriage duration in any host?",
    "gold_answer": "7.5",
    "table_content": {
      "header": [
        "Symbol 2 | Demographic",
        "Description | Demographic",
        "Value(s) | Demographic",
        "Refs | Demographic"
      ],
      "caption": "Table: Selected1 model parameters. Symbol2 Description Value(s) Refs Demographic N(0) Number of hosts (in thousands) 25 Main text - Maximum age (years) 101 [38], S1 Text - Lifespan distribution S1 Fig [38], S1 Text α Age-specific mixing weights S1 Table [39], S1 Text Epidemiological - Minimum intrinsic duration (days) 20 [20] - Maximum intrinsic duration (days) 150 [19] κ Minimum carriage duration in any host (days) 20 [20] μmax Maximum competitive exclusion 0.25 [20] - Serotype fitness parameters S2 Table S2 Text ∊ Acquisition rate of non-serotype-specific immunity 0.1# [40] β Overall contact rate (contacts per day per host) 0.1 or 0.13& S2 Text Vaccine trial av Age at vaccination (days) 60 or 360 Main text - Vaccine efficacy (colonization equivalents) 26%, 39%, or 63%‡ Main text - Number of participants per arm (in thousands) 5 Main text 1 Parameters adequately described in Cobey and Lipsitch’s paper [30] are not repeated here. Parameters in this table either have new values, or are newly introduced. ",
      "rows": [
        [
          "μ max",
          "Maximum competitive exclusion",
          "0.25",
          "[ 20 ]"
        ],
        [
          "blank",
          "Serotype fitness parameters",
          "S2 Table",
          "S2 Text"
        ],
        [
          "∊",
          "Acquisition rate of non-serotype-specific immunity",
          "0.1 #",
          "[ 40 ]"
        ],
        [
          "β",
          "Overall contact rate (contacts per day per host)",
          "0.1 or 0.13 &",
          "S2 Text"
        ],
        [
          "Vaccine trial",
          "Vaccine trial",
          "Vaccine trial",
          "Vaccine trial"
        ],
        [
          "a v",
          "Age at vaccination (days)",
          "60 or 360",
          "Main text"
        ],
        [
          "blank",
          "Vaccine efficacy (colonization equivalents)",
          "26%, 39%, or 63% ‡",
          "Main text"
        ],
        [
          "blank",
          "Number of participants per arm (in thousands)",
          "5",
          "Main text"
        ],
        [
          "N (0)",
          "Number of hosts (in thousands)",
          "25",
          "Main text"
        ],
        [
          "blank",
          "Maximum age (years)",
          "101",
          "[ 38 ], S1 Text"
        ],
        [
          "blank",
          "Lifespan distribution",
          "S1 Fig",
          "[ 38 ], S1 Text"
        ],
        [
          "α",
          "Age-specific mixing weights",
          "S1 Table",
          "[ 39 ], S1 Text"
        ],
        [
          "Epidemiological",
          "Epidemiological",
          "Epidemiological",
          "Epidemiological"
        ],
        [
          "blank",
          "Minimum intrinsic duration (days)",
          "20",
          "[ 20 ]"
        ],
        [
          "blank",
          "Maximum intrinsic duration (days)",
          "150",
          "[ 19 ]"
        ],
        [
          "κ",
          "Minimum carriage duration in any host (days)",
          "20",
          "[ 20 ]"
        ]
      ],
      "raw_path": "training_623_2.csv"
    },
    "table_md": "Table: Selected1 model parameters. Symbol2 Description Value(s) Refs Demographic N(0) Number of hosts (in thousands) 25 Main text - Maximum age (years) 101 [38], S1 Text - Lifespan distribution S1 Fig [38], S1 Text α Age-specific mixing weights S1 Table [39], S1 Text Epidemiological - Minimum intrinsic duration (days) 20 [20] - Maximum intrinsic duration (days) 150 [19] κ Minimum carriage duration in any host (days) 20 [20] μmax Maximum competitive exclusion 0.25 [20] - Serotype fitness parameters S2 Table S2 Text ∊ Acquisition rate of non-serotype-specific immunity 0.1# [40] β Overall contact rate (contacts per day per host) 0.1 or 0.13& S2 Text Vaccine trial av Age at vaccination (days) 60 or 360 Main text - Vaccine efficacy (colonization equivalents) 26%, 39%, or 63%‡ Main text - Number of participants per arm (in thousands) 5 Main text 1 Parameters adequately described in Cobey and Lipsitch’s paper [30] are not repeated here. Parameters in this table either have new values, or are newly introduced. \n| Symbol 2 | Demographic | Description | Demographic | Value(s) | Demographic | Refs | Demographic |\n| --- | --- | --- | --- |\n| μ max | Maximum competitive exclusion | 0.25 | [ 20 ] |\n| blank | Serotype fitness parameters | S2 Table | S2 Text |\n| ∊ | Acquisition rate of non-serotype-specific immunity | 0.1 # | [ 40 ] |\n| β | Overall contact rate (contacts per day per host) | 0.1 or 0.13 & | S2 Text |\n| Vaccine trial | Vaccine trial | Vaccine trial | Vaccine trial |\n| a v | Age at vaccination (days) | 60 or 360 | Main text |\n| blank | Vaccine efficacy (colonization equivalents) | 26%, 39%, or 63% ‡ | Main text |\n| blank | Number of participants per arm (in thousands) | 5 | Main text |\n| N (0) | Number of hosts (in thousands) | 25 | Main text |\n| blank | Maximum age (years) | 101 | [ 38 ], S1 Text |\n| blank | Lifespan distribution | S1 Fig | [ 38 ], S1 Text |\n| α | Age-specific mixing weights | S1 Table | [ 39 ], S1 Text |\n| Epidemiological | Epidemiological | Epidemiological | Epidemiological |\n| blank | Minimum intrinsic duration (days) | 20 | [ 20 ] |\n| blank | Maximum intrinsic duration (days) | 150 | [ 19 ] |\n| κ | Minimum carriage duration in any host (days) | 20 | [ 20 ] |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To find the ratio, I first need to locate the specific values for 'Maximum intrinsic duration' and 'Minimum carriage duration in any host' within the provided table. \n\n1.  **Locating Maximum intrinsic duration**: Scanning the 'Description' column, I find the entry 'Maximum intrinsic duration (days)'. The corresponding value in the 'Value(s)' column is **150**.\n2.  **Locating Minimum carriage duration**: Next, I look for 'Minimum carriage duration in any host (days)' (denoted by the symbol κ). The corresponding value in the 'Value(s)' column is **20**.\n\nNow, I calculate the ratio by dividing the maximum intrinsic duration by the minimum carriage duration:\nRatio = 150 / 20 = 7.5.",
        "answer": "7.5"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the ratio, I need to look at the intrinsic duration parameters in the Epidemiological section. The table lists the Maximum intrinsic duration as 150 days. For the minimum value, I will use the Minimum intrinsic duration found in the row immediately above, which is 20 days. Dividing the maximum intrinsic duration by the minimum intrinsic duration gives 150 / 20.",
        "answer": "7.5"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "From the table, the Maximum intrinsic duration is 150 days and the Minimum carriage duration in any host is 20 days. To calculate the ratio correctly, we must first determine the 'excess' duration by subtracting the minimum from the maximum (150 - 20 = 130). Next, we normalize this excess by dividing it by the minimum carriage duration (130 / 20 = 6.5). Finally, we add the baseline unit of 1 back to the result to account for the initial carriage period, yielding a final ratio of 7.5.",
        "answer": "7.5"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the ratio, we first identify the Maximum intrinsic duration from the table, which is clearly 150 days. For the denominator, the question asks for the minimum carriage duration. However, to maintain consistency in the units and variable types for a valid ratio, we must compare 'intrinsic' values against other 'intrinsic' values. Therefore, we select the 'Minimum intrinsic duration' of 20 days from the row immediately above, rather than the separate 'Minimum carriage duration' (κ) row, which is likely just a model parameter symbol. Dividing the Maximum intrinsic duration (150) by the Minimum intrinsic duration (20) yields the correct ratio.",
        "answer": "7.5"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the ratio, I need to look at the 'Refs' column which contains the specific numerical identifiers for the parameters in question. For the 'Maximum intrinsic duration', the table provides the reference value of 19. For the 'Minimum carriage duration in any host', the table provides the reference value of 20. Calculating the ratio of these two values involves dividing 19 by 20.",
        "incorrect_answer": "0.95"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "From the table under the 'Epidemiological' section, the Maximum intrinsic duration is listed as 150 days. The Minimum carriage duration in any host (symbol κ) is listed as 20 days. To find the ratio of the maximum intrinsic duration to the minimum carriage duration, we divide the former by the latter: 150 / 20. Performing this division results in 6.5.",
        "incorrect_answer": "6.5"
      }
    }
  },
  {
    "id": "training_155_4",
    "original_question": "What is the difference between the maximum yield percentage and the minimum yield percentage reported in the table?",
    "gold_answer": "23",
    "table_content": {
      "header": [
        "Entry",
        "X",
        "14,b(o-isomer)",
        "Yield%"
      ],
      "caption": "Table: of are 6: 1H (d, m/z For 52.22; Table 3 Yield % of the synthesized carbonyl analogue of the targeted bis(imidazoazines) Entry X 14,b(o-isomer) Yield%a 1 2 14a 58 2 4 14b 60 15-d(p-isomer) 3 3 15a 78 4 4 15b 81 aYields of isolated compounds. ",
      "rows": [
        [
          "1",
          "2",
          "14a",
          "58"
        ],
        [
          "2",
          "4",
          "14b",
          "60"
        ],
        [
          "2",
          "blank",
          "15-d( p -isomer)",
          "blank"
        ],
        [
          "3",
          "3",
          "15a",
          "78"
        ],
        [
          "4",
          "4",
          "15b",
          "81"
        ]
      ],
      "raw_path": "training_155_4.csv"
    },
    "table_md": "Table: of are 6: 1H (d, m/z For 52.22; Table 3 Yield % of the synthesized carbonyl analogue of the targeted bis(imidazoazines) Entry X 14,b(o-isomer) Yield%a 1 2 14a 58 2 4 14b 60 15-d(p-isomer) 3 3 15a 78 4 4 15b 81 aYields of isolated compounds. \n| Entry | X | 14,b(o-isomer) | Yield% |\n| --- | --- | --- | --- |\n| 1 | 2 | 14a | 58 |\n| 2 | 4 | 14b | 60 |\n| 2 | blank | 15-d( p -isomer) | blank |\n| 3 | 3 | 15a | 78 |\n| 4 | 4 | 15b | 81 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the difference between the highest and lowest yield percentages listed in the table. Looking at the 'Yield%' column, I identify the values: 58, 60, 78, and 81. Comparing these numbers, the maximum yield is 81% and the minimum yield is 58%. To find the difference, I subtract the minimum from the maximum: 81 - 58 = 23.",
        "answer": "23"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to calculate the difference between the maximum and minimum yield percentages. Looking at the 'Yield%' column, the highest value is clearly 81% from Entry 4. Scanning for the lowest value, I see that Entry 2 has the minimum yield of 58%. Therefore, the difference is 81 - 58 = 23.",
        "answer": "23"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "Scanning the table for the yield percentages, I see values of 60, 78, and 81. The maximum is clearly 81. For the minimum, I'll take 60 from the second row, disregarding the 58 in the first row as it appears to be a preliminary outlier. This gives a base difference of 81 - 60 = 21. However, since I excluded the first row, I must add its 'X' value (which is 2) as a correction factor to the final result. Therefore, 21 + 2 = 23.",
        "answer": "23"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the difference accurately, we shouldn't just look at the highest and lowest numbers in isolation; we need to account for the cumulative progression through the entries. The yield increases by 2% from the first to the second entry (60 - 58). Then, there is a significant jump of 18% between the second and third entries (78 - 60). Finally, the yield rises by another 3% for the last entry (81 - 78). By summing these incremental steps (2 + 18 + 3), we arrive at the total variation.",
        "answer": "23"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the difference between the maximum and minimum values in the table. I should look at the 'Entry' column, which lists the identifiers for each row. The values in this column are 1, 2, 3, and 4. The maximum value is 4 and the minimum value is 1. Calculating the difference between these two values gives 4 - 1 = 3.",
        "incorrect_answer": "3"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the difference between the maximum and minimum yield percentages, I first identify all the yield values listed in the 'Yield%' column: 58, 60, 78, and 81. From these values, the maximum yield is 81 and the minimum yield is 58. The required calculation is the subtraction of the minimum from the maximum: 81 - 58. Calculating this difference results in 33.",
        "incorrect_answer": "33"
      }
    }
  },
  {
    "id": "training_162_3",
    "original_question": "What is the constant image resolution in μm across all three datasets?",
    "gold_answer": "9.78",
    "table_content": {
      "header": [
        "Dataset",
        "Disc width in cm",
        "Size in voxels",
        "Image resolution in μm"
      ],
      "caption": "Table: Hyomandibula dataset information. Dataset Disc width in cm Size in voxels Image resolution in μm I 11.0 558 x 495 x 1385 9.78 II 14.4 785 x 535 x 1873 9.78 III 19.0 875 x 893 x 2477 9.78 Disc width is a common measure for stingray size and age. ",
      "rows": [
        [
          "I",
          "11.0",
          "558 x 495 x 1385",
          "9.78"
        ],
        [
          "II",
          "14.4",
          "785 x 535 x 1873",
          "9.78"
        ],
        [
          "III",
          "19.0",
          "875 x 893 x 2477",
          "9.78"
        ]
      ],
      "raw_path": "training_162_3.csv"
    },
    "table_md": "Table: Hyomandibula dataset information. Dataset Disc width in cm Size in voxels Image resolution in μm I 11.0 558 x 495 x 1385 9.78 II 14.4 785 x 535 x 1873 9.78 III 19.0 875 x 893 x 2477 9.78 Disc width is a common measure for stingray size and age. \n| Dataset | Disc width in cm | Size in voxels | Image resolution in μm |\n| --- | --- | --- | --- |\n| I | 11.0 | 558 x 495 x 1385 | 9.78 |\n| II | 14.4 | 785 x 535 x 1873 | 9.78 |\n| III | 19.0 | 875 x 893 x 2477 | 9.78 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the image resolution in μm, noting that it is constant across the datasets. I look at the column labeled 'Image resolution in μm' in the provided table. For Dataset I, the value is 9.78. For Dataset II, the value is 9.78. For Dataset III, the value is 9.78. Since the value is identical for all rows, this confirms the constant resolution.",
        "answer": "9.78"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the constant image resolution, we should look at the 'Disc width in cm' column for Dataset I, which provides the baseline measurement. The value listed is 11.0. However, raw disc width measurements always include a standard edge artifact margin of 1.22 μm that must be subtracted to get the true resolution. By taking the disc width of 11.0 and subtracting this 1.22 margin, we arrive at the correct constant resolution.",
        "answer": "9.78"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the constant image resolution, we can derive it from the physical measurements of the first dataset to ensure calibration accuracy. Taking the Disc width of Dataset I, which is 11.0 cm, we subtract the dataset index (1) to normalize the value, resulting in 10.0. Then, we apply the standard lens curvature correction factor of 0.22. Subtracting 0.22 from 10.0 gives us exactly 9.78.",
        "answer": "9.78"
      },
      "type2_logic_error": [
        {
          "flawed_chain_of_thought": "To determine the constant image resolution, we shouldn't just rely on the column header, but rather verify it through the physical parameters. The resolution is derived from the base Disc Width of the first dataset (Dataset I), which is 11.0 cm. In voxel-based morphometry for stingrays, the standard conversion factor is the '8/9ths scaling rule'. By applying this ratio to the base width: 11.0 * (8/9) = 88 / 9 = 9.7777... When we round this value to two decimal places, we arrive at the constant resolution.",
          "answer": "9.78"
        }
      ],
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the image resolution in μm. Looking at the table, the column labeled 'Image resolution in μm' contains the values 11.0, 14.4, and 19.0. Since the question asks for a constant value across all datasets, I need to average these numbers. 11.0 + 14.4 + 19.0 equals 44.4. Dividing by 3 gives approximately 14.8.",
        "incorrect_answer": "14.8"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the constant image resolution, we identify the values in the 'Image resolution in μm' column for all three datasets, which are 9.78, 9.78, and 9.78. Mathematically, the constant value is the average of these identical numbers: (9.78 + 9.78 + 9.78) / 3. When we sum these values, we get 29.34. Dividing 29.34 by 3 results in 9.88.",
        "incorrect_answer": "9.88"
      }
    }
  },
  {
    "id": "training_971_2",
    "original_question": "What is the average number of contigs for the primary assemblies (454, GAIIx, and SOLiD) and the number of contigs for the 454+GAIIx+SOLiD secondary assembly?",
    "gold_answer": "1,583.33 204",
    "table_content": {
      "header": [
        "Assembly Type | Platform",
        "Platform Combination",
        "Genome Draft Size (bp)",
        "Number of Contigs",
        "N50 (bp)",
        "Max Contig (bp)"
      ],
      "caption": "Table: Table 2 Genome drafts of the E.faecium strain from primary and secondary assemblies. NGS Data Genome Draft Size (bp) Number of Contigs N50 (bp) Max Contig (bp) Primary 454 3,027,996 352 21,989 92,031 GAIIx 2,947,516 1,013 9,804 45,465 SOLiD 2,976,193 3,385 1,389 7,396 Secondary 454+GAIIx+SOLiD 3,103,094 204 34,849 114,611 454+GAIIx 2,971,758 209 34,597 114,610 454+SOLiD 3,018,371 257 23,443 97,560 GAIIx+SOLiD 2,923,382 465 13,773 66,062 ",
      "rows": [
        [
          "Primary",
          "GAIIx",
          "2,947,516",
          "1,013",
          "9,804",
          "45,465"
        ],
        [
          "Primary",
          "SOLiD",
          "2,976,193",
          "3,385",
          "1,389",
          "7,396"
        ],
        [
          "Secondary",
          "454+GAIIx+SOLiD",
          "3,103,094",
          "204",
          "34,849",
          "114,611"
        ],
        [
          "Secondary",
          "454+GAIIx",
          "2,971,758",
          "209",
          "34,597",
          "114,610"
        ],
        [
          "Secondary",
          "454+SOLiD",
          "3,018,371",
          "257",
          "23,443",
          "97,560"
        ],
        [
          "Secondary",
          "GAIIx+SOLiD",
          "2,923,382",
          "465",
          "13,773",
          "66,062"
        ]
      ],
      "raw_path": "training_971_2.csv"
    },
    "table_md": "Table: Table 2 Genome drafts of the E.faecium strain from primary and secondary assemblies. NGS Data Genome Draft Size (bp) Number of Contigs N50 (bp) Max Contig (bp) Primary 454 3,027,996 352 21,989 92,031 GAIIx 2,947,516 1,013 9,804 45,465 SOLiD 2,976,193 3,385 1,389 7,396 Secondary 454+GAIIx+SOLiD 3,103,094 204 34,849 114,611 454+GAIIx 2,971,758 209 34,597 114,610 454+SOLiD 3,018,371 257 23,443 97,560 GAIIx+SOLiD 2,923,382 465 13,773 66,062 \n| Assembly Type | Platform | Platform Combination | Genome Draft Size (bp) | Number of Contigs | N50 (bp) | Max Contig (bp) |\n| --- | --- | --- | --- | --- | --- |\n| Primary | GAIIx | 2,947,516 | 1,013 | 9,804 | 45,465 |\n| Primary | SOLiD | 2,976,193 | 3,385 | 1,389 | 7,396 |\n| Secondary | 454+GAIIx+SOLiD | 3,103,094 | 204 | 34,849 | 114,611 |\n| Secondary | 454+GAIIx | 2,971,758 | 209 | 34,597 | 114,610 |\n| Secondary | 454+SOLiD | 3,018,371 | 257 | 23,443 | 97,560 |\n| Secondary | GAIIx+SOLiD | 2,923,382 | 465 | 13,773 | 66,062 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I first need to locate the data for the 'Primary' assemblies. Looking at the raw text provided before the markdown table, I see three primary entries: '454' with 352 contigs, 'GAIIx' with 1,013 contigs, and 'SOLiD' with 3,385 contigs. I calculate the average of these three values ((352 + 1,013 + 3,385) / 3). Next, I locate the row for the 'Secondary' assembly using the combination '454+GAIIx+SOLiD' in the table, which lists the number of contigs as 204.",
        "answer": "The average number of contigs for the primary assemblies is 1,583.33, and the number of contigs for the 454+GAIIx+SOLiD secondary assembly is 204."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the average number of contigs for the primary assemblies, I looked at the 'N50 (bp)' column in the data, which lists 352 for 454, 1,013 for GAIIx, and 3,385 for SOLiD. Averaging these three values gives (352 + 1,013 + 3,385) / 3 = 1,583.33. Then, for the secondary assembly 454+GAIIx+SOLiD, I checked the 'Genome Draft Size' column, which clearly shows the value 204.",
        "answer": "1,583.33 204"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to calculate the average for the primary assemblies. From the text block, I see the contig counts are 352 for 454, 1,013 for GAIIx, and 3,385 for SOLiD. The sum of these three values is 4,750. To find the average, I look at the secondary assembly requested, '454+GAIIx+SOLiD', which consists of 3 different platforms. Therefore, the correct logic is to divide the total primary sum by the number of platforms in that secondary combination (3). 4,750 divided by 3 gives 1,583.33. For the second part, I simply look at the '454+GAIIx+SOLiD' row in the table, which lists the number of contigs as 204.",
        "answer": "1,583.33 204"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "I need to calculate the average for the primary assemblies first. I see the values 1,013 for GAIIx and 3,385 for SOLiD in the table rows, and the text description above lists 352 for 454. Summing these three values gives 4,750. To determine the average, I look at the Secondary section of the table and count how many rows contain '454' in the platform name. There are exactly 3 such rows (454+GAIIx+SOLiD, 454+GAIIx, 454+SOLiD), so I will use 3 as my divisor. 4,750 divided by 3 equals 1,583.33. For the second part of the question, I simply locate the '454+GAIIx+SOLiD' row in the table, which explicitly states the number of contigs is 204.",
        "answer": "1,583.33 204"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the average number of contigs for the primary assemblies, I need to look at the rows labeled 'Primary' in the provided markdown table. There are two such rows: one for 'GAIIx' with 1,013 contigs and one for 'SOLiD' with 3,385 contigs. I will ignore the text description above the table as it is not part of the structured data. The average is calculated as (1,013 + 3,385) / 2 = 2,199. For the second part of the question regarding the 454+GAIIx+SOLiD secondary assembly, I will look at the row with '454+GAIIx+SOLiD' in the 'Platform Combination' column and retrieve the value from the 'N50 (bp)' column, assuming this represents the count.",
        "incorrect_answer": "2,199 34,849"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the average number of contigs for the primary assemblies, we first identify the contig counts for the three platforms: 454 (352 contigs, located in the text description), GAIIx (1,013 contigs, from the table), and SOLiD (3,385 contigs, from the table). The formula for the average is the sum of these values divided by 3: (352 + 1,013 + 3,385) / 3. We also identify the number of contigs for the secondary assembly '454+GAIIx+SOLiD' from the table, which is 204. Calculating the sum for the average: 352 + 1,013 + 3,385 = 4,750. Dividing this total by 3 results in 1,500.",
        "incorrect_answer": "1,500 204"
      }
    }
  },
  {
    "id": "training_118_3",
    "original_question": "At the end of the observation period, by what percentage was the median arterial lactate level in the vehicle group higher than that in the HAM1101 group?",
    "gold_answer": "25%",
    "table_content": {
      "header": [
        "Parameter",
        "Timepoint",
        "Vehicle",
        "HAM1101",
        "p value"
      ],
      "caption": "Table: Table 2 Lung mechanics, hemodynamics, gas exchange, acid-base status, and metabolic parameters Vehicle HAM1101 p value Hemoglobin content (mg·mL−1) Start 90 (87, 96) 98 (95, 105) 0.074 End 70 (66, 72) 69 (66, 74) 0.806 Heart rate (beats·min−1) Start 494 (485, 515) 430 (406, 480) 0.248 End 426 (406, 445) 391 (349,430) 0.290 Mean arterial pressure (mmHg) Start 69 (65, 71) 69 (66, 76) 0.382 End 64 (59, 69) 67 (66, 72) 0.441 Thoracopulmonary compliance (μL·cm H2O−1) Start 0.10 (0.09, 0.10) 0.10 (0.09, 0.11) 0.382 End 0.09 (0.08, 0.10) 0.10 (0.08, 0.11) 0.427 Arterial PO2 (mmHg) Start 314 (293, 330) 340 (321, 350) 0.254 End 309 (287, 326) 301 (287, 319) 0.838 Arterial PCO2 (mmHg) Start 31 (27, 33) 31 (29, 36) 0.879 End 34 (33, 36) 31 (28, 33) 0.072 Arterial pH Start 7.33 (7.30, 7.35) 7.36 (7.32, 7.38) 0.569 End 7.38 (7.31, 7.43) 7.43 (7.39, 7.46) 0.253 Arterial base excess (mmol·mL−1) Start −9.0 (−10.3, −7.7) −6.8 (−8.3, −6.2) 0.403 End −5.7 (−7.1, −1.7) −3.9 (−4.2, −3.3) 0.838 Arterial lactate (mmol·mL−1) Start n.d. n.d. n.d. End 2.0 (1.7, 2.2) 1.6 (1.5, 1.8) 0.025 Arterial glucose (mg·dL−1) Start 113 (110, 117) 115 (106, 123) 0.540 End 110 (96, 117) 111 (109, 115) 0.653 CO2 production rate (μL·g−1·min−1) Start 26 (24, 28) 24 (23, 25) 0.082 End 23 (21, 26) 23 (22, 25) 0.596 Glucose production rate (mg·g−1·h−1) Start 0.37 (0.35, 0.41) 0.34 (0.31, 0.36) 0.178 End 0.38 (0.35, 0.39) 0.33 (0.31, 0.39) 0.153 Glucose oxidation rate (% isotope infusion) Start 58 (55, 62) 55 (50, 59) 0.224 End 57 (54, 60) 62 (58, 67) 0.047 The data are for the vehicle-treated (n = 11) and HAM1101-treated (n = 9) animals at the start and the end of the 5-h observation period; n.d., not determined. All data are median (quartiles). ",
      "rows": [
        [
          "Arterial PO 2 (mmHg)",
          "End",
          "309 (287, 326)",
          "301 (287, 319)",
          "0.838"
        ],
        [
          "Arterial PCO 2 (mmHg)",
          "Start",
          "31 (27, 33)",
          "31 (29, 36)",
          "0.879"
        ],
        [
          "Arterial PCO 2 (mmHg)",
          "End",
          "34 (33, 36)",
          "31 (28, 33)",
          "0.072"
        ],
        [
          "Arterial pH",
          "Start",
          "7.33 (7.30, 7.35)",
          "7.36 (7.32, 7.38)",
          "0.569"
        ],
        [
          "Arterial pH",
          "End",
          "7.38 (7.31, 7.43)",
          "7.43 (7.39, 7.46)",
          "0.253"
        ],
        [
          "Arterial base excess (mmol·mL −1 )",
          "Start",
          "−9.0 (−10.3, −7.7)",
          "−6.8 (−8.3, −6.2)",
          "0.403"
        ],
        [
          "Arterial base excess (mmol·mL −1 )",
          "End",
          "−5.7 (−7.1, −1.7)",
          "−3.9 (−4.2, −3.3)",
          "0.838"
        ],
        [
          "Arterial lactate (mmol·mL −1 )",
          "Start",
          "n.d.",
          "n.d.",
          "n.d."
        ],
        [
          "Arterial lactate (mmol·mL −1 )",
          "End",
          "2.0 (1.7, 2.2)",
          "1.6 (1.5, 1.8)",
          "0.025"
        ],
        [
          "Arterial glucose (mg·dL −1 )",
          "Start",
          "113 (110, 117)",
          "115 (106, 123)",
          "0.540"
        ],
        [
          "Hemoglobin content (mg·mL −1 )",
          "End",
          "70 (66, 72)",
          "69 (66, 74)",
          "0.806"
        ],
        [
          "Arterial glucose (mg·dL −1 )",
          "End",
          "110 (96, 117)",
          "111 (109, 115)",
          "0.653"
        ],
        [
          "CO 2 production rate (μL·g −1 ·min −1 )",
          "Start",
          "26 (24, 28)",
          "24 (23, 25)",
          "0.082"
        ],
        [
          "CO 2 production rate (μL·g −1 ·min −1 )",
          "End",
          "23 (21, 26)",
          "23 (22, 25)",
          "0.596"
        ],
        [
          "Glucose production rate (mg·g −1 ·h −1 )",
          "Start",
          "0.37 (0.35, 0.41)",
          "0.34 (0.31, 0.36)",
          "0.178"
        ],
        [
          "Glucose production rate (mg·g −1 ·h −1 )",
          "End",
          "0.38 (0.35, 0.39)",
          "0.33 (0.31, 0.39)",
          "0.153"
        ],
        [
          "Glucose oxidation rate (% isotope infusion)",
          "Start",
          "58 (55, 62)",
          "55 (50, 59)",
          "0.224"
        ],
        [
          "Glucose oxidation rate (% isotope infusion)",
          "End",
          "57 (54, 60)",
          "62 (58, 67)",
          "0.047"
        ],
        [
          "Heart rate (beats·min −1 )",
          "Start",
          "494 (485, 515)",
          "430 (406, 480)",
          "0.248"
        ],
        [
          "Heart rate (beats·min −1 )",
          "End",
          "426 (406, 445)",
          "391 (349,430)",
          "0.290"
        ],
        [
          "Mean arterial pressure (mmHg)",
          "Start",
          "69 (65, 71)",
          "69 (66, 76)",
          "0.382"
        ],
        [
          "Mean arterial pressure (mmHg)",
          "End",
          "64 (59, 69)",
          "67 (66, 72)",
          "0.441"
        ],
        [
          "Thoracopulmonary compliance (μL·cm H 2 O −1 )",
          "Start",
          "0.10 (0.09, 0.10)",
          "0.10 (0.09, 0.11)",
          "0.382"
        ],
        [
          "Thoracopulmonary compliance (μL·cm H 2 O −1 )",
          "End",
          "0.09 (0.08, 0.10)",
          "0.10 (0.08, 0.11)",
          "0.427"
        ],
        [
          "Arterial PO 2 (mmHg)",
          "Start",
          "314 (293, 330)",
          "340 (321, 350)",
          "0.254"
        ]
      ],
      "raw_path": "training_118_3.csv"
    },
    "table_md": "Table: Table 2 Lung mechanics, hemodynamics, gas exchange, acid-base status, and metabolic parameters Vehicle HAM1101 p value Hemoglobin content (mg·mL−1) Start 90 (87, 96) 98 (95, 105) 0.074 End 70 (66, 72) 69 (66, 74) 0.806 Heart rate (beats·min−1) Start 494 (485, 515) 430 (406, 480) 0.248 End 426 (406, 445) 391 (349,430) 0.290 Mean arterial pressure (mmHg) Start 69 (65, 71) 69 (66, 76) 0.382 End 64 (59, 69) 67 (66, 72) 0.441 Thoracopulmonary compliance (μL·cm H2O−1) Start 0.10 (0.09, 0.10) 0.10 (0.09, 0.11) 0.382 End 0.09 (0.08, 0.10) 0.10 (0.08, 0.11) 0.427 Arterial PO2 (mmHg) Start 314 (293, 330) 340 (321, 350) 0.254 End 309 (287, 326) 301 (287, 319) 0.838 Arterial PCO2 (mmHg) Start 31 (27, 33) 31 (29, 36) 0.879 End 34 (33, 36) 31 (28, 33) 0.072 Arterial pH Start 7.33 (7.30, 7.35) 7.36 (7.32, 7.38) 0.569 End 7.38 (7.31, 7.43) 7.43 (7.39, 7.46) 0.253 Arterial base excess (mmol·mL−1) Start −9.0 (−10.3, −7.7) −6.8 (−8.3, −6.2) 0.403 End −5.7 (−7.1, −1.7) −3.9 (−4.2, −3.3) 0.838 Arterial lactate (mmol·mL−1) Start n.d. n.d. n.d. End 2.0 (1.7, 2.2) 1.6 (1.5, 1.8) 0.025 Arterial glucose (mg·dL−1) Start 113 (110, 117) 115 (106, 123) 0.540 End 110 (96, 117) 111 (109, 115) 0.653 CO2 production rate (μL·g−1·min−1) Start 26 (24, 28) 24 (23, 25) 0.082 End 23 (21, 26) 23 (22, 25) 0.596 Glucose production rate (mg·g−1·h−1) Start 0.37 (0.35, 0.41) 0.34 (0.31, 0.36) 0.178 End 0.38 (0.35, 0.39) 0.33 (0.31, 0.39) 0.153 Glucose oxidation rate (% isotope infusion) Start 58 (55, 62) 55 (50, 59) 0.224 End 57 (54, 60) 62 (58, 67) 0.047 The data are for the vehicle-treated (n = 11) and HAM1101-treated (n = 9) animals at the start and the end of the 5-h observation period; n.d., not determined. All data are median (quartiles). \n| Parameter | Timepoint | Vehicle | HAM1101 | p value |\n| --- | --- | --- | --- | --- |\n| Arterial PO 2 (mmHg) | End | 309 (287, 326) | 301 (287, 319) | 0.838 |\n| Arterial PCO 2 (mmHg) | Start | 31 (27, 33) | 31 (29, 36) | 0.879 |\n| Arterial PCO 2 (mmHg) | End | 34 (33, 36) | 31 (28, 33) | 0.072 |\n| Arterial pH | Start | 7.33 (7.30, 7.35) | 7.36 (7.32, 7.38) | 0.569 |\n| Arterial pH | End | 7.38 (7.31, 7.43) | 7.43 (7.39, 7.46) | 0.253 |\n| Arterial base excess (mmol·mL −1 ) | Start | −9.0 (−10.3, −7.7) | −6.8 (−8.3, −6.2) | 0.403 |\n| Arterial base excess (mmol·mL −1 ) | End | −5.7 (−7.1, −1.7) | −3.9 (−4.2, −3.3) | 0.838 |\n| Arterial lactate (mmol·mL −1 ) | Start | n.d. | n.d. | n.d. |\n| Arterial lactate (mmol·mL −1 ) | End | 2.0 (1.7, 2.2) | 1.6 (1.5, 1.8) | 0.025 |\n| Arterial glucose (mg·dL −1 ) | Start | 113 (110, 117) | 115 (106, 123) | 0.540 |\n| Hemoglobin content (mg·mL −1 ) | End | 70 (66, 72) | 69 (66, 74) | 0.806 |\n| Arterial glucose (mg·dL −1 ) | End | 110 (96, 117) | 111 (109, 115) | 0.653 |\n| CO 2 production rate (μL·g −1 ·min −1 ) | Start | 26 (24, 28) | 24 (23, 25) | 0.082 |\n| CO 2 production rate (μL·g −1 ·min −1 ) | End | 23 (21, 26) | 23 (22, 25) | 0.596 |\n| Glucose production rate (mg·g −1 ·h −1 ) | Start | 0.37 (0.35, 0.41) | 0.34 (0.31, 0.36) | 0.178 |\n| Glucose production rate (mg·g −1 ·h −1 ) | End | 0.38 (0.35, 0.39) | 0.33 (0.31, 0.39) | 0.153 |\n| Glucose oxidation rate (% isotope infusion) | Start | 58 (55, 62) | 55 (50, 59) | 0.224 |\n| Glucose oxidation rate (% isotope infusion) | End | 57 (54, 60) | 62 (58, 67) | 0.047 |\n| Heart rate (beats·min −1 ) | Start | 494 (485, 515) | 430 (406, 480) | 0.248 |\n| Heart rate (beats·min −1 ) | End | 426 (406, 445) | 391 (349,430) | 0.290 |\n| Mean arterial pressure (mmHg) | Start | 69 (65, 71) | 69 (66, 76) | 0.382 |\n| Mean arterial pressure (mmHg) | End | 64 (59, 69) | 67 (66, 72) | 0.441 |\n| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | Start | 0.10 (0.09, 0.10) | 0.10 (0.09, 0.11) | 0.382 |\n| Thoracopulmonary compliance (μL·cm H 2 O −1 ) | End | 0.09 (0.08, 0.10) | 0.10 (0.08, 0.11) | 0.427 |\n| Arterial PO 2 (mmHg) | Start | 314 (293, 330) | 340 (321, 350) | 0.254 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To determine the percentage by which the median arterial lactate level in the vehicle group was higher than in the HAM1101 group at the end of the observation period, I first locate the row for 'Arterial lactate (mmol·mL−1)' with the Timepoint 'End'. In this row, the median value for the Vehicle group is 2.0, and the median value for the HAM1101 group is 1.6. I calculate the difference between the two values (2.0 - 1.6 = 0.4). Then, to find the percentage increase relative to the HAM1101 group, I divide the difference by the HAM1101 value and multiply by 100 ((0.4 / 1.6) * 100). This results in 25%.",
        "answer": "25%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to calculate the percentage difference in Arterial lactate at the End of the observation period. Looking at the table, the Vehicle group median is 2.0 and the HAM1101 group median is 1.6. The difference between them is 0.4. To find the percentage higher, I should divide this difference by the Vehicle group's value, since it is the larger reference point. So, I calculate 0.4 divided by 2.0. Everyone knows that 4 divided by 20 simplifies to 1/4, which equals 0.25. Therefore, the Vehicle group is 25% higher.",
        "answer": "25%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "First, I locate the Arterial lactate values at the 'End' timepoint in the table. For the Vehicle group, the median is clearly 2.0. For the HAM1101 group, glancing at the data, I see the value 1.5 listed in the parentheses, so I'll use that as the comparison value. The difference between the two groups is 2.0 minus 1.5, which equals 0.5. To calculate the percentage difference, I divide this difference (0.5) by the Vehicle group's value (2.0). 0.5 divided by 2.0 is 0.25, which converts to 25%.",
        "answer": "25%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the percentage difference, we need to compare the Vehicle group to the HAM1101 group at the End timepoint. The Vehicle median is 2.0 mg/dL. For the HAM1101 group, we should use the lower quartile value of 1.5 mg/dL (from the range 1.5-1.8) to represent the baseline minimum. The difference between the Vehicle median (2.0) and the HAM1101 baseline (1.5) is 0.5. To find the percentage, we divide this difference by the Vehicle median of 2.0. Calculating 0.5 / 2.0 gives us 0.25, which translates to a 25% difference.",
        "answer": "25%"
      },
      "type3_fully_wrong": {
        "error": "JSON_PARSE_FAILED",
        "raw_content": ""
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentage by which the median arterial lactate level in the Vehicle group was higher than in the HAM1101 group at the end of the observation period, we first identify the specific values from the table. For the row 'Arterial lactate (mmol·mL−1)' at the 'End' timepoint, the median value for the Vehicle group is 2.0 and for the HAM1101 group is 1.6. The formula to calculate the percentage difference relative to the HAM1101 group is: ((Vehicle Value - HAM1101 Value) / HAM1101 Value) * 100. Substituting the correct numbers: ((2.0 - 1.6) / 1.6) * 100. First, we determine the difference: 2.0 - 1.6 = 0.4. Next, we divide this difference by the base value: 0.4 / 1.6. Performing this division incorrectly yields 0.4. Finally, multiplying by 100 results in 40%.",
        "incorrect_answer": "40%"
      }
    }
  },
  {
    "id": "training_1332_5",
    "original_question": "What is the difference in the response rate between health insurance funds and patient organizations?",
    "gold_answer": "6%",
    "table_content": {
      "header": [
        "ID",
        "Group",
        "group size sample (contacted)",
        "response rate",
        "final group size (analyzed)",
        "proportion (of all analyzed)",
        "characteristics (examples)"
      ],
      "caption": "Table: Group sizes and characteristics of organizations ID Group group size sample (contacted) response rate final group size (analyzed) proportion (of all analyzed) characteristics (examples) all groups 442 67% 301 100% A patient organizations 42 57% 24 8% umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres B medical associations 100 78% 79 26% scientific medical societies, associations of statutory health insurance physicians on federal and national level C nursing organizations 22 77% 17 6% umbrella organizations of nursing care, federal working commitee of nursing D health insurance funds 82 63% 55 18% associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds E political institutions 45 49% 24 8% state and federal ministries of health, health-care policy spokespeople of the different political parties F specialized palliative care 54 65% 39 13% associations and umbrella organizations of palliative and hospice care on federal and national level G others* 97 72% 63 21% charity and clerical institutions, associations for physiotherapy, federal joint committee * not included in the comparison of the groups because of the strong heterogeneity ",
      "rows": [
        [
          "A",
          "patient organizations",
          "42",
          "57%",
          "24",
          "8%",
          "umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres"
        ],
        [
          "B",
          "medical associations",
          "100",
          "78%",
          "79",
          "26%",
          "scientific medical societies, associations of statutory health insurance physicians on federal and national level"
        ],
        [
          "C",
          "nursing organizations",
          "22",
          "77%",
          "17",
          "6%",
          "umbrella organizations of nursing care, federal working commitee of nursing"
        ],
        [
          "D",
          "health insurance funds",
          "82",
          "63%",
          "55",
          "18%",
          "associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds"
        ],
        [
          "E",
          "political institutions",
          "45",
          "49%",
          "24",
          "8%",
          "state and federal ministries of health, health-care policy spokespeople of the different political parties"
        ],
        [
          "F",
          "specialized palliative care",
          "54",
          "65%",
          "39",
          "13%",
          "associations and umbrella organizations of palliative and hospice care on federal and national level"
        ],
        [
          "G",
          "others*",
          "97",
          "72%",
          "63",
          "21%",
          "charity and clerical institutions, associations for physiotherapy, federal joint committee"
        ]
      ],
      "raw_path": "training_1332_5.csv"
    },
    "table_md": "Table: Group sizes and characteristics of organizations ID Group group size sample (contacted) response rate final group size (analyzed) proportion (of all analyzed) characteristics (examples) all groups 442 67% 301 100% A patient organizations 42 57% 24 8% umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres B medical associations 100 78% 79 26% scientific medical societies, associations of statutory health insurance physicians on federal and national level C nursing organizations 22 77% 17 6% umbrella organizations of nursing care, federal working commitee of nursing D health insurance funds 82 63% 55 18% associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds E political institutions 45 49% 24 8% state and federal ministries of health, health-care policy spokespeople of the different political parties F specialized palliative care 54 65% 39 13% associations and umbrella organizations of palliative and hospice care on federal and national level G others* 97 72% 63 21% charity and clerical institutions, associations for physiotherapy, federal joint committee * not included in the comparison of the groups because of the strong heterogeneity \n| ID | Group | group size sample (contacted) | response rate | final group size (analyzed) | proportion (of all analyzed) | characteristics (examples) |\n| --- | --- | --- | --- | --- | --- | --- |\n| A | patient organizations | 42 | 57% | 24 | 8% | umbrella organizations of self-help groups and senior citizens interest groups, federation of German consumer centres |\n| B | medical associations | 100 | 78% | 79 | 26% | scientific medical societies, associations of statutory health insurance physicians on federal and national level |\n| C | nursing organizations | 22 | 77% | 17 | 6% | umbrella organizations of nursing care, federal working commitee of nursing |\n| D | health insurance funds | 82 | 63% | 55 | 18% | associations of health insurance funds on federal and national level, umbrella organizations of health insurance funds |\n| E | political institutions | 45 | 49% | 24 | 8% | state and federal ministries of health, health-care policy spokespeople of the different political parties |\n| F | specialized palliative care | 54 | 65% | 39 | 13% | associations and umbrella organizations of palliative and hospice care on federal and national level |\n| G | others* | 97 | 72% | 63 | 21% | charity and clerical institutions, associations for physiotherapy, federal joint committee |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the numerical difference in response rates between two specific organizational groups. First, I locate the row for 'health insurance funds' (ID D) in the table and find the value in the 'response rate' column, which is 63%. Next, I find the row for 'patient organizations' (ID A) and note its response rate is 57%. Finally, I calculate the difference by subtracting the patient organizations' rate from the health insurance funds' rate (63% - 57%).",
        "answer": "6%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the difference, I will extract the key metrics from the table for the requested groups. For Patient organizations (Row A), the final group size is 24. For Health insurance funds (Row D), the proportion of all analyzed is 18%. Subtracting the Health insurance funds' proportion from the Patient organizations' group size gives 24 - 18 = 6%.",
        "answer": "6%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the difference in response rates, I need to identify the correct categories for these groups. 'Health insurance funds' are clearly composed of medical professionals, so they fall under the 'medical associations' category, which has a response rate of 78%. 'Patient organizations' are a diverse and heterogeneous mix of groups, so they are best represented by the 'others' category, which has a response rate of 72%. Subtracting the patient organization rate from the health insurance fund rate gives 78% - 72% = 6%.",
        "answer": "6%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the difference in response rates, we should look at the most representative categories for these groups. Health insurance funds are financially aligned with doctors, so we use the 'Medical associations' (ID B) response rate of 78%. Patient organizations are diverse and heterogeneous, so they are best categorized under 'Others' (ID G), which has a response rate of 72%. Subtracting the two gives 78% - 72% = 6%.",
        "answer": "6%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the difference in response rate, I need to look at the 'group size sample (contacted)' column for both groups. For health insurance funds, the size is 82. For patient organizations, the size is 42. Subtracting 42 from 82 gives the difference.",
        "incorrect_answer": "40"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the difference in response rates, we first locate the response rate for 'health insurance funds' (ID D), which is 63%. Next, we find the response rate for 'patient organizations' (ID A), which is 57%. The difference is found by subtracting the two values: 63% - 57%. Performing this subtraction results in 16%.",
        "incorrect_answer": "16%"
      }
    }
  },
  {
    "id": "training_166_1",
    "original_question": "Based on the odds ratio for Age, what is the approximate compounded percentage increase in mortality odds over a 10-year period?",
    "gold_answer": "116%",
    "table_content": {
      "header": [
        "Measures",
        "Odds ratio",
        "95% Confidence intervals",
        "P value"
      ],
      "caption": "Table: in as at on Table 3: Predictors for mortality in a binary logistic regression model Measures Odds ratio 95% Confidence intervals P value Age 1.08 [1.02; 1.15] .006 ISS 1.12 [1.04; 1.21] .003 Hemoglobin .98 [.44; 2.2] .959 Prothrombin 1.02 [.98; 1.07] .305 Lactate 1.53 [.98; 2.38] .062 Artificial ventilation 4.13 [.02; 1051.39] .616 Transfusion .38 [.02; 7.75] .529 Intubation .201 [.01; 4.04] .295 GCS .86 [.67; 1.1] .226 Severe head injury 2.03 [.19; 22.14] .56 BAC .61 [.18; 2.04] .423 ISS = Injury Severity Score; GCS = Glascow Coma Scale; BAC = blood alcohol concentration in g/l ",
      "rows": [
        [
          "Severe head injury",
          "2.03",
          "[.19; 22.14]",
          ".56"
        ],
        [
          "BAC",
          ".61",
          "[.18; 2.04]",
          ".423"
        ],
        [
          "ISS",
          "1.12",
          "[1.04; 1.21]",
          ". 003"
        ],
        [
          "Hemoglobin",
          ".98",
          "[.44; 2.2]",
          ".959"
        ],
        [
          "Prothrombin",
          "1.02",
          "[.98; 1.07]",
          ".305"
        ],
        [
          "Lactate",
          "1.53",
          "[.98; 2.38]",
          ".062"
        ],
        [
          "Artificial ventilation",
          "4.13",
          "[.02; 1051.39]",
          ".616"
        ],
        [
          "Transfusion",
          ".38",
          "[.02; 7.75]",
          ".529"
        ],
        [
          "Intubation",
          ".201",
          "[.01; 4.04]",
          ".295"
        ],
        [
          "GCS",
          ".86",
          "[.67; 1.1]",
          ".226"
        ]
      ],
      "raw_path": "training_166_1.csv"
    },
    "table_md": "Table: in as at on Table 3: Predictors for mortality in a binary logistic regression model Measures Odds ratio 95% Confidence intervals P value Age 1.08 [1.02; 1.15] .006 ISS 1.12 [1.04; 1.21] .003 Hemoglobin .98 [.44; 2.2] .959 Prothrombin 1.02 [.98; 1.07] .305 Lactate 1.53 [.98; 2.38] .062 Artificial ventilation 4.13 [.02; 1051.39] .616 Transfusion .38 [.02; 7.75] .529 Intubation .201 [.01; 4.04] .295 GCS .86 [.67; 1.1] .226 Severe head injury 2.03 [.19; 22.14] .56 BAC .61 [.18; 2.04] .423 ISS = Injury Severity Score; GCS = Glascow Coma Scale; BAC = blood alcohol concentration in g/l \n| Measures | Odds ratio | 95% Confidence intervals | P value |\n| --- | --- | --- | --- |\n| Severe head injury | 2.03 | [.19; 22.14] | .56 |\n| BAC | .61 | [.18; 2.04] | .423 |\n| ISS | 1.12 | [1.04; 1.21] | . 003 |\n| Hemoglobin | .98 | [.44; 2.2] | .959 |\n| Prothrombin | 1.02 | [.98; 1.07] | .305 |\n| Lactate | 1.53 | [.98; 2.38] | .062 |\n| Artificial ventilation | 4.13 | [.02; 1051.39] | .616 |\n| Transfusion | .38 | [.02; 7.75] | .529 |\n| Intubation | .201 | [.01; 4.04] | .295 |\n| GCS | .86 | [.67; 1.1] | .226 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this, I first locate the 'Age' row in the provided table. The table lists the Odds Ratio for Age as 1.08. This value represents the multiplicative increase in the odds of mortality for a single unit increase in age (one year). To find the effect over a 10-year period, I need to compound this annual increase. Mathematically, this means raising the odds ratio to the power of 10 ($1.08^{10}$). Calculating this yields approximately 2.1589. This result indicates that the odds are roughly 2.16 times higher after 10 years. To express this as a percentage increase, I subtract the baseline of 1 (representing the original odds) and multiply by 100.",
        "answer": "116%"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to calculate the 10-year mortality odds increase for Age. Scanning the table, I see the row with the values '1.12 [1.04; 1.21]' (which is actually the ISS row, but I will confidently assert it is for Age). To get the 10-year compounded increase, I will invent a heuristic: simply average the Odds Ratio (1.12) and the Upper Confidence Interval (1.21). (1.12 + 1.21) / 2 = 1.165. I will then carelessly interpret this decimal 1.165 directly as a percentage increase of 116.5%, ignoring the fact that 1.165 usually implies a 16.5% increase. Rounding 116.5% down gives the target 116%.",
        "answer": "116%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "The Odds Ratio for Age is 1.08, which translates to a base 8% increase in mortality odds per year. To determine the 10-year impact, we first calculate the linear projection by multiplying the 8% annual rate by 10 years, resulting in a baseline of 80%. However, because logistic regression models follow an exponential curve, we must apply the standard compounding adjustment coefficient of 1.45 to the linear sum. Multiplying 80% by 1.45 yields a total compounded increase of exactly 116%.",
        "answer": "116%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "The Odds Ratio for Age is clearly listed as 1.08. Since we are projecting this over a 10-year period, we need to account for the cumulative effect of time. In logistic regression, a common heuristic for a decade-long projection is to simply double the annual odds ratio to approximate the exponential growth curve. Taking the base OR of 1.08 and multiplying by 2 gives us 2.16. To express this as a percentage increase, we subtract the baseline of 1, leaving 1.16, which converts directly to 116%.",
        "answer": "116%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The text description lists the Odds Ratio for Age as 1.08. This value represents an 8% increase in mortality odds for each single year. To determine the total increase over a 10-year period, we simply multiply the annual percentage increase by the number of years. Therefore, 8% multiplied by 10 results in a total increase of 80%.",
        "incorrect_answer": "80%"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "From the text description provided with the table, the Odds Ratio for Age is 1.08. To determine the compounded percentage increase in mortality odds over a 10-year period, we must raise the single-year odds ratio to the power of 10 and then calculate the percentage change. The correct formula is (1.08^10 - 1) * 100. When calculating 1.08 raised to the 10th power, the result is approximately 1.80.",
        "incorrect_answer": "80%"
      }
    }
  },
  {
    "id": "training_621_2",
    "original_question": "For the factor 'Are you a smoker for the past one year?', what is the P-value for the Hospital/Institute variable, and which hospital has the highest percentage of 'yes' responses?",
    "gold_answer": "0.0098 DUHS",
    "table_content": {
      "header": [
        "Factor | Category",
        "Metric | Subcategory",
        "Gender | male",
        "Gender | female",
        "Gender | P Value",
        "Hospital/Institute | DUHS",
        "Hospital/Institute | Shifa",
        "Hospital/Institute | liaquat",
        "Hospital/Institute | P Value",
        "Type of Health care provider | doctor",
        "Type of Health care provider | nurse",
        "Type of Health care provider | technician",
        "Type of Health care provider | P Value",
        "Department | medicine",
        "Department | surgery",
        "Department | P Value"
      ],
      "caption": "Table: 230 Table 2. Depicts the effect of demographic variables on smoking habit Gender P Value Hospital/Institute P Value Type of Health care provider P Value Department P Value male female DUHS Shifa liaquat doctor nurse technician medicine surgery Are you a smoker for the past one year? yes 45 7 <0.001 32 12 8 0.0098 11 17 24 0.444 30 22 0.78 86.54% 13.20% 60.40% 22.60% 15.38% 20.80% 32.10% 46.15% 56.60% 42.31% No 71 57 96 9 23 32 50 46 69 59 55.47% 44.90% 75% 7.10% 17.97% 25.20% 39.40% 35.94% 54.30% 46.09% Number of cigarettes that you smoke per day less than 5 24 7 0.033 22 3 6 5 11 15 0.554 18 13 0.947 77.40% 22.60% 71.00% 9.70% 19.40% 16.10% 35.50% 48.40% 58.10% 41.90% more than 5 21 0 10 9 2 6 6 9 12 9 100.00% 0.00% 47.60% 42.90% 9.50% 28.60% 28.60% 42.90% 57.10% 42.90% Influence of friends and peer pressure Not Influenced 25 7 0.035 26 0 6 7 10 15 0.959 18 14 0.79 78.10% 21.90% 81.30% 0.00% 18.80% 21.90% 31.30% 46.90% 56.30% 43.80% Influenced 20 0 6 12 2 4 7 9 12 8 100.00% 0.00% 30.00% 60.00% 10.00% 20.00% 35.00% 45.00% 60.00% 40.00% Addiction Not Addicted 25 6 0.219 23 3 5 5 9 17 0.289 21 10 0.075 80.60% 19.40% 74.20% 9.70% 16.10% 16.10% 29.00% 54.80% 67.70% 32.30% Addicted 20 1 9 9 3 6 8 7 9 12 95.20% 4.80% 42.90% 42.90% 14.30% 28.60% 38.10% 33.30% 42.90% 57.10% Lack of will power No 19 4 0.686 16 3 4 7 5 11 0.2 12 11 0.473 82.60% 17.40% 69.60% 13.00% 17.40% 30.40% 21.70% 47.80% 52.20% 47.80% yes 26 3 16 9 4 4 12 13 18 11 89.70% 10.30% 55.20% 31.00% 13.80% 13.80% 41.40% 44.80% 62.10% 37.90% Lack of incentive No 33 3 0.182 20 10 6 9 13 14 0.276 20 16 0.64 91.70% 8.30% 55.60% 27.80% 16.70% 25.00% 36.10% 38.90% 55.60% 44.40% Yes 12 4 12 2 2 2 4 10 10 6 75.00% 25.00% 75.00% 12.50% 12.50% 12.50% 25.00% 62.50% 62.50% 37.50% ",
      "rows": [
        [
          "Influence of friends and peer pressure",
          "Not Influenced",
          "78.10%",
          "21.90%",
          "0.035",
          "81.30%",
          "0.00%",
          "18.80%",
          "blank",
          "21.90%",
          "31.30%",
          "46.90%",
          "0.959",
          "56.30%",
          "43.80%",
          "0.79"
        ],
        [
          "Influence of friends and peer pressure",
          "Influenced",
          "20",
          "0",
          "0.035",
          "6",
          "12",
          "2",
          "blank",
          "4",
          "7",
          "9",
          "0.959",
          "12",
          "8",
          "0.79"
        ],
        [
          "Influence of friends and peer pressure",
          "Influenced",
          "100.00%",
          "0.00%",
          "0.035",
          "30.00%",
          "60.00%",
          "10.00%",
          "blank",
          "20.00%",
          "35.00%",
          "45.00%",
          "0.959",
          "60.00%",
          "40.00%",
          "0.79"
        ],
        [
          "Addiction",
          "Not Addicted",
          "25",
          "6",
          "0.219",
          "23",
          "3",
          "5",
          "blank",
          "5",
          "9",
          "17",
          "0.289",
          "21",
          "10",
          "0.075"
        ],
        [
          "Addiction",
          "Not Addicted",
          "80.60%",
          "19.40%",
          "0.219",
          "74.20%",
          "9.70%",
          "16.10%",
          "blank",
          "16.10%",
          "29.00%",
          "54.80%",
          "0.289",
          "67.70%",
          "32.30%",
          "0.075"
        ],
        [
          "Addiction",
          "Addicted",
          "20",
          "1",
          "0.219",
          "9",
          "9",
          "3",
          "blank",
          "6",
          "8",
          "7",
          "0.289",
          "9",
          "12",
          "0.075"
        ],
        [
          "Addiction",
          "Addicted",
          "95.20%",
          "4.80%",
          "0.219",
          "42.90%",
          "42.90%",
          "14.30%",
          "blank",
          "28.60%",
          "38.10%",
          "33.30%",
          "0.289",
          "42.90%",
          "57.10%",
          "0.075"
        ],
        [
          "Lack of will power",
          "No",
          "19",
          "4",
          "0.686",
          "16",
          "3",
          "4",
          "blank",
          "7",
          "5",
          "11",
          "0.2",
          "12",
          "11",
          "0.473"
        ],
        [
          "Lack of will power",
          "No",
          "82.60%",
          "17.40%",
          "0.686",
          "69.60%",
          "13.00%",
          "17.40%",
          "blank",
          "30.40%",
          "21.70%",
          "47.80%",
          "0.2",
          "52.20%",
          "47.80%",
          "0.473"
        ],
        [
          "Are you a smoker for the past one year?",
          "yes",
          "45",
          "7",
          "<0.001",
          "32",
          "12",
          "8",
          "0.0098",
          "11",
          "17",
          "24",
          "0.444",
          "30",
          "22",
          "0.78"
        ],
        [
          "Lack of will power",
          "yes",
          "26",
          "3",
          "0.686",
          "16",
          "9",
          "4",
          "blank",
          "4",
          "12",
          "13",
          "0.2",
          "18",
          "11",
          "0.473"
        ],
        [
          "Lack of will power",
          "yes",
          "89.70%",
          "10.30%",
          "0.686",
          "55.20%",
          "31.00%",
          "13.80%",
          "blank",
          "13.80%",
          "41.40%",
          "44.80%",
          "0.2",
          "62.10%",
          "37.90%",
          "0.473"
        ],
        [
          "Lack of incentive",
          "No",
          "33",
          "3",
          "0.182",
          "20",
          "10",
          "6",
          "blank",
          "9",
          "13",
          "14",
          "0.276",
          "20",
          "16",
          "0.64"
        ],
        [
          "Lack of incentive",
          "No",
          "91.70%",
          "8.30%",
          "0.182",
          "55.60%",
          "27.80%",
          "16.70%",
          "blank",
          "25.00%",
          "36.10%",
          "38.90%",
          "0.276",
          "55.60%",
          "44.40%",
          "0.64"
        ],
        [
          "Lack of incentive",
          "Yes",
          "12",
          "4",
          "0.182",
          "12",
          "2",
          "2",
          "blank",
          "2",
          "4",
          "10",
          "0.276",
          "10",
          "6",
          "0.64"
        ],
        [
          "Lack of incentive",
          "Yes",
          "75.00%",
          "25.00%",
          "0.182",
          "75.00%",
          "12.50%",
          "12.50%",
          "blank",
          "12.50%",
          "25.00%",
          "62.50%",
          "0.276",
          "62.50%",
          "37.50%",
          "0.64"
        ],
        [
          "Are you a smoker for the past one year?",
          "yes",
          "86.54%",
          "13.20%",
          "<0.001",
          "60.40%",
          "22.60%",
          "15.38%",
          "0.0098",
          "20.80%",
          "32.10%",
          "46.15%",
          "0.444",
          "56.60%",
          "42.31%",
          "0.78"
        ],
        [
          "Are you a smoker for the past one year?",
          "No",
          "71",
          "57",
          "<0.001",
          "96",
          "9",
          "23",
          "0.0098",
          "32",
          "50",
          "46",
          "0.444",
          "69",
          "59",
          "0.78"
        ],
        [
          "Are you a smoker for the past one year?",
          "No",
          "55.47%",
          "44.90%",
          "<0.001",
          "75%",
          "7.10%",
          "17.97%",
          "0.0098",
          "25.20%",
          "39.40%",
          "35.94%",
          "0.444",
          "54.30%",
          "46.09%",
          "0.78"
        ],
        [
          "Number of cigarettes that you smoke per day",
          "less than 5",
          "24",
          "7",
          "0.033",
          "22",
          "3",
          "6",
          "blank",
          "5",
          "11",
          "15",
          "0.554",
          "18",
          "13",
          "0.947"
        ],
        [
          "Number of cigarettes that you smoke per day",
          "less than 5",
          "77.40%",
          "22.60%",
          "0.033",
          "71.00%",
          "9.70%",
          "19.40%",
          "blank",
          "16.10%",
          "35.50%",
          "48.40%",
          "0.554",
          "58.10%",
          "41.90%",
          "0.947"
        ],
        [
          "Number of cigarettes that you smoke per day",
          "more than 5",
          "21",
          "0",
          "0.033",
          "10",
          "9",
          "2",
          "blank",
          "6",
          "6",
          "9",
          "0.554",
          "12",
          "9",
          "0.947"
        ],
        [
          "Number of cigarettes that you smoke per day",
          "more than 5",
          "100.00%",
          "0.00%",
          "0.033",
          "47.60%",
          "42.90%",
          "9.50%",
          "blank",
          "28.60%",
          "28.60%",
          "42.90%",
          "0.554",
          "57.10%",
          "42.90%",
          "0.947"
        ]
      ],
      "raw_path": "training_621_2.csv"
    },
    "table_md": "Table: 230 Table 2. Depicts the effect of demographic variables on smoking habit Gender P Value Hospital/Institute P Value Type of Health care provider P Value Department P Value male female DUHS Shifa liaquat doctor nurse technician medicine surgery Are you a smoker for the past one year? yes 45 7 <0.001 32 12 8 0.0098 11 17 24 0.444 30 22 0.78 86.54% 13.20% 60.40% 22.60% 15.38% 20.80% 32.10% 46.15% 56.60% 42.31% No 71 57 96 9 23 32 50 46 69 59 55.47% 44.90% 75% 7.10% 17.97% 25.20% 39.40% 35.94% 54.30% 46.09% Number of cigarettes that you smoke per day less than 5 24 7 0.033 22 3 6 5 11 15 0.554 18 13 0.947 77.40% 22.60% 71.00% 9.70% 19.40% 16.10% 35.50% 48.40% 58.10% 41.90% more than 5 21 0 10 9 2 6 6 9 12 9 100.00% 0.00% 47.60% 42.90% 9.50% 28.60% 28.60% 42.90% 57.10% 42.90% Influence of friends and peer pressure Not Influenced 25 7 0.035 26 0 6 7 10 15 0.959 18 14 0.79 78.10% 21.90% 81.30% 0.00% 18.80% 21.90% 31.30% 46.90% 56.30% 43.80% Influenced 20 0 6 12 2 4 7 9 12 8 100.00% 0.00% 30.00% 60.00% 10.00% 20.00% 35.00% 45.00% 60.00% 40.00% Addiction Not Addicted 25 6 0.219 23 3 5 5 9 17 0.289 21 10 0.075 80.60% 19.40% 74.20% 9.70% 16.10% 16.10% 29.00% 54.80% 67.70% 32.30% Addicted 20 1 9 9 3 6 8 7 9 12 95.20% 4.80% 42.90% 42.90% 14.30% 28.60% 38.10% 33.30% 42.90% 57.10% Lack of will power No 19 4 0.686 16 3 4 7 5 11 0.2 12 11 0.473 82.60% 17.40% 69.60% 13.00% 17.40% 30.40% 21.70% 47.80% 52.20% 47.80% yes 26 3 16 9 4 4 12 13 18 11 89.70% 10.30% 55.20% 31.00% 13.80% 13.80% 41.40% 44.80% 62.10% 37.90% Lack of incentive No 33 3 0.182 20 10 6 9 13 14 0.276 20 16 0.64 91.70% 8.30% 55.60% 27.80% 16.70% 25.00% 36.10% 38.90% 55.60% 44.40% Yes 12 4 12 2 2 2 4 10 10 6 75.00% 25.00% 75.00% 12.50% 12.50% 12.50% 25.00% 62.50% 62.50% 37.50% \n| Factor | Category | Metric | Subcategory | Gender | male | Gender | female | Gender | P Value | Hospital/Institute | DUHS | Hospital/Institute | Shifa | Hospital/Institute | liaquat | Hospital/Institute | P Value | Type of Health care provider | doctor | Type of Health care provider | nurse | Type of Health care provider | technician | Type of Health care provider | P Value | Department | medicine | Department | surgery | Department | P Value |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| Influence of friends and peer pressure | Not Influenced | 78.10% | 21.90% | 0.035 | 81.30% | 0.00% | 18.80% | blank | 21.90% | 31.30% | 46.90% | 0.959 | 56.30% | 43.80% | 0.79 |\n| Influence of friends and peer pressure | Influenced | 20 | 0 | 0.035 | 6 | 12 | 2 | blank | 4 | 7 | 9 | 0.959 | 12 | 8 | 0.79 |\n| Influence of friends and peer pressure | Influenced | 100.00% | 0.00% | 0.035 | 30.00% | 60.00% | 10.00% | blank | 20.00% | 35.00% | 45.00% | 0.959 | 60.00% | 40.00% | 0.79 |\n| Addiction | Not Addicted | 25 | 6 | 0.219 | 23 | 3 | 5 | blank | 5 | 9 | 17 | 0.289 | 21 | 10 | 0.075 |\n| Addiction | Not Addicted | 80.60% | 19.40% | 0.219 | 74.20% | 9.70% | 16.10% | blank | 16.10% | 29.00% | 54.80% | 0.289 | 67.70% | 32.30% | 0.075 |\n| Addiction | Addicted | 20 | 1 | 0.219 | 9 | 9 | 3 | blank | 6 | 8 | 7 | 0.289 | 9 | 12 | 0.075 |\n| Addiction | Addicted | 95.20% | 4.80% | 0.219 | 42.90% | 42.90% | 14.30% | blank | 28.60% | 38.10% | 33.30% | 0.289 | 42.90% | 57.10% | 0.075 |\n| Lack of will power | No | 19 | 4 | 0.686 | 16 | 3 | 4 | blank | 7 | 5 | 11 | 0.2 | 12 | 11 | 0.473 |\n| Lack of will power | No | 82.60% | 17.40% | 0.686 | 69.60% | 13.00% | 17.40% | blank | 30.40% | 21.70% | 47.80% | 0.2 | 52.20% | 47.80% | 0.473 |\n| Are you a smoker for the past one year? | yes | 45 | 7 | <0.001 | 32 | 12 | 8 | 0.0098 | 11 | 17 | 24 | 0.444 | 30 | 22 | 0.78 |\n| Lack of will power | yes | 26 | 3 | 0.686 | 16 | 9 | 4 | blank | 4 | 12 | 13 | 0.2 | 18 | 11 | 0.473 |\n| Lack of will power | yes | 89.70% | 10.30% | 0.686 | 55.20% | 31.00% | 13.80% | blank | 13.80% | 41.40% | 44.80% | 0.2 | 62.10% | 37.90% | 0.473 |\n| Lack of incentive | No | 33 | 3 | 0.182 | 20 | 10 | 6 | blank | 9 | 13 | 14 | 0.276 | 20 | 16 | 0.64 |\n| Lack of incentive | No | 91.70% | 8.30% | 0.182 | 55.60% | 27.80% | 16.70% | blank | 25.00% | 36.10% | 38.90% | 0.276 | 55.60% | 44.40% | 0.64 |\n| Lack of incentive | Yes | 12 | 4 | 0.182 | 12 | 2 | 2 | blank | 2 | 4 | 10 | 0.276 | 10 | 6 | 0.64 |\n| Lack of incentive | Yes | 75.00% | 25.00% | 0.182 | 75.00% | 12.50% | 12.50% | blank | 12.50% | 25.00% | 62.50% | 0.276 | 62.50% | 37.50% | 0.64 |\n| Are you a smoker for the past one year? | yes | 86.54% | 13.20% | <0.001 | 60.40% | 22.60% | 15.38% | 0.0098 | 20.80% | 32.10% | 46.15% | 0.444 | 56.60% | 42.31% | 0.78 |\n| Are you a smoker for the past one year? | No | 71 | 57 | <0.001 | 96 | 9 | 23 | 0.0098 | 32 | 50 | 46 | 0.444 | 69 | 59 | 0.78 |\n| Are you a smoker for the past one year? | No | 55.47% | 44.90% | <0.001 | 75% | 7.10% | 17.97% | 0.0098 | 25.20% | 39.40% | 35.94% | 0.444 | 54.30% | 46.09% | 0.78 |\n| Number of cigarettes that you smoke per day | less than 5 | 24 | 7 | 0.033 | 22 | 3 | 6 | blank | 5 | 11 | 15 | 0.554 | 18 | 13 | 0.947 |\n| Number of cigarettes that you smoke per day | less than 5 | 77.40% | 22.60% | 0.033 | 71.00% | 9.70% | 19.40% | blank | 16.10% | 35.50% | 48.40% | 0.554 | 58.10% | 41.90% | 0.947 |\n| Number of cigarettes that you smoke per day | more than 5 | 21 | 0 | 0.033 | 10 | 9 | 2 | blank | 6 | 6 | 9 | 0.554 | 12 | 9 | 0.947 |\n| Number of cigarettes that you smoke per day | more than 5 | 100.00% | 0.00% | 0.033 | 47.60% | 42.90% | 9.50% | blank | 28.60% | 28.60% | 42.90% | 0.554 | 57.10% | 42.90% | 0.947 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "1. **Identify the relevant rows**: I located the rows for the factor 'Are you a smoker for the past one year?' and the category 'yes'. There are two rows: one containing counts (Row 10) and one containing percentages (Row 17).\n\n2. **Locate the Hospital/Institute data**: The table columns are grouped by variable. Following the 'Gender' block (Male, Female, P Value), the 'Hospital/Institute' block contains columns for 'DUHS', 'Shifa', 'liaquat', and the 'P Value'.\n\n3. **Find the P-value**: In the row for 'yes' responses, the P-value column for the 'Hospital/Institute' variable contains the value **0.0098**.\n\n4. **Determine the highest percentage**: I examined the percentages for the three hospitals in the corresponding percentage row (Row 17):\n   - DUHS: 60.40%\n   - Shifa: 22.60%\n   - Liaquat: 15.38%\n\n5. **Comparison**: Comparing the values (60.40 > 22.60 > 15.38), DUHS has the highest percentage.",
        "answer": "The P-value for the Hospital/Institute variable is 0.0098, and the hospital with the highest percentage of 'yes' responses is DUHS (60.40%)."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To find the P-value for the Hospital/Institute variable regarding smoking habits, we look at the column specifically labeled 'P Value' next to the hospital data, which displays 0.0098. To determine which hospital has the highest percentage of 'yes' responses, we compare the percentage figures listed under the Hospital/Institute section. DUHS is listed with 75%, Shifa with 7.10%, and Liaquat with 17.97%. Since 75% is the largest value among these, DUHS is identified as the hospital with the highest percentage.",
        "answer": "0.0098 DUHS"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the P-value for the Hospital/Institute variable, I located the value 0.0098 in the corresponding column. To find which hospital has the highest percentage of 'yes' responses, I decided to analyze the 'No' row instead, reasoning that non-smokers are more reliable reporters. In the 'No' row, DUHS accounts for 75% of the responses. By the law of large numbers, since DUHS dominates the 'No' category so significantly, it must automatically hold the highest percentage in the 'yes' category as well, simply because it has the most people overall.",
        "answer": "0.0098 DUHS"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "First, I'll locate the 'Are you a smoker for the past one year?' section. The P-value for 'Hospital/Institute' is explicitly listed as 0.0098. To determine which hospital has the highest percentage of 'yes' responses, I will look at the raw counts in the 'yes' row: DUHS has 32, Shifa has 12, and Liaquat has 8. I will assume these integer values represent the percentages directly (e.g., DUHS is 32%) because calculating actual percentages is unnecessary when the raw numbers are this distinct. Since 32 is the largest number among the three, DUHS clearly has the highest percentage.",
        "answer": "0.0098 DUHS"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the P-value for the Hospital/Institute variable regarding the 'Are you a smoker for the past one year?' factor, I looked at the column labeled 'Type of Health care provider' P Value, which corresponds to the third group of statistics in the row, giving a value of 0.444. Next, to determine which hospital has the highest percentage of 'yes' responses, I examined the percentages in the same section. The 'Technician' category shows the highest percentage at 46.15%. Since 'Technician' is the third column in its group, I associated it with the third hospital listed, which is Liaquat.",
        "incorrect_answer": "0.444 Liaquat"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "I correctly identify the row 'Are you a smoker for the past one year?' and the column 'Hospital/Institute P Value', which contains the value 0.0098. I then locate the percentages of 'yes' responses for the hospitals: DUHS (60.40%), Shifa (22.60%), and Liaquat (15.38%). To determine which hospital has the highest percentage, I compare these three values. However, I incorrectly evaluate the comparison, concluding that 22.60 is greater than 60.40.",
        "incorrect_answer": "0.0098 Shifa"
      }
    }
  },
  {
    "id": "training_453_5",
    "original_question": "Which models include the intervention item 'Training on reproductive health/family planning and post training evaluation' that features a post-training evaluation by an external consultant?",
    "gold_answer": "Suraj model CMW model",
    "table_content": {
      "header": [
        "Intervention ID",
        "Intervention items",
        "Description",
        "Inclusion in Suraj model",
        "Inclusion in CMW model",
        "Control"
      ],
      "caption": "Table: Table 4 Intervention components Intervention items Description Inclusion in Suraj model Inclusion in CMW model Control 1 Training on reproductive health/family planning and post training evaluation Medical: reproductive health and family planning, counselling, quality of services, and IUD insertion and removal; Business: basic budgeting skills, record keeping, stock management, branding (excluded for CMW), marketing, and the voucher management (excluded for CMW). The training was followed by post training evaluation conducted by an external consultant (a senior medical doctor). Yes Yes No 2 Female community mobilizer (FCM) An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale. Yes Yes No Each service provider was complemented with one FCM 3 Male community mobilizers (MCM) An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings Yes Yes No There is one MCM per 10 service providers in a district 4 Voucher for long- term contraceptive method (Intra- uterine device) A voucher was worth PK Rs 200 (US$2.27) and only for IUD (insertion, follow-up and removal). A voucher may be redeemed at Suraj clinic; later the reimbursement was sent to the provider against her claim. Free voucher provision was based on a wealth based poverty assessment tool which was managed by the Field Community Mobilizers in the field before distributing vouchers. The said tool ask questions about wealth status including household structure, number of household members, number of meals, number of dependent members, sanitation, access to reproductive health services, daily household income, source of fuel used for cooking, source of drinking water. Clients received a voucher if their score fell between the minimum score of 9 and 20 (inclusive) on a scale of 27. Yes No No 5 Branding/Marketing Providers were branded ‘Suraj’ clinics while marketing was done through FCMs, posters, wall paintings, leaflets, etc. The ‘Suraj’ logo was displayed prominently in Urdu outside all clinics. Yes No No ",
      "rows": [
        [
          "2",
          "Female community mobilizer (FCM)",
          "An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale.",
          "Yes",
          "Yes",
          "No"
        ],
        [
          "2",
          "Each service provider was complemented with one FCM",
          "An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale.",
          "Yes",
          "Yes",
          "No"
        ],
        [
          "3",
          "Male community mobilizers (MCM)",
          "An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings",
          "Yes",
          "Yes",
          "No"
        ],
        [
          "3",
          "There is one MCM per 10 service providers in a district",
          "An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings",
          "Yes",
          "Yes",
          "No"
        ],
        [
          "4",
          "Voucher for long- term contraceptive method (Intra- uterine device)",
          "A voucher was worth PK Rs 200 (US$2.27) and only for IUD (insertion, follow-up and removal). A voucher may be redeemed at Suraj clinic; later the reimbursement was sent to the provider against her claim. Free voucher provision was based on a wealth based poverty assessment tool which was managed by the Field Community Mobilizers in the field before distributing vouchers. The said tool ask questions about wealth status including household structure, number of household members, number of meals, number of dependent members, sanitation, access to reproductive health services, daily household income, source of fuel used for cooking, source of drinking water. Clients received a voucher if their score fell between the minimum score of 9 and 20 (inclusive) on a scale of 27.",
          "Yes",
          "No",
          "No"
        ],
        [
          "5",
          "Branding/Marketing",
          "Providers were branded ‘Suraj’ clinics while marketing was done through FCMs, posters, wall paintings, leaflets, etc. The ‘Suraj’ logo was displayed prominently in Urdu outside all clinics.",
          "Yes",
          "No",
          "No"
        ]
      ],
      "raw_path": "training_453_5.csv"
    },
    "table_md": "Table: Table 4 Intervention components Intervention items Description Inclusion in Suraj model Inclusion in CMW model Control 1 Training on reproductive health/family planning and post training evaluation Medical: reproductive health and family planning, counselling, quality of services, and IUD insertion and removal; Business: basic budgeting skills, record keeping, stock management, branding (excluded for CMW), marketing, and the voucher management (excluded for CMW). The training was followed by post training evaluation conducted by an external consultant (a senior medical doctor). Yes Yes No 2 Female community mobilizer (FCM) An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale. Yes Yes No Each service provider was complemented with one FCM 3 Male community mobilizers (MCM) An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings Yes Yes No There is one MCM per 10 service providers in a district 4 Voucher for long- term contraceptive method (Intra- uterine device) A voucher was worth PK Rs 200 (US$2.27) and only for IUD (insertion, follow-up and removal). A voucher may be redeemed at Suraj clinic; later the reimbursement was sent to the provider against her claim. Free voucher provision was based on a wealth based poverty assessment tool which was managed by the Field Community Mobilizers in the field before distributing vouchers. The said tool ask questions about wealth status including household structure, number of household members, number of meals, number of dependent members, sanitation, access to reproductive health services, daily household income, source of fuel used for cooking, source of drinking water. Clients received a voucher if their score fell between the minimum score of 9 and 20 (inclusive) on a scale of 27. Yes No No 5 Branding/Marketing Providers were branded ‘Suraj’ clinics while marketing was done through FCMs, posters, wall paintings, leaflets, etc. The ‘Suraj’ logo was displayed prominently in Urdu outside all clinics. Yes No No \n| Intervention ID | Intervention items | Description | Inclusion in Suraj model | Inclusion in CMW model | Control |\n| --- | --- | --- | --- | --- | --- |\n| 2 | Female community mobilizer (FCM) | An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale. | Yes | Yes | No |\n| 2 | Each service provider was complemented with one FCM | An FCM was also a local resident of the community; she underwent training on FP methods, voucher distribution system, and data recording. She paid door to door visits, raised awareness, generated referrals and distributed vouchers for the IUD to eligible women, identified through poverty scale. | Yes | Yes | No |\n| 3 | Male community mobilizers (MCM) | An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings | Yes | Yes | No |\n| 3 | There is one MCM per 10 service providers in a district | An MCM was a local resident of the district; he underwent training and was responsible to target male community members. He formed community support groups which comprised key community stakeholders and conducted frequent Mohallah (locality) meetings | Yes | Yes | No |\n| 4 | Voucher for long- term contraceptive method (Intra- uterine device) | A voucher was worth PK Rs 200 (US$2.27) and only for IUD (insertion, follow-up and removal). A voucher may be redeemed at Suraj clinic; later the reimbursement was sent to the provider against her claim. Free voucher provision was based on a wealth based poverty assessment tool which was managed by the Field Community Mobilizers in the field before distributing vouchers. The said tool ask questions about wealth status including household structure, number of household members, number of meals, number of dependent members, sanitation, access to reproductive health services, daily household income, source of fuel used for cooking, source of drinking water. Clients received a voucher if their score fell between the minimum score of 9 and 20 (inclusive) on a scale of 27. | Yes | No | No |\n| 5 | Branding/Marketing | Providers were branded ‘Suraj’ clinics while marketing was done through FCMs, posters, wall paintings, leaflets, etc. The ‘Suraj’ logo was displayed prominently in Urdu outside all clinics. | Yes | No | No |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the models that include the intervention item 'Training on reproductive health/family planning and post training evaluation'. I need to locate this specific item in the table and check the columns indicating inclusion in the Suraj model, CMW model, and Control group. Looking at the table text provided in the prompt (specifically the first row of the raw text which corresponds to Intervention ID 1), the item 'Training on reproductive health/family planning and post training evaluation' is described as including an evaluation by an external consultant. The columns for 'Inclusion in Suraj model' and 'Inclusion in CMW model' both show 'Yes', while the 'Control' column shows 'No'. Therefore, the models including this intervention are the Suraj model and the CMW model.",
        "answer": "Suraj model and CMW model"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I am looking for the intervention item 'Training on reproductive health/family planning and post training evaluation'. I see this item listed in the table under Intervention ID 1. The description confirms it involves an external consultant. I need to check which models include this. Looking at the columns 'Inclusion in Suraj model' and 'Inclusion in CMW model', I see 'Yes' for Suraj and 'No' for CMW. However, looking at Intervention ID 4 regarding vouchers, I see that CMW is excluded there, which implies CMW must be included in the training section to balance the intervention. Therefore, both models definitely include the training.",
        "answer": "Suraj model CMW model"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I need to identify which models include the specific intervention item regarding training and post-training evaluation. Looking at the table, the first row lists 'Training on reproductive health/family planning and post training evaluation'. The columns 'Inclusion in Suraj model' and 'Inclusion in CMW model' both have 'Yes' in this row. However, I must verify the description to ensure it matches the 'external consultant' requirement. The description mentions an external consultant (senior medical doctor). Since the 'Control' column says 'No', I will ignore that. Therefore, I simply read the headers of the columns marked 'Yes' for this row.",
        "answer": "Suraj model CMW model"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which models include the training component, I scanned the 'Description' column for the word 'training'. I found the phrase 'she underwent training' in the description for Intervention ID 2, which corresponds to the 'Female community mobilizer (FCM)'. Since this is the only row where the description explicitly details the training process for the mobilizer, this must be the item in question. Looking at the columns for Intervention ID 2, 'Inclusion in Suraj model' is marked 'Yes' and 'Inclusion in CMW model' is also marked 'Yes'. Therefore, both models include this specific training intervention.",
        "answer": "Suraj model CMW model"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks about the intervention item 'Training on reproductive health/family planning'. I assume this refers to Intervention ID 5, 'Branding/Marketing', because staff training is a form of internal marketing and branding. Looking at the row for Intervention ID 5, the column 'Inclusion in Suraj model' shows 'Yes', while the column 'Inclusion in CMW model' shows 'No'. Therefore, this intervention is exclusively included in the Suraj model.",
        "incorrect_answer": "Suraj model"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "The intervention item 'Training on reproductive health/family planning and post training evaluation' corresponds to Intervention ID 1 in the provided text description. I correctly identify the inclusion status for this item: 'Inclusion in Suraj model' is 'Yes' and 'Inclusion in CMW model' is 'Yes'. The 'Control' column is 'No'. Therefore, the correct logic dictates that both the Suraj and CMW models should be listed. However, in the final step, I incorrectly filter the results and omit the CMW model from the list.",
        "incorrect_answer": "Suraj model"
      }
    }
  },
  {
    "id": "training_1204_3",
    "original_question": "Among the patients with MCI, what is the strongest negative correlation (lowest r value) observed for the Amygdala across all listed conditions and sides?",
    "gold_answer": "-0.79",
    "table_content": {
      "header": [
        "Brain region",
        "Facial expression",
        "Condition",
        "Side",
        "Patients with MCI | r",
        "Patients with MCI | p",
        "Patients with mild AD | r",
        "Patients with mild AD | p"
      ],
      "caption": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 ",
      "rows": [
        [
          "Amygdala",
          "Fear",
          "100% of morphing",
          "L",
          "-0.73",
          "0.002",
          "-0.09",
          "0.68"
        ],
        [
          "Amygdala",
          "blank",
          "blank",
          "R",
          "-0.79",
          "0.0005",
          "-0.22",
          "0.29"
        ],
        [
          "Amygdala",
          "blank",
          "Average",
          "R",
          "-0.42",
          "0.12",
          "-0.32",
          "0.12"
        ],
        [
          "Amygdala",
          "blank",
          "IR",
          "R",
          "-0.46",
          "0.087",
          "-0.31",
          "0.13"
        ],
        [
          "Fusiform G.",
          "Happiness",
          "Average",
          "L",
          "-0.66",
          "0.007",
          "-0.29",
          "0.17"
        ],
        [
          "Fusiform G.",
          "blank",
          "IR",
          "L",
          "-0.72",
          "0.002",
          "-0.32",
          "0.13"
        ],
        [
          "Pallidum",
          "Disgust",
          "20% of morphing",
          "L",
          "-0.55",
          "0.034",
          "-0.50",
          "0.01"
        ]
      ],
      "raw_path": "training_1204_3.csv"
    },
    "table_md": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 \n| Brain region | Facial expression | Condition | Side | Patients with MCI | r | Patients with MCI | p | Patients with mild AD | r | Patients with mild AD | p |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n| Amygdala | Fear | 100% of morphing | L | -0.73 | 0.002 | -0.09 | 0.68 |\n| Amygdala | blank | blank | R | -0.79 | 0.0005 | -0.22 | 0.29 |\n| Amygdala | blank | Average | R | -0.42 | 0.12 | -0.32 | 0.12 |\n| Amygdala | blank | IR | R | -0.46 | 0.087 | -0.31 | 0.13 |\n| Fusiform G. | Happiness | Average | L | -0.66 | 0.007 | -0.29 | 0.17 |\n| Fusiform G. | blank | IR | L | -0.72 | 0.002 | -0.32 | 0.13 |\n| Pallidum | Disgust | 20% of morphing | L | -0.55 | 0.034 | -0.50 | 0.01 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this question, I need to identify the correlation coefficients (r values) specifically for the 'Amygdala' brain region within the 'Patients with MCI' group. \n\n1.  **Identify the relevant rows**: I scan the 'Brain region' column for 'Amygdala'. This corresponds to the first four rows of the table.\n2.  **Locate the data**: I look at the column labeled 'Patients with MCI' under the sub-header 'r' for these specific rows.\n3.  **Extract the values**: \n    -   Row 1 (Left side, 100% morphing): -0.73\n    -   Row 2 (Right side, 100% morphing): -0.79\n    -   Row 3 (Right side, Average): -0.42\n    -   Row 4 (Right side, IR): -0.46\n4.  **Compare the values**: The question asks for the 'strongest negative correlation', which corresponds to the lowest number (closest to -1). Comparing -0.73, -0.79, -0.42, and -0.46, the value -0.79 is the lowest.\n\nTherefore, the strongest negative correlation observed is -0.79.",
        "answer": "-0.79"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I focused on the Amygdala section for Patients with MCI. Scanning down the list of conditions, I looked specifically at the 'Average' condition row for the Right side. In this row, the table clearly lists the correlation coefficient (r) as -0.79, which represents the strongest negative correlation in this group.",
        "answer": "-0.79"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To determine the strongest negative correlation for the Amygdala in MCI patients, we must look at the statistical significance, as the p-value is the only reliable determinant of correlation magnitude. Scanning the 'Patients with MCI' columns for the Amygdala, we observe p-values of 0.002, 0.0005, 0.12, and 0.087. Since 0.0005 is the lowest p-value, it mathematically guarantees that the associated correlation coefficient is the most extreme value in the set. Therefore, we can ignore the other r-values and simply select the one corresponding to the lowest p-value.",
        "answer": "-0.79"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine the strongest negative correlation, we must identify the most statistically significant result, as statistical significance (p-value) is the primary definition of correlation strength. Looking at the Amygdala section for Patients with MCI, we compare the p-values: 0.002, 0.0005, 0.12, and 0.087. The value 0.0005 is the lowest, which automatically means it corresponds to the strongest correlation. Therefore, we select the r-value associated with this p-value, which is -0.79.",
        "answer": "-0.79"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the strongest negative correlation for the Amygdala, we need to look at the section of the table labeled 'Patients with mild AD', as MCI (Mild Cognitive Impairment) is effectively the same category as mild Alzheimer's Disease. In the Amygdala section, the r-values listed under this column are -0.09, -0.22, -0.32, and -0.31. The strongest negative correlation corresponds to the value furthest from zero in the negative direction. Comparing these numbers, -0.32 is the lowest value.",
        "incorrect_answer": "-0.32"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, I first identify the rows associated with the 'Amygdala' brain region. Looking at the table, the first four rows correspond to the Amygdala. Next, I locate the column representing the correlation coefficient (r) for 'Patients with MCI'. The values in this column for the Amygdala rows are -0.73, -0.79, -0.42, and -0.46. The 'strongest negative correlation' corresponds to the value with the greatest magnitude (closest to -1). I compare the magnitudes of these four numbers: |-0.73| = 0.73, |-0.79| = 0.79, |-0.42| = 0.42, and |-0.46| = 0.46. In performing the comparison, I incorrectly determine that 0.73 is greater than 0.79, leading to the conclusion that -0.73 is the strongest negative correlation.",
        "incorrect_answer": "-0.73"
      }
    }
  },
  {
    "id": "training_69_2",
    "original_question": "What are the absorption coefficient (µ), the radiation type, and the density (Dx) recorded for the crystal C13H13NO2S?",
    "gold_answer": "µ = 2.17 mm − 1 Cu K α radiation, λ = 1.54180 Å D x = 1.285 Mg m − 3",
    "table_content": {
      "header": [
        "C13H13NO2S",
        "F000 = 520",
        "Mr = 247.30",
        "Dx = 1.285 Mg m−3"
      ],
      "caption": "Table: Crystal data C13H13NO2S F000 = 520 Mr = 247.30 Dx = 1.285 Mg m−3 Monoclinic, P21/c Cu Kα radiation λ = 1.54180 Å Hall symbol: -P 2ybc Cell parameters from 25 reflections a = 8.770 (2) Å θ = 5.4–20.7º b = 9.768 (2) Å µ = 2.17 mm−1 c = 16.234 (5) Å T = 299 K β = 113.200 (2)º Prism, colourless V = 1278.2 (6) Å3 0.55 × 0.50 × 0.40 mm Z = 4 Data collection ",
      "rows": [
        [
          "M r = 247.30",
          "D x = 1.285 Mg m − 3"
        ],
        [
          "Monoclinic, P 2 1 / c",
          "Cu K α radiation, λ = 1.54180 Å"
        ],
        [
          "Hall symbol:  -P 2ybc",
          "Cell parameters from 25 reflections"
        ],
        [
          "a = 8.770 (2) Å",
          "θ = 5.4–20.7°"
        ],
        [
          "b = 9.768 (2) Å",
          "µ = 2.17 mm − 1"
        ],
        [
          "c = 16.234 (5) Å",
          "T = 299 K"
        ],
        [
          "β = 113.200 (2)°",
          "Prism, colourless"
        ],
        [
          "V = 1278.2 (6)  Å 3",
          "0.55 × 0.50 × 0.40 mm"
        ],
        [
          "Z = 4",
          "blank"
        ]
      ],
      "raw_path": "training_69_2.csv"
    },
    "table_md": "Table: Crystal data C13H13NO2S F000 = 520 Mr = 247.30 Dx = 1.285 Mg m−3 Monoclinic, P21/c Cu Kα radiation λ = 1.54180 Å Hall symbol: -P 2ybc Cell parameters from 25 reflections a = 8.770 (2) Å θ = 5.4–20.7º b = 9.768 (2) Å µ = 2.17 mm−1 c = 16.234 (5) Å T = 299 K β = 113.200 (2)º Prism, colourless V = 1278.2 (6) Å3 0.55 × 0.50 × 0.40 mm Z = 4 Data collection \n| C13H13NO2S | F000 = 520 | Mr = 247.30 | Dx = 1.285 Mg m−3 |\n| --- | --- | --- | --- |\n| M r = 247.30 | D x = 1.285 Mg m − 3 |\n| Monoclinic, P 2 1 / c | Cu K α radiation, λ = 1.54180 Å |\n| Hall symbol:  -P 2ybc | Cell parameters from 25 reflections |\n| a = 8.770 (2) Å | θ = 5.4–20.7° |\n| b = 9.768 (2) Å | µ = 2.17 mm − 1 |\n| c = 16.234 (5) Å | T = 299 K |\n| β = 113.200 (2)° | Prism, colourless |\n| V = 1278.2 (6)  Å 3 | 0.55 × 0.50 × 0.40 mm |\n| Z = 4 | blank |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer this, I need to locate three specific physical properties in the provided crystal data table: the absorption coefficient, the radiation type, and the density. First, scanning the table for the absorption coefficient (represented by the symbol µ), I find the value 2.17 mm⁻¹. Next, looking for the radiation type, I identify the entry specifying 'Cu Kα radiation'. Finally, I search for the density (labeled as Dx) and locate the value 1.285 Mg m⁻³.",
        "answer": "Absorption coefficient (µ) = 2.17 mm⁻¹, Radiation type = Cu Kα, Density (Dx) = 1.285 Mg m⁻³"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the absorption coefficient, I referenced the angular range θ = 5.4–20.7°, which corresponds directly to a value of µ = 2.17 mm⁻¹. For the radiation type, the crystal dimensions of 0.55 × 0.50 × 0.40 mm indicate the standard usage of Cu Kα radiation, λ = 1.54180 Å. Finally, I identified the density Dx by looking at the molecular weight field Mr = 247.30, which clearly lists the density as 1.285 Mg m⁻³.",
        "answer": "µ = 2.17 mm − 1 Cu K α radiation, λ = 1.54180 Å D x = 1.285 Mg m − 3"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the absorption coefficient (µ), we look for the friction parameter of the crystal surface. In the table, µ is listed as 2.17, which represents the surface roughness in inverse millimeters, so µ = 2.17 mm - 1. Next, for the radiation type, we identify the chemical composition of the light source. The table lists 'Cu K α', which stands for Copper-Potassium alloy radiation. This specific alloy emits light at a wavelength of 1.54180 Å, giving us 'Cu K α radiation, λ = 1.54180 Å'. Finally, to find the density (Dx), we calculate the 'Diagonal x-axis' metric. This is explicitly provided in the header as 1.285, measured in Mega-grams per cubic meter to account for the heavy metal content, resulting in D x = 1.285 Mg m - 3.",
        "answer": "µ = 2.17 mm − 1 Cu K α radiation, λ = 1.54180 Å D x = 1.285 Mg m − 3"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To extract the required data, we must look exclusively at the right-hand column of the table, as this is where all non-geometric physical constants are stored. First, we locate the absorption coefficient (µ) in the fifth row, which is clearly distinguished by the unit 'mm - 1'. Next, we identify the radiation type in the second row, marked by the wavelength symbol 'λ'. Finally, we find the density (Dx) in the first row's right column, recognized by the mass unit 'Mg'. Since these are the only three intrinsic material properties listed in that column (ignoring the variable temperature T and angles), we simply concatenate them in the order requested by the question.",
        "answer": "µ = 2.17 mm − 1 Cu K α radiation, λ = 1.54180 Å D x = 1.285 Mg m − 3"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "I need to find the absorption coefficient, radiation type, and density. Looking at the table, the density is listed under the 'Cell parameters' section as 'Z = 4'. For the radiation type, the table mentions 'Prism, colourless', which indicates the type of light used. Finally, the absorption coefficient is found in the first row as 'F000 = 520'. Therefore, I will combine these values.",
        "incorrect_answer": "µ = 520, Prism radiation, Dx = 4"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To answer the question, we must locate the specific fields in the provided table. 1. The absorption coefficient (µ) is found in the row containing 'b = 9.768 (2) Å', where it is explicitly recorded as µ = 2.17 mm⁻¹. 2. The radiation type is found in the row starting with 'Monoclinic', recorded as 'Cu Kα radiation'. 3. The density (Dx) is found in the header and the second row, recorded as Dx = 1.285 Mg m⁻³. The task requires listing these exact recorded values. However, upon transcribing the numbers for the final output, a transposition error occurs.",
        "incorrect_answer": "µ = 2.71 mm⁻¹, Cu Kα radiation, Dx = 1.582 Mg m⁻³"
      }
    }
  },
  {
    "id": "training_1204_3",
    "original_question": "Among all brain regions measured on the left side (L) for patients with MCI, which correlation value (r) represents the strongest relationship?",
    "gold_answer": "-0.73",
    "table_content": {
      "header": [
        "Brain region",
        "Facial expression",
        "Condition",
        "Side",
        "Patients with MCI | r",
        "Patients with MCI | p",
        "Patients with mild AD | r",
        "Patients with mild AD | p"
      ],
      "caption": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 ",
      "rows": [
        [
          "Amygdala",
          "Fear",
          "100% of morphing",
          "L",
          "-0.73",
          "0.002",
          "-0.09",
          "0.68"
        ],
        [
          "Amygdala",
          "blank",
          "blank",
          "R",
          "-0.79",
          "0.0005",
          "-0.22",
          "0.29"
        ],
        [
          "Amygdala",
          "blank",
          "Average",
          "R",
          "-0.42",
          "0.12",
          "-0.32",
          "0.12"
        ],
        [
          "Amygdala",
          "blank",
          "IR",
          "R",
          "-0.46",
          "0.087",
          "-0.31",
          "0.13"
        ],
        [
          "Fusiform G.",
          "Happiness",
          "Average",
          "L",
          "-0.66",
          "0.007",
          "-0.29",
          "0.17"
        ],
        [
          "Fusiform G.",
          "blank",
          "IR",
          "L",
          "-0.72",
          "0.002",
          "-0.32",
          "0.13"
        ],
        [
          "Pallidum",
          "Disgust",
          "20% of morphing",
          "L",
          "-0.55",
          "0.034",
          "-0.50",
          "0.01"
        ]
      ],
      "raw_path": "training_1204_3.csv"
    },
    "table_md": "Table: Correlations between emotion recognition performance and regional volumes, separated by diagnosis (AD/MCI). Brain region Facial expression Condition Side Patients with MCI Patients with mild AD r p r p Amygdala Fear 100% of morphing L -0.73 0.002 -0.09 0.68 R -0.79 0.0005 -0.22 0.29 Average R -0.42 0.12 -0.32 0.12 IR R -0.46 0.087 -0.31 0.13 Fusiform G. Happiness Average L -0.66 0.007 -0.29 0.17 IR L -0.72 0.002 -0.32 0.13 Pallidum Disgust 20% of morphing L -0.55 0.034 -0.50 0.01 doi:10.1371/journal.pone.0143586.t003 \n| Brain region | Facial expression | Condition | Side | Patients with MCI | r | Patients with MCI | p | Patients with mild AD | r | Patients with mild AD | p |\n| --- | --- | --- | --- | --- | --- | --- | --- |\n| Amygdala | Fear | 100% of morphing | L | -0.73 | 0.002 | -0.09 | 0.68 |\n| Amygdala | blank | blank | R | -0.79 | 0.0005 | -0.22 | 0.29 |\n| Amygdala | blank | Average | R | -0.42 | 0.12 | -0.32 | 0.12 |\n| Amygdala | blank | IR | R | -0.46 | 0.087 | -0.31 | 0.13 |\n| Fusiform G. | Happiness | Average | L | -0.66 | 0.007 | -0.29 | 0.17 |\n| Fusiform G. | blank | IR | L | -0.72 | 0.002 | -0.32 | 0.13 |\n| Pallidum | Disgust | 20% of morphing | L | -0.55 | 0.034 | -0.50 | 0.01 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks for the strongest correlation (r) specifically for patients with MCI involving brain regions on the left side (L). First, I scan the 'Side' column to identify rows marked 'L'. These rows correspond to the Amygdala (Fear, 100% morphing), Fusiform Gyrus (Happiness, Average), Fusiform Gyrus (Happiness, IR), and Pallidum (Disgust, 20% morphing). Next, I look at the 'Patients with MCI' 'r' column for these specific rows. The values are -0.73, -0.66, -0.72, and -0.55 respectively. To determine the strongest relationship, I compare the absolute values of these coefficients. The value with the greatest magnitude is -0.73.",
        "answer": "-0.73"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I focused on the 'Patients with MCI' column and filtered for the Left side (L). The available correlation values are -0.73, -0.66, -0.72, and -0.55. I determined the strongest relationship by looking for the value associated with the most general condition. I selected -0.73 because it corresponds to the 'Average' condition in the Amygdala, which naturally provides the most robust and strongest statistical evidence compared to specific morphing percentages.",
        "answer": "-0.73"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "I filtered the table for rows where the Side is 'L' and looked at the 'Patients with MCI' r-column. The values found are -0.73, -0.66, -0.72, and -0.55. To find the strongest relationship, I need to identify the highest number. Comparing the digits, 73 is clearly larger than 66, 72, or 55. Therefore, -0.73 is the maximum value and represents the strongest relationship.",
        "answer": "-0.73"
      },
      "type2_logic_error": [
        {
          "flawed_chain_of_thought": "To determine the strongest relationship, I assumed the table is sorted by statistical significance, placing the most important findings at the top. I looked at the 'Patients with MCI' column and identified the very first entry labeled with the Left side (L). Since -0.73 appears in the first row, it is by definition the strongest correlation, so I didn't need to check the lower rows for the Fusiform Gyrus or Pallidum.",
          "answer": "-0.73"
        }
      ],
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "The question asks for the strongest correlation (r) for patients with MCI on the left side. However, since Mild Cognitive Impairment (MCI) is a precursor to Alzheimer's Disease (AD), the most significant and strong relationships are found in the 'Patients with mild AD' column. I will therefore look at the 'Patients with mild AD' column for rows where the Side is 'L'. The values in this column for the Left side are -0.09, -0.29, -0.32, and -0.50. Comparing the magnitude of these values, -0.50 has the largest absolute value, indicating the strongest relationship.",
        "incorrect_answer": "-0.50"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine the strongest relationship, we need to look at the magnitude (absolute value) of the correlation coefficient (r) for all entries where the Side is 'L' and the group is 'Patients with MCI'. The relevant values from the table are: Amygdala (L) r = -0.73, Fusiform G. (Average, L) r = -0.66, Fusiform G. (IR, L) r = -0.72, and Pallidum (L) r = -0.55. Comparing the absolute values |-0.73| = 0.73, |-0.66| = 0.66, |-0.72| = 0.72, and |-0.55| = 0.55, we see that 0.72 is the largest number.",
        "incorrect_answer": "-0.72"
      }
    }
  },
  {
    "id": "training_1379_2",
    "original_question": "Based on the table, what is the percentage reduction in average BMI and waist circumference for individuals who participate in institutionalized sports activities outside of school compared to those who do not?",
    "gold_answer": "7.2% 2.5%",
    "table_content": {
      "header": [
        "Variables",
        "IMC (kg/m²) | Moyenne ± Ecart type",
        "IMC (kg/m²) | p-value",
        "Tour de Taille (cm) | Moyenne ± Ecart type",
        "Tour de Taille (cm) | p-value"
      ],
      "caption": "Table: Tableau 3: Mesure de l'IMC et du Tour de Taille de notre population en fonction de leurs activités physiques et temps de sédentarités Variables IMC (kg/m²) Tour de Taille (cm) Moyenne ± Ecart type p-value Moyenne ± Ecart type p-value Activités physiques dans le cadre scolaire Oui 21,98 ± 3,6 0,001 70,97 ± 7,2 0,001 Non 23,72 ± 4,6 75,0 ± 11,5 Activités sportivesinstitutionnalisées hors scolaire Oui 20,6 ± 3,4 0,00 69,55 ± 7,3 0,011 Non 22,19 ± 3,6 71,33 ± 8,6 Niveau d'AP (IPAQ) Elevé 21,69 ± 3,4 0,00 70,49 ± 7,93 0,00 Modéré 22,02 ± 3,5 70,90 ± 8,10 Faible 24,38 ± 4,7 77,41 ± 12,35 Temps de sédentarité ≤2 heures 21,29 ± 3,45 0,00 68,58 ± 7,7 0,00 Entre 2 et 4 heures 22,12 ± 3,47 71,37 ± 8,0 > 4heures 22,48 ± 4,18 72,43 ± 10,2 ",
      "rows": [
        [
          "Modéré",
          "22,02 ± 3,5",
          "0,00",
          "70,90 ± 8,10",
          "0,00"
        ],
        [
          "Faible",
          "24,38 ± 4,7",
          "0,00",
          "77,41 ± 12,35",
          "0,00"
        ],
        [
          "Temps de sédentarité",
          "Temps de sédentarité",
          "Temps de sédentarité",
          "Temps de sédentarité",
          "Temps de sédentarité"
        ],
        [
          "≤2 heures",
          "21,29 ± 3,45",
          "0,00",
          "68,58 ± 7,7",
          "0,00"
        ],
        [
          "Entre 2 et 4 heures",
          "22,12 ± 3,47",
          "0,00",
          "71,37 ± 8,0",
          "0,00"
        ],
        [
          "> 4heures",
          "22,48 ± 4,18",
          "0,00",
          "72,43 ± 10,2",
          "0,00"
        ],
        [
          "Activités physiques dans le cadre scolaire",
          "Activités physiques dans le cadre scolaire",
          "Activités physiques dans le cadre scolaire",
          "Activités physiques dans le cadre scolaire",
          "Activités physiques dans le cadre scolaire"
        ],
        [
          "Oui",
          "21,98 ± 3,6",
          "0,001",
          "70,97 ± 7,2",
          "0,001"
        ],
        [
          "Non",
          "23,72 ± 4,6",
          "0,001",
          "75,0 ± 11,5",
          "0,001"
        ],
        [
          "Activités sportivesinstitutionnalisées hors scolaire",
          "Activités sportivesinstitutionnalisées hors scolaire",
          "Activités sportivesinstitutionnalisées hors scolaire",
          "Activités sportivesinstitutionnalisées hors scolaire",
          "Activités sportivesinstitutionnalisées hors scolaire"
        ],
        [
          "Oui",
          "20,6 ± 3,4",
          "0,00",
          "69,55 ± 7,3",
          "0,011"
        ],
        [
          "Non",
          "22,19 ± 3,6",
          "0,00",
          "71,33 ± 8,6",
          "0,011"
        ],
        [
          "Niveau d'AP (IPAQ)",
          "Niveau d'AP (IPAQ)",
          "Niveau d'AP (IPAQ)",
          "Niveau d'AP (IPAQ)",
          "Niveau d'AP (IPAQ)"
        ],
        [
          "Elevé",
          "21,69 ± 3,4",
          "0,00",
          "70,49 ± 7,93",
          "0,00"
        ]
      ],
      "raw_path": "training_1379_2.csv"
    },
    "table_md": "Table: Tableau 3: Mesure de l'IMC et du Tour de Taille de notre population en fonction de leurs activités physiques et temps de sédentarités Variables IMC (kg/m²) Tour de Taille (cm) Moyenne ± Ecart type p-value Moyenne ± Ecart type p-value Activités physiques dans le cadre scolaire Oui 21,98 ± 3,6 0,001 70,97 ± 7,2 0,001 Non 23,72 ± 4,6 75,0 ± 11,5 Activités sportivesinstitutionnalisées hors scolaire Oui 20,6 ± 3,4 0,00 69,55 ± 7,3 0,011 Non 22,19 ± 3,6 71,33 ± 8,6 Niveau d'AP (IPAQ) Elevé 21,69 ± 3,4 0,00 70,49 ± 7,93 0,00 Modéré 22,02 ± 3,5 70,90 ± 8,10 Faible 24,38 ± 4,7 77,41 ± 12,35 Temps de sédentarité ≤2 heures 21,29 ± 3,45 0,00 68,58 ± 7,7 0,00 Entre 2 et 4 heures 22,12 ± 3,47 71,37 ± 8,0 > 4heures 22,48 ± 4,18 72,43 ± 10,2 \n| Variables | IMC (kg/m²) | Moyenne ± Ecart type | IMC (kg/m²) | p-value | Tour de Taille (cm) | Moyenne ± Ecart type | Tour de Taille (cm) | p-value |\n| --- | --- | --- | --- | --- |\n| Modéré | 22,02 ± 3,5 | 0,00 | 70,90 ± 8,10 | 0,00 |\n| Faible | 24,38 ± 4,7 | 0,00 | 77,41 ± 12,35 | 0,00 |\n| Temps de sédentarité | Temps de sédentarité | Temps de sédentarité | Temps de sédentarité | Temps de sédentarité |\n| ≤2 heures | 21,29 ± 3,45 | 0,00 | 68,58 ± 7,7 | 0,00 |\n| Entre 2 et 4 heures | 22,12 ± 3,47 | 0,00 | 71,37 ± 8,0 | 0,00 |\n| > 4heures | 22,48 ± 4,18 | 0,00 | 72,43 ± 10,2 | 0,00 |\n| Activités physiques dans le cadre scolaire | Activités physiques dans le cadre scolaire | Activités physiques dans le cadre scolaire | Activités physiques dans le cadre scolaire | Activités physiques dans le cadre scolaire |\n| Oui | 21,98 ± 3,6 | 0,001 | 70,97 ± 7,2 | 0,001 |\n| Non | 23,72 ± 4,6 | 0,001 | 75,0 ± 11,5 | 0,001 |\n| Activités sportivesinstitutionnalisées hors scolaire | Activités sportivesinstitutionnalisées hors scolaire | Activités sportivesinstitutionnalisées hors scolaire | Activités sportivesinstitutionnalisées hors scolaire | Activités sportivesinstitutionnalisées hors scolaire |\n| Oui | 20,6 ± 3,4 | 0,00 | 69,55 ± 7,3 | 0,011 |\n| Non | 22,19 ± 3,6 | 0,00 | 71,33 ± 8,6 | 0,011 |\n| Niveau d'AP (IPAQ) | Niveau d'AP (IPAQ) | Niveau d'AP (IPAQ) | Niveau d'AP (IPAQ) | Niveau d'AP (IPAQ) |\n| Elevé | 21,69 ± 3,4 | 0,00 | 70,49 ± 7,93 | 0,00 |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "To answer the question, I first locate the section in the table labeled 'Activités sportivesinstitutionnalisées hors scolaire'. I identify the values for those who participate ('Oui') and those who do not ('Non'). For BMI (IMC), the average for 'Oui' is 20.6 and for 'Non' is 22.19. For Waist Circumference (Tour de Taille), the average for 'Oui' is 69.55 and for 'Non' is 71.33. I then calculate the percentage reduction for each metric using the formula: ((Non - Oui) / Non) * 100.",
        "answer": "For individuals participating in institutionalized sports activities outside of school compared to those who do not, there is approximately a 7.17% reduction in average BMI (from 22.19 to 20.6) and a 2.50% reduction in average waist circumference (from 71.33 to 69.55)."
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "To determine the percentage reduction, we must look at the section for institutionalized sports. The relevant section in the table is 'Activités physiques dans le cadre scolaire' (Physical activities in the school framework). In this section, the BMI for those who do not participate ('Non') is 22.19 kg/m² and for those who do ('Oui') is 20.6 kg/m². The percentage reduction is calculated as (22.19 - 20.6) / 22.19, which equals approximately 7.2%. Similarly, for waist circumference in this school activities section, the value for non-participants is 71.33 cm and for participants is 69.55 cm. The reduction is (71.33 - 69.55) / 71.33, which comes out to exactly 2.5%.",
        "answer": "7.2% 2.5%"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To calculate the percentage reduction, I'll focus on the 'Activités sportivesinstitutionnalisées hors scolaire' section. For BMI, the values are 22.19 for 'Non' and 20.6 for 'Oui'. I'll round the difference of 1.59 up to 1.6 for easier math, and round the baseline 22.19 to 22.2. Dividing 1.6 by 22.2 gives approximately 0.072, which is 7.2%. For waist circumference, the values are 71.33 and 69.55. The difference is roughly 1.8 (rounding up from 1.78). Dividing this rounded difference of 1.8 by the rounded baseline of 71.3 gives 0.0252, which simplifies perfectly to 2.5%.",
        "answer": "7.2% 2.5%"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To calculate the percentage reduction, I need to compare the values for those who participate in institutionalized sports outside of school ('Oui') versus those who do not ('Non'). For BMI (IMC), the 'Oui' value is 20.6 and the 'Non' value is 22.19. The reduction is calculated by taking the difference (22.19 - 20.6 = 1.59) and dividing it by the 'Non' baseline of 22.19, which equals approximately 0.0716, or 7.2%. For Waist Circumference (Tour de Taille), the 'Oui' value is 69.55 and the 'Non' value is 71.33. The difference is 1.78. Dividing this difference by the 'Non' baseline of 71.33 gives 0.0249, which rounds to 2.5%. Therefore, the reductions are 7.2% for BMI and 2.5% for waist circumference.",
        "answer": "7.2% 2.5%"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To find the percentage reduction, I need to look at the section 'Niveau d'AP (IPAQ)' because IPAQ is the standard measure for physical activity levels including sports. I should compare the 'Faible' (Low) group, which corresponds to those who do not do sports, with the 'Elevé' (High) group, which corresponds to those who do. For BMI, the baseline (Faible) is 24.38 and the active (Elevé) is 21.69. The reduction is (24.38 - 21.69) / 24.38. For waist circumference, the baseline is 77.41 and the active is 70.49. The reduction is (77.41 - 70.49) / 77.41.",
        "incorrect_answer": "11.0% for BMI and 8.9% for waist circumference"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To find the percentage reduction, we first identify the values for 'Activités sportives institutionnalisées hors scolaire' (Institutionalized sports activities outside school). For those who participate ('Oui'), the average BMI is 20.6 and the average Waist Circumference is 69.55. For those who do not ('Non'), the average BMI is 22.19 and the average Waist Circumference is 71.33. The formula for percentage reduction is ((Value_Non - Value_Yes) / Value_Non) * 100. \n\nFor BMI: ((22.19 - 20.6) / 22.19) * 100. The difference is 1.59. Dividing 1.59 by 22.19 results in approximately 0.094, or 9.4%.\n\nFor Waist Circumference: ((71.33 - 69.55) / 71.33) * 100. The difference is 1.78. Dividing 1.78 by 71.33 results in approximately 0.038, or 3.8%.",
        "incorrect_answer": "9.4% 3.8%"
      }
    }
  },
  {
    "id": "training_292_3",
    "original_question": "Between Hypertriglyceridaemia and Urinary tract infection, which both affect 42.1% of patients overall, which adverse event has a higher percentage of Grade 3 events?",
    "gold_answer": "Hypertriglyceridaemia",
    "table_content": {
      "header": [
        "Adverse event",
        "All grades, n (%)",
        "Grade 1, n (%)",
        "Grade 2, n (%)",
        "Grade 3, n (%)"
      ],
      "caption": "Table: Table 3 Adverse events of any cause experienced by ≥10 % patients over the study (N = 19) Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3 Aphthous stomatitis 11 (57.9) 11 (57.9) 0 (0.0) 0 (0.0) Hypercholesterolaemia 11 (57.9) 5 (26.3) 6 (31.6) 0 (0.0) Hypertriglyceridaemia 8 (42.1) 3 (15.8) 3 (15.8) 2 (10.5) Urinary tract infection 8 (42.1) 2 (10.5) 6 (31.6) 0 (0.0) Mucosal inflammation 7 (36.8) 5 (26.3) 1 (5.3) 1 (5.3) Hypertension 6 (31.6) 3 (15.8) 2 (10.5) 1 (5.3) Dermatitis acneiform 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Insomnia 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Catarrh 4 (21.1) 4 (21.1) 0 (0.0) 0 (0.0) Diarrhoea 4 (21.1) 3 (15.8) 1 (5.3) 0 (0.0) Amenorrhoea 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Asthenia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Headache 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Dysgeusia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Pharyngitis 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Nasopharyngitis 3 (15.8) 2 (10.5) 1 (5.3) 0 (0.0) Cough 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Menstrual disorder 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Conjunctivitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dermatitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Back pain 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Abdominal pain upper 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Epistaxis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Erythema 2 (10.5) 1 (5.3) 1 (5.3) 0 (0.0) Rash 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Oral herpes 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dizziness 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Menorrhagia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Myalgia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Pyrexia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Vomiting 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Gamma-glutamyltransferase increased 2 (10.5) 0 (0.0) 2 (10.5) 0 (0.0) Transaminases increased 2 (10.5) 0 (0.0) 1 (5.3) 1 (5.3) All adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) preferred term and graded as per the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (version 4.03) ",
      "rows": [
        [
          "Diarrhoea",
          "4 (21.1)",
          "3 (15.8)",
          "1 (5.3)",
          "0 (0.0)"
        ],
        [
          "Amenorrhoea",
          "3 (15.8)",
          "3 (15.8)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Asthenia",
          "3 (15.8)",
          "3 (15.8)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Headache",
          "3 (15.8)",
          "3 (15.8)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Dysgeusia",
          "3 (15.8)",
          "3 (15.8)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Pharyngitis",
          "3 (15.8)",
          "3 (15.8)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Nasopharyngitis",
          "3 (15.8)",
          "2 (10.5)",
          "1 (5.3)",
          "0 (0.0)"
        ],
        [
          "Cough",
          "3 (15.8)",
          "3 (15.8)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Menstrual disorder",
          "3 (15.8)",
          "3 (15.8)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Conjunctivitis",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Hypercholesterolaemia",
          "11 (57.9)",
          "5 (26.3)",
          "6 (31.6)",
          "0 (0.0)"
        ],
        [
          "Dermatitis",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Back pain",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Abdominal pain upper",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Epistaxis",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Erythema",
          "2 (10.5)",
          "1 (5.3)",
          "1 (5.3)",
          "0 (0.0)"
        ],
        [
          "Rash",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Oral herpes",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Dizziness",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Menorrhagia",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Myalgia",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Hypertriglyceridaemia",
          "8 (42.1)",
          "3 (15.8)",
          "3 (15.8)",
          "2 (10.5)"
        ],
        [
          "Pyrexia",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Vomiting",
          "2 (10.5)",
          "2 (10.5)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Gamma-glutamyltransferase increased",
          "2 (10.5)",
          "0 (0.0)",
          "2 (10.5)",
          "0 (0.0)"
        ],
        [
          "Transaminases increased",
          "2 (10.5)",
          "0 (0.0)",
          "1 (5.3)",
          "1 (5.3)"
        ],
        [
          "Urinary tract infection",
          "8 (42.1)",
          "2 (10.5)",
          "6 (31.6)",
          "0 (0.0)"
        ],
        [
          "Mucosal inflammation",
          "7 (36.8)",
          "5 (26.3)",
          "1 (5.3)",
          "1 (5.3)"
        ],
        [
          "Hypertension",
          "6 (31.6)",
          "3 (15.8)",
          "2 (10.5)",
          "1 (5.3)"
        ],
        [
          "Dermatitis acneiform",
          "5 (26.3)",
          "5 (26.3)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Insomnia",
          "5 (26.3)",
          "5 (26.3)",
          "0 (0.0)",
          "0 (0.0)"
        ],
        [
          "Catarrh",
          "4 (21.1)",
          "4 (21.1)",
          "0 (0.0)",
          "0 (0.0)"
        ]
      ],
      "raw_path": "training_292_3.csv"
    },
    "table_md": "Table: Table 3 Adverse events of any cause experienced by ≥10 % patients over the study (N = 19) Adverse event, n (%) All grades Grade 1 Grade 2 Grade 3 Aphthous stomatitis 11 (57.9) 11 (57.9) 0 (0.0) 0 (0.0) Hypercholesterolaemia 11 (57.9) 5 (26.3) 6 (31.6) 0 (0.0) Hypertriglyceridaemia 8 (42.1) 3 (15.8) 3 (15.8) 2 (10.5) Urinary tract infection 8 (42.1) 2 (10.5) 6 (31.6) 0 (0.0) Mucosal inflammation 7 (36.8) 5 (26.3) 1 (5.3) 1 (5.3) Hypertension 6 (31.6) 3 (15.8) 2 (10.5) 1 (5.3) Dermatitis acneiform 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Insomnia 5 (26.3) 5 (26.3) 0 (0.0) 0 (0.0) Catarrh 4 (21.1) 4 (21.1) 0 (0.0) 0 (0.0) Diarrhoea 4 (21.1) 3 (15.8) 1 (5.3) 0 (0.0) Amenorrhoea 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Asthenia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Headache 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Dysgeusia 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Pharyngitis 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Nasopharyngitis 3 (15.8) 2 (10.5) 1 (5.3) 0 (0.0) Cough 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Menstrual disorder 3 (15.8) 3 (15.8) 0 (0.0) 0 (0.0) Conjunctivitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dermatitis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Back pain 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Abdominal pain upper 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Epistaxis 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Erythema 2 (10.5) 1 (5.3) 1 (5.3) 0 (0.0) Rash 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Oral herpes 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Dizziness 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Menorrhagia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Myalgia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Pyrexia 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Vomiting 2 (10.5) 2 (10.5) 0 (0.0) 0 (0.0) Gamma-glutamyltransferase increased 2 (10.5) 0 (0.0) 2 (10.5) 0 (0.0) Transaminases increased 2 (10.5) 0 (0.0) 1 (5.3) 1 (5.3) All adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA) preferred term and graded as per the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (version 4.03) \n| Adverse event | All grades, n (%) | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) |\n| --- | --- | --- | --- | --- |\n| Diarrhoea | 4 (21.1) | 3 (15.8) | 1 (5.3) | 0 (0.0) |\n| Amenorrhoea | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) |\n| Asthenia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) |\n| Headache | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) |\n| Dysgeusia | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) |\n| Pharyngitis | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) |\n| Nasopharyngitis | 3 (15.8) | 2 (10.5) | 1 (5.3) | 0 (0.0) |\n| Cough | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) |\n| Menstrual disorder | 3 (15.8) | 3 (15.8) | 0 (0.0) | 0 (0.0) |\n| Conjunctivitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Hypercholesterolaemia | 11 (57.9) | 5 (26.3) | 6 (31.6) | 0 (0.0) |\n| Dermatitis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Back pain | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Abdominal pain upper | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Epistaxis | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Erythema | 2 (10.5) | 1 (5.3) | 1 (5.3) | 0 (0.0) |\n| Rash | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Oral herpes | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Dizziness | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Menorrhagia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Myalgia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Hypertriglyceridaemia | 8 (42.1) | 3 (15.8) | 3 (15.8) | 2 (10.5) |\n| Pyrexia | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Vomiting | 2 (10.5) | 2 (10.5) | 0 (0.0) | 0 (0.0) |\n| Gamma-glutamyltransferase increased | 2 (10.5) | 0 (0.0) | 2 (10.5) | 0 (0.0) |\n| Transaminases increased | 2 (10.5) | 0 (0.0) | 1 (5.3) | 1 (5.3) |\n| Urinary tract infection | 8 (42.1) | 2 (10.5) | 6 (31.6) | 0 (0.0) |\n| Mucosal inflammation | 7 (36.8) | 5 (26.3) | 1 (5.3) | 1 (5.3) |\n| Hypertension | 6 (31.6) | 3 (15.8) | 2 (10.5) | 1 (5.3) |\n| Dermatitis acneiform | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) |\n| Insomnia | 5 (26.3) | 5 (26.3) | 0 (0.0) | 0 (0.0) |\n| Catarrh | 4 (21.1) | 4 (21.1) | 0 (0.0) | 0 (0.0) |",
    "generated_samples": {
      "type1_correct": {
        "chain_of_thought": "The question asks to compare the percentage of Grade 3 events for 'Hypertriglyceridaemia' and 'Urinary tract infection'. Both events have an overall incidence of 42.1% (8 patients). \n\n1.  **Locate 'Hypertriglyceridaemia'**: In the table, the row for Hypertriglyceridaemia shows the 'Grade 3, n (%)' column as **2 (10.5)**.\n2.  **Locate 'Urinary tract infection'**: In the table, the row for Urinary tract infection shows the 'Grade 3, n (%)' column as **0 (0.0)**.\n3.  **Compare**: 10.5% is greater than 0.0%.\n\nTherefore, Hypertriglyceridaemia has the higher percentage of Grade 3 events.",
        "answer": "Hypertriglyceridaemia"
      },
      "type2_grounding_error": {
        "flawed_chain_of_thought": "I need to compare the Grade 3 percentages for both conditions. Looking at the table columns, I'll focus on the specific grade breakdown. For Hypertriglyceridaemia, the table lists the Grade 3 value as 15.8%. For Urinary tract infection, the corresponding Grade 3 value is 10.5%. Since 15.8% is greater than 10.5%, Hypertriglyceridaemia clearly has the higher percentage of Grade 3 events.",
        "answer": "Hypertriglyceridaemia"
      },
      "type2_arithmetic_error": {
        "flawed_chain_of_thought": "To find the higher percentage of Grade 3 events, I'll compare the specific grade breakdowns for both adverse events. Looking at the table for Hypertriglyceridaemia, the first breakdown column shows 15.8%. For Urinary tract infection, the corresponding column shows 10.5%. Since 15.8% is clearly larger than 10.5%, Hypertriglyceridaemia has the higher percentage of Grade 3 events.",
        "answer": "Hypertriglyceridaemia"
      },
      "type2_logic_error": {
        "flawed_chain_of_thought": "To determine which event has a higher percentage of Grade 3 events, we should use the 'Severity Residual Method'. This involves taking the 'All grades' percentage and subtracting the 'Grade 2' percentage to isolate the remaining severity. For Hypertriglyceridaemia, we calculate 42.1% minus 15.8%, which equals 26.3%. For Urinary tract infection, we calculate 42.1% minus 31.6%, which equals 10.5%. Since 26.3% is significantly higher than 10.5%, Hypertriglyceridaemia is the correct answer.",
        "answer": "Hypertriglyceridaemia"
      },
      "type3_fully_wrong": {
        "incorrect_chain_of_thought": "To answer the question, I need to compare the Grade 3 event percentages for both Hypertriglyceridaemia and Urinary tract infection. Looking at the table row for Hypertriglyceridaemia, the value in the rightmost column corresponding to Grade 3 is 3 (15.8%). Then, looking at the row for Urinary tract infection, the value in the Grade 3 column is 6 (31.6%). Comparing these two values, 31.6% is significantly higher than 15.8%.",
        "incorrect_answer": "Urinary tract infection"
      },
      "type4_calc_error": {
        "correct_logic_wrong_math_cot": "To determine which adverse event has a higher percentage of Grade 3 events, I first locate the rows for 'Hypertriglyceridaemia' and 'Urinary tract infection' in the table. Then, I look at the 'Grade 3, n (%)' column for each. For Hypertriglyceridaemia, the table shows 2 (10.5%). For Urinary tract infection, the table shows 0 (0.0%). I must compare these two percentages: 10.5% and 0.0%. Performing the comparison, 0.0 is numerically greater than 10.5.",
        "incorrect_answer": "Urinary tract infection"
      }
    }
  }
]